Document

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In March, April, May and December 2016, the FASB issued additional guidance related to Topic 606.

The new standard superseded nearly all existing revenue recognition guidance. Under Topic 606, an entity is required to recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. Topic 606 defines a five-step process in order to achieve this core principle, which may require the use of judgment and estimates, and also requires expanded qualitative and quantitative disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including significant judgments and estimates used. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.

January 1, 2018

We adopted the new guidance on January 1, 2018 using the modified retrospective approach. Refer to Notes 2 “Revenue Recognition” and 4 for additional detail regarding the impact of this adoption.

0001159036-18-000043.txt : 20181106 0001159036-18-000043.hdr.sgml : 20181106 20181106161456 ACCESSION NUMBER: 0001159036-18-000043 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181106 DATE AS OF CHANGE: 20181106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS INC CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 181163136 BUSINESS ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 10-Q 1 halo3q2018-10q.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-32335

___________________________

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

___________________________



Delaware		88-0488686
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

11388 Sorrento Valley Road, San Diego, CA		92121
(Address of principal executive offices)		(Zip Code)

(858) 794-8889

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer x	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company ¨	Emerging growth company ¨
		(Do not check if a smaller reporting company)
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 144,557,543 as of October 30, 2018.

HALOZYME THERAPEUTICS, INC.

INDEX



		Page
PART I — FINANCIAL INFORMATION
Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets (Unaudited) - September 30, 2018 and December 31, 2017	3
	Condensed Consolidated Statements of Operations (Unaudited) - Three and Nine Months Ended September 30, 2018 and 2017	4
	Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - Three and Nine Months Ended September 30, 2018 and 2017	5
	Condensed Consolidated Statements of Cash Flows (Unaudited) - Nine Months Ended September 30, 2018 and 2017	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	30
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	66
Item 4.	Controls and Procedures	66

PART II — OTHER INFORMATION
Item 1.	Legal Proceedings	67
Item 1A.	Risk Factors	67
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	67
Item 3.	Defaults Upon Senior Securities	67
Item 4.	Mine Safety Disclosures	67
Item 5.	Other Information	67
Item 6.	Exhibits	68
	SIGNATURES	69

PART I — FINANCIAL INFORMATION


Item 1.	Financial Statements

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except per share amounts)



	September 30, 2018			December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	55,019		$	168,740
Marketable securities, available-for-sale	309,347			300,474
Accounts receivable, net and other contract assets	27,656			22,133
Inventories	18,285			5,146
Prepaid expenses and other assets	19,619			13,879
Total current assets	429,926			510,372
Property and equipment, net	6,790			3,520
Prepaid expenses and other assets	7,291			5,553
Restricted cash	500			500
Total assets	$	444,507		$	519,945

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	3,331		$	7,948
Accrued expenses	43,020			39,601
Deferred revenue, current portion	4,247			6,568
Current portion of long-term debt, net	88,521			77,211
Total current liabilities	139,119			131,328
Deferred revenue, net of current portion	5,507			54,297
Long-term debt, net	57,940			125,140
Other long-term liabilities	2,203			814
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding	—			—
Common stock - $0.001 par value; 200,000 shares authorized; 144,522 and 142,789 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	145			143
Additional paid-in capital	769,382			731,044
Accumulated other comprehensive loss	(478		)	(450		)
Accumulated deficit	(529,311		)	(522,371		)
Total stockholders’ equity	239,738			208,366
Total liabilities and stockholders’ equity	$	444,507		$	519,945

See accompanying notes to condensed consolidated financial statements.

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share amounts)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Revenues:
Royalties	$	18,710		$	17,119		$	59,643		$	45,839
Product sales, net	6,269			13,589			17,553			37,803
Revenues under collaborative agreements	577			33,023			14,434			43,407
Total revenues	25,556			63,731			91,630			127,049
Operating expenses:
Cost of product sales	626			8,332			4,514			23,664
Research and development	35,540			33,993			113,602			109,267
Selling, general and administrative	14,864			13,329			42,773			39,045
Total operating expenses	51,030			55,654			160,889			171,976
Operating (loss) income	(25,474		)	8,077			(69,259		)	(44,927		)
Other income (expense):
Investment and other income, net	1,910			790			5,561			1,512
Interest expense	(4,286		)	(5,538		)	(14,286		)	(16,526		)
Net (loss) income before income taxes	(27,850		)	3,329			(77,984		)	(59,941		)
Income tax expense	—			580			220			970
Net (loss) income	$	(27,850	)	$	2,749		$	(78,204	)	$	(60,911	)

Net (loss) income per share:
Basic	$	(0.19	)	$	0.02		$	(0.55	)	$	(0.45	)
Diluted	$	(0.19	)	$	0.02		$	(0.55	)	$	(0.45	)

Shares used in computing net (loss) income per share:
Basic	143,949			141,190			143,396			134,633
Diluted	143,949			143,236			143,396			134,633

See accompanying notes to condensed consolidated financial statements.

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(Unaudited)

(In thousands)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Net (loss) income	$	(27,850	)	$	2,749		$	(78,204	)	$	(60,911	)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	256			24			(17		)	(40		)
Foreign currency translation adjustment	2			1			(11		)	(6		)
Unrealized loss on foreign currency	—			(17		)	—			(1		)
Total comprehensive (loss) income	$	(27,592	)	$	2,757		$	(78,232	)	$	(60,958	)

See accompanying notes to condensed consolidated financial statements.

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)



	Nine Months Ended September 30,
	Nine Months Ended September 30,
	2018			2017
Operating activities:
Net loss	$	(78,204	)	$	(60,911	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	26,684			23,268
Depreciation and amortization	1,798			1,668
Non-cash interest expense	2,000			2,378
Accretion of discounts on marketable securities, net	(2,166		)	(94		)
Deferral of unearned revenue	3,000			422
Recognition of deferred revenue	(2,333		)	(4,192		)
Deferral (recognition) of rent expense	78			(125		)
Other	(10		)	38
Changes in operating assets and liabilities:
Accounts receivable, net and other contract assets	13,962			985
Inventories	(13,139		)	5,292
Prepaid expenses and other assets	(7,477		)	8,998
Accounts payable and accrued expenses	(4,155		)	3,077
Net cash used in operating activities	(59,962		)	(19,196		)
Investing activities:
Purchases of marketable securities	(272,643		)	(198,748		)
Proceeds from maturities of marketable securities	265,917			184,494
Purchases of property and equipment	(1,590		)	(490		)
Net cash used in investing activities	(8,316		)	(14,744		)
Financing activities:
Proceeds from issuance of common stock, net	—			134,875
Repayment of long-term debt	(57,099		)	(10,988		)
Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement	11,656			7,686
Net cash (used in) provided by financing activities	(45,443		)	131,573
Net (decrease) increase in cash, cash equivalents and restricted cash	(113,721		)	97,633
Cash, cash equivalents and restricted cash at beginning of period	169,240			67,264
Cash, cash equivalents and restricted cash at end of period	$	55,519		$	164,897

Supplemental disclosure of non-cash investing and financing activities:
Amounts accrued for purchases of property and equipment	$	2,345		$	266
Leasehold improvements paid by lessor	$	1,322		$	—

See accompanying notes to condensed consolidated financial statements.

HALOZYME THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Business

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.

Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds.

The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex^® recombinant, and it works by temporarily breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE^® Drug Delivery Technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.

We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”) and Alexion Pharma Holding (“Alexion”).We receive royalties from two of these collaborations, including royalties from sales of one product from the Baxalta collaboration and two products from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.

Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is Pegvorhyaluronidase alfa (PVHA), also referred to as PEGylated recombinant human hyaluronidase (“PEGPH20”), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause increased pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. Through our efforts and efforts of our partners and collaborators, we are currently in Phase 3 clinical testing for PEGPH20 with ABRAXANE^®(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (HALO 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA^® (pembrolizumab) in

non-small cell lung cancer and gastric cancer (HALO 107-101), in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq® (atezolizumab) in patients with previously treated metastatic PDA, in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with gastric cancer and in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX).

Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on February 20, 2018. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated statement of cash flows within operating activities to conform to the current period presentation. There was no change to net cash used in operating activities. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.

The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.

Cash Equivalents and Marketable Securities

Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of September 30, 2018, our cash equivalents consisted of money market funds and commercial paper.

Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted

for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.

Restricted Cash

Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At September 30, 2018 and December 31, 2017, restricted cash of $0.5 million was pledged as collateral for the letters of credit.

Fair Value of Financial Instruments

The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.

Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.

Inventories

Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.

We capitalize inventory costs associated with our drug candidates prior to receipt of regulatory approval, based on management’s judgment of probable future commercialization. We would be required to expense these capitalized costs upon a change in such judgment, due to, among other factors, a decision denying approval of the drug candidate by regulatory agencies.

Bulk rHuPH20 formulations manufactured for partner use prior to our partner receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries and with no alternative future use are recorded as research and development expense. All direct manufacturing costs incurred after the partner receives marketing approval are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in any stage of development or in commercial product, and ENHANZE drug product used by our partners in clinical trials, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.

As of September 30, 2018 and December 31, 2017, inventories consisted of $2.4 million and $2.9 million, respectively, of Hylenex recombinant inventory, net and $15.9 million and $2.2 million, respectively, of bulk rHuPH20.

Revenue Recognition

We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, Revenue from Contracts with Customers (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted. Accordingly, the reported revenue amounts for the three and nine months ended September 30, 2018 and 2017 are based on different accounting policies.

Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.

Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018

Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services.

We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs,

and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.

Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers.

Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE^® technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.

When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).

We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements representations and are not obligations to provide goods or services.

We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.

Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals

and successful completion of clinical trials. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.

When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target if the exchange right is exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.

Because our agreements only have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.

We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners.

Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner.

Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups.

In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.

Refer to Note 4 Revenue, for further discussion on our collaborative arrangements.

Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final

royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other differences in revenue to be recognized under the previously existing authoritative accounting literature and ASC 606 applied to our collaborative agreements.

Product Sales, Net - as reported under ASC 606 beginning January 1, 2018

Hylenex Recombinant

We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders. We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.

Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.

We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.

Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.

We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.

Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustments.

In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of a practical expedient allowed in ASC 606.

Bulk rHuPH20

We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.

We recognize revenue from bulk rHuPH20 formulations as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.

There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.

ENHANZE Drug Product

We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.

We recognize revenue from ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.

There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.

Revenue Presentation

In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms and sales of bulk rHuPH20 that has no alternative future use. We report royalties received from collaboration partners as a separate line in our statements of operations.

Revenues from sales of Hylenex recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.

In footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront amounts, event-based development and regulatory milestones and other fees, sales milestones and royalties).

Cost of Product Sales

Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 and ENHANZE drug product that has alternative future use. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. Prior to bulk rHuPH20 and ENHANZE drug product having alternative future use, all costs related to the manufacturing of those products were charged to research and development expenses in the periods such costs were incurred. During the three and nine months ended September 30, 2018, sales of bulk rHuPH20 and ENHANZE drug product included $1.7 million and $2.3 million, respectively, of cost of sales that were previously expensed as research and development. Of the bulk rHuPH20 and ENHANZE drug product that has alternative future use on hand as of September 30, 2018, approximately $2.0 million in manufacturing costs were previously recorded as research and development expenses. We expect to sell this inventory by the end of 2020.

Research and Development Expenses

Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. The manufacturing costs of bulk rHuPH20 for the approved collaboration products, Herceptin SC, MabThera SC (RITUXAN HYCELA™ in the U.S.) and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in any stage of development or in commercial products, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.

We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.

Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.

Clinical Trial Expenses

We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.

Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other

incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.

Share-Based Compensation

We record compensation expense associated with stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and RSUs with performance conditions (“PRSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.

Income Taxes

We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to zero, with the exception of the alternative minimum tax ("AMT") credit carryover of $5.5 million. Under the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017, the AMT credit carryover will either be utilized, or if unutilized fully refunded in 2022. For all other deferred tax assets the valuation allowance will reduce the net value to zero until such time as we can demonstrate an ability to realize them.

The Act reduces the U.S. federal corporate tax rate from 35% to 21%. As a result, the Company evaluated and adjusted its deferred tax assets to reflect the new corporate tax rates as of December 31, 2017. The Company is still evaluating other potential impacts and planning opportunities related to tax reform. As of September 30, 2018, the Company believes that its disclosures in its financial statements as of December 31, 2017 are still reasonably accurate.

Net (Loss) Income Per Share

Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the three and nine months ended September 30, 2018, approximately 13.8 million shares of outstanding stock options, unvested RSAs, unvested RSUs were excluded from the calculation of diluted net loss per common share because a net loss was reported in each of these periods and therefore their effect was anti-dilutive. Outstanding common stock equivalents totaling approximately 7.8 million and 14.3 million, respectively, were excluded from the calculation of diluted net (loss) income per common share for the three and nine months ended September 30, 2017, respectively, because their effect was anti-dilutive. A reconciliation of the numerators

and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):



	Three Months Ended September 30,					Nine Months Ended September 30,
	2018			2017		2018			2017
Numerator:
Net (loss) income	$	(27,850	)	$	2,749	$	(78,204	)	$	(60,911	)
Denominator:
Weighted average common shares outstanding for basic net (loss) income per share	143,949			141,190		143,396			134,633
Net effect of dilutive common stock equivalents	—			2,046		—			—
Weighted average common shares outstanding for diluted net (loss) income per share	143,949			143,236		143,396			134,633
Net (loss) income per share:
Basic	$	(0.19	)	$	0.02	$	(0.55	)	$	(0.45	)
Diluted	$	(0.19	)	$	0.02	$	(0.55	)	$	(0.45	)

Segment Information

We operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Our long-lived assets located in foreign countries had minimal book value as of September 30, 2018 and December 31, 2017.

Adoption and Pending Adoption of Recent Accounting Pronouncements

The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters

In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.	The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.	January 1, 2018	We currently do not hold equity securities. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.

In October 2016, the FASB issued ASU 2016-16, Income Taxes; Intra-Entity Transfers of Assets Other Than Inventory.	The new guidance removes the current requirement to defer the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) until the asset has been sold to an outside party. As a result, the income tax consequences of an intercompany transfer of assets other than inventory will be recognized in the current period income statement rather than being deferred until the assets leave the consolidated entity.	January 1, 2018	We adopted the new guidance on January 1, 2018. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.

3. Fair Value Measurement

Available-for-sale marketable securities consisted of the following (in thousands):



	September 30, 2018
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value

Asset-backed securities	$	39,721	$	—	$	(24	)	$	39,697
Corporate debt securities	74,699		—		(181		)	74,518
U.S. Treasury securities	99,716		—		(248		)	99,468
Commercial paper	95,664		—		—			95,664
	$	309,800	$	—	$	(453	)	$	309,347



	December 31, 2017
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value

Corporate debt securities	$	117,427	$	—	$	(235	)	$	117,192
U.S. Treasury securities	66,601		—		(201		)	66,400
Commercial paper	116,882		—		—			116,882
	$	300,910	$	—	$	(436	)	$	300,474

As of September 30, 2018, all of our available-for-sale debt securities were scheduled to mature within the next 12 months and 27 available-for-sale marketable securities were in a gross unrealized loss position, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe we had no other than-temporary impairments on these securities as of September 30, 2018, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.

The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):



	September 30, 2018						December 31, 2017
	Level 1		Level 2		Total estimated fair value		Level 1		Level 2		Total estimated fair value
Cash equivalents:
Money market funds	$	55,271	$	—	$	55,271	$	142,091	$	—	$	142,091
Commercial paper	—		—		—		—		15,700		15,700

Available-for-sale marketable securities:
Asset-backed securities	—		39,697		39,697		—		—		—
Corporate debt securities	—		74,518		74,518		—		117,192		117,192
U.S. Treasury securities	99,468		—		99,468		66,400		—		66,400
Commercial paper	—		95,664		95,664		—		116,882		116,882
	$	154,739	$	209,879	$	364,618	$	208,491	$	249,774	$	458,265

There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the nine months ended September 30, 2018. We had no instruments that were classified within Level 3 as of September 30, 2018 and December 31, 2017.

4. Revenue

Our disaggregated revenues were as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Royalties	$	18,710	$	17,119	$	59,643	$	45,839

Product sales, net
Sales of bulk rHuPH20	$	2,402	$	9,748	$	6,350	$	26,825
Sales of ENHANZE drug product	186		—		322		—
Sales of Hylenex	3,681		3,841		10,881		10,978
Total product sales, net	6,269		13,589		17,553		37,803

Revenues under collaborative agreements:
Upfront license fees	—		30,352		1,336		31,054
Event-based development milestones and other fees	—		329		11,000		988
Sales-based milestones	—		342		—		1,028
Research and development services	577		2,000		2,098		10,337
Total revenues under collaborative agreements	577		33,023		14,434		43,407

Total revenue	$	25,556	$	63,731	$	91,630	$	127,049

During the three months ended September 30, 2018 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $18.7 million. This amount represents royalties earned in the current period. We recognized revenue of $0.5 million during the three months ended September 30, 2018 that had been included in deferred revenues at December 31, 2017. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.

During the nine months ended September 30, 2018 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $70.6 million. This amount represents royalties earned in the current period, development milestones of $1.0 million from Roche and $5.0 million from Alexion, and $5.0 million of variable consideration in the contract where uncertainties have been resolved and the development milestone is expected to be achieved. We also recognized revenue of $2.3 million during the nine months ended September 30, 2018 that had been included in deferred revenues at December 31, 2017. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.

Revenue recognized during the three and nine months ended September 30, 2017 was determined in accordance with the accounting rules applicable prior to the adoption of ASC 606 on January 1, 2018.

Upon the adoption of ASC 606, we recognized an adjustment to increase our accounts receivable by $19.4 million, decrease deferred revenues by $51.8 million, and decrease accumulated deficit by $71.2 million. The impact of applying the provisions of ASC 606 in the three and nine months ended September 30, 2018 was to decrease revenues by $6.4 million and to increase revenues by $2.6 million, respectively. Under the previously existing authoritative accounting literature, at September 30, 2018 our accounts receivable and other contract assets would have been $18.7 million lower, and our deferred revenue $48.7 million higher, than the amounts reported in our condensed consolidated balance sheet. ASC 606 did not have an aggregate impact on our net cash used in operating activities, but resulted in offsetting changes in net loss and certain assets and liabilities within net cash used in operating activities in the condensed consolidated statement of cash flows.

Accounts receivable, net, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):



	September 30, 2018		December 31, 2017
Accounts receivable, net	$	22,656	$	22,133
Other contract assets	5,000		—
Deferred revenues	9,754		60,865

As of September 30, 2018, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $9.8 million. This amount has been collected and is reported as deferred revenues. Of the total deferred revenues, $3.0 million represents pre-payment of bulk rHuPH20 that we estimate will be delivered in 2019. Of the remaining deferred revenues, for which the timing of when these goods and services will be provided is controlled by our customers, $4.5 million can be used by the customers at any time through 2022 and the remaining $2.3 million at any time through 2019.

We recognized contract assets of $5.0 million related to collaborative agreements as of September 30, 2018, for amounts considered probable to receive for development milestones that relate to intellectual property licenses granted to collaboration partners in prior periods. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of September 30, 2018 (in thousands):



	Upfront (1)		Development (2)		Sales (3)		Royalty		Total
Collaboration partner and agreement date:
Roche (December 2006 and September 2017)	$	70,000	$	25,000	$	22,000	$	211,613	$	328,613
Baxalta (September 2007)	10,000		3,000		9,000		22,438		44,438
Pfizer (December 2012)	14,500		2,000		—		—		16,500
Janssen (December 2014)	15,250		15,000		—		—		30,250
AbbVie (June 2015)	23,000		6,000		—		—		29,000
Lilly (December 2015)	33,000		—		—		—		33,000
BMS (September 2017)	105,000		5,000		—		—		110,000
Alexion (December 2017)	40,000		5,000		—		—		45,000


(1)	Upfront and additional target selection fees


(2)	Event-based development and regulatory milestone amounts and other fees


(3)	Sales-based milestone amounts

Through September 30, 2018, our collaboration partners have completed development, obtained marketing authorization approvals for certain indications and commenced commercialization of the following products:


•	Roche, for Herceptin SC in the European Union (“EU”) in August 2013; and MabThera SC in the EU in March 2014 and its equivalent RITUXAN HYCELA™ in the US in June 2017; and Herceptin SC in Canada in September 2018;


•	Baxalta, for HYQVIA in the EU and in the US in May 2013.

The remaining targets and products are currently in the process of development by the collaboration partners.

5. Certain Balance Sheet Items

Accounts receivable, net and other contract assets consisted of the following (in thousands):



	September 30, 2018			December 31, 2017
Accounts receivable from product sales to collaborators	$	1,980		$	18,475
Accounts receivable from revenues under collaborative agreements	451			2,142
Accounts receivable from royalty payments	18,777			—
Accounts receivable from other product sales	1,949			2,075
Other contract assets	5,000			—
Subtotal	28,157			22,692
Allowance for distribution fees and discounts	(501		)	(559		)
Total accounts receivable, net and other contract assets	$	27,656		$	22,133

Inventories consisted of the following (in thousands):



	September 30, 2018		December 31, 2017
Raw materials	$	625	$	377
Work-in-process	15,401		2,131
Finished goods	2,259		2,638
Total inventories	$	18,285	$	5,146

Prepaid expenses and other assets consisted of the following (in thousands):



	September 30, 2018		December 31, 2017
Prepaid manufacturing expenses	$	8,844	$	2,337
Prepaid research and development expenses	9,195		7,793
Other prepaid expenses	2,344		2,585
Other assets	6,527		6,717
Total prepaid expenses and other assets	26,910		19,432
Less long-term portion	7,291		5,553
Total prepaid expenses and other assets, current	$	19,619	$	13,879

Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations. Such amounts are reclassified to work-in-process inventory as materials are used or the CMO services are complete.

Property and equipment, net consisted of the following (in thousands):



	September 30, 2018			December 31, 2017
Research equipment	$	9,528		$	9,268
Manufacturing equipment	3,979			1,702
Computer and office equipment	4,811			3,725
Leasehold improvements	4,160			2,715
Subtotal	22,478			17,410
Accumulated depreciation and amortization	(15,688		)	(13,890		)
Property and equipment, net	$	6,790		$	3,520

Depreciation and amortization expense totaled $0.6 million and $0.5 million for the three months ended September 30, 2018 and 2017, and $1.8 million and $1.7 million for the nine months ended September 30, 2018 and 2017, respectively.

Accrued expenses consisted of the following (in thousands):



	September 30, 2018		December 31, 2017
Accrued outsourced research and development expenses	$	19,786	$	18,757
Accrued compensation and payroll taxes	12,914		13,384
Accrued outsourced manufacturing expenses	4,743		2,504
Other accrued expenses	6,142		5,396
Total accrued expenses	43,585		40,041
Less long-term portion	565		440
Total accrued expenses, current	$	43,020	$	39,601

Deferred revenue consisted of the following (in thousands):



	September 30, 2018		December 31, 2017
Collaborative agreements
License fees and event-based payments:
Roche	$	—	$	39,379
Other	2,265		15,999
Total license fees and event-based payments	2,265		55,378
Product sales	7,489		5,487
Total deferred revenue	9,754		60,865
Less current portion	4,247		6,568
Deferred revenue, net of current portion	$	5,507	$	54,297

6. Long-Term Debt, Net

Royalty-backed Loan

In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (“Halozyme Royalty”), we received a $150 million loan (the “Royalty-backed Loan”) pursuant to a credit agreement (the “Credit Agreement”) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the “Royalty-backed Lenders”). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (“Collaboration Agreements”). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the “Royalty Payments”). The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of September 30, 2018 was 10.25%.

The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first to pay interest and second to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance

of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps.

Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050. Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan.

As of September 30, 2018, we were in compliance with all covenants under the Royalty-backed Loan and there was no material adverse change in our business, operations or financial condition.

We began making principal and interest payments against the Royalty-backed Loan in the first quarter of 2017 and therefore had no capitalized interest in the three and nine months ended September 30, 2018. In addition, we recorded accrued interest, which is included in accrued expenses, of $0.5 million and $0.7 million as of September 30, 2018 and December 31, 2017, respectively

In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of $1.5 million and incurred additional debt issuance costs totaling $0.4 million, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of September 30, 2018, and are being amortized over the estimated term of the debt using the effective interest method. For the three months ended September 30, 2018 and 2017, the Company recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of $3.1 million and $4.2 million, respectively, and $10.5 million and $12.4 million for the nine months ended September 30, 2018 and 2017, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of September 30, 2018 was $101.0 million, net of unamortized debt discount of $0.4 million.

Oxford and SVB Loan and Security Agreement

In June 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (collectively, the “Lenders”), providing a senior secured loan facility of up to an aggregate principal amount of $70.0 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we had the option to draw during the second quarter of 2017 and did not exercise. The initial proceeds were partially used to pay the outstanding principal and final payment of $4.25 million owed on a previous loan agreement with the Lenders. The remaining proceeds are being used for working capital and general business requirements. The senior secured loan facility carries a fixed interest rate of 8.25%. The repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provides for a final payment equal to 5.50% of the initial $55.0 million principal amount. The final payment is due when the Loan Agreement becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the Loan Agreement in full, subject to a prepayment fee of 2% in the first year and 1% in the second year of the Loan Agreement.

In connection with the Loan Agreement, the debt offering costs have been recorded as a debt discount in our condensed consolidated balance sheets which, together with the final payment and fixed interest rate payments, are being amortized and recorded as interest expense throughout the life of the loan using the effective interest rate method.

The Loan Agreement is secured by substantially all of the assets of the Company and our subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any of our intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our subsidiary, Halozyme, Inc.

The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of the Lender’s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan. In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.

As of September 30, 2018, we were in compliance with all covenants under the Loan Agreement and there was no material adverse change in our business, operations or financial condition.

Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.2 million and $1.4 million for the three months ended September 30, 2018 and 2017, respectively, and $3.8 million and $4.1 million for the nine months ended September 30, 2018 and 2017, respectively. Accrued interest, which is included in accrued expenses, was $0.3 million and $0.4 million as of September 30, 2018 and December 31, 2017, respectively. The outstanding term loan balance was $45.5 million as of September 30, 2018, inclusive of $2.0 million of accretion of the final payment and net of unamortized debt discount related to offering costs of $0.2 million.

7. Share-based Compensation

Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Research and development	$	4,407	$	3,060	$	13,107	$	9,891
Selling, general and administrative	4,460		4,702		13,577		13,377
Share-based compensation expense	$	8,867	$	7,762	$	26,684	$	23,268

Share-based compensation expense by type of share-based award (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Stock options	$	4,645	$	4,973	$	14,026	$	14,971
RSAs, RSUs and PRSUs	4,222		2,789		12,658		8,297
	$	8,867	$	7,762	$	26,684	$	23,268

We granted stock options to purchase approximately 0.4 million and 0.1 million shares of common stock during the three months ended September 30, 2018 and 2017, respectively, and 2.3 million and 2.5 million shares of the Company’s common stock during the nine months ended September 30, 2018 and 2017, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (“Black-Scholes model”). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:



	Three Months Ended September 30,		Nine Months Ended September 30,
	2018	2017	2018	2017
Expected volatility	58.6-60.6%	70.5-70.8%	58.7-70.1%	70.5-71.7%
Average expected term (in years)	5.4	5.6	5.5	5.6
Risk-free interest rate	2.75-2.87%	1.73-1.93%	2.25-2.87%	1.73-1.94%
Expected dividend yield	—	—	—	—

Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):



	September 30, 2018
	Unrecognized Expense		Remaining Weighted-Average Recognition Period (years)
Stock options	$	38,966	2.45
RSAs	$	2,743	1.09
RSUs	$	26,434	2.24

8. Stockholders’ Equity

In May 2017, we completed an underwritten public offering pursuant to which we sold 11.5 million shares of common stock, including 1.5 million shares sold pursuant to the full exercise of an option to purchase additional shares granted to the underwriters. All of the shares were offered at a public offering price of $12.50 per share, generating $134.9 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. We intend to use the net proceeds from this offering to fund continued development of our PEGPH20 oncology program and for other general corporate purposes.

During the nine months ended September 30, 2018 and 2017, we issued an aggregate of 1,280,996 and 1,020,028 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $11.13 and $8.71 per share, respectively, for net proceeds of approximately $14.3 million and $8.9 million, respectively. For the nine months ended September 30, 2018 and 2017, we issued 438,536 and 375,906 shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered 138,986 and 96,069 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $4.2 million and $1.9 million, respectively. In addition, we issued 67,959 and 98,945 shares of common stock in connection with the grants of RSAs during the nine months ended September 30, 2018 and 2017, respectively. Stock options and unvested restricted units totaling approximately 13.4 million shares and 14.7 million shares of our common stock were outstanding as of September 30, 2018 and December 31, 2017, respectively.

9. Commitments and Contingencies

From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.

10. Subsequent Events

In October 2018, we entered into an agreement with Roche for the right to develop and commercialize one additional exclusive target and an option to select two additional targets within four years using our ENHANZE technology for an upfront payment of $25.0 million. We will receive potential milestone payments of up to $160.0 million to $165.0 million per target, subject to the achievement of specific development, regulatory and sales-based milestones. We will also receive mid-single digit royalties on sales of commercialized products.


Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

As used in this report, unless the context suggests otherwise, references to “Halozyme,” “the Company,” “we,” “our,” “ours,” and “us” refer to Halozyme Therapeutics, Inc., its wholly owned subsidiary, Halozyme, Inc. and Halozyme Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. References to “Notes” refer to the Notes to Condensed Consolidated Financial Statements included herein (refer to Item 1 of Part I).

The following information should be read in conjunction with the interim unaudited condensed consolidated financial statements and Notes thereto included in Item 1 of this Quarterly Report on Form 10-Q, as well as the audited financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended December 31, 2017, included in our Annual Report on Form 10-K for the year ended December 31, 2017. Past financial or operating performance is not necessarily a reliable indicator of future performance, and our historical performance should not be used to anticipate results or future period trends.

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this report other than statements of historical fact are, or may be deemed to be, forward-looking statements. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “think,” “may,” “could,” “will,” “would,” “should,” “continue,” “potential,” “likely,” “opportunity,” “project” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this report. Additionally, statements concerning future matters such as the anticipated timing and scope of planned clinical trials, the development or regulatory approval of new products, enhancements of existing products or technologies, timing and success of the launch of new products by us or by our collaborators, third party performance under key collaboration agreements, revenue, expense and cash burn levels and expected trends, expected repayment of the Royalty-backed Loan and trends and other statements regarding matters that are not historical are forward-looking statements. Such statements reflect management’s current forecast of certain aspects of our future, are based on currently available operating, financial and competitive information and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to, those set forth below under the section entitled “Risks Factors” and elsewhere in this Quarterly Report on Form 10-Q and our most recent Annual Report on Form 10-K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report.

Overview

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds.

The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is Pegvorhyaluronidase alfa (PVHA), also referred to as PEGylated recombinant human hyaluronidase (PEGPH20), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. Through our efforts and efforts of our partners and collaborators, we are currently in Phase 3 clinical testing for PEGPH20 with ABRAXANE^® (nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (PDA) (HALO 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA^® (pembrolizumab) in non-small cell lung cancer and gastric cancer (HALO 107-101), in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq^® (atezolizumab) in patients with previously treated metastatic PDA, in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with gastric cancer and in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX).

We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE^® Drug Delivery Technology (ENHANZE). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (Baxalta), Pfizer Inc. (Pfizer), Janssen Biotech, Inc. (Janssen), AbbVie, Inc. (AbbVie), Eli Lilly and Company (Lilly), Bristol-Myers Squibb Company (BMS) and Alexion Pharma Holding (Alexion).We receive royalties from two of these collaborations, including royalties from sales of one product from the Baxalta collaboration and two products from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.

Our third quarter of 2018 and recent key events include:

•


•	In October 2018, BMS dosed the first patient in a Phase 1 study evaluating the safety, pharmacokinetics and pharmacodynamics of BMS-986179, an investigational anti-CD-73 antibody, and ENHANZE technology, triggering a $5 million milestone payment which, under current revenue recognition standards, was recorded as revenue in the second quarter of 2018.


•	In September 2018, we announced that Roche received approval from Health Canada for a subcutaneous formulation of Herceptin (trastuzumab) for the treatment of patients with HER2-positive breast cancer. This is a co-formulation with our ENHANZE technology.


•	In August 2018, Alexion initiated a Phase 1 trial to study a next-generation subcutaneous formulation of ALXN1210 co-administered with ENHANZE technology, triggering a $5 million milestone payment which, under current revenue recognition standards, was recorded as revenue in the second quarter of 2018.


•	In July 2018, we announced the FDA accepted a Biologics License Application (BLA) from Genentech, a member of the Roche Group, for a subcutaneous version of Herceptin in its FDA-approved breast cancer indications. This is the same co-formulation with ENHANZE marketed under the Herceptin SC brand in many countries outside the U.S.

Product and Product Candidates

We have one marketed proprietary product, three partnered products, one proprietary product candidate targeting several indications in various stages of development, and one preclinical product candidate. The following table summarizes our proprietary product and product candidate as well as products and product candidates under development with our collaborators:

Proprietary Pipeline

Hylenex Recombinant (hyaluronidase human injection)

Hylenex recombinant is a formulation of rHuPH20 that has received U.S. Food and Drug Administration (FDA) approval to facilitate subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Hylenex recombinant is currently the number one prescribed branded hyaluronidase.

PEGPH20

We are developing PEGPH20 in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. ‘PEG’ refers to the attachment of polyethylene glycol to rHuPH20, thereby creating PEGPH20. One of the novel properties of PEGPH20 is that it lasts for an extended duration in the bloodstream and, therefore, can be administered systemically to maintain its therapeutic effect to treat disease.

Cancer malignancies, including pancreatic, lung, breast, gastric, and biliary tract cancers can accumulate high levels of HA and therefore we believe that PEGPH20 has the potential to help patients with these types of cancer when used with certain currently approved cancer therapies. Among solid tumors, PDA has been reported to be associated with one of the highest frequencies of HA accumulation. There are approximately 65,000 annual diagnoses of PDA in the United States and the European Union, and we estimate that 35-40% have high levels of HA based on our companion diagnostic assay cutpoint.

The pathologic accumulation of HA, along with other matrix components, creates a unique microenvironment for the growth of tumor cells compared to normal cells. We believe that degrading the HA component of the tumor microenvironment with PEGPH20 remodels the tumor microenvironment, resulting in tumor growth inhibition in animal models. Removal of HA from the tumor microenvironment results in expansion of previously constricted blood vessels allowing increased blood flow, potentially increasing the access of activated immune cells and factors in the blood into the tumor microenvironment. If PEGPH20 is administered in conjunction with other anti-cancer therapies, the increase in blood flow may allow anti-cancer therapies to have greater access to the tumor, which may enhance the treatment effect of therapeutic modalities like chemotherapies, monoclonal antibodies and other agents.

We are developing PEGPH20 as a targeted therapy, for patients who have tumors with high levels of HA. We have a collaboration with Ventana Medical Systems Inc. (Ventana), a member of the Roche Group, to develop, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with PEGPH20. The companion diagnostic assay is being used to identify high levels of HA in tumor biopsies, and may be the first diagnostic to target tumor-associated HA and possibly the first companion diagnostic assay in pancreatic cancer.

Pancreatic cancer indications:

HALO 109-201:

In January 2015, we presented the final results from HALO 109-201, a multi-center, international open label dose escalation Phase 1b clinical study of PEGPH20 in combination with gemcitabine for the treatment of patients with stage IV PDA at the 2015 Gastrointestinal Cancers Symposium (also known as ASCO-GI meeting). This study enrolled 28 patients with previously untreated stage IV PDA. Patients were treated with one of three doses of PEGPH20 (1.0, 1.6 and 3.0 µg/kg twice weekly for four weeks, then weekly thereafter) in combination with gemcitabine 1000 mg/m2 administered intravenously. In this study, the confirmed overall response rate (complete response + partial response confirmed on a second scan as assessed by an independent radiology review) was 29 percent (7 of 24 patients) for those treated at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Median progression-free survival (PFS) was 154 days (95% CI, 50-166) in the efficacy-evaluable population (n = 24). Among efficacy-evaluable patients with baseline tumor HA staining (n = 17), the median PFS in patients with high baseline tumor HA staining (6/17 patients) was substantially longer, 219 days, than in the patients with low baseline tumor HA staining (11/17 patients), 108 days. Median overall survival (OS) was 200 days (95% CI, 123-370) in the efficacy-evaluable population (n = 24). Among efficacy-evaluable patients with baseline tumor HA staining (n = 17), the median OS in patients with high baseline tumor HA staining (6/17 patients) was substantially longer, 395 days, than in the patients with low baseline tumor HA staining (11/17 patients), 174 days. The most common treatment-emergent adverse events (occurring in ≥ 15% of patients) were peripheral edema, muscle spasms, thrombocytopenia, fatigue, myalgia, anemia, and nausea. Thromboembolic (TE) events were reported in 8 patients (28.6%) and musculoskeletal events were reported in 21 patients (75%) which were generally grade 1/2 in severity.

HALO 109-202:

In the second quarter of 2013, we initiated HALO 109-202 (HALO-202), a Phase 2 multicenter randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV PDA. The study was designed to enroll patients who would receive gemcitabine and nab-paclitaxel (ABRAXANE®) either with or without PEGPH20. The primary endpoint is to measure the improvement in PFS in patients receiving PEGPH20 plus gemcitabine and ABRAXANE (PAG arm) compared to those who are receiving gemcitabine and ABRAXANE alone (AG arm). In April 2014, after 146 patients had been enrolled, the trial was put on clinical hold by Halozyme and the FDA to assess a question raised by the Data Monitoring Committee regarding a possible difference in the TE events rate between the group of patients treated in the PAG arm versus the group of patients treated in the AG arm. This portion of the study and patients in this portion are now referred to as Stage 1. At the time of the clinical hold all patients remaining in the study continued on gemcitabine and ABRAXANE. In July 2014, HALO-202 was reinitiated (Stage 2) under a revised protocol, which excludes patients that are expected to be at a greater risk for TE events. The revised protocol provides for thromboembolism prophylaxis of all patients in both arms of the study with low molecular weight heparin, and adds evaluation of the TE events rate in Stage 2 PEGPH20-treated patients as a co-primary endpoint. Stage 2 of HALO-202 enrolled an additional 133 patients, to add to the 146 patients already in the clinical trial, with a 2:1 randomization for the PAG arm compared to the AG arm.

In March 2016, our partner Ventana received approval for an investigational device exemption (IDE) application from the FDA for our companion diagnostic test to enable patient selection in our Phase 3 Study HALO-301 of PEGPH20 in HA-High patients. Based on the cutpoint for the Ventana diagnostic, we expect approximately 35 to 40 percent of stage IV PDA patients to have HA-High tumors, similar to the previously reported interim results from Stage 1 of Study HALO-202 using the Halozyme prototype assay.

In January 2017, we announced topline results from the combined analysis of Stage 1 and Stage 2, and Stage 2 alone, based on a December 2016 data cutoff. The combined analysis included 135 treated patients in Stage 1, of whom a total of 45 patients (24 in the PAG arm and 21 in the AG arm) were determined to have high HA, and 125 treated patients in Stage 2, of whom a total of 35 patients (24 in the PAG arm and 11 in the AG arm) were determined to have high HA. This analysis of secondary and exploratory endpoints was conducted using the Ventana companion diagnostic to prospectively identify high levels of HA. The key results showed in the combined Stage 1 and Stage 2 dataset:


•	The primary endpoint of PFS in the efficacy evaluable population (total of 231 patients) was met with statistical significance with a median PFS of 6.0 months in the PAG arm compared to 5.3 months in the AG arm, hazard ratio (HR) with a 95% confidence interval (CI): 0.73 (0.53, 1.00); p=0.048;


•	The secondary endpoint of PFS in the HA-High intent to treat population (total of 84 HA-High patients) was met with statistical significance with a median PFS of 9.2 months in the PAG arm compared to 5.2 months in the AG arm, HR 0.51 (95% CI: 0.26, 1.00); p=0.048;

•

The exploratory analysis of median OS was 11.5 months vs. 8.5 months in the PAG vs. AG arms, respectively, of the combined Stage 1 and Stage 2 HA-High patients. Factors potentially having an impact on these results include less aggressive disease among patients in the AG arm within the Stage 1 patient population, and 9 of the 24 patients in the PAG arm (approximately 40 percent) discontinued PEGPH20 treatment at the time of the clinical hold, resulting in many patients receiving AG alone in both arms.

In the Stage 2 cohort population, in a total of 35 HA-High patients, the key results showed:


•	Median PFS was 8.6 months in the PAG arm compared to 4.5 months in the AG arm, hazard ratio of 0.63 (95% CI: 0.21, 1.93);


•	Median overall survival (OS) was 11.7 months in the PAG arm compared to 7.8 months in the AG arm, hazard ratio of 0.52 (95% CI: 0.22, 1.23);

•

The primary safety endpoint of decreasing the rate of TE events in Stage 2 was also met with the rate of TE events reducing from 43 percent to 10 percent in the PAG arm and from 25 percent to 6 percent in the AG arm, following a protocol amendment that excluded patients at high risk of TE events and with the introduction of prophylaxis with low molecular weight heparin (enoxaparin) in Stage 2 of the study with the current 1mg/kg/day dose of enoxaparin prophylaxis given in both treatment arms of the study.

In June 2017, results from Study HALO-202 were presented at the ESMO World Congress of Gastrointestinal Cancer and the Annual Meeting of the American Society of Clinical Oncology (ASCO). In May 2018, the database was locked, an updated analysis is being performed and the Final Study Report is currently being generated. In September 2018 the last remaining patient receiving study medication was discontinued from the study.

HALO 109-301:

In March 2015, we met with the FDA to discuss both the interim efficacy and safety data from HALO-202, which included the potential risk profile including TE event rate. Based on the feedback from that meeting, we proceeded with HALO 109-301 (HALO-301), a Phase 3 clinical study of PEGPH20 in patients with stage IV PDA, using a design allowing for potential marketing application based on PFS (accelerated approval pathway) or OS. The study will enroll patients whose tumors accumulate high levels of HA measured using the Ventana companion diagnostic test. The FDA provided feedback on the current companion diagnostic approach and confirmed that an approved IDE is required for the Phase 3 study.

The use of PFS as the basis for marketing approval will be subject to the overall benefit and risk associated with PEGPH20 combined with gemcitabine and ABRAXANE therapy, including the:


•	Magnitude of the PFS treatment effect observed;


•	Toxicity profile; and


•	Interim OS data.

In June 2015, we received scientific advice/protocol assistance from the European Medicines Agency (EMA) regarding our Phase 3 study. The EMA agreed to the patient population, and the use of both PFS and OS as co-primary endpoints stating that OS is the preferred endpoint and that ultimate approval would require an overall positive benefit:risk balance.

In March 2016, we dosed the first patient in HALO-301, a Phase 3 multicenter randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV PDA. The study will evaluate the effects on PFS and OS of PEGPH20 with gemcitabine and ABRAXANE compared with gemcitabine and ABRAXANE alone in stage IV PDA patients. In May 2018, our independent Data Safety Monitoring Committee met to review ongoing safety data from the trial and informed us the study should proceed as planned. Over 200 sites in 22 countries located in North America, Europe, South America and Asia have been initiated to participate in the HALO-301 study. An interim analysis will be conducted for our first primary endpoint when we achieve the target number of PFS events. We project that the target number of PFS events will be achieved between December 2018 and February 2019. We project we will have enrolled approximately 500 patients by the end of 2018.

SWOG Study S1313:

In October 2013, SWOG, a cancer research cooperative group of more than 4,000 researchers in over 500 institutions around the world, initiated a 144 patient Phase 1b/2 randomized clinical trial in some of their study centers, examining PEGPH20 in combination with modified FOLFIRINOX chemotherapy compared to modified FOLFIRINOX treatment alone in patients with stage IV PDA, irrespective of HA levels, referred to as an all-comer population. This study was funded by the National Cancer Institute. In March 2017 SWOG stopped enrollment in the Phase 1b/2 trial following a recommendation of SWOG’s independent Data Monitoring committee after a preplanned futility analysis. In January 2018, SWOG presented final data of the all-comers population at the ASCO-GI conference. The median overall survival was 7.7 months for the PEGPH20 arm vs. 14.4 months in the modified FOLFIRINOX alone arm. Also, increased GI-toxicities and substantially shorter median treatment duration for modified FOLFIRINOX were reported for the PEGPH20 arm compared to the modified FOLFIRINOX alone arm. Collection of biopsy samples from participating sites, to the extent available, is ongoing to potentially enable an HA biomarker subgroup analysis. Our PEGPH20 studies and clinical collaborations in combination with agents other than modified FOLFIRINOX continue unchanged.

Clinical collaboration:

In October 2016, we announced that PEGPH20 will be included in a pancreatic cancer clinical trial initiative called Precision Promise, an initiative that aims to change the current treatment approach to pancreatic cancer by offering options to patients based on the molecular profile of their tumor. This is being accomplished through the Pancreatic Cancer Action Network leading a collaboration that brings together clinicians, researchers, and drug developers. Pancreatic Cancer Action Network continues to work to finalize the trial design and protocol which may include a potential PEGPH20 trial arm or trial.

Other indications outside of pancreatic cancer:

HALO 107-101:

In November 2015, we initiated a Phase 1b study exploring the combination of PEGPH20 and KEYTRUDA^®, an immuno-oncology agent in relapsed non-small cell lung cancer (NSCLC) and gastric cancer. In December 2016, we identified a dose of PEGPH20, namely 2.2 ug/kg, to move into the dose expansion phase of the study with KEYTRUDA in combination with PEGPH20. In September 2017, our standing Independent Data Monitoring Safety Committee met to review ongoing safety data from the trial and informed us that the study should proceed with study protocol modifications to exclude patients at risk and increase liver safety monitoring, after observing clinical and laboratory signs of hepato-biliary dysfunction. In April 2018 we informed participating sites to stop screening for new patients in the gastric cancer cohort of the study as the overall enrollment goal has been reached. Patients already in screening prior to the notification date were allowed to enter the study contingent of all eligibility

criteria being met. Following the results of Merck’s KEYNOTE-189 study evaluating KEYTRUDA in combination with chemotherapy as a first-line treatment, the standard of care in lung cancer is expected to change. As we are seeking to enroll second line immune checkpoint inhibitor naïve patients, we have closed enrollment in the lung cohort of the study and investigators were given the option to continue treatment of ongoing patients.

HALO 107-101 is an ongoing study with an open database and enrollment has ended in both the NSCLC and gastric cancer cohorts. In the NSCLC cohort we enrolled 17 of the target 30 patients in the dose expansion cohort prior to closing enrollment. Two patients are ongoing. Of the 13 currently evaluable patients, four patients experienced a greater than 30% reduction in tumor volume as assessed by investigator sites. Two of these patients had a further scan confirming the greater than 30% reduction was maintained. Of the four patients experiencing a greater than 30% reduction, three were PD-L1 negative, while data was unavailable for the fourth. Discussions are ongoing with advisers and investigators regarding the data and any next steps.

In the gastric cancer cohort, we reached target enrollment of 34 patients in the dose finding and dose expansion cohort. Of the 26 currently evaluable patients, we have seen one responder in a PD-L1 positive patient. This response rate does not meet our threshold to continue development of PEGPH20 in combination with Keytruda alone in gastric cancer.

We continue to collect and receive data on both NSCLC and gastric patients. When the database is considered complete and locked, a Final Study Report will be generated and data presented.

Clinical collaborations:

In July 2015, we entered into a clinical collaboration agreement with Eisai Co., Ltd. (Eisai) to evaluate Eisai's HALAVEN^® (eribulin) with PEGPH20 in HER2-negative metastatic breast cancer. Halozyme and Eisai jointly share the costs to conduct this global study. In July 2016, the first patient was dosed in a Phase 1b/2 study for patients treated with up to two lines of prior therapy for HER2-negative metastatic breast cancer. In January 2018, the Phase 1b portion of the study closed enrollment with 14 patients. As a result of an Eisai portfolio decision, no further clinical development is planned on the Phase 2 portion of this study. We presented the data from our Phase 1 study in October at the 2018 European Society for Medical Oncology Congress. Based on a data cut off in February 2018, the addition of PEGPH20 to eribulin showed an overall response rate of 28.6% in this single arm trial. A fifth response was reported following the data cut off resulting in a 36% overall response rate, double the response rate reported with single-agent eribulin, in prior studies of patients with HER2-negative metastatic breast cancer. This is our first demonstration of PEGPH20’s positive effect outside of pancreas cancer.

In November 2016, we entered into an agreement with Genentech, a member of the Roche Group, to collaborate on clinical studies to evaluate their cancer immunotherapy Tecentriq, an anti-PD-L1 monoclonal antibody, in combination with PEGPH20, in up to eight different tumor types. Genentech initiated a Phase 1b/2 clinical trial in patients with previously treated metastatic PDA in July 2017 and a Phase 1b/2 clinical trial in patients with gastric cancer in October 2017, as part of its Morpheus master protocol. We will supply PEGPH20 for the Genentech-funded studies. In October 2017, we initiated a Phase 1b/2 clinical trial to assess Tecentriq with PEGPH20 in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX). Genentech will supply Tecentriq for the Halozyme sponsored study.

Regulatory

The FDA has granted Fast Track designation for our program investigating PEGPH20 in combination with gemcitabine and nab-paclitaxel for the treatment of patients with stage IV PDA to demonstrate an improvement in OS. The Fast Track designation process was developed by the FDA to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases and address unmet medical needs.

The FDA has granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer. The FDA Office of Orphan Products Development’s mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. Similarly, the European Committee for Orphan Medicinal Products of the EMA designated PEGPH20 an orphan medicinal product for the treatment of pancreatic cancer.

Other Pipeline Asset

PEG-ADA2: PEGylated adenosine deaminase 2, or PEG-ADA2, is an immune checkpoint inhibitor that targets adenosine, which may accumulate to high levels in the tumor microenvironment and has been linked to immunosuppression. We are currently in preclinical development with PEG-ADA2 and are exploring potential collaboration or partnership interest in this program prior to making additional investments in the development of PEG-ADA2.

ENHANZE Collaborations

Roche Collaboration

In December 2006, we and Roche entered into a collaboration and license agreement under which Roche obtained a worldwide license to develop and commercialize product combinations of rHuPH20 and up to thirteen Roche target compounds (the Roche Collaboration). Roche initially had the exclusive right to apply rHuPH20 to three pre-defined Roche biologic targets with the option to develop and commercialize rHuPH20 with ten additional targets. Roche had the right to exercise this option to identify additional targets for ten years. As of the ten year anniversary of the Roche Collaboration in December 2016, Roche had elected a total of eight targets, two of which are exclusive.

In September 2013, Roche launched a subcutaneous (SC) formulation of Herceptin (trastuzumab) (Herceptin SC) in Europe for the treatment of patients with HER2-positive breast cancer. This formulation utilizes our patented ENHANZE technology and is administered in two to five minutes, compared to 30 to 90 minutes with the standard intravenous form. Roche received European marketing approval for Herceptin SC in August 2013. Breast cancer is the most common cancer among women worldwide. HER2-positive cancer is reported to be a particularly aggressive form of breast cancer. Directed at the same target, Roche initiated a Phase 1 study of rHuPH20 with PERJETA® (pertuzumab) and Herceptin (trastuzumab) in patients with early breast cancer in March 2016. In June 2018, Roche initiated a global Phase 3 study of a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin (trastuzumab) with ENHANZE in patients with HER2-positive early breast cancer. This study follows supportive Phase 1 results from the same combination shared at the 2017 San Antonio Breast Cancer Symposium. In July 2018, we announced the FDA accepted a BLA from Genentech for a subcutaneous version of Herceptin in its FDA-approved breast cancer indications. This is the same co-formulation with ENHANZE marketed under the Herceptin SC brand in many countries outside the U.S. In September 2018, we announced that Roche received approval from Health Canada for Herceptin SC for the treatment of patients with HER2-positive breast cancer.

In June 2014, Roche launched MabThera SC in Europe for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). This formulation utilizes our patented ENHANZE technology and is administered in approximately five minutes compared to the approximately 1.5 to 4 hour infusion time for intravenous MabThera. The European Commission approved MabThera SC in March 2014. In May 2016, Roche announced that the EMA approved Mabthera SC to treat patients with chronic lymphocytic leukemia (CLL). In June 2017, the FDA approved Genentech’s RITUXAN HYCELA™, a combination of rituximab and rHuPH20 (approved and marketed under the MabThera SC brand in countries outside the U.S.), for CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma.

In September 2017, we and Roche entered into an agreement providing Roche the right to develop and commercialize one additional exclusive target using our ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche’s achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are commercialized.

In January 2018, Roche initiated a Phase 1 study of an undisclosed target with ENHANZE technology.

Baxalta Collaboration

In September 2007, we and Baxalta entered into a collaboration and license agreement under which Baxalta obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID (HYQVIA) (the Baxalta Collaboration). HYQVIA is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system.

In May 2013, the European Commission granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxalta launched HYQVIA in the first EU country in July 2013 and has continued to launch in additional countries.

In September 2014, HYQVIA was approved by the FDA for treatment of adult patients with primary immunodeficiency in the U.S. HYQVIA is the first subcutaneous immune globulin (IG) treatment approved for adult primary immunodeficiency patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion in most patients, to deliver a full therapeutic dose of IG. Prior to the approval of HYQVIA, the majority of primary immunodeficiency patients received intravenous infusions in a doctor’s office or infusion center, and other subcutaneous IG treatments require weekly or bi-weekly treatment with multiple infusion sites per treatment. The FDA’s approval of HYQVIA was a significant milestone for us as it represented the first U.S. approved BLA which utilizes our rHuPH20 platform.

In May 2016, Baxalta announced that HYQVIA received a marketing authorization from the European Commission for a pediatric indication, which is being launched in Europe to treat primary and certain secondary immunodeficiencies.

Pfizer Collaboration

In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprietary biologics directed to up to six targets in primary care and specialty care indications. Targets may be selected on an exclusive or non-exclusive basis. Pfizer has elected five targets on an exclusive basis and returned two targets.

Janssen Collaboration

In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Janssen proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Janssen has elected CD38 as the first target on an exclusive basis. In November 2015, Janssen initiated dosing in a Phase 1b clinical trial evaluating subcutaneous delivery of DARZALEX (daratumumab), directed at CD38, using ENHANZE technology, in multiple myeloma patients. In December 2016, Janssen announced results of the trial, which supported continued development of daratumumab with rHuPH20. In December 2017, Janssen announced data which demonstrated that subcutaneous administration of DARZALEX and rHuPH20 was well-tolerated, with rates of infusion reactions lower than those observed with IV administration of DARZALEX. Janssen has initiated four Phase 3 studies and one Phase 1 study of daratumumab combined with the ENHANZE technology in patients with Amyloidosis, Smoldering Myeloma and Multiple Myeloma. A Phase 2 study of daratumumab combined with the ENHANZE technology was initiated in the second quarter of 2018 for patients with multiple myeloma.

AbbVie Collaboration

In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics directed to up to nine targets. Targets may be selected on an exclusive basis. AbbVie elected one target on an exclusive basis, TNF alpha, for which it has discontinued development and returned the target.

Lilly Collaboration

In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Lilly has elected two targets on an exclusive basis and one target on a semi-exclusive basis. In August 2017, Lilly initiated a Phase 1 study of an investigational new therapy in combination with rHuPH20.

BMS Collaboration

In September 2017, we and BMS entered into a collaboration and license agreement, which became effective in November 2017, under which BMS has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with BMS immuno-oncology targets directed at up to eleven targets. Targets may be selected on an exclusive basis, with the exception of one co-exclusive target. BMS has designated multiple immuno-oncology targets including programmed death 1 (PD-1) and has an option to select additional targets within five years from the effective date. In October 2018, BMS dosed the first patient in a Phase 1 study evaluating the safety, pharmacokinetics and pharmacodynamics of BMS-986179, an investigational anti-CD-73 antibody and ENHANZE technology. BMS plans to dose the first patients in a Phase 1 study of OPDIVO® nivolumab with ENHANZE in the fourth quarter of 2018 and a Phase 1 study of an undisclosed target in the first quarter of 2019.

Alexion Collaboration

In December 2017, we and Alexion entered into a collaboration and license agreement, under which Alexion has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Alexion’s portfolio of products directed at up to four targets. Targets may be selected on an exclusive basis. Alexion elected two targets on an exclusive basis, including a C5 complement inhibitor and has an option to select two additional targets within five years from the effective date. In August 2018, Alexion initiated a Phase 1 trial to study a next-generation subcutaneous formulation of ALXN1210 with ENHANZE technology.

For a further discussion of the collaboration agreements, refer to Note 4, Revenue.

Results of Operations

Three Months Ended September 30, 2018 Compared to Three Months Ended September 30, 2017

Royalties – Royalty revenue was $18.7 million for the three months ended September 30, 2018 compared to $17.1 million for the three months ended September 30, 2017. The increase was driven by higher sales of MabThera SC (RITUXAN HYCELA™ in the U.S.) by Roche. In general, we expect royalty revenue to increase in future periods reflecting expected increases in sales of collaboration products, although there may be periods with flat or declining royalty revenue as sales of products under collaborations vary.

Product Sales, Net – Product sales, net were as follows (in thousands):



	Three Months Ended
	September 30,
	2018		2017		Change
Sales of bulk rHuPH20:
Roche	$	159	$	5,947	$	(5,788	)
Baxalta	—		3,302		(3,302		)
Janssen	1,904		—		1,904
Other	498		499		(1		)
Sales of ENHANZE drug product	27		—		27
Sales of Hylenex	3,681		3,841		(160		)
Total product sales, net	$	6,269	$	13,589	$	(7,320	)

Product sales, net decreased in the three months ended September 30, 2018 compared to the same period in 2017, mainly due to a decrease in the sales of bulk rHuPH20 to Roche and Baxalta and a decrease in sales of Hylenex offset by an increase in sales of bulk rHuPH20 to Janssen. We expect that product sales of bulk rHuPH20 and ENHANZE drug product will fluctuate in future periods based on the needs of our collaborators. In 2016, we performed services for Roche to bring on-line a second contract manufacturing facility for bulk rHuPH20. This new facility may become the primary source for Roche of bulk rHuPH20 once it receives regulatory approval. As a result, we anticipated Roche would deplete their existing inventory of bulk rHuPH20 ahead of the transition to the new facility, which resulted in lower bulk rHuPH20 product sales during 2017 and year to date 2018, and will likely continue to result in lower bulk rHuPH20 product sales during the remainder of 2018. We expect that future product sales of Hylenex to be flat or experience modest growth, although there may be periods with declining revenue as we experience competition for market share.

Revenues Under Collaborative Agreements – Revenues under collaborative agreements were as follows (in thousands):



	Three Months Ended
	September 30,
	2018		2017		Change
Upfront license fees, license fees for the election of additional targets, license maintenance fees and other license fees and event-based payments:
Roche	—		30,831		(30,831		)
Baxalta	—		192		(192		)
	—		31,023		(31,023		)
Reimbursements for research and development services	577		2,000		(1,423		)
Total revenues under collaborative agreements	$	577	$	33,023	$	(32,446	)

Revenue from license fees decreased in the three months ended September 30, 2018, compared to the same period in 2017 mainly due to a $30.0 million upfront license fee for the Roche Collaboration recognized in the three months ended September 30,

2017 and no such revenue recognized in the three months ended September 30, 2018. Revenue from upfront licenses fees, license fees for the election of additional targets, license maintenance fees and other license fees and event-based payments vary from period to period based on our ENHANZE collaboration activity. We expect these revenues to continue to fluctuate in future periods based on our collaborators’ abilities to meet various clinical and regulatory milestones set forth in such agreements and our abilities to obtain new collaborative agreements.

Revenue from reimbursements for research and development services decreased in the three months ended September 30, 2018, compared to the same period in 2017 mainly due to a decrease in services provided to Roche related to work associated with bringing on-line a second contract manufacturing facility. The validation of the new facility was completed in the second quarter of 2017 and, therefore, we expect to continue to see a decrease in research and development service revenue from Roche going forward. Research and development services rendered by us on behalf of our collaborators are at the request of the collaborators; therefore, the amount and timing of future revenues related to reimbursable research and development services is uncertain.

Cost of Product Sales – Cost of product sales were $0.6 million for the three months ended September 30, 2018 compared to $8.3 million for the three months ended September 30, 2017. The decrease of $7.7 million in cost of product sales was mainly due to a decrease in sales of bulk rHuPH20 to Roche and Baxalta.

There were $1.7 million of costs of bulk rHuPH20 and ENHANZE drug product sales for the three months ended September 30, 2018 that were previously expensed as research and development. The estimated selling price of the zero-cost inventory of bulk rHuPH20 on hand as of September 30, 2018 was approximately $2.0 million. We expect to sell this inventory by the end of 2020. After this zero-cost inventory has been consumed, we expect the estimated cost of product sales to be approximately 83% of bulk rHuPH20 product sales revenue.

Research and Development – Research and development expenses consist of external costs, salaries and benefits and allocation of facilities and other overhead expenses related to research manufacturing, clinical trials, preclinical and regulatory activities. Research and development expenses incurred were as follows (in thousands):



	Three Months Ended
	September 30,
Programs	2018		2017		Change
PEGPH20	$	31,096	$	29,279	$	1,817
ENHANZE collaborations and rHuPH20 platform	4,040		4,081		(41		)
Other	404		633		(229		)
Total research and development expenses	$	35,540	$	33,993	$	1,547

Research and development expenses relating to our PEGPH20 programs for the three months ended September 30, 2018 increased by 6%, compared to the same period in 2017, primarily due to increased clinical trial activities. We expect PEGPH20 program expenses to increase in future periods reflecting expected increases in our PEGPH20 development activities.

Research and development expenses relating to our ENHANZE collaborations and our rHuPH20 platform for the three months ended September 30, 2018 decreased by 1%, compared to the same period in 2017, primarily due to a decrease in manufacturing expenses related to inventory with no alternative future use, partially offset by increased costs to support new partners and targets related to our ENHANZE collaboration activity. The rHuPH20 platform includes research, development and manufacturing expenses related to our proprietary rHuPH20 enzyme. These expenses were not designated to a specific program at the time the expenses were incurred.

Research and development expenses relating to other programs for the three months ended September 30, 2018 decreased by 36%, compared to the same period in 2017, due to a decrease in preclinical development of HTI-1511 and PEG-ADA2.

Selling, General and Administrative – Selling, general and administrative (SG&A) expenses were $14.9 million for the three months ended September 30, 2018 compared to $13.3 million for the three months ended September 30, 2017. The increase of $1.6 million, or 12%, was primarily due to an increase in market research expenses as we prepare for a potential commercial launch

of PEGPH20 and compensation expense including stock compensation. We expect SG&A expenses to increase moderately in future periods as our operations expand.

Interest Expense – Interest expense was $4.3 million for the three months ended September 30, 2018 compared to $5.5 million for the three months ended September 30, 2017. The decrease of $1.2 million was primarily due to a decrease in the Royalty-backed Loan balance.

Income Tax Expense – Income tax expense was zero for the three months ended September 30, 2018, compared to $0.6 million for the three months ended September 30, 2017, which was comprised of U.S. federal alternative minimum tax.

Nine Months Ended September 30, 2018 Compared to Nine Months Ended September 30, 2017

Royalties – Royalty revenue was $59.6 million for the nine months ended September 30, 2018 compared to $45.8 million for the nine months ended September 30, 2017. The increase was driven by higher sales of Herceptin SC and MabThera SC (RITUXAN HYCELA in the U.S.) by Roche and of HYQVIA by Baxalta. In general, we expect royalty revenue to increase in future periods reflecting expected increases in sales of collaboration products, although there may be periods with flat or declining royalty revenue as sales of products under collaborations vary.

Product Sales, Net – Product sales, net were as follows (in thousands):



	Nine Months Ended
	September 30,
	2018		2017		Change
Sales of bulk rHuPH20
Roche	$	2,290	$	16,543	$	(14,253	)
Baxalta	712		9,328		(8,616		)
Janssen	2,510		—		2,510
Other	998		954		44
Sales of ENHANZE drug product	162		—		162
Sales of Hylenex	10,881		10,978		(97		)
Total product sales, net	$	17,553	$	37,803	$	(20,250	)

Product sales, net decreased in the nine months ended September 30, 2018 compared to the same period in 2017, primarily due to a decrease in the sale of bulk rHuPH20 to Roche and Baxalta offset by an increase in sales of bulk rHuPH20 to Janssen. We expect that product sales of bulk rHuPH20 and ENHANZE drug product will fluctuate in future periods based on the needs of our collaborators. In 2016, we performed services for Roche to bring on-line a second contract manufacturing facility for bulk rHuPH20. This new facility may become the primary source for Roche of bulk rHuPH20 once it receives regulatory approval. As a result, we anticipated Roche would deplete their existing inventory of rHuPH20 ahead of the transition to the new facility, which resulted in lower bulk rHuPH20 product sales during 2017 and year to date 2018, and will likely continue to result in lower bulk rHuPH20 product sales during the remainder of 2018. We expect that future product sales of Hylenex to be flat or experience modest growth, although there may be periods with declining revenue as we experience competition for market share.

Revenues Under Collaborative Agreements – Revenues under collaborative agreements were as follows (in thousands):



	Nine Months Ended
	September 30,
	2018		2017		Change
Upfront license fees, license fees for the election of additional targets, license maintenance fees and amortization of deferred upfront and other license fees and event-based payments:
BMS	$	6,336	$	—	$	6,336
Alexion	5,000		—		5,000
Roche	1,000		32,496		(31,496		)
Baxalta	—		574		(574		)
	12,336		33,070		(20,734		)
Reimbursements for research and development services	2,098		10,337		(8,239		)
Total revenues under collaborative agreements	$	14,434	$	43,407	$	(28,973	)

Revenue from license fees decreased in the nine months ended September 30, 2018, compared to the same period in 2017 due to a $30.0 million upfront license fee for the Roche Collaboration recognized in the nine months ended September 30, 2017 compared to $12.3 million in upfront and milestone revenue for the BMS, Alexion and Roche Collaborations recognized in the nine months ended September 30, 2018. Revenue from upfront licenses fees, license fees for the election of additional targets, license maintenance fees and other license fees and event-based payments vary from period to period based on our ENHANZE collaboration activity. We expect these revenues to continue to fluctuate in future periods based on our collaborators’ abilities to meet various clinical and regulatory milestones set forth in such agreements and our abilities to obtain new collaborative agreements.

Revenue from reimbursements for research and development services decreased in the nine months ended September 30, 2018, compared to the same period in 2017 mainly due to a decrease in services provided to Roche related to the validation of a new manufacturing facility, partially offset by an increase in services provided to Janssen and Baxalta. The validation of the new Roche facility was completed in the second quarter of 2017 and, therefore, we expect to continue to see a decrease in research and development service revenue from Roche going forward. Research and development services rendered by us on behalf of our collaborators are at the request of the collaborators; therefore, the amount of future revenues related to reimbursable research and development services is uncertain. We expect the non-reimbursement revenues under our collaborative agreements to continue to fluctuate in future periods based on our collaborators’ abilities to meet various clinical and regulatory milestones set forth in such agreements and our abilities to obtain new collaborative agreements.

Cost of Product Sales – Cost of product sales were $4.5 million for the nine months ended September 30, 2018 compared to $23.7 million for the nine months ended September 30, 2017. The decrease of $19.2 million in cost of product sales was mainly due to a decrease in sales of bulk rHuPH20 to Roche and Baxalta. There were $2.3 million in costs of bulk rHuPH20 and ENHANZE drug product sales for the nine months ended September 30, 2018 that were previously expensed as research and development.



	Nine Months Ended
	September 30,
Programs	2018		2017		Change
PEGPH20	$	99,026	$	89,023	$	10,003
ENHANZE collaborations and rHuPH20 platform	13,309		13,305		4
Other	1,267		6,939		(5,672		)
Total research and development expenses	$	113,602	$	109,267	$	4,335

Research and development expenses relating to our PEGPH20 program for the nine months ended September 30, 2018 increased by 11%, compared to the same period in 2017, primarily due to increased clinical trial activities. We expect these expenses to increase in future periods reflecting expected increases in our PEGPH20 development activities.

Research and development expenses relating to our ENHANZE collaborations and our rHuPH20 platform for the nine months ended September 30, 2018 remained flat compared to the same period in 2017, primarily due to a decrease in manufacturing expenses related to Roche’s second contract manufacturing facility and a decrease in manufacturing inventory with no alternative future use, offset by increased costs to support new partners and targets related to our ENHANZE collaboration activity. The rHuPH20 platform includes research, development and manufacturing expenses related to our proprietary rHuPH20 enzyme. These expenses were not designated to a specific program at the time the expenses were incurred.

Research and development expenses relating to other programs for the nine months ended September 30, 2018 decreased by 82%, compared to the same period in 2017, due to a decrease in preclinical development of HTI-1511 and PEG-ADA2.

Selling, General and Administrative – SG&A expenses were $42.8 million for the nine months ended September 30, 2018 compared to $39.0 million for the nine months ended September 30, 2017. The increase of $3.8 million, or 10%, was primarily due to an increase in market research expense as we prepare for a potential commercial launch of PEGPH20 and compensation expense including stock compensation. We expect SG&A expenses to increase moderately in future periods as our operations expand.

Interest Expense – Interest expense was $14.3 million for the nine months ended September 30, 2018 compared to $16.5 million for the nine months ended September 30, 2017. The decrease of $2.2 million was primarily due to a decrease in the Royalty-backed Loan balance.

Income Tax Expense – Income tax expense was $0.2 million for the nine months ended September 30, 2018, which was comprised of state taxes, compared to $1.0 million for the nine months ended September 30, 2017, which was comprised of U.S. federal alternative minimum tax.

Liquidity and Capital Resources

Overview

Our principal sources of liquidity are our existing cash, cash equivalents and available-for-sale marketable securities. As of September 30, 2018, we had cash, cash equivalents and marketable securities of $364.4 million. We will continue to have significant cash requirements to support product development activities. The amount and timing of cash requirements and cash on hand will depend on the progress and success of our clinical development programs, regulatory and market acceptance, the resources we devote to research and commercialization activities and the achievement of various milestones and royalties under our existing collaborative agreements.

We believe that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. We expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborations and cash that we may raise through future transactions. We may raise cash through any one of the following financing vehicles: (i) the public offering of securities; (ii) new collaborative agreements; (iii) expansions or revisions to existing collaborative relationships; (iv) private financings; (v) other equity or debt financings; and/or (vi) monetizing assets.

In February 2017, we filed an automatic shelf registration statement on Form S-3 (Registration No. 333-216315) with the SEC, which allow us, from time to time, to offer and sell equity, debt securities and warrants to purchase any of such securities, either individually or in units. In May 2017, we completed an underwritten public offering pursuant to which we sold 11.5 million shares of common stock, generating $134.9 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. We may, in the future, offer and sell additional equity, debt securities and warrants to purchase any of such securities, either individually or in units to raise capital to fund the continued development of our product candidates, the commercialization of our products or for other general corporate purposes.

Our existing cash, cash equivalents and marketable securities may not be adequate to fund our operations until we become profitable, if ever. We cannot be certain that additional financing will be available when needed or, if available, financing will be obtained on favorable terms. If we are unable to raise sufficient funds, we may need to delay, scale back or eliminate some or all of our research and development programs, delay the launch of our product candidates, if approved, and/or restructure our operations. If we raise additional funds by issuing equity securities, substantial dilution to existing stockholders could result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations, the issuance of warrants that may ultimately dilute existing stockholders when exercised and covenants that may restrict our ability to operate our business.

Cash Flows

Operating Activities

Net cash used in operations was $60.0 million for the nine months ended September 30, 2018 compared to $19.2 million for the nine months ended September 30, 2017. The $40.8 million increase in utilization of cash in operations was mainly due to an increase in working capital for the nine months ended September 30, 2018 compared to the corresponding period in the prior year.

Investing Activities

Net cash used in investing activities was $8.3 million for the nine months ended September 30, 2018 compared to $14.7 million for the nine months ended September 30, 2017. The decrease in net cash used in investing activities was primarily due to an increase in proceeds from maturities of marketable securities for the nine months ended September 30, 2018.

Financing Activities

Net cash used in financing activities was $45.4 million for the nine months ended September 30, 2018, compared to net cash provided by financing activities of $131.6 million for the nine months ended September 30, 2017, mainly due to $134.9 million in net proceeds from the sale of common stock in a public offering in May 2017 compared to no sale of common stock in a public offering occurring and increased amount of repayments of long-term debt in the nine months ended September 30, 2018.

Long-Term Debt

Royalty-backed Loan

In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (Halozyme Royalty), we received a $150 million loan (the Royalty-backed Loan) pursuant to a credit agreement (the Credit Agreement) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the Royalty-backed Lenders). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (Collaboration Agreements). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the Royalty Payments). The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of September 30, 2018 was 10.25%. The outstanding balance of the Royalty-backed Loan as of September 30, 2018 was $101.0 million net of unamortized debt discount of $0.4 million.

The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments were required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first, to pay interest and second, to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps.

The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050. Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan.

Oxford and SVB Loan and Security Agreement

In June 2016, we entered into a Loan and Security Agreement (the Loan Agreement) with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB) (collectively, the Lenders), providing a senior secured loan facility of up to an aggregate principal amount of $70 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we had the option to draw during the second quarter of 2017 and did not exercise. The proceeds were partially used to pay the outstanding principal and final payment owed on a previous loan agreement with the Lenders. The remaining proceeds are being used for working capital and general business requirements. The Loan Agreement repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provides for a final payment equal to 5.50% of the initial $55 million principal amount. The final payment is due when the Loan Agreement becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the Loan Agreement in full, subject to a prepayment fee of 2% in the first year and 1% in the second year of the term loan. The Loan Agreement carries a fixed interest rate of 8.25%. The outstanding term loan balance was $45.5 million as of September 30, 2018 net of unamortized debt discount of $1.2 million.

The Loan Agreement is secured by substantially all of the assets of the Company and its subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc. and any intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our domestic subsidiary.

The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of the Lender’s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan. In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.

Off-Balance Sheet Arrangements

As of September 30, 2018, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we did not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities.

As described in our 2017 Form 10-K, the most critical accounting policies and estimates upon which our condensed consolidated financial statements were prepared were those relating to revenue recognition, debt classification, stock compensation and research and development expenses - clinical trials. We have reviewed our policies and estimates and determined that these remain the most critical accounting policies and estimates for the nine months ended September 30, 2018. We have updated our revenue recognition policies in conjunction with our adoption of ASC 606 as further described in Note 2 to the accompanying financial statements. Readers should refer to our 2017 Form 10-K under “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates” and Note 1 to the accompanying financial statements for descriptions of these policies and estimates.

Recent Accounting Pronouncements

Refer to Note 2, Summary of Significant Accounting Policies, of our condensed consolidated financial statements for a discussion of recent accounting pronouncements and their effect, if any.

Risk Factors

Risks Related To Our Business

We have generated only limited revenues from product sales to date; we have a history of net losses and negative cash flows, and we may never achieve or maintain profitability.

Relative to expenses incurred in our operations, we have generated only limited revenues from product sales, royalties, licensing fees, milestone payments, bulk rHuPH20 supply payments and research reimbursements to date and we may never generate sufficient revenues from future product sales, licensing fees and milestone payments to offset expenses. Even if we ultimately do achieve significant revenues from product sales, royalties, licensing fees, research reimbursements, bulk rHuPH20 supply payments and/or milestone payments, we expect to incur significant operating losses over the next few years and we may never become profitable on an extended basis. Through September 30, 2018, we have incurred aggregate net losses of $529.3 million.

If our product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.

Approval from the FDA or equivalent health authorities is necessary to manufacture and market pharmaceutical products in the U.S. and the other countries in which we anticipate doing business have similar requirements. The process for obtaining FDA and other regulatory approvals is extensive, time-consuming, risky and costly, and there is no guarantee that the FDA or other regulatory bodies will approve any applications that may be filed with respect to any of our product candidates, or that the timing of any such approval will be appropriate for the desired product launch schedule for a product candidate. We and our collaborators attempt to provide guidance as to the timing for the filing and acceptance of such regulatory approvals, but such filings and approvals may not occur when we or our collaborators expect, or at all. The FDA or other foreign regulatory agency may refuse or delay approval of our product candidates for failure to collect sufficient clinical or animal safety data and require us or our collaborators to conduct additional clinical or animal safety studies which may cause lengthy delays and increased costs to our programs. For example, the approval of Baxalta’s HYQVIA BLA in the U.S. was delayed until we and Baxalta provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was approved by the FDA in September 2014, we cannot assure you that they will not arise and have an adverse impact on future development of products which include rHuPH20, future sales of Hylenex recombinant, our ability to enter into collaborations, or be raised by the FDA or other health authorities in connection with testing or approval of products including rHuPH20.

We and our collaborators may not be successful in obtaining approvals for any additional potential products in a timely manner, or at all. Refer to the risk factor titled “Our proprietary and collaboration product candidates or companion diagnostic assays may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns” for additional information relating to the approval of product candidates.

Additionally, even with respect to products which have been approved for commercialization, in order to continue to manufacture and market pharmaceutical products, we or our collaborators must maintain our regulatory approvals. If we or any of our collaborators are unsuccessful in maintaining our regulatory approvals, our ability to generate revenues would be adversely affected.

We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.

We may need to raise additional capital in the future to continue the development of our product candidates or for other current corporate purposes. Our current cash reserves and expected revenues during the next few years will not be sufficient for us to continue the development of our proprietary product candidates, to fund general operations and conduct our business at the level desired. In addition, if we engage in acquisitions of companies, products or technologies in order to execute our business strategy, we may need to raise additional capital. We may raise additional capital in the future through one or more financing vehicles that may be available to us including (i) the public offering of securities; (ii) new collaborative agreements; (iii) expansions or revisions to existing collaborative relationships; (iv) private financings; (v) other equity or debt financings; and/or (vi) monetizing assets.

In view of our stage of development, business prospects, the nature of our capital structure and general market conditions, if we are required to raise additional capital in the future, the additional financing may not be available on favorable terms, or at all. If additional capital is not available on favorable terms when needed, we will be required to raise capital on adverse terms or significantly reduce operating expenses through the restructuring of our operations or deferral of one or more product development programs. If we raise additional capital, a substantial number of additional shares may be issued, which may negatively affect our stock price and these additional shares will dilute the ownership interest of our current investors.

Use of our product candidates or those of our collaborators could be associated with side effects or adverse events.

As with most pharmaceutical products, use of our product candidates or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our product candidates or those of our collaborators may be observed at any time, including in clinical trials or when a product is commercialized, and any such side effects or adverse events may negatively affect our or our collaborators’ ability to obtain or maintain regulatory approval or market our product candidates. Side effects such as toxicity or other safety issues associated with the use of our product candidates or those of our collaborators could require us or our collaborators to perform additional studies or halt development or commercialization of these product candidates or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our pharmaceutical product candidates which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition. For example, in April 2014, a clinical hold was placed on patient enrollment and dosing of PEGPH20 in Study HALO-202 as a result of a possible difference in the TE event rate that had been observed at that time in the trial between the group of patients treated with PEGPH20 versus the group of patients treated without PEGPH20. The clinical hold was lifted by the FDA in June 2014, and we have completed enrollment and continue to monitor ongoing patients who remain either on treatment or in follow-up on Study HALO-202 under a revised clinical protocol.

If our contract manufacturers are unable to manufacture and supply to us bulk rHuPH20 or other raw materials in the quantity and quality required by us or our collaborators for use in our products and product candidates, our product development and commercialization efforts could be delayed or stopped and our collaborations could be damaged.

We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Catalent Indiana LLC (formerly Cook Pharmica LLC) (Catalent) to produce bulk rHuPH20. These manufacturers each produce bulk rHuPH20 under cGMP for clinical uses. Catalent currently produces bulk rHuPH20 for use in Hylenex recombinant, product candidates and collaboration product candidates. Avid currently produces bulk rHuPH20 for use in collaboration products. In addition to supply obligations, Avid and Catalent will also provide support for the chemistry, manufacturing and controls sections for FDA and other regulatory filings. We rely on their ability to successfully manufacture these batches according to product specifications. If either Avid or Catalent: (i) is unable to retain its status as an FDA approved manufacturing facility; (ii) is unable to otherwise successfully scale up bulk rHuPH20 production to meet corporate or regulatory authority quality standards; or (iii) fails to manufacture and supply bulk rHuPH20 in the quantity and quality required by us or our collaborators for use in our proprietary and collaboration products and product candidates for any other reason, our business will be adversely affected. In addition, a significant change in such parties’ or other third party manufacturers’ business or financial condition could adversely

affect their abilities to fulfill their contractual obligations to us. We have not established, and may not be able to establish, favorable arrangements with additional bulk rHuPH20 manufacturers and suppliers of the ingredients necessary to manufacture bulk rHuPH20 should the existing manufacturers and suppliers become unavailable or in the event that our existing manufacturers and suppliers are unable to adequately perform their responsibilities. We have attempted to mitigate the impact of a potential supply interruption through the establishment of excess bulk rHuPH20 inventory where possible, but there can be no assurances that this safety stock will be maintained or that it will be sufficient to address any delays, interruptions or other problems experienced by Avid and/or Catalent. Any delays, interruptions or other problems regarding the ability of Avid and/or Catalent to supply bulk rHuPH20 or the ability of other third party manufacturers, to supply other raw materials or ingredients necessary to produce our products on a timely basis could: (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of proprietary or collaboration product candidates; (ii) delay or prevent the effective commercialization of proprietary or collaboration products; and/or (iii) cause us to breach contractual obligations to deliver bulk rHuPH20 to our collaborators. Such delays would likely damage our relationship with our collaborators, and they would have a material adverse effect on royalties and thus our business and financial condition.

If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if a key collaboration agreement, is terminated for any reason, our business could significantly suffer.

We have entered into multiple collaboration agreements under which we may receive significant future payments in the form of milestone payments, target designation fees, maintenance fees and royalties. We are dependent on our collaborators to develop and commercialize product candidates subject to our collaborations in order for us to realize any financial benefits from these collaborations. Our collaborators may not devote the attention and resources to such efforts that we would ourselves, change their clinical development plans, promotional efforts or simultaneously develop and commercialize products in competition to those products we have licensed to them. Any of these actions could not be visible to us immediately and could negatively impact the benefits and revenue we receive from such collaboration. In addition, in the event that a party fails to perform under a key collaboration agreement, or if a key collaboration agreement is terminated, the reduction in anticipated revenues could delay or suspend our product development activities for some of our product candidates, as well as our commercialization efforts for some or all of our products. Specifically, the termination of a key collaboration agreement by one of our collaborators could materially impact our ability to enter into additional collaboration agreements with new collaborators on favorable terms, if at all. In certain circumstances, the termination of a key collaboration agreement would require us to revise our corporate strategy going forward and reevaluate the applications and value of our technology.

Most of our current proprietary and collaboration products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential collaborations, as well as proprietary programs.

rHuPH20 is a key technological component of ENHANZE technology and our most advanced proprietary and collaboration products and product candidates, including the current and future products and product candidates under our ENHANZE collaborations, our PEGPH20 program, and Hylenex recombinant. If there is an adverse development for rHuPH20 (e.g., an adverse regulatory determination relating to rHuPH20, if we are unable to obtain sufficient quantities of rHuPH20, if we are unable to obtain or maintain material proprietary rights to rHuPH20 or if we discover negative characteristics of rHuPH20), multiple areas of our business, including current and potential collaborations, as well as proprietary programs would be substantially impacted. For example, elevated anti-rHuPH20 antibody titers were detected in the registration trial for Baxalta’s HYQVIA product as well as in a former collaborator’s product in a Phase 2 clinical trial with rHuPH20, but have not been associated, in either case, with any adverse events. We monitor for antibodies to rHuPH20 in our collaboration and proprietary programs, and although we do not believe at this time that the incidence of non-neutralizing anti-rHuPH20 antibodies in either the HYQVIA program or the former collaborator’s program will have a significant impact on our other proprietary and other collaboration product candidates, there can be no assurance that there will not be other such occurrences in the foregoing programs or our other programs or that concerns regarding these antibodies will not also be raised by the FDA or other health authorities in the future, which could result in delays or discontinuations of our development or commercialization activities or deter entry into additional collaborations with third parties.

We routinely evaluate, and may modify, our business strategy and our strategic focus to only a few fields or applications of our technology which may increase the risk for potential negative impact from adverse developments.

We routinely evaluate our business strategy, and may modify this strategy in the future in light of our assessment of unmet medical needs, growth potential, resource requirements, regulatory issues, competition, risks and other factors. As a result of these strategic evaluations, we may focus our resources and efforts on one or a few programs or fields and may suspend or reduce our efforts on other programs and fields. For example, in the third quarter of 2014, we decided to focus our resources on advancing PEGPH20 and expanding utilization of our ENHANZE technology. While we believe these are applications with the greatest potential value, we have reduced the diversification of our programs and increased our dependence on the success of the areas we are pursuing. By focusing on one or a few areas, we increase the potential impact on us if one of those programs or product candidates does not successfully complete clinical trials, achieve commercial acceptance or meet expectations regarding sales and revenue. Our decision to focus on one or a few programs may also reduce the value of programs that are no longer within our principal strategic focus, which could impair our ability to pursue collaborations or other strategic alternatives for those programs we are not pursuing.

Our proprietary and collaboration product candidates or companion diagnostic assays may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns.

Clinical testing of pharmaceutical products is a long, expensive and uncertain process, and the failure or delay of a clinical trial can occur at any stage, including the patient enrollment stage. Even if initial results of preclinical and nonclinical studies or clinical trial results are promising, we or our collaborators may obtain different results in subsequent trials or studies that fail to show the desired levels of safety and efficacy, or we may not, or our collaborators may not, obtain applicable regulatory approval for a variety of other reasons. Preclinical, nonclinical, and clinical trials for any of our proprietary or collaboration product candidates or development of any collaboration companion diagnostic assays could be unsuccessful, which would delay or preclude regulatory approval and commercialization of the product candidates or companion diagnostic assays. In the U.S. and other jurisdictions, regulatory approval can be delayed, limited or not granted for many reasons, including, among others:


•	during the course of clinical studies, the final data may differ from initial reported data, and clinical results may not meet prescribed endpoints for the studies or otherwise provide sufficient data to support the efficacy of our product candidates;

•

clinical and nonclinical test results may reveal side effects, adverse events or unexpected safety issues associated with the use of our product candidates; for example, in April 2014, a clinical hold was placed on patient enrollment and dosing of PEGPH20 in Study HALO-202 as a result of a possible difference in the TE event rate that had been observed at that time in the trial between the group of patients treated with PEGPH20 versus the group of patients treated without PEGPH20. The clinical hold was lifted by the FDA in June 2014, and we have completed enrollment and continue to monitor patients who remain either on treatment or in follow-up on Study HALO-202 under a revised clinical protocol;


•	completion of clinical trials may be delayed for a variety of reasons including the amount of time it may take to identify and enroll patients with high levels of HA in our target population, and the ability to procure drug supply required in clinical trial protocols;


•	clinical trial results may be negatively impacted if our companion diagnostic does not accurately identify patients most likely to respond to the therapy, including the level of HA in patients;


•	third parties, such as contract research organizations, upon whom we rely to help conduct and manage our clinical trials may not perform satisfactorily, fulfill their contractual obligations to us, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols;


•	regulatory review may not find a product candidate safe or effective enough to merit either continued testing or final approval;


•	regulatory review may not find that the data from preclinical testing and clinical trials justifies approval;


•	regulatory authorities may require that we change our studies or conduct additional studies which may significantly delay or make continued pursuit of approval commercially unattractive;


•	a regulatory agency may reject our trial data or disagree with our interpretations of either clinical trial data or applicable regulations;


•	a regulatory agency may approve only a narrow use of our product or may require additional safety monitoring and reporting through Risk Evaluation and Mitigation Strategies or conditions to assure safe use programs;


•	the cost of clinical trials required for product approval may be greater than what we originally anticipate, and we may decide to not pursue regulatory approval for such a product;


•	a regulatory agency may not approve our manufacturing processes or facilities, or the processes or facilities of our collaborators, our contract manufacturers or our raw material suppliers;


•	a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities, or the existing processes or facilities of our collaborators, our contract manufacturers or our raw material suppliers;


•	a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new regulations or raise new issues or concerns late in the approval process; or


•	a product candidate may be approved only for indications that are narrow or under conditions that place the product at a competitive disadvantage, which may limit the sales and marketing activities for such product candidate or otherwise adversely impact the commercial potential of a product.

If a proprietary or collaboration product candidate or companion diagnostic assay is not approved in a timely fashion or obtained on commercially viable terms, or if development of any product candidate or a companion diagnostic assay is terminated due to difficulties or delays encountered in the regulatory approval process, it could have a material adverse impact on our business, and we would become more dependent on the development of other proprietary or collaboration product candidates and/or our ability to successfully acquire other products and technologies. There can be no assurances that any proprietary or collaboration product candidate or companion diagnostic assay will receive regulatory approval in a timely manner, or at all. There can be no assurance that we will be able to gain clarity as to the FDA’s requirements or that the requirements may be satisfied in a commercially feasible way, in which case our ability to enter into collaborations with third parties or explore other strategic alternatives to exploit this opportunity will be limited or may not be possible.

We anticipate that certain proprietary and collaboration products will be marketed, and perhaps manufactured, in foreign countries. The process of obtaining regulatory approvals in foreign countries is subject to delay and failure for the reasons set forth above, as well as for reasons that vary from jurisdiction to jurisdiction. The approval process varies among countries and jurisdictions and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. Foreign regulatory agencies may not provide approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.

Our third party collaborators are responsible for providing certain proprietary materials that are essential components of our collaboration products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these collaboration products and product candidates and/or damage our collaborations.

Our development and commercialization collaborators are responsible for providing certain proprietary materials that are essential components of our collaboration products and product candidates. For example, Roche is responsible for producing the Herceptin and MabThera required for its subcutaneous products and Baxalta is responsible for producing the GAMMAGARD LIQUID for its product HYQVIA. If a collaborator, or any applicable third party service provider of a collaborator, encounters difficulties in the manufacture, storage, delivery, fill, finish or packaging of the collaboration product or product candidate or component of such product or product candidate, such difficulties could (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of collaboration product candidates; and/or (ii) delay or prevent the effective commercialization of collaboration products. Such delays could have a material adverse effect on our business and financial condition.

We rely on third parties to manufacture, prepare, fill, finish and package our products and product candidates, and if such third parties should fail to perform, our commercialization and development efforts for our products and product candidates could be delayed or stopped.

We rely on third parties to manufacture, prepare, fill, finish, package, store and ship our products and product candidates on our behalf. If we are unable to locate third parties to perform these functions on terms that are acceptable to us, or if the third parties we identify fail to perform their obligations, the progress of clinical trials could be delayed or even suspended and the commercialization of approved product candidates could be delayed or prevented. In addition, we are scaling up our manufacturing of PEGPH20 with third party suppliers to support additional clinical trials, including the Phase 3 trial, and ultimately, if approved, potential commercial supply. If our contract manufacturers are unable to successfully manufacture and supply PEGPH20, the progress of our clinical trials could be delayed or halted for a period of time.

If we are unable to sufficiently develop our sales, marketing and distribution capabilities or enter into successful agreements with third parties to perform these functions, we will not be able to fully commercialize our products.

We may not be successful in marketing and promoting our approved product, Hylenex recombinant, or any other products we develop or acquire in the future. Our sales, marketing and distribution capabilities are very limited. In order to commercialize any products successfully, we must internally develop substantial sales, marketing and distribution capabilities or establish collaborations or other arrangements with third parties to perform these services. We do not have extensive experience in these areas, and we may not be able to establish adequate in-house sales, marketing and distribution capabilities or engage and effectively manage relationships with third parties to perform any or all of such services. To the extent that we enter into co-promotion or other licensing arrangements, our product revenues are likely to be lower than if we directly marketed and sold our products, and any revenues we receive will depend upon the efforts of third parties, whose efforts may not meet our expectations or be successful. These third parties would be largely responsible for the speed and scope of sales and marketing efforts, and may not dedicate the resources necessary to maximize product opportunities. Our ability to cause these third parties to increase the speed and scope of their efforts may also be limited. In addition, sales and marketing efforts could be negatively impacted by the delay or failure to obtain additional supportive clinical trial data for our products. In some cases, third party collaborators are responsible for conducting these additional clinical trials, and our ability to increase the efforts and resources allocated to these trials may be limited.

If we or our collaborators fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could significantly harm our business.

Any approved products, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for these products, are subject to continual requirements and review by the FDA, state and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer and the manufacturing facilities to continual review and periodic inspections. We, our collaborators and our respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of drug products, required submissions of safety and other post-market information and reports, registration requirements, cGMP regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our collaborators and our respective contractors, suppliers and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.

In particular, regulatory requirements applicable to pharmaceutical products make the substitution of suppliers and manufacturers costly and time consuming. We have minimal internal manufacturing capabilities and are, and expect to be in the future, entirely dependent on contract manufacturers and suppliers for the manufacture of our products and for their active and other ingredients. The disqualification of these manufacturers and suppliers through their failure to comply with regulatory requirements could negatively impact our business because the delays and costs in obtaining and qualifying alternate suppliers (if such alternative suppliers are available, which we cannot assure) could delay clinical trials or otherwise inhibit our ability to bring approved products to market, which would have a material adverse effect on our business and financial condition. Likewise, if we, our collaborators and our respective contractors, suppliers and vendors involved in sales and promotion of our products do

not comply with applicable laws and regulations, for example off-label or false or misleading promotion, this could materially harm our business and financial condition.

Failure to comply with regulatory requirements may result in any of the following:


•	restrictions on our products or manufacturing processes;


•	warning letters;


•	withdrawal of the products from the market;


•	voluntary or mandatory recall;


•	fines;


•	suspension or withdrawal of regulatory approvals;


•	suspension or termination of any of our ongoing clinical trials;


•	refusal to permit the import or export of our products;


•	refusal to approve pending applications or supplements to approved applications that we submit;


•	product seizure;


•	injunctions; or


•	imposition of civil or criminal penalties.

We currently have significant debt and failure by us to fulfill our obligations under the applicable loan agreements may cause the repayment obligations to accelerate.

In December 2015, our subsidiaries, Halozyme, Inc. (Halozyme) and Halozyme Royalty LLC (Halozyme Royalty) entered into a credit agreement (the Credit Agreement) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the Royalty-backed Lenders) pursuant to which we borrowed $150 million through Halozyme Royalty (the Royalty-backed Loan). The Royalty-backed Loan will be repaid primarily from a specified percentage of the royalty payments we receive under our collaboration agreements with Roche and Baxalta (the Royalty Payments).

The obligations of Halozyme Royalty under the Credit Agreement to repay the Royalty-backed Loan may be accelerated upon the occurrence of certain events of default under the Credit Agreement, including but not limited to:


•	if any payment of principal is not made within three days of when such payment is due and payable or otherwise made in accordance with the terms of the Credit Agreement;


•	if any representations or warranties made in the Credit Agreement or any other transaction document proves to be incorrect or misleading in any material respect when made;


•	if there occurs a default in the performance of affirmative and negative covenants set forth in the Credit Agreement or any other transaction document;


•	the failure by either Baxalta or Roche to pay material amounts owed under our collaboration agreements because of an actual breach or default by us under the collaboration agreements;


•	the voluntary or involuntary commencement of bankruptcy proceedings by either Halozyme or Halozyme Royalty and other insolvency related defaults;


•	any materially adverse effect on the binding nature of any of the transaction documents or the collaboration agreements with Baxalta and Roche; or


•	Halozyme ceases to own, of record and beneficially, 100% of the equity interests in Halozyme Royalty.

The Credit Agreement also contains covenants applicable to Halozyme and Halozyme Royalty, including certain visitation, information and audits rights granted to the collateral agent and the lenders and restrictions on the conduct of business, including continued compliance with the Baxalta and Roche collaboration agreements and specified affirmative actions regarding the escrow account established to facilitate payment of Royalty Payments to the Royalty-backed Lenders or other specified parties. The Credit Agreement also contains covenants solely applicable to Halozyme Royalty, including restrictions on incurring indebtedness, creating or granting liens, making acquisitions and making specified restricted payments. These covenants could make it more difficult for us to execute our business strategy.

In connection with the Royalty-backed Loan, Halozyme Royalty granted a first priority lien and security interest (subject only to permitted liens) in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the Royalty Payments.

In June 2016, we entered into a Loan and Security Agreement (the Loan Agreement) with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB) (collectively, the Lenders), providing a senior secured loan facility of up to an aggregate principal amount of $70 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we had the option to draw during the second quarter of 2017 and did not exercise. The initial proceeds were partially used to pay the outstanding principal and final payment owed on our previous loan agreement with the Lenders. The remaining proceeds are to be used for working capital and general business requirements. The Loan Agreement is secured by substantially all of the assets of the Company and its subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; and enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our domestic subsidiary. Complying with these covenants may make it more difficult for us to successfully execute our business strategy.

Our ability to make payments on our debt will depend on our future operating performance and ability to generate cash and may also depend on our ability to obtain additional debt or equity financing. We will need to use cash to pay principal and interest on our debt, thereby reducing the funds available to fund our research and development programs, strategic initiatives and working capital requirements. If we are unable to generate sufficient cash to service our debt obligation, an event of default may occur. In the event of default by us under the Credit Agreement or the Loan Agreement, the lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Credit Agreement or the Loan Agreement which could harm our financial condition.

If proprietary or collaboration product candidates are approved for marketing but do not gain market acceptance, our business may suffer and we may not be able to fund future operations.

Assuming that our proprietary or collaboration product candidates obtain the necessary regulatory approvals for commercial sale, a number of factors may affect the market acceptance of these existing product candidates or any other products which are developed or acquired in the future, including, among others:


•	the price of products relative to other therapies for the same or similar treatments;


•	the perception by patients, physicians and other members of the health care community of the effectiveness and safety of these products for their prescribed treatments relative to other therapies for the same or similar treatments;


•	our ability to fund our sales and marketing efforts and the ability and willingness of our collaborators to fund sales and marketing efforts;


•	the degree to which the use of these products is restricted by the approved product label;


•	the effectiveness of our sales and marketing efforts and the effectiveness of the sales and marketing efforts of our collaborators;


•	the introduction of generic competitors; and


•	the extent to which reimbursement for our products and related treatments will be available from third party payors including government insurance programs (Medicare and Medicaid) and private insurers.

If these products do not gain market acceptance, we may not be able to fund future operations, including the development or acquisition of new product candidates and/or our sales and marketing efforts for our approved products, which would cause our business to suffer.

In addition, our proprietary and collaboration product candidates will be restricted to the labels approved by FDA and applicable regulatory bodies, and these restrictions may limit the marketing and promotion of the ultimate products. If the approved labels are restrictive, the sales and marketing efforts for these products may be negatively affected.

Developing and marketing pharmaceutical products for human use involves significant product liability risks for which we currently have limited insurance coverage.

The testing, marketing and sale of pharmaceutical products involves the risk of product liability claims by consumers and other third parties. Although we maintain product liability insurance coverage, product liability claims can be high in the pharmaceutical industry, and our insurance may not sufficiently cover our actual liabilities. If product liability claims were to be made against us, it is possible that the liabilities may exceed the limits of our insurance policy, or our insurance carriers may deny, or attempt to deny, coverage in certain instances. If a lawsuit against us is successful, then the lack or insufficiency of insurance coverage could materially and adversely affect our business and financial condition. Furthermore, various distributors of pharmaceutical products require minimum product liability insurance coverage before purchase or acceptance of products for distribution. Failure to satisfy these insurance requirements could impede our ability to achieve broad distribution of our proposed products, and higher insurance requirements could impose additional costs on us. In addition, since many of our collaboration product candidates include the pharmaceutical products of a third party, we run the risk that problems with the third party pharmaceutical product will give rise to liability claims against us.

Our inability to attract, hire and retain key management and scientific personnel could negatively affect our business.

Our success depends on the performance of key management and scientific employees with relevant experience. For example, in order to pursue our current business strategy, we will need to recruit and retain personnel experienced in oncology drug development which is a highly competitive market for talent. We depend substantially on our ability to hire, train, motivate and retain high quality personnel, especially our scientists and management team. Particularly in view of the small number of employees on our staff to cover our numerous programs and key functions, if we are unable to retain existing personnel or identify or hire additional personnel, we may not be able to research, develop, commercialize or market our products and product candidates as expected or on a timely basis and we may not be able to adequately support current and future alliances with strategic collaborators. Our use of domestic and international third-party contractors, consultants and staffing agencies also subjects us to potential co-employment liability claims.

Furthermore, if we were to lose key management personnel, we would likely lose some portion of our institutional knowledge and technical know-how, potentially causing a substantial delay in one or more of our development programs until adequate replacement personnel could be hired and trained. We currently have a severance policy applicable to all employees and a change in control policy applicable to senior executives.

We do not have key man life insurance policies on the lives of any of our employees.

Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.

Our operations, including laboratories, offices and other research facilities, are located in four buildings in San Diego, California. In addition, we have a satellite office in South San Francisco, California. We depend on our facilities and on our collaborators, contractors and vendors for the continued operation of our business. Natural disasters or other catastrophic events, interruptions in the supply of natural resources, political and governmental changes, wildfires and other fires, floods, explosions, actions of animal rights activists, earthquakes and civil unrest could disrupt our operations or those of our collaborators, contractors and vendors. Even though we believe we carry commercially reasonable business interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we may suffer losses as a result of business interruptions that exceed the coverage available under our and our contractors’ insurance policies or for which we or our contractors do not have coverage. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our research and development programs.

If we or our collaborators do not achieve projected development, clinical, regulatory or sales goals in the timeframes we publicly announce or otherwise expect, the commercialization of our products and the development of our product candidates may be delayed and, as a result, our stock price may decline, and we may face lawsuits relating to such declines.

From time to time, we or our collaborators may publicly articulate the estimated timing for the accomplishment of certain scientific, clinical, regulatory and other product development goals. The accomplishment of any goal is typically based on numerous assumptions, and the achievement of a particular goal may be delayed for any number of reasons both within and outside of our control. If scientific, regulatory, strategic or other factors cause us to not meet a goal, regardless of whether that goal has been publicly articulated or not, our stock price may decline rapidly. For example, the announcement in April 2014 of the temporary halting of our Phase 2 clinical trial for PEGPH20 caused a rapid decline in our stock price. Stock price declines may also trigger direct or derivative shareholder lawsuits. As with any litigation proceeding, the eventual outcome of any legal action is difficult to predict. If any such lawsuits occur, we will incur expenses in connection with the defense of these lawsuits, and we may have to pay substantial damages or settlement costs in connection with any resolution thereof. Although we have insurance coverage against which we may claim recovery against some of these expenses and costs, the amount of coverage may not be adequate to cover the full amount or certain expenses and costs may be outside the scope of the policies we maintain. In the event of an adverse outcome or outcomes, our business could be materially harmed from depletion of cash resources, negative impact on our reputation, or restrictions or changes to our governance or other processes that may result from any final disposition of the lawsuit. Moreover, responding to and defending pending litigation significantly diverts management’s attention from our operations.

In addition, the consistent failure to meet publicly announced milestones may erode the credibility of our management team with respect to future milestone estimates.

Future acquisitions could disrupt our business and harm our financial condition.

In order to augment our product pipeline or otherwise strengthen our business, we may decide to acquire additional businesses, products and technologies. As we have limited experience in evaluating and completing acquisitions, our ability as an organization to make such acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including, but not limited to, the following:


•	we may have to issue convertible debt or equity securities to complete an acquisition, which would dilute our stockholders and could adversely affect the market price of our common stock;


•	an acquisition may negatively impact our results of operations because it may require us to amortize or write down amounts related to goodwill and other intangible assets, or incur or assume substantial debt or liabilities, or it may cause adverse tax consequences, substantial depreciation or deferred compensation charges;


•	we may encounter difficulties in assimilating and integrating the business, products, technologies, personnel or operations of companies that we acquire;


•	certain acquisitions may impact our relationship with existing or potential collaborators who are competitive with the acquired business, products or technologies;


•	acquisitions may require significant capital infusions and the acquired businesses, products or technologies may not generate sufficient value to justify acquisition costs;


•	we may take on liabilities from the acquired company such as debt, legal liabilities or business risk which could be significant;


•	an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;


•	acquisitions may involve the entry into a geographic or business market in which we have little or no prior experience; and


•	key personnel of an acquired company may decide not to work for us.

If any of these risks occurred, it could adversely affect our business, financial condition and operating results. There is no assurance that we will be able to identify or consummate any future acquisitions on acceptable terms, or at all. If we do pursue any acquisitions, it is possible that we may not realize the anticipated benefits from such acquisitions or that the market will not view such acquisitions positively.

Security breaches may disrupt our operations and harm our operating results.

We and our partners are subject to increasingly sophisticated attempts to gain unauthorized access to our information technology storage and access systems and are devoting resources to protect against such intrusion. The wrongful use, theft, deliberate sabotage or any other type of security breach with respect to any of our or any of our vendors and partners’ information technology storage and access systems could result in the disruption of our ability to use such systems or disclosure or dissemination of our or our partners’ proprietary and confidential information that is electronically stored, including research or clinical data and information regarding strategic initiatives, resulting in a material adverse impact on our business, operating results and financial condition. Our security and data recovery measures may not be adequate to protect against computer viruses, break-ins, and similar disruptions from unauthorized tampering with our electronic storage systems. Furthermore, any physical break-in or trespass of our facilities could result in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data or damage to our research and development equipment and assets. Such adverse effects could be material and irrevocable to our business, operating results and financial condition.

Risks Related To Ownership of Our Common Stock

Our stock price is subject to significant volatility.

We participate in a highly dynamic industry which often results in significant volatility in the market price of common stock irrespective of company performance. The high and low sales prices of our common stock during the twelve months ended September 30, 2018 were $21.48 and $16.06, respectively. We expect our stock price to continue to be subject to significant volatility and, in addition to the other risks and uncertainties described elsewhere in this Quarterly Report on Form 10-Q and all other risks and uncertainties that are either not known to us at this time or which we deem to be immaterial, any of the following factors may lead to a significant drop in our stock price:


•	the presence of competitive products to those being developed by us;


•	failure (actual or perceived) of our collaborators to devote attention or resources to the development or commercialization of product candidates licensed to such collaborator;


•	a dispute regarding our failure, or the failure of one of our third party collaborators, to comply with the terms of a collaboration agreement;


•	the termination, for any reason, of any of our collaboration agreements;


•	the sale of common stock by any significant stockholder, including, but not limited to, direct or indirect sales by members of management or our Board of Directors;


•	the resignation, or other departure, of members of management or our Board of Directors;


•	general negative conditions in the healthcare industry;


•	general negative conditions in the financial markets;


•	the cost associated with obtaining regulatory approval for any of our proprietary or collaboration product candidates;


•	the failure, for any reason, to secure or defend our intellectual property position;


•	for those products that are not yet approved for commercial sale, the failure or delay of applicable regulatory bodies to approve such products;


•	identification of safety or tolerability issues;


•	failure of clinical trials to meet efficacy endpoints;


•	suspensions or delays in the conduct of clinical trials or securing of regulatory approvals;


•	adverse regulatory action with respect to our and our collaborators’ products and product candidates such as clinical holds, imposition of onerous requirements for approval or product recalls;


•	our failure, or the failure of our third party collaborators, to successfully commercialize products approved by applicable regulatory bodies such as the FDA;


•	our failure, or the failure of our third party collaborators, to generate product revenues anticipated by investors;


•	disruptions in our clinical or commercial supply chains, including disruptions caused by problems with a bulk rHuPH20 contract manufacturer or a fill and finish manufacturer for any product or product candidate;


•	the sale of additional debt and/or equity securities by us;


•	our failure to obtain financing on acceptable terms or at all; or


•	a restructuring of our operations.

Future transactions where we raise capital may negatively affect our stock price.

We are currently a “Well-Known Seasoned Issuer” and may file automatic shelf registration statements at any time with the SEC. In February 2017, we filed an automatic shelf registration statement on Form S-3 (Registration No. 333-216315) with the SEC. Sales of substantial amounts of shares of our common stock or other securities under our current or future shelf registration statements could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities.

Anti-takeover provisions in our charter documents and Delaware law may make an acquisition of us more difficult.

Anti-takeover provisions in our charter documents and Delaware law may make an acquisition of us more difficult. First, our board of directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation’s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation, as amended, does not provide otherwise. In addition, our bylaws limit who may call special meetings of stockholders, permitting only stockholders holding at least 50% of our outstanding shares to call a special meeting of stockholders. Our amended and restated certificate of incorporation, as amended, does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals.

These provisions may discourage potential takeover attempts, discourage bids for our common stock at a premium over market price or adversely affect the market price of, and the voting and other rights of the holders of, our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors other than the candidates nominated by our board of directors.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit large stockholders from consummating a merger with, or acquisition of, us.

These provisions may deter an acquisition of us that might otherwise be attractive to stockholders.

Risks Related to Our Industry

Our products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of product sales, introductions or modifications.

Extensive industry regulation has had, and will continue to have, a significant impact on our business. All pharmaceutical companies, including ours, are subject to extensive, complex, costly and evolving regulation by the health regulatory agencies including the FDA (and with respect to controlled drug substances, the U.S. Drug Enforcement Administration (DEA)) and equivalent foreign regulatory agencies and state and local/regional government agencies. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other domestic and foreign statutes and regulations govern or influence the testing, manufacturing, packaging, labeling, storing, recordkeeping, safety, approval, advertising, promotion, sale and distribution of our products. We are dependent on receiving FDA and other governmental approvals, including regulatory approvals in jurisdictions outside the United States, prior to manufacturing, marketing and shipping our products. Consequently, there is always a risk that the FDA or other applicable governmental authorities, including those outside the United States, will not approve our products or may impose onerous, costly and time-consuming requirements such as additional clinical or animal testing. Regulatory authorities may require that we change our studies or conduct additional studies, which may significantly delay or make continued pursuit of approval commercially unattractive. For example, the approval of Baxalta’s HYQVIA BLA was delayed by the FDA until we and Baxalta provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was approved by the FDA in September 2014, the FDA or other foreign regulatory agency may, at any time, halt our and our collaborators’ development and commercialization activities due to safety concerns. In addition, even if our products are approved, regulatory agencies may also take post-approval action limiting or revoking our ability to sell our products. Any of these regulatory actions may adversely affect the economic benefit we may derive from our products and therefore harm our financial condition.

Under certain of these regulations, we and our contract suppliers and manufacturers are subject to periodic inspection of our or their respective facilities, procedures and operations and/or the testing of products by the FDA, the DEA and other authorities, which conduct periodic inspections to confirm that we and our contract suppliers and manufacturers are in compliance with all applicable regulations. The FDA also conducts pre-approval and post-approval reviews and plant inspections to determine whether our systems, or our contract suppliers’ and manufacturers’ processes, are in compliance with cGMP and other FDA regulations. If we, or our contract supplier, fail these inspections, we may not be able to commercialize our product in a timely manner without incurring significant additional costs, or at all.

In addition, the FDA imposes a number of complex regulatory requirements on entities that advertise and promote pharmaceuticals including, but not limited to, standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet.

We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.

Our business operations and activities may be directly, or indirectly, subject to various broad federal and state healthcare laws, including without limitation, anti-kickback laws, the Foreign Corrupt Practices Act, false claims laws, civil monetary penalty laws, data privacy and security laws, tracing and tracking laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects,

as well as sales, marketing and education programs. Many states have similar healthcare fraud and abuse laws, some of which may be broader in scope and may not be limited to items or services for which payment is made by a government health care program.

Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While we have adopted a healthcare corporate compliance program, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.

In addition, any sales of products outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.

We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of the development and commercialization of our products.

We primarily rely on patents to protect our intellectual property rights. The strength of this protection, however, is uncertain. For example, it is not certain that:


•	we will be able to obtain patent protection for our products and technologies;


•	the scope of any of our issued patents will be sufficient to provide commercially significant exclusivity for our products and technologies;


•	others will not independently develop similar or alternative technologies or duplicate our technologies and obtain patent protection before we do; and


•	any of our issued patents, or patent pending applications that result in issued patents, will be held valid, enforceable and infringed in the event the patents are asserted against others.

We currently own or license several patents and also have pending patent applications applicable to rHuPH20 and other proprietary materials. There can be no assurance that our existing patents, or any patents issued to us as a result of our pending patent applications, will provide a basis for commercially viable products, will provide us with any competitive advantages, or will not face third party challenges or be the subject of further proceedings limiting their scope or enforceability. Any weaknesses or limitations in our patent portfolio could have a material adverse effect on our business and financial condition. In addition, if any of our pending patent applications do not result in issued patents, or result in issued patents with narrow or limited claims, this could result in us having no or limited protection against generic or biosimilar competition against our product candidates which would have a material adverse effect on our business and financial condition.

We may become involved in interference proceedings in the U.S. Patent and Trademark Office, or other proceedings in other jurisdictions, to determine the priority, validity or enforceability of our patents. In addition, costly litigation could be necessary to protect our patent position.

We also rely on trademarks to protect the names of our products (e.g. Hylenex recombinant). We may not be able to obtain trademark protection for any proposed product names we select. In addition, product names for pharmaceutical products must be approved by health regulatory authorities such as the FDA in addition to meeting the legal standards required for trademark protection and product names we propose may not be timely approved by regulatory agencies which may delay product launch. In addition, our trademarks may be challenged by others. If we enforce our trademarks against third parties, such enforcement proceedings may be expensive.

We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to protect with confidentiality agreements with employees, consultants and others with whom we discuss our business. Disputes may

arise concerning the ownership of intellectual property or the applicability or enforceability of these agreements, and we might not be able to resolve these disputes in our favor.

In addition to protecting our own intellectual property rights, third parties may assert patent, trademark or copyright infringement or other intellectual property claims against us. If we become involved in any intellectual property litigation, we may be required to pay substantial damages, including but not limited to treble damages, attorneys’ fees and costs, for past infringement if it is ultimately determined that our products infringe a third party’s intellectual property rights. Even if infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert management’s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products until we obtain a license from the owner of the relevant technology or other intellectual property rights. If such a license is available at all, it may require us to pay substantial royalties or other fees.

Patent protection for protein-based therapeutic products and other biotechnology inventions is subject to a great deal of uncertainty, and if patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize products based on our discoveries.

Patent protection for protein-based therapeutic products is highly uncertain and involves complex legal and factual questions. In recent years, there have been significant changes in patent law, including the legal standards that govern the scope of protein and biotechnology patents. Standards for patentability of full-length and partial genes, and their corresponding proteins, are changing. Recent court decisions have made it more difficult to obtain patents, by making it more difficult to satisfy the patentable subject matter requirement and the requirement of non-obviousness, have decreased the availability of injunctions against infringers, and have increased the likelihood of challenging the validity of a patent through a declaratory judgment action. Taken together, these decisions could make it more difficult and costly for us to obtain, license and enforce our patents. In addition, the Leahy-Smith America Invents Act (HR 1249) was signed into law in September 2011, which among other changes to the U.S. patent laws, changes patent priority from “first to invent” to “first to file,” implements a post-grant opposition system for patents and provides for a prior user defense to infringement. These judicial and legislative changes have introduced significant uncertainty in the patent law landscape and may potentially negatively impact our ability to procure, maintain and enforce patents to provide exclusivity for our products.

There also have been, and continue to be, policy discussions concerning the scope of patent protection awarded to biotechnology inventions. Social and political opposition to biotechnology patents may lead to narrower patent protection within the biotechnology industry. Social and political opposition to patents on genes and proteins and recent court decisions concerning patentability of isolated genes may lead to narrower patent protection, or narrower claim interpretation, for isolated genes, their corresponding proteins and inventions related to their use, formulation and manufacture. Patent protection relating to biotechnology products is also subject to a great deal of uncertainty outside the U.S., and patent laws are evolving and undergoing revision in many countries. Changes in, or different interpretations of, patent laws worldwide may result in our inability to obtain or enforce patents, and may allow others to use our discoveries to develop and commercialize competitive products, which would impair our business.

If third party reimbursement and customer contracts are not available, our products may not be accepted in the market.

Our ability to earn sufficient returns on our products will depend in part on the extent to which reimbursement for our products and related treatments will be available from government health administration authorities, private health insurers, managed care organizations and other healthcare providers.

Third-party payors are increasingly attempting to limit both the coverage and the level of reimbursement of new drug products to contain costs. Consequently, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Third party payors may not establish adequate levels of reimbursement for the products that we commercialize, which could limit their market acceptance and result in a material adverse effect on our revenues and financial condition.

Customer contracts, such as with group purchasing organizations and hospital formularies, will often not offer contract or formulary status without either the lowest price or substantial proven clinical differentiation. If, for example, Hylenex is compared to animal-derived hyaluronidases by these entities, it is possible that neither of these conditions will be met, which could limit market acceptance and result in a material adverse effect on our revenues and financial condition.

The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures that could cause us to sell our products at lower prices, resulting in less revenue to us.

Any of the proprietary or collaboration products that have been, or in the future are, approved by the FDA may be purchased or reimbursed by state and federal government authorities, private health insurers and other organizations, such as health maintenance organizations and managed care organizations. Such third party payors increasingly challenge pharmaceutical product pricing. The trend toward managed healthcare in the U.S., the growth of such organizations, and various legislative proposals and enactments to reform healthcare and government insurance programs, including the Medicare Prescription Drug Modernization Act of 2003, could significantly influence the manner in which pharmaceutical products are prescribed and purchased, resulting in lower prices and/or a reduction in demand. Such cost containment measures and healthcare reforms could adversely affect our ability to sell our products.

In March 2010, the U.S. adopted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the PPACA). This law substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The PPACA contains a number of provisions that are expected to impact our business and operations, in some cases in ways we cannot currently predict. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, fraud and abuse and enforcement. These changes will impact existing government healthcare programs and will result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program.

Additional provisions of the PPACA may negatively affect our revenues in the future. For example, the PPACA imposes a non-deductible excise tax on pharmaceutical manufacturers or importers that sell branded prescription drugs to U.S. government programs that we believe will impact our revenues from our products. In addition, as part of the PPACA’s provisions closing a funding gap that currently exists in the Medicare Part D prescription drug program, we will also be required to provide a 50% discount on branded prescription drugs dispensed to beneficiaries under this prescription drug program. Recently, Congress and the current administration have proposed and taken various steps to revise, repeal or delay implementation of, various aspects of the Healthcare Reform Act. We expect that the PPACA, as it may be amended, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to maintain or increase our product sales or successfully commercialize our product candidates and could limit or eliminate our future spending on development projects.

Furthermore, individual states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third party payors or other restrictions could negatively and materially impact our revenues and financial condition. We anticipate that we will encounter similar regulatory and legislative issues in most other countries outside the U.S.

We face intense competition and rapid technological change that could result in the development of products by others that are superior to our proprietary and collaboration products under development.

Our proprietary and collaboration products have numerous competitors in the U.S. and abroad including, among others, major pharmaceutical and specialized biotechnology firms, universities and other research institutions that have developed competing products. The competitors for Hylenex recombinant include, but are not limited to, Valeant Pharmaceuticals International, Inc.’s FDA-approved product, Vitrase^®, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.’s product, Amphadase^®, a bovine (bull) hyaluronidase. For our PEGPH20 product candidate, such competitors may include major pharmaceutical and specialized biotechnology firms. These competitors may develop technologies and products that are more effective, safer, or less costly than our current or future proprietary and collaboration product candidates or that could render our

technologies and product candidates obsolete or noncompetitive. Many of these competitors have substantially more resources and product development, manufacturing and marketing experience and capabilities than we do. In addition, many of our competitors have significantly greater experience than we do in undertaking preclinical testing and clinical trials of pharmaceutical product candidates and obtaining FDA and other regulatory approvals of products and therapies for use in healthcare.


Item 3.	Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in our market risks during the quarter ended September 30, 2018.

As of September 30, 2018, our cash equivalents and marketable securities consisted of investments in money market funds, U.S. Treasury securities, corporate debt obligations and commercial paper. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments that we invest in could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. Based on our current investment portfolio as of September 30, 2018, we do not believe that our results of operations would be materially impacted by an immediate change of 10% in interest rates.

We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. We made this determination based on discussions with our investment advisors and a review of our holdings. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. All of our cash equivalents and marketable securities are recorded at fair market value.


Item 4.	Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.

Changes in Internal Control Over Financial Reporting

There have been no significant changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION


Item 1.	Legal Proceedings


Item 1A.	Risk Factors

We have provided updated Risk Factors in the section labeled “Risk Factors” in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. The “Risk Factors” section provides updated information in certain areas, particularly with respect to the risks and uncertainties regarding the regulatory approval of proprietary and collaboration product candidates. We do not believe the updates have materially changed the type or magnitude of risks we face in comparison to the disclosure provided in our most recent Annual Report on Form 10-K.


Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds

None.


Item 3.	Defaults Upon Senior Securities

Not applicable.


Item 4.	Mine Safety Disclosures

Not applicable.


Item 5.	Other Information

None.


Item 6.	Exhibits



3.1		Composite Certificate of Incorporation (1)

3.2		Bylaws, as amended (2)

10.1#		Halozyme Therapeutics, Inc. Severance Policy

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended

32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Instance Document

101.SCH		Taxonomy Extension Schema Document

101.CAL		Taxonomy Extension Calculation Linkbase Document

101.DEF		Taxonomy Extension Definition Linkbase Document

101.LAB		Taxonomy Extension Label Linkbase Document

101.PRE		Taxonomy Extension Presentation Linkbase Document


(1)	Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q, filed August 7, 2013 (File No. 001-32335).


(2)	Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed December 19, 2016 (File No. 001-32335).

# Indicates management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		Halozyme Therapeutics, Inc., a Delaware corporation
		Halozyme Therapeutics, Inc., a Delaware corporation

Dated:	November 6, 2018	/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.
		Helen I. Torley, M.B. Ch.B., M.R.C.P. President and Chief Executive Officer (Principal Executive Officer)



Dated:	November 6, 2018	/s/ Laurie D. Stelzer
		Laurie D. Stelzer Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

EX-10.1 2 ex101q32018.htm EXHIBIT 10.1 Exhibit

EXHIBIT 10.1

HALOZYME THERAPEUTICS, INC.

SEVERANCE POLICY

Under the Severance Policy of Halozyme Therapeutics, Inc. (the “Company”), the particular amount of cash severance for an employee terminated by the Company without cause will generally be dictated by the employee’s position in the organization as well their completed years of service with the Company. The Severance Policy is applicable to members of senior management in the following respects: (i) the cash severance for the Chief Executive Officer (the “CEO”) will be equal to the CEO’s then-current annual base salary; (ii) the cash severance for certain other senior officers as designated by the Compensation Committee of the Board of Directors (the “Compensation Committee”) will be equal to one half of the then-current annual base salary for such officers; and (iii) the cash severance for certain other officers as designated by the Compensation Committee will initially be equal to sixteen weeks of the then-current annual base salary for such employee, provided that the employee will receive an additional four weeks of cash severance for each completed year of employment with the Company (up to a maximum of 26 weeks). In addition to cash severance, which will normally be made in a lump sum payment (subject to standard taxes and withholdings), the Company will also pay certain health coverage costs (“Subsidized Healthcare”) during the term of the applicable severance period. Despite the establishment of the Severance Policy, however, the Board of Directors retains the right to amend, alter or terminate the Severance Policy at any time and an employee’s eligibility for cash severance and Subsidized Healthcare will be conditioned upon that employee releasing the Company for any claims relating to their employment (including the termination of employment).

EX-31.1 3 ex311q32018.htm EXHIBIT 31.1 Exhibit

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of Halozyme Therapeutics, Inc. certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;


4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:


a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and


5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):


a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and


b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

EX-31.2 4 ex312q32018.htm EXHIBIT 31.2 Exhibit

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Laurie D. Stelzer, Chief Financial Officer of Halozyme Therapeutics, Inc. certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;


4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:


a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and


5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):


a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and


b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

EX-32 5 ex32q32018.htm EXHIBIT 32 Exhibit

EXHIBIT 32

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the “Registrant”) on Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Laurie D. Stelzer, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

EX-101.INS 6 halo-20180930.xml XBRL INSTANCE DOCUMENT 0001159036 2018-01-01 2018-09-30 0001159036 halo:OthercollaboratorsMember 2018-01-01 2018-09-30 0001159036 2018-10-30 0001159036 2018-09-30 0001159036 2017-12-31 0001159036 2017-07-01 2017-09-30 0001159036 2017-01-01 2017-09-30 0001159036 2018-07-01 2018-09-30 0001159036 2017-09-30 0001159036 2016-12-31 0001159036 halo:BulkrHuPH20Member 2017-12-31 0001159036 halo:HylenexRecombinantMember 2017-12-31 0001159036 halo:CostsexpensedtoRDDomain 2018-09-30 0001159036 halo:HylenexRecombinantMember 2018-09-30 0001159036 halo:InlicensetechnologiesMember 2018-01-01 2018-09-30 0001159036 halo:BulkrHuPH20Member 2018-09-30 0001159036 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001159036 us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0001159036 us-gaap:MoneyMarketFundsMember 2018-09-30 0001159036 us-gaap:CommercialPaperMember 2017-12-31 0001159036 us-gaap:CommercialPaperMember 2018-09-30 0001159036 us-gaap:FairValueInputsLevel2Member 2018-09-30 0001159036 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001159036 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001159036 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2018-09-30 0001159036 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001159036 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001159036 us-gaap:AssetBackedSecuritiesMember 2018-09-30 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001159036 us-gaap:MoneyMarketFundsMember 2017-12-31 0001159036 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001159036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001159036 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001159036 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001159036 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001159036 us-gaap:FairValueInputsLevel1Member 2018-09-30 0001159036 us-gaap:USTreasurySecuritiesMember 2017-12-31 0001159036 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001159036 us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0001159036 us-gaap:CommercialPaperMember 2018-09-30 0001159036 us-gaap:USTreasurySecuritiesMember 2018-09-30 0001159036 us-gaap:FairValueInputsLevel3Member 2018-09-30 0001159036 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001159036 us-gaap:USTreasurySecuritiesMember 2017-12-31 0001159036 us-gaap:CommercialPaperMember 2017-12-31 0001159036 halo:LillyMember 2018-01-01 2018-09-30 0001159036 halo:DevelopmentFeesMember halo:PfizerMember 2018-01-01 2018-09-30 0001159036 halo:DevelopmentFeesMember halo:AbbVieMember 2018-01-01 2018-09-30 0001159036 halo:JanssenMember 2018-01-01 2018-09-30 0001159036 halo:DevelopmentFeesMember halo:JanssenMember 2018-01-01 2018-09-30 0001159036 halo:BMSMember 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember halo:BaxaltaMember 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember halo:AbbVieMember 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember halo:RocheMember 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember halo:BMSMember 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember halo:AlexionMember 2018-01-01 2018-09-30 0001159036 halo:PfizerMember 2018-01-01 2018-09-30 0001159036 halo:DevelopmentFeesMember halo:BaxaltaMember 2018-01-01 2018-09-30 0001159036 halo:SalesbasedmilestoneMember halo:RocheMember 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember halo:JanssenMember 2018-01-01 2018-09-30 0001159036 halo:BaxaltaMember 2018-01-01 2018-09-30 0001159036 halo:RocheMember 2018-01-01 2018-09-30 0001159036 halo:AbbVieMember 2018-01-01 2018-09-30 0001159036 halo:SalesbasedmilestoneMember halo:BaxaltaMember 2018-01-01 2018-09-30 0001159036 halo:AlexionMember 2018-01-01 2018-09-30 0001159036 halo:DevelopmentFeesMember halo:RocheMember 2018-01-01 2018-09-30 0001159036 halo:DevelopmentFeesMember halo:AlexionMember 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember halo:LillyMember 2018-01-01 2018-09-30 0001159036 halo:DevelopmentFeesMember halo:BMSMember 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember halo:PfizerMember 2018-01-01 2018-09-30 0001159036 halo:RoyaltyMember halo:BaxaltaMember 2018-01-01 2018-09-30 0001159036 halo:RoyaltyMember halo:RocheMember 2018-01-01 2018-09-30 0001159036 halo:ResearchandDevelopmentServicesMember 2017-07-01 2017-09-30 0001159036 halo:SalesbasedmilestoneMember 2017-01-01 2017-09-30 0001159036 halo:HylenexRecombinantMember 2018-07-01 2018-09-30 0001159036 halo:ENHANZEdrugproductMemberDomain 2017-01-01 2017-09-30 0001159036 halo:DevelopmentFeesMember 2017-01-01 2017-09-30 0001159036 halo:UpfrontfeesMember 2017-07-01 2017-09-30 0001159036 halo:HylenexRecombinantMember 2017-01-01 2017-09-30 0001159036 halo:DevelopmentFeesMember 2017-07-01 2017-09-30 0001159036 halo:BulkrHuPH20Member 2017-01-01 2017-09-30 0001159036 halo:DevelopmentFeesMember 2018-07-01 2018-09-30 0001159036 halo:ENHANZEdrugproductMemberDomain 2017-07-01 2017-09-30 0001159036 halo:BulkrHuPH20Member 2018-07-01 2018-09-30 0001159036 halo:ENHANZEdrugproductMemberDomain 2018-07-01 2018-09-30 0001159036 halo:DevelopmentFeesMember 2018-01-01 2018-09-30 0001159036 halo:SalesbasedmilestoneMember 2017-07-01 2017-09-30 0001159036 halo:HylenexRecombinantMember 2017-07-01 2017-09-30 0001159036 halo:ResearchandDevelopmentServicesMember 2018-07-01 2018-09-30 0001159036 halo:SalesbasedmilestoneMember 2018-01-01 2018-09-30 0001159036 halo:HylenexRecombinantMember 2018-01-01 2018-09-30 0001159036 halo:SalesbasedmilestoneMember 2018-07-01 2018-09-30 0001159036 halo:BulkrHuPH20Member 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember 2018-07-01 2018-09-30 0001159036 halo:ENHANZEdrugproductMemberDomain 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember 2017-01-01 2017-09-30 0001159036 halo:ResearchandDevelopmentServicesMember 2017-01-01 2017-09-30 0001159036 halo:ResearchandDevelopmentServicesMember 2018-01-01 2018-09-30 0001159036 halo:UpfrontfeesMember 2018-01-01 2018-09-30 0001159036 halo:BulkrHuPH20Member 2017-07-01 2017-09-30 0001159036 halo:A2017RocheMember 2018-01-01 2018-09-30 0001159036 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-09-30 0001159036 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-09-30 0001159036 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-07-01 2018-09-30 0001159036 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-09-30 0001159036 halo:OthercollaboratorsMember 2018-09-30 0001159036

2022-12-31

2018-09-30 0001159036

2019-12-31

2018-09-30 0001159036 halo:BulkrHuPH20Member

2019-12-31

2018-09-30 0001159036 us-gaap:CollaborativeArrangementMember 2017-12-31 0001159036 us-gaap:ProductMember 2018-09-30 0001159036 us-gaap:CollaborativeArrangementMember 2018-09-30 0001159036 halo:RocheMember 2018-09-30 0001159036 halo:InlicensetechnologiesMember 2017-12-31 0001159036 us-gaap:ProductMember 2017-12-31 0001159036 halo:RocheMember 2017-12-31 0001159036 halo:InlicensetechnologiesMember 2018-09-30 0001159036 us-gaap:MachineryAndEquipmentMember 2018-09-30 0001159036 halo:ManufacturingEquipmentMemberDomain 2018-09-30 0001159036 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001159036 us-gaap:LeaseholdImprovementsMember 2018-09-30 0001159036 us-gaap:MachineryAndEquipmentMember 2017-12-31 0001159036 halo:ResearchEquipmentMember 2017-12-31 0001159036 halo:ResearchEquipmentMember 2018-09-30 0001159036 halo:ManufacturingEquipmentMemberDomain 2017-12-31 0001159036 us-gaap:SeniorLoansMember 2018-07-01 2018-09-30 0001159036 halo:RoyaltybackedLoanMember 2017-01-01 2017-09-30 0001159036 us-gaap:SeniorLoansMember 2018-01-01 2018-09-30 0001159036 halo:RoyaltybackedLoanMember 2018-01-01 2018-09-30 0001159036 halo:A2017Member halo:RoyaltybackedLoanMember 2018-01-01 2018-09-30 0001159036 halo:RoyaltybackedLoanMember 2018-09-30 0001159036 us-gaap:SeniorLoansMember 2018-09-30 0001159036 halo:RoyaltybackedLoanMember us-gaap:MaximumMember 2018-01-01 2018-09-30 0001159036 halo:A2019QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2018-01-01 2018-09-30 0001159036 us-gaap:SecuredDebtMember 2017-03-31 0001159036 halo:RoyaltybackedLoanMember 2018-07-01 2018-09-30 0001159036 halo:A2016Member halo:RoyaltybackedLoanMember 2018-01-01 2018-09-30 0001159036 halo:RoyaltybackedLoanMember us-gaap:MinimumMember 2018-01-01 2018-09-30 0001159036 us-gaap:SeniorLoansMember 2017-12-31 0001159036 us-gaap:SeniorLoansMember 2017-01-01 2017-09-30 0001159036 halo:A2020QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2018-01-01 2018-09-30 0001159036 halo:RoyaltybackedLoanMember 2017-07-01 2017-09-30 0001159036 us-gaap:SeniorLoansMember us-gaap:MaximumMember 2018-09-30 0001159036 halo:A2017QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2018-01-01 2018-09-30 0001159036 us-gaap:SeniorLoansMember 2017-07-01 2017-09-30 0001159036 us-gaap:SeniorLoansMember us-gaap:MinimumMember 2018-09-30 0001159036 halo:RoyaltybackedLoanMember 2017-01-01 2017-12-31 0001159036 halo:A2018QuarterlyMaximumPaymentMember halo:RoyaltybackedLoanMember 2018-01-01 2018-09-30 0001159036 halo:A2018andthereafterMember halo:RoyaltybackedLoanMember 2018-01-01 2018-09-30 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001159036 us-gaap:RestrictedStockMember 2018-09-30 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0001159036 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001159036 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001159036 us-gaap:EmployeeStockOptionMember 2018-09-30 0001159036 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001159036 halo:RSURSAandPRSUawardsMember 2018-01-01 2018-09-30 0001159036 halo:RSURSAandPRSUawardsMember 2018-07-01 2018-09-30 0001159036 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001159036 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001159036 halo:RSURSAandPRSUawardsMember 2017-01-01 2017-09-30 0001159036 halo:RSURSAandPRSUawardsMember 2017-07-01 2017-09-30 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001159036 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001159036 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001159036 us-gaap:MaximumMember 2018-01-01 2018-09-30 0001159036 us-gaap:MinimumMember 2018-01-01 2018-09-30 0001159036 us-gaap:MaximumMember 2017-01-01 2017-09-30 0001159036 us-gaap:MaximumMember 2017-07-01 2017-09-30 0001159036 us-gaap:MinimumMember 2018-07-01 2018-09-30 0001159036 us-gaap:MinimumMember 2017-01-01 2017-09-30 0001159036 us-gaap:MaximumMember 2018-07-01 2018-09-30 0001159036 us-gaap:MinimumMember 2017-07-01 2017-09-30 0001159036 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001159036 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001159036 2017-05-01 2017-05-31 xbrli:shares xbrli:pure iso4217:USD xbrli:shares halo:Segment iso4217:USD false --12-31 Q3 2018 2018-09-30 10-Q 0001159036 144557543 Large Accelerated Filer HALOZYME THERAPEUTICS INC. HALO 2142000 451000 2075000 1949000 18475000 1980000 0 18777000 2000000 18757000 19786000 440000 565000 2504000 4743000 165000000 160000000 559000 501000 1.05 0.02 0.01 0.055 5000000 25000000 1000000 5000000 0 5000000 7793000 9195000 18700000 70600000 1700000 2300000 0 0.5 1 55000000 1500000

22133000

27656000

7948000

3331000

22692000

28157000

22133000

22656000

18700000

94000

2166000

40041000

43585000

39601000

43020000

13890000

15688000

-450000

-478000

731044000

769382000

7762000

2789000

4973000

3060000

4702000

23268000

8297000

14971000

9891000

13377000

8867000

4222000

4645000

4407000

4460000

26684000

12658000

14026000

13107000

13577000

2378000

2000000

7800000

14300000

13800000

519945000

444507000

510372000

429926000

458265000

208491000

249774000

364618000

154739000

209879000

436000

235000

201000

453000

24000

181000

248000

300474000

116882000

117192000

66400000

116882000

117192000

66400000

309347000

39697000

95664000

74518000

99468000

39697000

95664000

74518000

99468000

300910000

116882000

117427000

66601000

309800000

39721000

95664000

74699000

99716000

300474000

309347000

266000

2345000

168740000

55019000

15700000

142091000

55271000

67264000

164897000

169240000

55519000

97633000

-113721000

0.001

200000000

142789000

144522000

142789000

144522000

143000

145000

2757000

-60958000

-27592000

-78232000

5000000

19400000

51800000

8332000

23664000

626000

4514000

55654000

171976000

51030000

160889000

0.015

0.007

in compliance

8.75% plus the three-month LIBOR rate

150000000

70000000

1500000

700000

500000

0.0825

2016-01-26

2016-06-07

2050-12-31

2021-01-01

final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050

interest only payments for the first 18 months

13750000

18750000

21250000

22500000

4250000

400000

200000

15000000

0.1025

400000

60865000

55378000

39379000

15999000

5487000

9754000

-48700000

2265000

7489000

3000000

2300000

4500000

9800000

6568000

4247000

54297000

5507000

500000

2300000

5500000

500000

1700000

1668000

600000

1800000

1798000

0.02

-0.45

-0.19

-0.55

0.02

-0.45

-0.19

-0.55

13384000

12914000

38966000

2743000

26434000

P2Y5M12D

P1Y1M2D

P2Y2M27D

-17000

-1000

3329000

-59941000

-27850000

-77984000

580000

970000

220000

3077000

-4155000

-985000

-13962000

422000

3000000

-5292000

13139000

-8998000

7477000

5538000

16526000

4286000

14286000

4200000

1400000

12400000

4100000

3100000

1200000

10500000

3800000

2638000

2259000

5146000

2200000

2900000

18285000

15900000

2000000

2400000

377000

625000

2131000

15401000

519945000

444507000

131328000

139119000

33023000

329000

2000000

342000

30352000

43407000

988000

10337000

1028000

31054000

577000

14434000

11000000

2098000

1336000

125140000

57940000

77211000

88521000

131573000

-45443000

-14744000

-8316000

-19196000

-59962000

2749000

-60911000

-27850000

-78204000

71200000

500000

8077000

-44927000

-25474000

-69259000

5396000

6142000

400000

300000

6717000

6527000

-1000

6000

-2000

11000

24000

-40000

256000

-17000

814000

2203000

790000

1512000

1910000

5561000

38000

-10000

2585000

2344000

1322000

1900000

4200000

198748000

272643000

490000

1590000

0.001

20000000

19432000

26910000

13879000

19619000

5553000

7291000

2337000

8844000

134875000

7686000

11656000

184494000

265917000

8900000

14300000

17410000

1702000

9268000

2715000

3725000

22478000

3979000

9528000

4160000

4811000

3520000

6790000

4192000

2333000

10988000

57099000

33993000

109267000

35540000

113602000

500000

-522371000

-529311000

6000

5000

3000

15000

2000

25000

22438

211613

9000

22000

23000

40000

105000

10000

15250

33000

14500

70000

29000

45000

110000

44438

30250

33000

16500

328613

63731000

127049000

25556000

6400000

91630000

2600000

17119000

45839000

18710000

59643000

12.50

13589000

9748000

3841000

37803000

26825000

10978000

6269000

2402000

186000

3681000

17553000

6350000

322000

10881000

101000000

45500000

13329000

39045000

14864000

42773000

23268000

26684000

0.000

0.0193

0.0194

0.0287

0.0173

0.0275

0.0225

0.708

0.705

0.717

0.705

0.606

0.586

0.701

0.587

100000

2500000

400000

2300000

14700000

13400000

8.71

11.13

P5Y7M

P5Y5M

P5Y6M0D

96069

138986

11500000

98945

375906

67959

438536

1020028

1280996

208366000

239738000

125000

-78000

2046000

143236000

134633000

143949000

143396000

141190000

134633000

143949000

143396000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,721</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,697</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(248</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,347</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(235</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(436</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 20, 2018. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated statement of cash flows within operating activities to conform to the current period presentation. There was no change to net cash used in operating activities. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our disaggregated revenues were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Sales of bulk rHuPH20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Sales of ENHANZE drug product</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,681</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,841</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,978</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total product sales, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,553</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues under collaborative agreements:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Upfront license fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,054</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Event-based development milestones and other fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Sales-based milestones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Research and development services</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">577</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,434</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,049</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of </font><font style="font-family:inherit;font-size:10pt;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;">. This amount represents royalties earned in the current period. We recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> that had been included in deferred revenues at December 31, 2017. We did not recognize any adjustments to reduce sales reserves and allowances liability related to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant sales in prior periods.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of </font><font style="font-family:inherit;font-size:10pt;">$70.6 million</font><font style="font-family:inherit;font-size:10pt;">. This amount represents royalties earned in the current period, development milestones of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Roche and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Alexion, and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> of variable consideration in the contract where uncertainties have been resolved and the development milestone is expected to be achieved. We also recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> that had been included in deferred revenues at December 31, 2017. We did not recognize any adjustments to reduce sales reserves and allowances liability related to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant sales in prior periods.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> was determined in accordance with the accounting rules applicable prior to the adoption of ASC 606 on January 1, 2018. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the adoption of ASC 606, we recognized an adjustment to increase our accounts receivable by </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;">, decrease deferred revenues by </font><font style="font-family:inherit;font-size:10pt;">$51.8 million</font><font style="font-family:inherit;font-size:10pt;">, and decrease accumulated deficit by </font><font style="font-family:inherit;font-size:10pt;">$71.2 million</font><font style="font-family:inherit;font-size:10pt;">. The impact of applying the provisions of ASC 606 in the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> was to decrease revenues by </font><font style="font-family:inherit;font-size:10pt;">$6.4 million</font><font style="font-family:inherit;font-size:10pt;"> and to increase revenues by </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Under the previously existing authoritative accounting literature, at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> our accounts receivable and other contract assets would have been </font><font style="font-family:inherit;font-size:10pt;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;"> lower, and our deferred revenue </font><font style="font-family:inherit;font-size:10pt;">$48.7 million</font><font style="font-family:inherit;font-size:10pt;"> higher, than the amounts reported in our condensed consolidated balance sheet. ASC 606 did not have an aggregate impact on our net cash used in operating activities, but resulted in offsetting changes in net loss and certain assets and liabilities within net cash used in operating activities in the condensed consolidated statement of cash flows. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands): </font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other contract assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">. This amount has been collected and is reported as deferred revenues. Of the total deferred revenues, </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> represents pre-payment of bulk rHuPH20 that we estimate will be delivered in 2019. Of the remaining deferred revenues, for which the timing of when these goods and services will be provided is controlled by our customers, </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;"> can be used by the customers at any time through 2022 and the remaining </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> at any time through 2019. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized contract assets of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to collaborative agreements as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, for amounts considered probable to receive for development milestones that relate to intellectual property licenses granted to collaboration partners in prior periods. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Upfront</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Development</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sales</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration partner and agreement date:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche (December 2006 and September 2017)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baxalta (September 2007)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pfizer (December 2012)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen (December 2014)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AbbVie (June 2015)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lilly (December 2015)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BMS (September 2017)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alexion (December 2017)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront and additional target selection fees</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Event-based development and regulatory milestone amounts and other fees</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based milestone amounts</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our collaboration partners have completed development, obtained marketing authorization approvals for certain indications and commenced commercialization of the following products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche, for Herceptin SC in the European Union (“EU”) in August 2013; and MabThera SC in the EU in March 2014 and its equivalent RITUXAN HYCELA™ in the US in June 2017; and Herceptin SC in Canada in September 2018;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baxalta, for HYQVIA in the EU and in the US in May 2013.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The remaining targets and products are currently in the process of development by the collaboration partners.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands): </font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other contract assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees and event-based payments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total license fees and event-based payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,489</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,487</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,568</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,507</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,297</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our disaggregated revenues were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Sales of bulk rHuPH20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Sales of ENHANZE drug product</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,681</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,841</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,978</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total product sales, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,553</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues under collaborative agreements:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Upfront license fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,054</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Event-based development milestones and other fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Sales-based milestones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  Research and development services</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">577</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,434</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,049</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net (Loss) Income Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,091</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,091</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,697</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,697</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364,618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,721</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,697</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(248</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,347</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,427</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(235</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,192</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(436</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, all of our available-for-sale debt securities were scheduled to mature within the next 12 months and </font><font style="font-family:inherit;font-size:10pt;">27</font><font style="font-family:inherit;font-size:10pt;"> available-for-sale marketable securities were in a gross unrealized loss position, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe we had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> other than-temporary impairments on these securities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total estimated fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,091</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,091</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable </font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,697</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,697</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364,618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> transfers between Level 1 and Level 2 of the fair value hierarchy during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">. We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> instruments that were classified within Level 3 as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption and Pending Adoption of Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently do not hold equity securities. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU 2016-16, Income Taxes; Intra-Entity Transfers of Assets Other Than Inventory.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance removes the current requirement to defer the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) until the asset has been sold to an outside party. As a result, the income tax consequences of an intercompany transfer of assets other than inventory will be recognized in the current period income statement rather than being deferred until the assets leave the consolidated entity.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We adopted the new guidance on January 1, 2018. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In March, April, May and December 2016, the FASB issued additional guidance related to Topic 606.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new standard superseded nearly all existing revenue recognition guidance. Under Topic 606, an entity is required to recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. Topic 606 defines a five-step process in order to achieve this core principle, which may require the use of judgment and estimates, and also requires expanded qualitative and quantitative disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including significant judgments and estimates used. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We adopted the new guidance on January 1, 2018 using the modified retrospective approach. Refer to Notes 2 “Revenue Recognition” and 4 for additional detail regarding the impact of this adoption.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In July 2018, the FASB issued additional guidance related to Topic 842.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2019. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to implement the guidance on January 1, 2019 using a modified retrospective transition basis for leases existing as of the period of adoption. In order to adopt the new standard, we will be using available practical expedients and newly implemented processes and internal controls for lease accounting. The practical expedients allow us to carry forward our historical assessment of whether existing agreements are or contain a lease and the classification of our existing lease arrangements. We expect all of our real-estate and automobile operating lease commitments will be recognized as lease liabilities with corresponding right-of-use assets upon adoption, resulting in an increase in the assets and liabilities of the consolidated balance sheet. We anticipate that the adoption will have a material impact on our consolidated financial statements. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance removes, modifies and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our condensed consolidated financial position or results of operations.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,702</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Property and equipment, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:10pt;">When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. The manufacturing costs of bulk rHuPH20 for the approved collaboration products, Herceptin SC, MabThera SC (RITUXAN HYCELA™ in the U.S.) and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in any stage of development or in commercial products, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> contract assets of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to collaborative agreements as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, for amounts considered probable to receive for development milestones that relate to intellectual property licenses granted to collaboration partners in prior periods. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Upfront</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Development</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sales</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration partner and agreement date:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche (December 2006 and September 2017)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baxalta (September 2007)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pfizer (December 2012)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen (December 2014)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AbbVie (June 2015)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lilly (December 2015)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BMS (September 2017)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alexion (December 2017)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted. Accordingly, the reported revenue amounts for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are based on different accounting policies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements representations and are not obligations to provide goods or services.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals and successful completion of clinical trials. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target if the exchange right is exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because our agreements only have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to Note 4</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue</font><font style="font-family:inherit;font-size:10pt;">, for further discussion on our collaborative arrangements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other differences in revenue to be recognized under the previously existing authoritative accounting literature and ASC 606 applied to our collaborative agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net - as reported under ASC 606 beginning January 1, 2018</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hylenex </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recombinant</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex </font><font style="font-family:inherit;font-size:10pt;">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon recognition of revenue from product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustments.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of a practical expedient allowed in ASC 606. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Bulk rHuPH20</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from bulk rHuPH20 formulations as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ENHANZE Drug Product</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms and sales of bulk rHuPH20 that has no alternative future use.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">We report royalties received from collaboration partners as a separate line in our statements of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront amounts, event-based development and regulatory milestones and other fees, sales milestones and royalties).</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net and other contract assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales to collaborators</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">451</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from royalty payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from other product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,075</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other contract assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for distribution fees and discounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(501</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accounts receivable, net and other contract assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and payroll taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,914</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accrued expenses, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense by type of share-based award (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs, RSUs and PRSUs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,658</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,297</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,749</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78,204</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,911</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding for basic<br clear="none"/> net (loss) income per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,190</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,633</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net effect of dilutive common stock equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding for diluted <br clear="none"/> net (loss) income per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,396</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income per share:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.45</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,702</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,762</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,793</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,527</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,619</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The assumptions used in the Black-Scholes model were as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/> September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/> September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58.6-60.6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.5-70.8%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58.7-70.1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.5-71.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average expected term (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.75-2.87%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73-1.93%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.25-2.87%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73-1.94%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</font></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrecognized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Recognition Period</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.45</font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSAs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,743</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.09</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.24</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on February 20, 2018. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated statement of cash flows within operating activities to conform to the current period presentation. There was no change to net cash used in operating activities. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents and Marketable Securities </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our cash equivalents consisted of money market funds and commercial paper.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, restricted cash of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> was pledged as collateral for the letters of credit.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We capitalize inventory costs associated with our drug candidates prior to receipt of regulatory approval, based on management’s judgment of probable future commercialization.  We would be required to expense these capitalized costs upon a change in such judgment, due to, among other factors, a decision denying approval of the drug candidate by regulatory agencies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bulk rHuPH20 formulations manufactured for partner use prior to our partner receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries and with no alternative future use are recorded as research and development expense. All direct manufacturing costs incurred after the partner receives marketing approval are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in any stage of development or in commercial product, and ENHANZE drug product used by our partners in clinical trials, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, inventories consisted of </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant inventory, net and </font><font style="font-family:inherit;font-size:10pt;">$15.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of bulk rHuPH20. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted. Accordingly, the reported revenue amounts for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are based on different accounting policies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements representations and are not obligations to provide goods or services.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals and successful completion of clinical trials. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target if the exchange right is exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because our agreements only have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to Note 4</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue</font><font style="font-family:inherit;font-size:10pt;">, for further discussion on our collaborative arrangements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other differences in revenue to be recognized under the previously existing authoritative accounting literature and ASC 606 applied to our collaborative agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net - as reported under ASC 606 beginning January 1, 2018</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Hylenex </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recombinant</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex </font><font style="font-family:inherit;font-size:10pt;">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon recognition of revenue from product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustments.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of a practical expedient allowed in ASC 606. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Bulk rHuPH20</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from bulk rHuPH20 formulations as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ENHANZE Drug Product</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms and sales of bulk rHuPH20 that has no alternative future use.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">We report royalties received from collaboration partners as a separate line in our statements of operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront amounts, event-based development and regulatory milestones and other fees, sales milestones and royalties).</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant and bulk rHuPH20 and ENHANZE drug product that has alternative future use. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. Prior to bulk rHuPH20 and ENHANZE drug product having alternative future use, all costs related to the manufacturing of those products were charged to research and development expenses in the periods such costs were incurred. During the</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, sales of bulk rHuPH20 and ENHANZE drug product included </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of cost of sales that were previously expensed as research and development. Of the bulk rHuPH20 and ENHANZE drug product that has alternative future use on hand as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> in manufacturing costs were previously recorded as research and development expenses. We expect to sell this inventory by the end of 2020. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:10pt;">When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. The manufacturing costs of bulk rHuPH20 for the approved collaboration products, Herceptin SC, MabThera SC (RITUXAN HYCELA™ in the U.S.) and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in any stage of development or in commercial products, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> in-licensed technologies that have alternative future uses in research and development projects or otherwise.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record compensation expense associated with stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and RSUs with performance conditions (“PRSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">, with the exception of the alternative minimum tax ("AMT") credit carryover of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">. Under the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017, the AMT credit carryover will either be utilized, or if unutilized fully refunded in 2022. For all other deferred tax assets the valuation allowance will reduce the net value to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> until such time as we can demonstrate an ability to realize them.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Act reduces the U.S. federal corporate tax rate from 35% to 21%. As a result, the Company evaluated and adjusted its deferred tax assets to reflect the new corporate tax rates as of December 31, 2017. The Company is still evaluating other potential impacts and planning opportunities related to tax reform.  As of September 30, 2018, the Company believes that its disclosures in its financial statements as of December 31, 2017 are still reasonably accurate.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net (Loss) Income Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> September 30, 2018, approximately </font><font style="font-family:inherit;font-size:10pt;">13.8 million</font><font style="font-family:inherit;font-size:10pt;"> shares of outstanding stock options, unvested RSAs, unvested RSUs were excluded from the calculation of diluted net loss per common share because a net loss was reported in each of these periods and therefore their effect was anti-dilutive.  Outstanding common stock equivalents totaling approximately </font><font style="font-family:inherit;font-size:10pt;">7.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">14.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, were excluded from the calculation of diluted net (loss) income per common share for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> September 30, 2017, respectively, because their effect was anti-dilutive.  A reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,749</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78,204</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,911</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding for basic<br clear="none"/> net (loss) income per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,190</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,633</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net effect of dilutive common stock equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding for diluted <br clear="none"/> net (loss) income per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,949</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,396</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income per share:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.45</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate our business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"> recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Our long-lived assets located in foreign countries had minimal book value as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption and Pending Adoption of Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018 </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently do not hold equity securities. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU 2016-16, Income Taxes; Intra-Entity Transfers of Assets Other Than Inventory.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance removes the current requirement to defer the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) until the asset has been sold to an outside party. As a result, the income tax consequences of an intercompany transfer of assets other than inventory will be recognized in the current period income statement rather than being deferred until the assets leave the consolidated entity.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We adopted the new guidance on January 1, 2018. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In March, April, May and December 2016, the FASB issued additional guidance related to Topic 606.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new standard superseded nearly all existing revenue recognition guidance. Under Topic 606, an entity is required to recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. Topic 606 defines a five-step process in order to achieve this core principle, which may require the use of judgment and estimates, and also requires expanded qualitative and quantitative disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including significant judgments and estimates used. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We adopted the new guidance on January 1, 2018 using the modified retrospective approach. Refer to Notes 2 “Revenue Recognition” and 4 for additional detail regarding the impact of this adoption.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Financial </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In July 2018, the FASB issued additional guidance related to Topic 842.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2019. Early adoption is permitted.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to implement the guidance on January 1, 2019 using a modified retrospective transition basis for leases existing as of the period of adoption. In order to adopt the new standard, we will be using available practical expedients and newly implemented processes and internal controls for lease accounting. The practical expedients allow us to carry forward our historical assessment of whether existing agreements are or contain a lease and the classification of our existing lease arrangements. We expect all of our real-estate and automobile operating lease commitments will be recognized as lease liabilities with corresponding right-of-use assets upon adoption, resulting in an increase in the assets and liabilities of the consolidated balance sheet. We anticipate that the adoption will have a material impact on our consolidated financial statements. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new guidance removes, modifies and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our condensed consolidated financial position or results of operations.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certain Balance Sheet Items</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net and other contract assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from product sales to collaborators</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from revenues under collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">451</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from royalty payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable from other product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,949</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,075</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other contract assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for distribution fees and discounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(501</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accounts receivable, net and other contract assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,656</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,401</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,638</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total inventories</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,285</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,146</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,793</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,527</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,717</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total prepaid expenses and other assets, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,619</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,879</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations. Such amounts are reclassified to work-in-process inventory as materials are used or the CMO services are complete.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,702</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Property and equipment, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:9pt;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense totaled </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced research and development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and payroll taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,914</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced manufacturing expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,396</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less long-term portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     Total accrued expenses, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees and event-based payments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total license fees and event-based payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,489</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,487</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,568</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,507</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,297</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

EX-101.SCH 7 halo-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2407402 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2407407 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2407408 - Disclosure - Certain Balance Sheet Items - Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Certain Balance Sheet Items - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Certain Balance Sheet Items (Notes) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Certain Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Fair Value Measurement Fair Value Measures (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Fair Value Measurement Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Fair Value Measurement (Notes) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Fair Value Measurement Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Long-Term Debt, Net Long-Term Debt Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Long-Term Debt, Net (Notes) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Revenue Collaborative Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Revenue Collaborative Agreements tables (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Revenue Collaborative Agreements Textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - Revenue Deferred Revenue Timing (Details) link:presentationLink link:calculationLink link:definitionLink 2404407 - Disclosure - Revenue Disaggregated Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2304302 - Disclosure - Revenue Disaggregated Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Revenue (Notes) link:presentationLink link:calculationLink link:definitionLink 2404408 - Disclosure - Revenue Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Revenue Revenue Adjustments - 606 Implementation (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Share-based Compensation (Notes) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Share-based Compensation Share-based compensation textuals (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Share-based Compensation Share-based compensation, unrecognized (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Share-based Compensation Share-based compensation, valuation (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Stockholders' Equity (Deficit) (Details) link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Stockholders' Equity (Deficit) Public Offering (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Subsequent Event (Notes) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Subsequent Event (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402410 - Disclosure - Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - Summary of Significant Accounting Policies Income tax (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - Summary of Significant Accounting Policies Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies Research and development (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies Revenue recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2402409 - Disclosure - Summary of Significant Accounting Policies Segment information (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 halo-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 halo-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 halo-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Collaborative Agreements Disclosure [Abstract] Collaborative Agreements Disclosure [Abstract] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Development Fees [Member] Development Fees [Member] Development Fees [Member] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] 2017 Roche [Member] 2017 Roche [Member] 2017 Roche [Member] Roche [Member] Roche [Member] Roche Baxalta [Member] Baxalta [Member] Baxalta [Member] Lilly [Member] Lilly [Member] Lilly [Member] AbbVie [Member] AbbVie [Member] AbbVie [Member] Janssen [Member] Janssen [Member] Janssen Collaboration [Member] Pfizer [Member] Pfizer [Member] Pfizer [Member] Alexion [Member] Alexion [Member] Alexion [Member] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Domain] Deferred Revenue [Domain] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Agreements Terms Collaborative Agreements Terms [Abstract] Collaborative Agreements Terms [Abstract] Deferred Revenue (Textual) [Abstract] Deferred Revenue (Textual) [Abstract] Deferred revenue. Deferred Revenue Deferred Revenue Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement Nonrefundable upfront license fee payment received under collaborative agreement. Collaborative Agreements (Textual) Collaborative Agreements (Textual) [Abstract] Collaborative agreements. Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Additional Maximum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones Additional Maximum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones Additional maximum proceeds receivable from collaborator of license and collaborative agreement upon achievement of clinical development milestones for elected targets. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Share-based Compensation [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block] Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities, available-for-sale Available-for-sale Securities, Current Accounts receivable, net Accounts and Other Receivables, Net, Current Inventories Inventory, Net Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Prepaid expenses and other assets Prepaid Expense and Other Assets, Noncurrent Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Deferred revenue, current portion Deferred Revenue, Current Current portion of long-term debt, net Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Deferred revenue, net of current portion Deferred Revenue, Noncurrent Long-term debt, net Long-term Debt Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies (Note 9) Commitments and Contingencies Stockholders' equity (deficit): Stockholders' Equity Attributable to Parent [Abstract] Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock - $0.001 par value; 200,000 shares authorized; 142,301 and 129,502 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity (deficit) Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity (deficit) Liabilities and Equity Property, Plant and Equipment [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Document and Entity Information [Abstract] -- None. No documentation exists for this element. -- Document Information [Table] Document Information [Table] Document Information, Document [Axis] Document Information, Document [Axis] Document [Domain] Document [Domain] Document Information [Line Items] Document Information [Line Items] Entity Registrant Name Entity Registrant Name Trading Symbol Trading Symbol Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Royalty-backed Loan Royalty-backed Loan [Member] Royalty-backed Loan [Member] Secured Debt Secured Debt [Member] Senior Loans [Member] Senior Loans [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2016 [Member] 2016 [Member] 2016 [Member] 2017 [Member] 2017 [Member] 2017 [Member] 2018 and thereafter [Member] 2018 and thereafter [Member] 2018 and thereafter [Member] 2017 Quarterly Maximum Payment [Member] 2017 Quarterly Maximum Payment [Member] 2017 Quarterly Maximum Payment [Member] 2018 Quarterly Maximum Payment [Member] 2018 Quarterly Maximum Payment [Member] 2018 Quarterly Maximum Payment [Member] 2019 Quarterly Maximum Payment [Member] 2019 Quarterly Maximum Payment [Member] 2019 Quarterly Maximum Payment [Member] 2020 Quarterly Maximum Payment [Member] 2020 Quarterly Maximum Payment [Member] 2020 Quarterly Maximum Payment [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Issuance date Debt Instrument, Issuance Date Total loan balance Debt Instrument, Face Amount Secured debt original draw Secured debt original draw Secured debt original draw Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Description of Variable Rate Basis Debt Instrument, Description of Variable Rate Basis Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Debt, Interest Rate Debt, Weighted Average Interest Rate Royalty payments to be applied to debt instrument Royalty payments to be applied to debt instrument Royalty payments to be applied to debt instrument Debt Instrument, Periodic Payment Debt Instrument, Periodic Payment Debt Instrument, Maturity Date, Description Debt Instrument, Maturity Date, Description Prepayment fee, percent Debt Instrument, Prepayment Fee, Percent Debt Instrument, Prepayment Fee,Percent Debt instrument, covenant in compliance Debt Instrument, Covenant Compliance Interest Costs Capitalized Interest Costs Capitalized Accrued Interest Debt Instrument, Increase, Accrued Interest Lender Fee Debt Instrument, Fee Amount Debt Issuance Cost Debt Issuance Costs, Gross Interest Expense, debt Interest Expense, Debt Outstanding loan balance Secured Debt Debt Instrument, Unamortized Discount Debt Instrument, Unamortized Discount Maturity date Debt Instrument, Maturity Date Final payment as percent of original principal Final payment as percent of original principal Final payment as percent of original principal Final payment Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Debt Instrument, Unused Borrowing Capacity, Amount Debt Instrument, Unused Borrowing Capacity, Amount Debt Instrument, interest only period Debt Instrument, Payment Terms Accrued interest, noncurrent Other Accrued Liabilities, Noncurrent Accretion of debt balloon payment Accretion of debt balloon payment Accretion of debt balloon payment Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Asset-backed Securities [Member] Asset-backed Securities [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Money Market Funds [Member] Money Market Funds [Member] US Treasury Securities [Member] US Treasury Securities [Member] Commercial Paper [Member] Commercial Paper [Member] Corporate Debt Securities [Member] Corporate Debt Securities [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Assets, Fair Value Disclosure Assets, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Available-for-sale Securities Available-for-sale Securities Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Investments, Fair Value Disclosure Investments, Fair Value Disclosure Statement of Cash Flows [Abstract] Capital Expenditures Incurred but Not yet Paid Capital Expenditures Incurred but Not yet Paid Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss) Attributable to Parent Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation Share-based Compensation Depreciation and amortization Non-cash interest expense Amortization of Debt Issuance Costs (Accretion of discounts) amortization of premiums on marketable securities, net Accretion (Amortization) of Discounts and Premiums, Investments Deferral of unearned revenue Increase (Decrease) in Deferred Revenue Recognition of deferred revenue Recognition of Deferred Revenue Recognition of deferred rent Straight Line Rent Other Other Operating Activities, Cash Flow Statement Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Available-for-sale Securities Proceeds from maturities of marketable securities Proceeds from Sale of Available-for-sale Securities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of common stock, net Proceeds from Issuance of Common Stock Repayment of long-term debt Repayments of Secured Debt Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash end of period Payments for Tenant Improvements Payments for Tenant Improvements Deferred Revenue Disclosure [Abstract] Collaborative Agreements Collaborative Arrangement Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] EX-101.PRE 11 halo-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 slide1a65.jpg begin 644 slide1a65.jpg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�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end GRAPHIC 13 slide2a54.jpg begin 644 slide2a54.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X2?V17AI9@ 34T *@ @ !@ + ( M F (8@$2 , ! $ $Q ( F (B $R ( 4 (KH=I M 0 ! (PNH< < @, 5@ $48'EZ@X2%AH>(B8J2DY25 MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08' M" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*! M"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*C MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S M]/7V]_CY^O_: P# 0 "$0,1 #\ ]NUZ[FL="O+J!@LL41921G!KS*/Q9XID MMTF&IVN& ^78N1D9Z?YZUZ6"H4ZD&YJ^IY.88BK3FHTW;0<_BGQ7&&)U&U(5 M03A%/6HD\9>*'FEC&H0?NWV9\H8/7D>W%=JP=!J_*>>\;B4[)[2-'.H0.&./EB7C@'^M..#H2=N4F>.Q,5?F* MG_"QO$O_ #]Q_P#?I:L6GCSQ-=SB%;^%">A>)0.M:2R^@E>QE',L0W:Y?_X2 M?Q9M)&IVA(."-J^_^'ZT'Q/XJ&W_ (FMF02 2$7CG'\ZQ^JX?^4Z/K>)_F*- MWX[\3VA4-?0MN&?EB6JX^(OB4D 7:$G@#REK:. H-7L82S+$)VN61XU\8L,@ ML1_U[CW]O8T@\;^,"VT.2<9_U I?4L,/Z_B^XB^.?%SDA9,X.#B <'\J0^.O M%PQF3J"1^X'2CZCA@_M#%=QQ\;^,!G+GCK^X'%5O^%C>)?\ G[C_ ._2TU@, M.]D2\RQ*W9ZQX5O[C4_#=G>73!II4RQ QGFMFO JQ49M+N?3T).5.,GU045F M:A10 44 %% &5XEC>;PW?QQHSNT) 51DFO';6RE@BC63PY=R.H 9R#SUYQCW M_05ZV7SBJ;3=M3Q,SIRE5BU&^@L5K?I@X]*& M[I3G(.T\?IS7?[2%_C/-5*=M8,C2SNMP,F@73 $':$QNP /[O'()X]?:IA;. M @_X1FZP&!.03D?E0ZD.DP5*?6#&K;3*3CPU=WC MTR[1"Q*KY9X'Y54*M-/61%2A4DO=@QG]B:Q_T#[O_OVU']AZN>NG7?\ WZ-: M_6*/\R,?JU?^5B?V%JW_ $#;K_OT:GM-'OX9]]QH]W,FTC8$*]>,YQVI2Q%) MJRD..&K)W<67[NSGGB=8O#EU$Q7"E5/RGCGIST_6LK^Q-7_Z!UW_ -^FJ*=: MFE9R1=2A5D[Q@T']AZN>NG7?_?HTJ:+K$;JZ:==!E.0?*/!K3ZQ1_F1G]5K_ M ,K+GE>)O,\SR+[<>2?+/H1_4_G0(O$JMN%K>?\ ?DX_E[5GSX?NC7DQ79B1 MP>)(MVRUO &)+#RC@YX]*7R?$N<_9;S=MVY\DYV^G3I[4<^'[H.3$]F B\2C M.+:]&003Y1Y!_"J/]A:M_P! VZ_[]&JC6H1V:(E0Q$MXL]L\&(UMX3L(IU,< MBIAE<8(Y-;WF)_>%?-5M:DFNY]=AU:E%/L'F)_>'YT>8G]X?G61M.F/Y M\U46D]2)Q'8R5*?G_ M -?\ZO8'I6E+VH *R[JZC2[D5KY MHBF,J1QR.!G\,TTTMQ--E3[=;LNX:L H<@C)ZX^G3D4Z34(5,:1ZL%;&6W)G M/&?3C_Z]5*2:T1,8M/5C6OA+&'360$SMRJ C)&1DX]J#?*"1_;*C<1@;.F?3 MCFH++D>JV=LBQ7%Z'DZEB,9SR/T-2?VSI^6!N5&WJ<&@"Y#,EQ"LL9RC<@^M M/H *@N+N&U"F9BH;.#CTY/Z<_A0!676].?I=+C) /K@X/ZBKTE+Y,7_/-/RH M ?H* .?2[F,)<:GIW4X8XXST[#\OUYXO)9ZGAF,]OEA\OR [??IS0!,UI>[ MLB6'[@!&W[QQWX],X_P_Q -,]#2T )W-5KJVEG=&CN#$%#!E M /S9&!T(Z4 0R6-VQA9+]UVJ%8!.&QWZ]TL MY[>5GFNVG!7 #+C'ZU
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�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
G:G_&+X4:)\;OAQJW@GQ$]TFC:IY/GM8R".8>7,DR[6*D#Y MHUSQTS7;T4 >7>./V=?!GQ&\3>&=:\0VRF96MIH;B+RI!*A7 MYCM'!!&#S7ETO[ ?A187TRS^(7Q+TWPBP*'PK:^)G&G!. (PC(6V #H6/0<\ M5]144 WT71;08AM;9>,GJS$\LQ[LQ)/2"27#.SG
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
6O[17[3^F>/\ 5$UGQ3IL M^@6DMW&#'%[2*<(.$,L:12, .K'CM7G7[+OP+^&O[1VBZS<>._$OB/2O MVH[/4+IM,WRCS0)(\8 Y1^[_.@#])JQ/&5] M/I7A'7+VU?RKJVL9YHI, [76-BIP>#@@=:^5/V%?CY<>)_%7CKX1W_CJW^)Z M^$!!=Z)XTMYEE?4].E PD[ G,T+$(S9RV>>F6^I?B%_R(/B;_L&7/_HIJ /+ M?V)_B-XB^+G[+O@+Q?XLU#^U?$6J6LTEW>>1'#YK+<2H#LC54'RJHX Z5[G7 MYK?L%_LNVW[1G[,_A#5OBY>WNN^#+-9[3PYX.M;R:SL$BCN9/,NK@1.K33-, M) -QVJJC@[N/2_A_X(;]C_\ ;,\'_#CP??WD?PJ^(NDW\MKX;O+N6YCTN_LX M_-=X&E9F"LF,C)R6.<[5( /MZBOEGX6W4S_\%!OC?;M-(T$?AO0V2(L2JDJ^ M2!T%=3^WE<2V?['WQ4F@E>&5-&01TH ]]HKX%_;,UJ_P!)_P"" M9_@S4;*:07T=EX;D5P[;G;;"<$@@G)Z\\YKLK7_@G+X2^)'AA=8^+^JZWXL^ M*U_&;B[\30ZK<0_V?._S>59PJPB2*,G"@H6<*S)/ TC%E+>8 MB$$DD9R3\NT ^Z:*^(]3TCQ#^W-\>O'7AZ^\1:EX=^"'P_U#^P[O2M'N3;7& MOZH@S,)94^98HR0-N><*0 Q)71\;?L&Z)\&] O\ Q=^SS=:G\/O&>F0O=+IJ MZGFZTJ*2;6ZBGD?(< J&!&TD'L" #[+HK\Z/A-J5Y)_P1EOKU[N9KO^P- M;/V@R,9,C4KH [LYZ5U_[/O[&^D?M ?!7P5XP^/4VH>.M2U'1K232]$?4;BU MT[1[(P*L"Q10R+NF:(AGDBZIJWVCPU96EKY3:;:9?]VYVCG:8UVY?'EEMQ+FO8*^3OV) M;R>Z^)G[323323)%\0[I(UDI?M,+\4K/Q]KNJ3? M"K1_&VK00^&;"]EM5U6\=P96NI8V$C11QF()&I W,Q[$$ _3&O(=<\%_%.Z_ M:.\.^)-,\;65G\*+72Y+?4O"LEJ&GN;L^9ME5]O RT1SO&/*("G>37SAXN^$ MFD_L._';X0:U\+9+[0?!?CCQ''X5U_PK)?37%C++<*?(N(UE9BDBL#R#T4 M L#WOCR\G3_@I+\+[<3R+;R>"-29H0YV%A,<$CIF@#ZPHKX#_:H^-6B_$O\ M:7E^"GB;XH1_"OX;>'=.AO\ Q)=1ZBEC>:S=3*KQ64VB;[#6M.\723QO*O(6XCEE,OVCM4UCXB^,M6B6]DTJ74KBTTW1PZ[A;V\,# MIMVA@&.<$@\=20#[4KYZ_:.^+OB?X>?&+X"^']#O8[;2_%GB">PU:-X$<:M>@72B!2 H M$V(>>\6PT ?4_P 7O!?Q5\2?$?X:ZGX$\<6/AKPII-^TWB;2KJU\R34['[37M72*S:]FN#M M: 2$,\KL[_,['YF.,X'&*Z/]J?QIXU^('QD\&_L^_#_7Y_!]UKFG3:]XE\26 MF/M-GI2.8@D!ZK))("NX8(.W!P6P ?6-%?(=Y_P3'^$EOI[7'AR]\6>%_&BK MNB\86?B"Z?4!,,%9'W/Y;#+[4(OA?\1-(U"6#PW?7DEU%IE_9IYK26[2,756CP""3DL2 M MB5]0U\=?\%+V;2_ /PA\1(-LFA_$O1;TR 9*J!,#_P"/;/RK[%H **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@#Y3\/_ !+\4_#']NO7/ASXKUNZU+P?X\TI=8\(_;&!6SN8 WVJSC/' M!&^3!S@+&!U.?J>25((V=V5$4%F9C@ #J2:^6_\ @H9\/=4U;X0Z;\2?"Z8\ M;?#'48_%&FR*"6>&,@W4)QU1HU#L._D@=":P?VM?VDAXE_9,\-'X?2^?XF^+ MXM="\/VZO^\7[6 )R3Q@QHS1EOX7=ZS=M\.[K M5CHW@_2,@6XMK;Y9;L#&296"G)/!$@Z8Q]+:]XBTKPKIDVI:UJ=II.G0X\R\ MOIT@A3)P,NQ '/J:YWX-?"_3/@O\*_"_@?1P/L&AV$=HLFW!E<#,DI']YW+. M?=C7R=X'^&]K^V[^T!\0O&7Q$=M:^'/@#Q!<>%?#GA%W8V$UU;@"XO9TSB0D MN,9&"#@Y" $ ^M/!OQB\!?$;[6/"?C?PWXH:T3S+@:-JUO=^2O\ >?RW;:/< MU=?XB>%(_#$/B1_$VCIX>F;;'J[7\0M'8L4PLV[83N!7@]1BOG[X\?L0^ M4 M\'WVN_#;P]I_PU^(FCP2W6C:SX7M$LHT?@#X/'@#X-^$] 7QC>"K;]B']J3X=KX%DFT_X6_$Z_ET74O"K3N]K8:F5#07-L&)V;SA2HXP M& XVA #[.M?$>DW^K7VCVNJ6=QJU@J-=V$5PC3VZN,H9(P=R!AR,@9'2I-:U MO3O#>F7&I:M?VVEZ?;KNFO+V9888ESC+.Q R1U/>OEKX'MM_P""AG[2P?AF MTOPXR@]2!:8)'MFNK_X*'?\ )EWQ5_[!B_\ H^*@#WBZ\0:98Z&^M76I6=MH M\*$!_>!6*,4[XSD;$M9^(7[/.HW_ M (6T6_U#5/B)I>EW]U69#YMY7929(O^F;$K[4 4/VC?LWP4_9#TA/ MA;\2->U;3F\7Z?'%K47B-KR<1R7 62V6YC8$Q#&-A)ZD&OM6?Q)I5KKEMHLV MJ6<.KW4;36^GR7"+<3(OWG2,G"_#WP__ &7=(T?POH.F M>&](C\7:2Z:?I-G':P*S7.6(CC4*"3R3CFMOXH?\I)?@I_V*6L?UH ^L))4@ MC9W941069F. .I)KR?XY:3I7QL_9_\ $-EI7Q(C\':1JENNSQGI-ZACME29 M2Q$HD52A*-&V'&0S#(KT;Q9_R*NL?]>4W_HMJ_/?P1_RA3N?^Q?U#_TY34 ? M?'PYT7_A'/A_X:TG^W+CQ,;+3;>W_MJZD$DM_LC5?/=@2&+XW9R%_#>HX!^R:OK5M:R\\CY)'!_2OG[X\?%OQ!\)?V(? Y M\(2+!XO\266B^&M'N6)'D7%U BB45%<8/6_"_\ 8+^#W@#P@NFZ MUX.TGX@:]< R:GXD\4V$=]?7UPV3)+OE#&/))P%(QQDD_,0#%_:"\>:I;?M/ M_LLVN@^(KR/P]K][K)O(=-OG%IJ,:V<3Q&14;9*H)++G(&21KG&66-V(&>YKY/TKP#;_ +;G[4/Q$N_'LLNH M?##X8ZFN@:1X3$C"SOM15";BYN5!&\H2 %Z8*@\!@_J?Q4_8=^'7B313?^ ? M#FE?#'Q_IF;G0O$?A:SCT^2VNE!*>8L*JLL9)VLK@Y4GVH H?\$X_%VN^.OV M5=!U?Q'K>H>(-5DU#44>^U2ZDN9V5;N55!D>&?"UY*N^.WUK6+>SD=?4+(ZDCWKXD_97^+MY\ O\ @E?J/CH0JVK: M.VIF".<847&0>JNA*G\#7SEX*\6Z[>?\%!_B5X;GUO4IO#]KX.T^ZM]*>[=K2"9 MI0&E2$G8KD=6 R:^8_AC\9OA9\,_VK_ [? 2;6K3P?XVO?[(\4>$IM,N[:PA MF?"VMY )D"QL)" P!^[P, G'T/\ #_\ Y28?%3_L1M-_]'"@#N_V:/!>F? ; MX5Z\FI_&";XC::NL7-Y<>(]*1PC#\B:Z+]A/Q??^&/"/BWX,>+;S/B;X57[:7]HN&VFYTE@9+&Z MYZ*8LJ!_"J)GK0!]+3^)M(L]>MM$FU6QAUFZB:>#3I+E%N)8U^\Z1D[F48.2 M!@8JSJ6I6>BV,]]?W<-A96ZF2:XN9!''&HZLS$@ >YKY._8[AD^.GQ:^)/[1 M=^C-I^K3MX8\'>8#A-'M9"'F3/($TREB.S*_K7CG[7_QL\">-OVN(_AG\5]2 MU6W^%7@W3H=0O=%TJVN9QK.J3*DD2W @4L(HXG5@"1\V?[W !]Q>%OCY\,O' M6L+I/AOXB^$_$.JL"5L=*URUN9SCKA$D+?I75^(/$.E^%=(GU36M3L]'TRWV M^=>W]PD$,>Y@J[G^%Y=+M?#,WA#4(T#66N> M&/!UW87MG*O*2K)% I<@@'Y\@_K57XC_ !DUOXT_\$C/'FH>)9IK[7='O+/1 M;K4KB)HWO_)U2R,=P58!@7BDC)SR6W$]: /T#UWXV?#OPOKS:)K7CSPSI&M) M$)VTZ_UBW@N!&1D.8V<-M(YSC%=C;S1W,*2PNLL4BADD4@JRD9!!'45\V_"G M]C7X<6_P5@L-=\,V&L^*O$.C.NO>*;ZW2;5;JXNX,7+_ &E@9%!9VVJ#A<# M[U6_8-\>:DWPQUOX8^*[D'QC\+;]_#E^\AQYUHF39W(R3\CP@ $]?+)[T ?1 M@T.35;*/6YX3<0Z:]P@N9(@2#(L9.XJ"#R!CBJOC3QAI7@/PS>ZU MK6I66DV5O&3]HO[A(8]^#M7!I=.U.Y/A M7P@S@X72+5\23)G^&:8%N#PROZU]'?%3PCH7CCP#K.F>(]%T_7M--O)-]CU2 MTCN8=Z*61MC@C*D @XR#0!\=_P#!./3]'\>>&_#WQ0UWXLZUXB^*VMIJ$^J^ M'[CQ(LL'E_:9(T!L>J*B*C+@ *7./EV@?;/BCQCH/@?3#J7B/6].T#3@VTWF MJ74=M"#@G&]R!G /?M7RG_P3%^&?@^Q_92^'?C"V\)Z';>+;JVOHY]?ATV%; M^5/MTZ[7G"^8PVHHP6Z*!V%#?B7X0^(UO+<>$_%>B^)X(_ M]9+HNHPWBI]3&S 5HWWB32M+U33M,O-4L[/4M2\S[%9W%PB377EJ&D\I"^$G@G4_C-\&--M/AMX^\$V[ZM_P 2&$6UEJ5I%B2X MMKBWCPC(45CT&<8/'(\Z_:\1/VF/B5^Q;+:W-UI&G^-K?4[FZ^Q3E)5LKBUL M9+F 2#!&Z%I8R?\ :/':@#[Q\)?$SPAX^GU&'POXKT7Q)-IKB.]CTC48;IK5 MR2 LHC8[#\K<-CH?2NIKCOAW$_!/PCTV:R\%>$]'\*V\RQK.NDV4=N9]@(1 MI64 R, 3\S$GD\\UY3^W-\6_$/PE^!,S>$'6W\8>)=3M?#6CW#,1Y%Q=,5$H MX^\J*Y7T8 \XP0#TWQ=\>1\DC@ M_I7B/[07CS5+;]I_]EFUT'Q%>1^'M?O=9-Y#IM\XM-1C6SB>(R*C;)5!)9 /""Z;K7@[2?B!KUP#)J?B3Q381WU]?7#9,DN^4,8\DG 4 MC'&23\Q^'O#NIWB[[:QU;58+ M6>92$#:3E>=HR,+D _0#7/$ MVD>&=*.IZSJMEI.FJ5!O+ZY2&$%B HWL0.20!SSFL+QI\8O /PWNK>U\6^-_ M#?A:ZN%W0PZUJUO9O(N<959'4D?2OE/_ (*&^!=)^%__ 3WU#POX4@FAT?2 M9]+@L(9)WN7"B\C*C>Y9FY/'/H!Q@5Z7$?V(OA_H6@KJOQ%\.Z7\2_B)JRK M=Z]X@\4V<>H//=, 76)9598HU/RHJ 84 4 ?0>BZ]IGB32X-1TC4;75=.N!N MBO+&=9H9!G&5=20>?0U)J6I6>BV,]]?W<-A96ZF2:XN9!''&HZLS$@ >YKXG MUKP';?L0_M-_#O4? <\FF_#+XF:O_P ([J_@]I6^QV>H2*/L]U:J20A9EP5] M 0.&4)P?[7_QL\">-OVN(_AG\5]2U6W^%7@W3H=0O=%TJVN9QK.J3*DD2W @ M4L(HXG5@"1\V?[W !]Q>%OCY\,O'6L+I/AOXB^$_$.JL"5L=*URUN9SCKA$D M+?I75^(/$.E^%=(GU36M3L]'TRWV^=>W]PD$,>Y@J[G^%Y=+M?#,WA#4(T#66N>&/!UW87MG*O*2K)% I<@@'Y\@_K57XC_ M !DUOXT_\$C/'FH>)9IK[7='O+/1;K4KB)HWO_)U2R,=P58!@7BDC)SR6W$] M: /T0;XG>#X_&47A%O%FAKXKF3S8]".I0B^=-I;<(-V\C:"<@=!FJVG?&#P% MK'BR?PO8>-O#M]XG@=HY=%MM6MY+V-EY96A#[P1W!%>)_#G]E71_!7P#N+CP M[I=B?C'JGAVZD;QQ?0J^IOJMU:L'F-TP,BKYK_=#8 '3O7AG[)O@']G/X@>" M_#'PN\4^!;/PC\:?"Y@EU.PU2%M/UN>^A(=[B&Z4K)-&Y4OM5SA". IH ^H MO%GPQ75?VJ/!7C;_ (6G?Z1)INDW%JGP_CNE6#4P?-W7!C+@MM\P;CL;F*/Y MEVU[->WMOIMI-=74\=K;0H7EGF<(B*!DLS'@ #N:^5/BA_RDE^"G_8I:Q_6L M#XJ:!/\ M=_M?ZI\)=;O+J#X4_#[2[34M=TBSN'B_MF_N0)+>*=D(/E*F&"Y MZJW]X%0#Z<\-_'#X=>,M:;2/#_C_ ,+Z[JRG#6.FZS;7$X/H8TF^!] M)\&:K"H?3_$'ANT2ROK*=3F.99(]IVBND(!#1N[@.""#E2>"*WO#OB;2/&&CV^K:#JMCK> ME7*[H+[3KA+B"4>JNA*L/H:^0_V+/V2_!NK? KP7XT^(^AZ=\1/&&O:'9S?; M/$5I'>1V5@8%%I:V\4@*1(D&P$J,LQ?96,*=$#J&8A>/NC&% !]G5\G_'CXS?%C7/VCM, M^"/PDF\/^'-2_P"$?/B74O$?B*)Y@(#,81';Q#AV#8))!'/\.TY^L*_/#]M; M7M3^,'Q^\,^'_@!IM]J'QS\""2YOO%&GSQQ6>EVKQMFRN'D!21W)XC;A26'. MYP #W/\ 97^//COQ7\1_B3\)_B?!HMUXS\#FSE;6O#>\6=]!<1[URC#,/2O+_BC\;?#_P4M1?>($O)(;Z\,,7V.)9#N$2$YRPP,5YV M/V^/AJ/^7?7/_ -/_CE=E/!XBM'GIP;1P5 M?2>31DU\V?\ #?/PU_Y]]<_\ T_^.4?\-\_#7_GWUS_P#3_XY1_9V+_Y]O[@ M_M7!?\_5]Y])Y-&37S9_PWS\-?\ GWUS_P T_\ CE'_ WS\-?^??7/_ -/ M_CE']G8O_GV_N#^U<%_S]7WGTGDT9-?-G_#?/PU_Y]]<_P# -/\ XY1_PWS\ M-?\ GWUS_P T_\ CE']G8O_ )]O[@_M7!?\_5]Y])Y-&37S9_PWS\-?^??7 M/_ -/_CE'_#?/PU_Y]]<_P# -/\ XY1_9V+_ .?;^X/[5P7_ #]7WGTGDU3U M;_D'R?[R_P#H0KYX_P"&^?AK_P ^^N?^ :?_ !RJ]]^WE\-[FV:-;?7-Q*G_ M (\T[$'_ )Z4?V=B_P#GV_N#^U<%_P _4?3>31DU\V?\-\_#7_GWUS_P#3_X MY1_PWS\-?^??7/\ P#3_ ..4?V=B_P#GV_N#^U<%_P _5]Y])Y-&37S9_P - M\_#7_GWUS_P#3_XY1_PWS\-?^??7/_ -/_CE']G8O_GV_N#^U<%_S]7WGTGD MT9-?-G_#?/PU_P"??7/_ #3_P".4?\ #?/PU_Y]]<_\ T_^.4?V=B_^?;^X M/[5P7_/U?>?2>31DU\V?\-\_#7_GWUS_ , T_P#CE'_#?/PU_P"??7/_ #3 M_P".4?V=B_\ GV_N#^U<%_S]7WGTGDT9-?-G_#?/PU_Y]]<_\ T_^.4?\-\_ M#7_GWUS_ , T_P#CE']G8O\ Y]O[@_M7!?\ /U?>?2>31DU\V?\ #?/PU_Y] M]<_\ T_^.4?\-\_#7_GWUS_P#3_XY1_9V+_Y]O[@_M7!?\_5]Y])Y-4]6_Y! M\G^\O_H0KYX_X;Y^&O\ S[ZY_P" :?\ QRJ]]^WE\-[FV:-;?7-Q*G_CS3L0 M?^>E']G8O_GV_N#^U<%_S]1]-Y-&37S9_P -\_#7_GWUS_P#3_XY1_PWS\-? M^??7/_ -/_CE']G8O_GV_N#^U<%_S]7WGTGDT9-?-G_#?/PU_P"??7/_ #3 M_P".4?\ #?/PU_Y]]<_\ T_^.4?V=B_^?;^X/[5P7_/U?>?2>31DU\V?\-\_ M#7_GWUS_ , T_P#CE'_#?/PU_P"??7/_ #3_P".4?V=B_\ GV_N#^U<%_S] M7WGTGDT9-?-G_#?/PU_Y]]<_\ T_^.4?\-\_#7_GWUS_ , T_P#CE']G8O\ MY]O[@_M7!?\ /U?>?2>31DU\V?\ #?/PU_Y]]<_\ T_^.4?\-\_#7_GWUS_P M#3_XY1_9V+_Y]O[@_M7!?\_5]Y])Y-&37S9_PWS\-?\ GWUS_P T_\ CE'_ M WS\-?^??7/_ -/_CE+^SL7_P ^W]P?VK@O^?J^\^E,"C KYTA_;N^&$T>Y MI=6A/]R2RR?T8BI/^&Z_A=_S]:G_ . +?XTO[/Q?_/M_]:3G M[&?^NTO_ *,:KF37SC8_MR?#"W@*/=:GGS)&_P"/%NA"_Y^K[SZ%R:,FOGK_ANKX6_\ M_6I_^ +?XT?\-U?"W_GZU/\ \ 6_QH_L_%_\^W]P?VG@O^?J^\^A"_Y^ MK[SZ%R:,FOGK_ANKX6_\_6I_^ +?XT?\-U?"W_GZU/\ \ 6_QH_L_%_\^W]P M?VG@O^?J^\^A"_Y^K[SZ%R:@O<_9)_\ KFW\J\!_X;J^%O\ S]:G_P" M+?XU'"_Y^K[SZ%R:,FOGK_ANKX6_P#/UJ?_ ( M_C1_PW5\+?\ MGZU/_P 6_QH_L_%_P#/M_<']IX+_GZOO/H7)HR:^>O^&ZOA;_S]:G_X M_C M1_PW5\+?^?K4_P#P!;_&C^S\7_S[?W!_:>"_Y^K[SZ%R:,FOGK_ANKX6_P#/ MUJ?_ ( M_C1_PW5\+?\ GZU/_P 6_QH_L_%_P#/M_<']IX+_GZOO/H7)HR: M^>O^&ZOA;_S]:G_X M_C1_PW5\+?^?K4_P#P!;_&C^S\7_S[?W!_:>"_Y^K[ MSZ%R:,FOGK_ANKX6_P#/UJ?_ ( M_C1_PW5\+?\ GZU/_P 6_QH_L_%_P#/ MM_<']IX+_GZOO/H3WK \8>.-#\ Z++K'B'4H=,T^/(\V8\LV"=JJ.6; /R@$ M\&O&1^W5\+O^?K4O_ %O\:^3/VJOCE!\:/&EHVDSW#>';"W"6T M_O;.*:=?+N[FU(A;Y$7J"6'(/) KWRPO[?5+.&[M)X[FVF0213PN&212,AE8 M<$$=Q7XR5]Y_\$^?&5_K/@OQ#X?NG:6TT>>&2U+?P+,)"R#V#1EL?[9KT\VR M6G@Z'MZ+>EKI^>AY.2Y_6QV(^KUXK6]FO+4^M:***^-/O HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "OD+]N=5T[XK_LN:U(<0P?$*WL"QZ!KA M0JY_%*^O:^6_^"C'P[UWQQ^SJVK>%K*?4/%?@_6;'Q+IEO:Q-++))!)M8*J\ MDA)7; Z[* ,[_@J!_P FL3_]C!I/_I4E?6M:;J,%O M?KI^L6:N8RRK(@>*1?E=21P1D$5U% 'R5^S+_P GQ?M=_P#7;PM_Z03UQ_[= M6L:W^R_\2O#7[17A/33J#RZ=<>$=?L%^[<"5&DL)6'HEPH!.,D;%'6OM"Q\. M:5INK:CJEGI=G::GJ1C-]>00(DUUY8*Q^:X&7V@D#<3@'BOG'X\^!?$?QR_: M<^%GA.XT2]3X8>%"WB[6=2F@(M+^_C)2SM%8\.R,3(R\@JY[B@#M/V.?@S'>$/B%:?L3?M&?$/ MPQ\00=&^'/Q'UZ7Q3H'BV1"MA!?3J/M-I;9:A;I/"^#D;D<$'\10!X'\9/VUO _ACPV]C\/=:T_ MXG_$+5(S%HGAWPM>17\LLK)E996B++%"H^=G<@;0<9KY0\-?\H.9O^O*[_\ M3_)7Z$^"?@S\/_AE-<2^$?!'AWPQ-<@K/)H^E06KRJ3DJQC0$KGL>!QZ5K1^ M ?#,7A4^&$\.:3'X:Y7^QEL8A9X+[R/)V[.7);IU.>M 'R?^UK;WWA+X<_ + MXL6^F7.KZ9\/=7L=2UFWLX]\T>G26PCGG4=]GR$CWR2 "1Z9XG_;V^ WASX> MW/BV/XE^']6@CMS<0Z7I]_')J,[8)6(6V?,5V(Q\ZJ!GYB!S7OL=K#%;K;I$ MB0*GEK$J@*%QC:!TQCM7GNG_ +./PGTGQ(NO6/PQ\(6>M*XD&H0:%:I.KY)W MAPF0V2T;&\&:/N7LFZII5E MKFFW.GZC9V]_87*&*>UNHEEBE0C!5E8$,".Q%+IVGVVCZ?;6-C;16=E:Q+!! M;V\8CCBC4!51% PJ@ < "@#XF_9;^+6C?L>M?_ +/OQ7O8/!JZ+>W=UX6\ M1ZLXM]-UC39IVF!6=R$61&E8,I;C.,D@UI_M:?M):)\7?"=W\#_@[J5G\0O' M?C:)M+GFT2X6ZLM'LW8+<7%U-'N50$++MSD9R>@#?6?B[P'X:^(&FC3_ !1X M=TKQ)8*VX6NKV45U$#C&=DBD9Q[54\$?"WP;\-+62V\(^$]$\+P28$B:/I\- MJ),9QN\M1NZGKZF@#Y5_:@\(V_@#5/V._"]J_F6NB^--,TV%MNW*0VXC4X[< M*.*^U:RM5\.:3KUQ8SZGI=EJ$]A.+FSDNK=)6MI1TDC+ [&']X8-:M 'P5^S MG_R;;^V7_P!CSXS_ /2.*NA\%_!FY_: _P""6_AOP'92Q1:AJGA.U:R>;A/M M$3K-$&/8%XU4GL"3STKZYLO"&A:;8ZE96FBZ=:V>J2RSW]O%:1I'=R2#$KRJ M!AV< !BV20.P% 'S=\ M OVV? 7B;P;::1X_\0:?\./B+HL"VFO^'_%5PFG30W$:?O'C\XJ'C;!<%2<* M><5X#^U1^T]IOQJ^,WP&\.^!(9-=\$:/\4-#;4?%]OSI\VH>=^ZM().DI6-I M79ERH^2ON7QU\%_ 'Q.N8I_%W@;P[XIN(=H2;6-*@N9%"G( 9U) SGCH_B4_%#PU>V/EF2.WL=0CGO9C@'RTME/FF3E?DVY&1G%>VR M1)/&R.JNC JRL,@@]017GVE?L\_"S0?$:>(--^&WA+3M/HUU"SW M=M:I:77D!XT!8R&!8V* $[F(QFL+]KSXL_LY_&;X(R?$[PUXNTJV^*]C$DOA M>]TB?R/$4=\K#RK=X$(F(W?*0ZE5#%@>A/WU8^'-*TW5M1U2STNSM-3U(QF^ MO(($2:Z\L%8_-<#+[02!N)P#Q7-Q_ _X=0^,!XLC\!>&4\4"3SAK*Z1;B\$F M2=_G;-^[)/S9S0!\N?M8> O$VJ^#?@/\8==\(1^,=6\![)_%OAI;-;AIK:[M MXDOF2$@AS$Z;@N..3P%-=18_%S]C.^\'KXD6]^$\6GM$)3#-8V*7B@C.TVI3 MSM_7Y=F>.E?6E><7O[.GPJU/7?[:O/AGX0N]8R2;Z;0K5YB2UJ'3H[*\UJU"@R3/$L:E8C( M4.X[AU *\^V_$+_D0?$W_8,N?_135OJHC4*H"@# Z"HKB&.YA>*9%EBD!5X MV *LI&""#U% 'SA_P3>_Y,E^%G_7E!WIE[X>U\Q=LGE.1N3\"?$#X)ZC\+? MASXBTOXD>/?'+1Z-INE>&;Z*^V;Y%+RRO&S+&JJI^\&](\7 M:/<:5KNE66M:5<+MFL=1MTG@E'HR."I'U%EI=7#W3BDU#PUI.K:IIV MIWNE65[J6FEVL;RXMTDFM2X E\4Z!XMD0K807TZC[3:7#_=C;**02<84$X#?+Z?\ &3]M;P/X M8\-O8_#W6M/^)_Q"U2,Q:)X=\+7D5_++*R9665HBRQ0J/G9W(&T'&:]\\0^& M=(\7Z3-I>NZ59:UIDV/-LM0MTGA?!R-R."#^(KG?!/P9^'_PRFN)?"/@CP[X M8FN05GDT?2H+5Y5)R58QH"5SV/ X]* /A;X0_P#*%2__ .Q?US_TY75?;_[/ M?_) _AI_V+.F?^DL==%;^!_#MGX7/AJWT#2X/#C(\9T>.RC6TVLQ9E\D+LP6 M))&.22:U;*R@TZS@M+6".VM8(UBB@A0(D:*,*JJ. .F* /E.S_Y2K7__ M &1\?^G=*^MJRQX=TE?$!UT:99#7#;?8SJ?V=/M)@W;_ "O-QNV;OFVYQGG% M:E 'R5^P[_R5#]J#_LHUU_Z *3_@FW_R3#XE?]E&US_T..OJ'2O#FDZ#<7T^ MF:79:?/?SFYO)+6W2)KF4]9)"H&]C_>.31H?AW2O#-O/!I&EV6E03SM=/N2Q[@=CKDX88(SUKY M \"ZOXD^.W[=VC^-T^'/C#P5X9\(^%+K2KF\\6:8;(7-W+-D)!RPD7:V[<#T M!R!E=P!A?%S0/"7[/_[9.O\ Q!^)WA;3M9^%WQ&L+.WDU_4=*6]@T35+9%A1 M9MR-Y22ICY^ 2>>%)'7?$;XU?LA?#[PV=2AL/AOXMOYEVV&A^%].L=1O;V8\ M)$D<*MM+-\N7P >]?6VIZ79:UI\UCJ%G!?V4Z[);>ZB62.1?1E8$$>QKCO"O MP&^&O@76CK'AOX>^%] U5F+_ &[3='M[><$C:<.B C()Z'N?4T >+>,O@?JO MQZ_88U;P<_@G1?ACXH\2::M]_P (]IRK';6MZDJ3PJY5$VLWE1!_E)4DC+;< MF?X$?MP> _%/A6UTCXA:_8?#?XCZ1 MKKWA_Q5<+ITL=RB@.\9F*AT;!<;22 M%/-?4%<5XZ^#7@'XH2))XO\ !7A[Q1+&H5)M8TN"Z=%!) 5G4D#D]#W/K0!Y MKX9_;.\"_$3XSZ;\/? "WOC^62"2XU/7O#ZI-IFE* 2GG3E@IW$$#86Y('). M*XC]L;_DXK]E3_L;;K_TG6OICPEX'\.?#_21IGA?P_I?AO30VX6>D64=K"&/ M4[(U S^%6=3\.:5K5YI]YJ&F6=_=Z=(9K*XN;=))+9R,%XV8$HQ'&5P: /E[ M]K;_ ).H_9/_ .Q@U3_TE2J7[3EUJ?[/'[2/A+]H8:3=ZUX+_L*3PAXM_LZ% MI9].M6G^T17FP?>C63ACV"@&])U:_P!.OK_2[.]OM.=I+*ZN+=)) M+9V&&:)B,H2."5QFK\T*31O'(BR1N"K*PR&!Z@CTH \-\1_MP? GPWX,F\3/ M\4/#FHVB0F6.STS4HKB]G8+D1I;JWF;SD#:0,$C=CK7F?[,OA'Q)J/@CXW_& M+Q=HTOAO5_B8\E_;:+=*1<6>G6]M)%:+-D#YRC,<8'!![X'O^G?L[_"O1M?& MN6'PT\(V6LJRL-0M]#M8YU8'(8.(\@YQR#G@>@KOKB&.YA>*9%EBD!5XV *L MI&""#U% 'SA_P3>_Y,E^%G_7E!WIE[X>U\Q=LGE.1N3L?&+]O+X5Z;_ &3?)X0^'.F7?B&]U*6V M=;2>^G"QP0I(1M:1,1R8!. 6]Z^MZ "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K7EK#>VLUM<1+/; MS(TE?J?#&L*[8T55R6PHP,DY)_$DFIJ /-/ MVEHWF_9S^*D<:M)(_A3555%&2Q-G+@ >M>'^#_@@?CY_P38\*?#R>4Z9>ZGX M0L%MYI5(\BZB6.6$L,9 \R--V.<$U]=T4 ?&?@+_ (*$^'?A[H,7AK]H:#4/ MA?\ $;2D%O?)=:;#/& MUKH&H>'_ (+_ \N)K_2]0U:V-O<^(=39 BND3_,L,7)#8Y((ZG$?VA)"LBX M90PR#AAGD'(/YU+0!\7?&'Q)>?LG?M::A\8=7T'4M4^%_C#0;?2M;U72[=KB M31[RV8^5--&HSY+1X&[U)[@*W%_M(?M6>'_VR/ 4_P %_@)'?>.=;\5RP6NI M:Q_9ES;6.BV8E5Y)IWFC0]$ &!C#'!+;5;]!:A@ACMU*1QJBY+;5 R223]2 M23^- 'CWQ9^-&B?LJ>#_ D=8T77K_PDI33+O6M,LS=1Z3%'$ DURJ?/M8@+ ME5/?OM#?.OP9\4>$OC;^W6GQ ^"-E=)X+MO#]S:^+_$%OI\EE8:M=NX-O&%= M4,DRM\S.5R0O7')^\:CCC6)0B (BC 51@"@"2BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH *^3_VY[.>[\8?LU&""281?$_2 MY)#&A;8H#Y8XZ#WKZPHH ^3O^"E5G/??L\Z7';P27$@\5Z0Q6)"QP+@9.!VH M_;"TWQ)\._BE\*/CIX?T"^\4Z=X->^T_Q%I6EQ^;=MIUW&JF>*/^(Q,I8@'N MN<*&(^L:* /B3XD?\%)_AMXQ\"ZCH'P@;5OB#\2-8M7L],\/V>C7<;Q32+LW MS-)&JA8]V3M)^[C(!W"7XC?!W4/@K_P2UUCP#@;YDSVW9YQ@X/A3_@I!X!\/:.NE?& MN#4OA/\ $.Q7RM2T.^TJ[FCDD7 ,EM)%&X>-LJR\YPW!8#-/CI^VQ^SKXL/A/4/#GPRCO]5@\/-JD+17 MM^1:9GO)8L9BB;,2QAN2%9OXL#]&J** /B7Q'JFO_L0_M#^-_&=YH&H^(?@G M\0;B+4M3U+2;U(*4=Y(D^9H9#@EL<94#E"OVA;75/AMXXT*VCL)[BYTVXNK'5!&F%N+ M:>!)%<.J9(X^;(&:^T:BDA61<,H89!PPSR#D'\Z /F?X3_M(>+OVD/BW877@ M'PW=:1\&=-@G_M'Q)XBT]X)=:N#@11V*%E950Y8R,"#\RE0<9S/ 5I.G_!27 MXH7!@D6W?P1IJK,4.PL)AD ],U]844 ?)W_!-VSGL?@MXM2X@D@=O&^LL%E0 MJ2IE7!Y[5P7[?GP7\?2^./#WC#X3E[;5_&UJ?AYXD:&-C_HERP,5RV"-OE[9 M%,AY *#.*^[J* .7^&G@'2?A7X \/>#]#B\K2=%L8K*W& "RHH&]L=68Y8GN M237S)\:+'Q'^S1^TQ/\ '72O#NI>+O GB32(M)\86>CQ":]TYX"/L]['$"#( M@7"L!G: Q)Y%?8=% 'R/KO\ P4I^%>HVG]G_ WCUSXG^-K@^59^&]'T:[BE M\XY $SS1(L2A@=QY( )P17-?MI6OQ"U'_@F?XJ7XA1V-QX[N+?39=0M]%MV6 M*)SJEJPB4;GW%%PK,#@E21Q7VPL:QL[*H!8Y8CN< 9/X ?E4M %#0X5M]%T^ M)!M6.WC4 ]@% K\__P#@H!X9\8_#[XS:-KOPQFABUOXP:6_P_P!3M68AC(63 MRKM0.=R1,Z%Q]P*I[U^A]?.@^#OBGQQ^V=_PL3Q39QV_@KP9HOV#PE"9TD:X MO;D?Z7=E 24(7,7S8)&PCH: /7?A5\.=+^$7PW\-^#-%39IFAV,5E$VT!I-B M@-(V/XG;(_$O@/XB:7J2?!^^U2YU;POXUT^S MDNX+-)F\R2RNDB5F0HQ8A@OS?,<8^[]UT4 ?"WQG_:>C_;"\.WGP@_9^M[WQ M.WB1#8:]XQGL)K;2]'L'.R=BTJH9)&7WY%IF>\EBQF M*)LQ+&&Y(5F_BP/T4DA25D+J&9&W*6&=IP1D>AP3^=34 ?)_@*TG3_@I+\4+ M@P2+;OX(TU5F*'86$PR >F:Y[XU_MI? _6_#_C/X>?%GPKKMGK,,UQ8P^$=7 MT*6:YU,C*PS6DB*\8+@JR/O4J6!!Z$_:-1M$K,K%02IRI(Z<8XH _-3XX>$/ M&'@[_@D'H7A_QK]H@\46_P#9ZR17A(FMXWU(-;Q/GE6CA:)"O5=N,<5[IX;_ M &\]"^%>G1>%_P!HA+KX;>/]-C\JXE.GW-UIVK!1_P ?5I-#&X97 SL.&5B5 MY(KMOV[/A'XG^.'[.6L^$_"-I'?ZW'=2\7>!/$F MD1:3XPL]'B$U[ISP$?9[V.($&1 N%8#.T!B3R*^PZ* /D?7?^"E/PKU&T_L_ MX;QZY\3_ !M<'RK/PWH^C7<4OG'( F>:)%B4,#N/) !."*YK]M*U^(6H_P#! M,_Q4OQ"CL;CQW<6^FRZA;Z+;LL43G5+5A$HW/N*+A68'!*DCBOMA8UC9V50" MQRQ'(I]+TSSHM'TL![JZ*1\1QAB, ML?[4L9M&<:-/:W_ (=9)T:: M2YG9 $B5-^X*[+G:W\.:_2:HQ&JR,X4!F !;')QT_F: /E'XF6EPW_!1GX,7 M AD>"/PIJZO,J'8K'. 3T%4/C=;>)_V9?VCI_CIHGAR_\7> _$FEP:3XRT_2 MH_,O=/:!L07\<8YD4(=K+V 8DC(Q]@T4 ?(?B3_@I5\,M3TEK'X71ZQ\3/'U MT/*T_P ,Z?I%W"_G$E0)WDB58T5@=QR2 "<8YKG[CX&Z_P#!W_@GG\7[+Q+( MM_XZ\3Z=K'B37A:@,@U"ZCW/&FW.[:%1<@D$J2."*^UUB2-I&554N=S$#&XX M R?7@ ?A4M 'F/[,MK]C_9N^%$!C:(P^$])C,; @KBSB&"#Z5X[>6D__ ]( MLKKR9/L__"HS'YVP[-W]KN=N[IG'.*^L** "OSC_ &7/VD/ 7[&@#\M_C1X=^(?[87Q$UCXF?LZ>$-<\ PVNBW%AJ'BZ^N M7TF;Q8I MX8<98@*0LK$?PABA1*^Q/V$?%W@G7OV?\ 1-%\&:5J?AD>'LV. MI^'M:>1KVPN]Q:42%P"P=R[!@ IR1M4@JOT;10 4444 %%%% !1110 4444 M94-G;WDU\)X(YPMQD"10V/W:>M3?V%IW_/A:_P#?E?\ "ET__CXU#_KX_P#: M:5>JN:2V9')%[HS_ .PM._Y\+7_ORO\ A1_86G_] ^U_[\K_ (5H44^>7<7L MX=C/_L+3_P#H'VO_ 'Y7_"C^PM/_ .@?:_\ ?E?\*T**.>7SAV,_P#L+3_^@?:_]^5_PJIJVAZ>MA)BPM1\R_\ +%?[ MP]JVZI:O_P @]_\ >7_T(4<\NX>SAV&?V%I__0/M?^_*_P"%']A:?_T#[7_O MRO\ A6A11SR[A[.'8S_["T__ *!]K_WY7_"C^PM/_P"@?:_]^5_PK0HHYY=P M]G#L9_\ 86G_ /0/M?\ ORO^%']A:?\ ] ^U_P"_*_X5H44<\NX>SAV,_P#L M+3_^@?:_]^5_PH_L+3_^@?:_]^5_PK0HHYY=P]G#L9_]A:?_ - ^U_[\K_A1 M_86G_P#0/M?^_*_X5:N)H[:%Y9G6**-2SR,0%50,DDGH*I:%KVF>*-+AU31] M1M=6TRXR8;RQG6:&3!*G:ZD@X((X/4&CGEW#V<.P_P#L+3_^@?:_]^5_PH_L M+3_^@?:_]^5_PJ'4/$VD:/J.G:?J&JV5C?ZBS)8VMS<)'+=,H!81(2"Y ()" M@XR*UJ.>7U2^ M)/$^D>#=%NM8U_5K+0](M5#3ZAJ5REO!""0 7D]R^"_%^B^*4M603_ -DWT=PT66&-ZJ25SVSUHYY=P]G#L=A_86G_ /0/M?\ MORO^%']A:?\ ] ^U_P"_*_X5H44<\NX>SAV,_P#L+3_^@?:_]^5_PH_L+3_^ M@?:_]^5_PK0JG<:A;6D]K!/7 MSAV,_\ L+3_ M /H'VO\ WY7_ H_L+3_ /H'VO\ WY7_ K0HHYY=P]G#L9_]A:?_P! ^U_[ M\K_A1_86G_\ 0/M?^_*_X5H44<\NX>SAV,_^PM/_ .@?:_\ ?E?\*/["T[_H M'VO_ 'Y7_"M"BCGEW#V<.QB7'@[0KJ3S)M$T^9_[TEK&Q_,BF?\ ""^'?^@! MIO\ X"1__$UN;:-M'M)]V+V5/^5',:7X(\/-:$G0=-)\V7_ETC_YZ-_LU;_X M07P[_P! #3?_ $C_P#B:T-)'^AG_KM+_P"C&JYMH]K/NP]E3_E1A_\ ""^' M?^@!IO\ X"1__$T?\(+X=_Z &F_^ D?_ ,36YMHVT>TGW8>RI_RHP_\ A!?# MO_0 TW_P$C_^)H_X07P[_P! #3?_ $C_P#B:W-M&VCVD^[#V5/^5&'_ ,(+ MX=_Z &F_^ D?_P 31_P@OAW_ * &F_\ @)'_ /$UIZA?6^DV%S?7"_&6B?$+POI_B/PYJ4.KZ)J$?FVM];DF.5TGW8>RI_P J,/\ X07P[_T --_\!(__ (FH;SP/X=6TG(T#30?+;_ET MC]/]VNBVU!>C_1)_^N;?RH]I/NP]E3_E1B6?@?PZUI 3H&FD^6O_ "Z1^G^[ M4W_""^'?^@!IO_@)'_\ $UJV0_T2#_KFO\JGVT>TGW8>RI_RHP_^$%\._P#0 M TW_ ,!(_P#XFC_A!?#O_0 TW_P$C_\ B:W-M&VCVD^[#V5/^5&'_P (+X=_ MZ &F_P#@)'_\31_P@OAW_H :;_X"1_\ Q-;FVC;1[2?=A[*G_*C#_P"$%\._ M] #3?_ 2/_XFC_A!?#O_ $ --_\ 2/_ .)KTGW8>RI_P J,/\ MX07P[_T --_\!(__ (FC_A!?#O\ T --_P# 2/\ ^)KOWACG( /U7^M#=C75A\96PM55:;U7?8X\5@*&+I.E4CH^VY^3ND? ML[_$K6M7_LZ#P9JT4X?8TEU;-#"IX/,C@+T(/7O7Z$?LX_!%/@AX#&F331W6 ML7C_ &B_N(<["^,*B9 .U1QD\DDGC.!Z9I^/M6H_]? _]%1U?_&O0Q^<5\?! M4YI*/EU/,RW(\/EU1U8-M^?06BBBO"/I HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO-?CM\ M>O"?[.W@D^)?%US.L$LZVEE8V4)FN[^Y8$I!!&/O.V#U( QDD4 >E45\DR_M M;?&K3;%=?U+]E7Q+;>$ OG275OXAM)]42$ DM_9P42;@ ?D)!KN_V>OVNO"_ M[2GCGQKHWA*W>?2O#MIIMU'J[2_\?7VN)W:,Q%08GB:-D923\P/3% 'I?P\^ M*WA;XK1^()/"VI_VHF@:Q<:!J1^SRP^1?0;3+%^\1=VW>OS+E3G@FNPK\XOV M8?VEK3X4W_QK\&:#X9U/XA?$C5_BMXBO+'POHY6-A;C[.IN+B=_D@AW KO;. M2" #@X]PO/VT/%/PMOK&7XW_ 7U;X8^&;R58!XGL=8@URPM9&P%%RT"*T() M.W)4\XQD<@ ^K:*\J^/_ ,?M'^ ?PWC\5W-C=>(Y;Z[M]-T?2M*P\VIWDYQ# M%&>GS8+;N>%. 3@'EOA%^T)X_P#%GCJV\)_$+X)Z]\-[Z]M'O+/4(M0AUC3G M5 -Z2W$*J(9/F&%8_45X/\>/VK]'^#OBG2_!>C>']6^(7Q(U6,3V? MA30$#3+!D@SSR'Y88\@_,V>F<8R1Y_)^W!XI^&M]82?&_P"".N?"KPW?3+;I MXE@U6#6K&W9ON?:6@4&('IT)SVZX /KBBO$OVEOVH=!_9K\%^$?%>J6PU70= M>\06>C/>V]R%CM89XY93=Y"MYB*D1.U>6!X-<=8?M:>-CX#\9_$'6/@IJ?AO MX?Z/H4VN:3J6J:W;K>:JJ %8VLU5GMBRY;+DX '7- 'T]17R%IO[=VM_$ZWT MY/@Q\'=6^*5Y]AMKK5YTU>#3=-TZ>6%93:"\F4I+-'NVLJ@8(QUR!V?PI_:\ M3Q1\18/AQ\1? ^K?";XA7:/+I^EZK,EU:ZDB E_LMW&/+E*X.1Q[9Y /7_B M-\3/#/PE\,MX@\6ZK'HVD+/%;&ZD1W7S)&"(N$4GEB!TK!^.7[0'@G]G'PG: M>(_'FJOI.DW5_'IL,L=O).S3.KL!M0$X"QNQ/HOJ0#\K_P#!5#QEXRM?A*^A MVOP]FOO";:CI=PWBL:O;(BW N01;?9B?-))"C?C:-_L:]+^*WQ^U'PW\$5\3 M_%WX'16#+XDLM.MO#FIZK9:FK^8RB.\$D:NBE79@%(W#9G(R* /J*.99HU=& M#HP#*R\@@]#4E*]2\&2 RQ7]YK5K::A+#R5=+!E,C9 R #S MD8)R,@'UW17F/P#_ &@_"7[1?@]]>\*W%PCVLQM-1TK4(C#>Z=<@9:&>,_=8 M>HR#@X)P:\.TG_@H)#XROM=\->#/AQK'B_XBZ?KVH:/%X9T^]B4>1:LB&^N; MEU"6L+LQ5=P.64CF@#Z_HKYG^'_[76O-\5M'^'GQ;^%M_P#";Q!KXD.@W#ZM M#JMAJ31@%XA<1*H27!R$(/49(+*#],4 %%>;?'3X^^$?V=_!?_"2>++F<133 MK:6-A8PF:[O[E@=D$$8^\YP>I ' MV^MVL^HQQ8!+-8!1(,+R02,8.<8. #Z\KPN+]LSX677QFD^&%IK-Y?>)HK[^ MS)VM=.GDM(+SG_1WN NQ7^5AC. 58$@@BNH\,_&_3/BA\&V^('PQM_\ A/(Y MK=Y+'38;A+.2XF4X-N[2X$+@\'?@#KT(-?(O_!.OXA?$0WWQ$L/^%37#Z)K' MQ(UB[UGQ%_;]GMTJY98O,@:#/F3%"J#?&-IWY'0T ?H-117@_P >/VK]'^#O MBG2_!>C>']6^(7Q(U6,3V?A30$#3+!D@SSR'Y88\@_,V>F<8R0 >\55O[Z#2 M[&XO+F016UO&TLLA!(5%!)/'H :^49/VX/%/PUOK"3XW_!'7/A5X;OIEMT\2 MP:K!K5C;LWW/M+0*#$#TZ$Y[=<>M?M$>-O%'A_X4W=]X'\$M\1!?VTRSK::O M;62V]LT#M]I#S';(O3Y5Y.[(H [7P7\2O#7Q$\#6GC'PYJD>J>&;N)[B#4(X MW57C1F5F"LH;@HPZ=J9\,_B9X;^,7@C3/%_A#4CJ_AS4@[6EX()8?,"2-&WR M2JKC#HPY4=/2OD'_ ()X^-?&VH?LI>'O#^H?#F?2O!MKX?OY+/Q@VLVLL=[) MY\G[L6JGSH_O2I?%;QII]IO^$/!B@/=ZYH_B"UUI[-#C]Y+!$BLB#/S$D8]#TKU?XU_M-:%\*? MV;=1^,^DP+XR\/06]G=6J6-R(A=QW%Q%"K*Y4[<>=D@KGY2#@] #VFL7Q=XJ MTWP-X7UGQ)K5R;+1M'LYM0O;C8S^5!$A>1MJ@DX52< $GM7B_P )/VE/%7QJ M\96&P*F9XG8 )(2H(.<#I7LGC74;;2 M/!NNW]W9KJ-I:V%Q/-9R %9T6-F:,Y!&& (Y!'- &1\(_BSX:^.7P_TGQIX0 MO6U#P_J0D,$TD31/E)&C=61@""'1A^&1D$&NUKYZ\#_M!:%I_P"QC#\7M#\& MPZ'H%EH5QJT'A>Q>.%(HXB^8D9$"KDJ3D)CGI7'Z)^V]XE^*^G65S\&/@WJ? MQ+VV5O/JMX^M6^E:=8W$D*R-9QW4RD7$T9<*X10%.,]\ 'UK7FOPU_:"\#_% MSQGXW\*^%]6:_P!:\&W@L-8@:"2,0REG7Y68 . T4BDJ3@IZ$$\U^SS^TU;_ M !LU+Q'X:UGPQJ'@#XA^&6C76/"VJ2+*\*R#,\>6")+JEGIMW'96.F!^56XO) 4C%?C7\*=5^#=UKEP+32=5N-2AU32[B<](FNHE58W)Q@ M$$>I% 'U117)?$[XF>&_@_X'U3Q=XMU2/1] TV/S+BZD!;J0%55 )9F) "@$ MDD5\YZ?^V!\8?&5DFO>"OV7?$FL>$)E$MO?ZQXBL]*O)HB3AULW5F((Y&&.0 M0>A!H ^N:Y2V^)GAF\^(E[X$@U:.7Q;96":I<:8$??';,^Q9"VW;@L<8!S[5 MYY\!_P!J;0?CTOB'3+/2-5\,^.?#AV:OX1UZ,6][;.1\I')5XV(P''J"0N1G MY*\.?%SXOP_M[>+]9A^ UY<>)YO!%K;S^&!XKTY7@MQT/X 6NA64^D:GXI\;>(9##HWA+0X_.O;QU&7/HL:YY< M_@#@X\HU;]M#XI?#>TCUSXI?LUZ_X0\&* ]WKFC^(+76GLT./WDL$2*R(,_, M21CT/2@#[ HK"\,>,-%\:>%=/\2Z)J=OJ.@ZA;+>6VHPO^[DB(R&R>G'7.", M$'!%?-*_MM>)?B5J6H#X&?!?6/BUH.GS-;R^))M7M]$T^>13AEMY+A3YP!(R M0!ZXQ@D ^@_B+\5_"WPFM-&N_%>J?V5;ZQJEOHEBWV>6;SKR;=Y46(T8KNVM M\S848Y(KL*_-O]J#]IV+XL6'PM\&^)?"6J_#?XCZ9\2?#]Y=>&=9*R&6V+3+ M]HMIU 6>(,0I8 8)P17Z24 %%%% !1110 4444 %%%% %'3_ /CXU#_KX_\ M::5>JCI__'QJ'_7Q_P"TTJ]0 4444 %%%% !1110 4444 %%%% !5+5_^0>_ M^\O_ *$*NU2U?_D'O_O+_P"A"@"[1110 4444 %%%% !1110!SWQ"_Y$'Q-_ MV#+G_P!%-7S_ /\ !,O_ ),;^&'_ %QOO_2^YKZ"\>PM<>!?$4<8W.^FW*J/ M4F)@*^?O^"99_P",'/AAC_GC??\ IPN: .?_ &O/^3O/V1_^PUK/_I-!7V!7 MR!^ULK3?M@_LC1)S)_:^MR;<\[5M8"Q_ 5]?T ?#O_!0@Z2OQ=_9Z;XCEG^" M;:S>1Z_#(S"T^VF%?L37.#@QAMQYX"B7/!KU";]C'X8:7\3/"GQ/\!V:^!;_ M $W)EA\)B.VL=6MY L%*^Y>-?!.@_$;POJ'ASQ/I5KKFA MZA&8KFQO(P\K'DI?ZA)(OVN'(QD);"56'.T1S#_EH*^V_P!J;XX6 MO[.?P)\4^.)52:]L[?R=-M6Y^T7LAV0)CJ1O8,V.=JL>U?(G[+<'[1'P"^$+ M^&G_ &6Y/%E[K%W<:KK.L7_CS3+:34I[@Y9I(65BOR;$*L2>#GJ10!]X?#?Q M[I'Q2\!Z#XOT"?[1H^M64=[;-WVNH.UAV93E2.Q!':O.?BM^UM\/O@C\18_" M?C*[NM&=M"D\0OJTD:&SCMTE\KRR0_F-*SX"HL;9R #GBOGS_@G1XH\2_"_Q M%XR_9_\ 'OA^X\&ZKI;OXD\-:+=W\5\T6EW$IW0K<1'9*(Y"#N7!)DDR!M(& ME\:/A_H/Q#_X*6^D^#;C5K:UN!E);F*ZE$?'*/"FKV^N:#J">;;7MJV5<9(((/*L"""K %2"" 1712(LBE64,K#! M##((]*^0?V1=*M?AW^U-^TI\/?#:"'P1I]YI&K6EA;G%OIUU=VS/<11J.%#$ M [5X4(!VH TX?^"CGPXU?P]I=SX>T'Q=XH\3ZG-=1V?@[1M,6ZU9T@D:-YWC MCD9(X=R'#,^2 2%X.-7P#^W5X8U[QSI7@SQMX0\7?"'Q)JV%TR+QIIPMK:_D M)P(X9PQ#.20,,%R2%!+$"O//^"4WP]T#0O@;KOBNRMXG\0:]XAODO[S&90D, MQ2*$GLH&7QZR$^E>R?MO> ?#WC[]EOXAIX@AA TG1[K5[&\<#?9W=O"\D,L; M=5;@#<^._[3G@O]G*^\*1>-);RSM/$5Q/;Q:A$B-;VGE1^8[SDN M&"XZ;%=B> *@^"_[1(^,TFM7/_" ^+_!GA^P@CNK;7/%5BEC;W\3!COC!7\;8^S6L]PB2LQ_NLO[L^TAH MIZA_P4,\.:MK.HVGPZ^&WQ!^+>G:;,8;O7?".BFXT_'D6SUWQ8VIZ!KD,!VG4K..W61&D ^]Y3'=D\_+&,X4"@#V_ MX.?'30/BEX@\=^&;&UU#3->\&ZN^GZII^J1QI)ARSQ3Q['<-#(N2K$@G:<@< M9G^.GQZ\/? 'P_I&I:[:ZEJEQK.JV^BZ9I6CQ1RW=Y=3$A$C5W1>Q))88QZD M _/WQQ_XQQ_:<\ ?&RWQ;>%/%4S^"_&17[JEY&-C=M_N.NUG[(@4?>JUI(_X M:6_;NOM4)^T^!O@O;M8VO.8KCQ!<+B9L="8(QM(ZJZ*<\T ?57BKQ5I/@?PW MJ6OZ]J$&DZ/IT#7-U>73A8XHU&22?Z=SP*^6E_X*(VNMV[:QX2^"/Q5\8^#% M+;?$FEZ ?(N$!P9(%9@SIUY.W&#D#!QA_P#!4&37]:$_";P5I-E%J%IXI\: MV=G=V-U<&WMK\J"T5I-(.561\"U\3>"=5_M"R60P7-O,ABN;.8# M)BFC/*,,_0CD$CFN7^.?[6O@SX%ZUIGARZM=9\7>-M4&^R$^%;+[;J4L?(\ MPQ[@$3(/+$$X. <''D7[-?PC^,GAO]JOQG\1?%WA30/!WASQ9HZQ:IIF@:K] MIBFU&*1/*NBA4$,8_-4XZEV8Y+59_8*T>T\4>)_CE\2=9C6[\=WWCO4]&N;B MX^:>PL[8QB&S4GE54$<#@@)G[HH 37/VYM UGP_KGA3QSX&\9_"76M9TN]M] M);QAIAM[74)?(;$44X)7S#D?*<#) SD@'N?^">/_ "9=\*O^P8W_ */EKNOV MF/A_X?\ B=\!_''A_P 26T-QIDFDW,V^8#_1Y8XV>.93_"R,H8'V],UPO_!/ M'_DR[X5?]@QO_1\M 'T71110 4444 %5[W_CTG_ZYM_*K%5[W_CTG_ZYM_*@ M LO^/2#_ *YK_*K%5[+_ (](/^N:_P JL4 %%%% !1110 4444 %%%% !111 M0 4444 4M/\ ^/K4O^O@?^BHZNU2T_\ X^M2_P"O@?\ HJ.KM !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !7R!\6+2UUS_@H]\&+'Q %DTJP\+:EJ.AV\Q)1M4#D2,%/ M!980'!Z@J#U KZ_KQC]IC]FO2OVC/#&F0MJUYX7\6:#=?VCX?\3:;QOC?]EO0=$\/?MR?M5VGA^."&S=M N9H;< (ES+;S M23CCN9&=CZ,Q':M5?#/[96H62^'KSQ?\*M.LV012^+K&QO9-3"$8,B6S8@\T M8)YPGS#&,&M;]E?]C]_V9?BA\3=9M=;DUO1?%$.F>3/J%Q)/J,EQ"DINI[EV M4*6EEE9QM)Z]J .$_P""<^FZ"OC#]I6_@BA_X29OB5JD%U+QY@M!(6@'J%WF MX]B0?2OJ7XQ:-H6O_"GQAI_B=(6\.3:3=+J!G *+!Y3%V.>FT#<#V(![5\F^ M$_V&?B3\+O%7CKXA^ ?'^FZ#\0M<\4ZEJBP7,4MQI.HZ7<.LD-I>1E0R21R> M:PDC!(\PCG/&SXE_9Y_:&_:4M[;PY\:O&G@_PU\/C,'U'1_AO%=K<:LJ-E8Y M9KGE$)Y(7/097/*@&-\"/@SJ/[3'_!.OX3:5J>MW7AOQ5I1CU;0==C'G26-S M:7,RVC<=!7HOP9_:(\>:/\5=-^#GQO\ #UGI7CB_M)KK0_$6 MARF33-?CA!,NU2-T,JJI8J>P)P@*AO0/B[\,_'#>!/#NF?!GQ18> ;_P[-$; M6PO+$3:;=VR1F,6LP +I&%.04YRH[X*^<_#3X"_%KQ=\2'2XXQ]D52>51U!X''[L=<"OI3XJ:#H7BGX<^)])\3I! M)X=NM-N([_[0 8UA\MM['/3:/FSV(!R,5XQ\:/V8_$]]\5HOBU\'_%=OX*^( MCVZ66J6^I0--I6N6Z<(MTB_,'48 D&3A5 QC(XOQ/\!?VC_VBK&/PS\8?&G@ MOPGX ED_XFNG?#>*\%YJD0/$+S7.?+1N^W.1P5.< ^9==MKWQQ_P3H_9,T_ MQ*C7@O?B+ING%)27,EIYNHPQ*0>WDA% ] /I7WO^VMQ^R1\7@.!_PC-]_P"B M6K+^/W[-!?&&D:\MK,KK']CLTE3R(@H/S8=<9P.# MDUI_MJ_\FC_%_P#[%F^_]%-0!#^Q-H&B>&_V3/A5;^'TA6RF\/6EY*T( $ES M+&LEPS?[1E:3.>AX[5YC_P %-[6VM_@;X;URU$ M"TNY;:.2:2RGA^=!(S$F-OE#$GOQZ1X'_9@\?>.OBSHGQ*^/?BK1_$6J>'&\ MSP_X5\+P2QZ+ITY'-R?._>2R@_=+FWS:G97PGO]_E M[89ED8?*I.2!@<4G[6WP-U;]H/X6V?AC1K^STV[AUNQU,S7V_P LI!+O91M4 MG<1TXQ0!Y;^VU8V_B3XX?LP^'?$&V3P7?>++B6^@F.89[R*!6LHW7HP9V=<' MU(PO#[3PA^V?X=TZ+PY9>-/A7K]C%$88_%&LV-^FJE1PKO$F83)C!Y!!(.2> MX!#X'LK?P_\ \%./B!9^'PD.G:OX M=3U^&!MJ?VDMVL<+LHXWF$YY&2')[G M.9_P36\+6-HOQ_\ $2VRQZI??$S5;&2XQ\SP0%'C7/H&GE_,U[1^S1^S9:?L M_P"DZU>7VN77C'QYXEN1?>(?%&H*!->S 85$7^"),MM3)QN/L S]EGX&ZO\ M ?0_'EAJ]]9Z@_B#QCJ7B.!K/?B.&Y\O9&^Y1\XV'.,CGK0!YO\ \%!E%K_P MSOJ$:A+R#XN:%'',/O*KB% MO'&F>*;DWN_$L%L)0\:;5/SGS!C.!P)/^"DWPBT_Q"%ET MG3/"%_JFAV\QW(^J"8K(P4\;UA57!Z@H#V!K[!KQC]I3]G&Q_:$T#1W@UJ\\ M(^,_#MT=0\/>)]. ,^GW&,$$<;XVPN],C.T<\5Y7>>$_VT=:TV7P]<>,_A1H M]G)$(6\4Z;8WS:H >&D2%OW(D R>@'(QCL 1?L>6-OX=_:=_:H\/Z LQ>%]#ENM0FEGDOM2U?4'WW>I7DAS)<3-W8X 'H% R3DG!_99^! MNK_ ?0_'EAJ]]9Z@_B#QCJ7B.!K/?B.&Y\O9&^Y1\XV'.,CGK0![?7Q]^QK8 M6^J_M#?M/^(-5VS>,X_%_P#99:7YY(=+CC'V15)Y5'4'@W2RU2WU*!IM*URW3A%ND7Y@ZC $@R<*H&,9 M![/\5-!T+Q3\.?$^D^)T@D\.W6FW$=_]H ,:P^6V]CGIM'S9[$ Y&*^=?V(M M2U;5/^"=?A6;6&>2Y70=1@B:0EF-O'+<) .>PB5 !Z ?2L[Q/\!?VC_VBK&/ MPS\8?&G@OPGX ED_XFNG?#>*\%YJD0/$+S7.?+1N^W.1P5.<#ZAD\$V6F_#N M3PEH-M!I6G1:6VF6-O&"(K>,1&-% ZX Q^5 'SW^P7_RC[\#?]@6^_\ 2BXK M+_X)3^%['0/V*/!U];6JPW>M76H7U[(%PTL@O)8%8^O[N&,?05ZO^S?\$]4^ M"_[,_AWX;:I?6=[JFFV%Q:27=GO\AFDEE<$;@&P!(.H[&IOV2?@SJ?[/O[// MA'X?ZQ?6NI:GHL=PDUU8[O)?S+F68;=P!X$@'(Z@T >4_M'0I9?MX_LGWL"+ M'=7 \3VTTRK\TD2V$95&/< NY [%B:\H\7:;\6?$W_!27XAR^ -3$V&MZ+X M6T^'3F\707%PJV$BHTQMUB^ZWGLX8^C>YKZA^+7P-U;X@_M#?!'X@65_9V^F M^ Y-8:^M9]_G7'VRVCAC\K"D?*4).XC@\9JA^T-^S5??$[Q3X>^('@;Q0_@7 MXI^'(9+?3]9\A9[:[MW.6M;N(CYXB2V,?=+L<$XH XNZ\*?MC7MK-;7/BCX. MSV\R-')$^EW[*ZD8*D$\@@XQ7@7Q>^#/B'X"_P#!*/XC^$]>UW1_$$<6IV]S MITV@S22VD-M+JMFWE(9!GY93-QS][KG->Z:U\/?VN_B9:MX<\0^._ASX#T"8 MF&\UGP5:WLNJRPG.[RAN?L7ZA\!_AV]GH4+ M06<-K&=)M(A!:V&E MVMK%$%VA$2)548[8 JO\6O\ DE?C+_L"WO\ Z(>NDL8#:V<$+$$QQJA(Z<#% M97C71)?$W@W7M'@D6*?4+"XM(Y'SM5I(V0$X[ F@#XG\#_\ *'6X_P"Q&U#_ M -"FKZ+_ &+_ O8^#_V3_A+8:?:K:12^&;"^EC5<9GN(%GF8^YDDR?"/PA=?# MWX4^#/"U[/%=7FAZ+9Z9--!GRY'A@2-F7(!VDJ2,C.* /G@J+'_@JB! JQ"] M^$8DN-O_ "T9=6*ACZD!%&?04O['/_)Q7[5?_8VVO_I.U>D3_ W5IOVR+?XP MB^LQH<7@<^%C8?/]I,_VYKCS/N[=FTXZYSVKS?\ 8Y_Y.*_:K_[&VU_])VH M^?/V(-$_:+UKP#XN\1> ]>^'-C)J_BK49M;_ .$BM+R?4#?B0"02.G!4#:5' M8,3U)KTWX]? G]I[XU?#'5O"7C?Q?\(8O#]X8FDN5L[Z"2"19%:.2.1LA&# M 'ODCG.*]'\7_LS_ !"^'WQ0\0_$'X"^*]%T.[\3R_:=?$^*[62;1[VZ"X% MRC0XEAD)R6V_>+$D\8K&O/VT8(&47*L>FT@&@#F_VJ-#OIO&7[(/@[Q]=P:IHLFNJFONY+V] M]JD-I&MOG< 65Y6F #8R'Y'-?<5>:?';X$^&_P!H'X;77@SQ LUK;&2.XLKZ MQ81W.GW,9S%/ V/E=>1[@L.AKQ2W\)_MD^#]/70M*\7_ M\:647[JW\1>)K M2^MM1\L7"HDTZ1@22*N=H9L M9(&XXSTR?6OE?PC_ ,I/?'O_ &3FR_\ 2Q:]#_9W^!'BOX:ZAXD\4>/OB%J/ MCSQKXC,?VM@S0:791INV0VMMG:H&X_.1D^@RVZ30_@;JVE_M<>)/BU)?V4FC M:IX6@T&.R7?]H66.<2%V^7;M(&.#G/:@#Y>\7:;\6?$W_!27XAR^ -3\(V&M MZ+X6T^'3F\707%PJV$BHTQMUB^ZWGLX8^C>YKUZZ\*?MC7MK-;7/BCX.SV\R M-')$^EW[*ZD8*D$\@@XQ7:?M#?LU7WQ.\4^'OB!X&\4/X%^*?AR&2WT_6?(6 M>VN[=SEK6[B(^>(DMC'W2['!.*X+6OA[^UW\3+5O#GB'QW\.? >@3$PWFL^" MK6]EU66$YW>4+CY(F*D#&IO$.E:YO*TMAH M7Q%6[,^D[R2T<,]OR\8.&PV."V!NRS %3_@I)H.A7/\ PH76+I(4\16OQ'TJ MVL9L#S3!(Y:=!WVYCB8^A5?6OM*OAKQY^P[\3/C)X@\&^/?B#X]TK5/'VB^( MK"^CT_3TG@T33-.AD,D\%K&07DFD<1DRR8)" <8%?:7.UI65F7Y200PZ;54>E?';_A=O_">?#+_ M (5:NC'PM_:A_P"$N_M+9YOV3?%CR]W.-GG?<^;<$[9KVNB@#YC_ &@OA;\7 M=$^+&E_%OX-ZK%K.J0V']EZQX%UV]=+'4K8,65X&9ML$P)Z_*#C.?O*_F]Q\ M)_CC^U#\3O _B/XR>&M)^&?@;P1J,>L6GAFQU*/4;O4;]7'EO)+&2@C7 XXX M)&#NROW)5+5_^0>_^\O_ *$* /(?CM_PNW_A//AE_P *M71CX6_M0_\ "7?V MEL\W[)OBQY>[G&SSON?-N"=LU[7110!\U?'?X$^*?CG^T1\*VU**U'PC\'R/ MKUY#).#)J&J+D6Z&+^Y'\K9/!#R+CD5]*T44 ?-W[3GP+\3^*/B5\+OBK\.T MMV\;^#]2\F[MKB<0)J&D39%Q 7/&X G;G@>8YZXKQ;]J'X6ZI\"K#5/V MBM%^+;ZI<)J.EZ!-H"::J+Y+QR2F0R%NNX$XQTH \ANO'G[7]]I\FAV_PM\! M:=K.#$?%;^(GDT[/ \U+39YV.I 8GIR.Q](_9E_9Y3X ^%-5&HZW)XK\;>(K MY]6\1>))X_+>^NFSP%R=L: D*O09)P,XKVBB@#\QOV%?"'QE\"_!RZ\=?":X MTGQ7I^L:WJ"ZOX'\0SFU4RQ3M&MQ9W"C$W>,/AC\?OVM M%MO#/Q'TW0_A)\+FG2;5]+T?5#J6J:NB.&%L9E"I'$VT9(YZ<,.![S^SI\"; M']G7X:Q^#M.U2XUBV6^NK[[3=(J/NFE,A7"\8!.*]2H ^=_CG\"=9\7?$S]G M_4?"UE96WA_P+K,ES>0^8(A!:^0L<:Q)CG&W&!T KUGXK?#/0_C'\.]?\%^) M+;[7HVM6K6TZC&Y,\K(A/1T8*ZGLR@UU]% 'Q[X/M?VJO@)H\/@ZU\/>'/C5 MHFGD6^E^([S6O[+O_LPX1;I'5@S*,#*DD@#)8\UTWP2_9Z\<:A\7IOC-\:=5 MT_4/&Z6KV&A>']'W-IWAZV?A_+=^7F<9#/CHS#+ C;].44 >:?Z9\=?@ MOXK\!ZMM6UUJWN+=9F7=Y$PD9HI@/5)%1Q_NU@?LA_ 5OV<_@7H?A6\G6^\0 MR-)J6NWZN7-U?S'=*Y<\OM^6,,>2L:D\UZ[I/_'F?^NTO_HQJNT >6_M%? ? M2OVB?AC>>$]2NYM)NEFBOM,UBU&9]-O8CNBN(^1R#D'D$JS#(SD>/6?C+]KW MPCI:Z'=_#CP5XZU&#]U'XKM_$'V&"=1PLLMJR!@Q&"P0@9S@8Q7UG10!X#^S M;\#/&/@G7O$_C_XG>*E\2?$/Q4L,=W;Z<7CTO2[>('9;6T;'D DY=AD_4LS\ MAXV^ _Q*^$/QBU[XF_ J71KZ'Q3(DOB?P/KTC06UY<*#_I=M,N?*F;/S C!) M9CNX ^K:* /B_P")'@G]I7]J;PGJ7A/Q%I6B_!?PA<6[KJ$.FZR-3U35OD.+ M99541PPNQ CV30726\HDC#& M5VX8=>&%>PT4 %%%% !1110 57O?^/2?_KFW\JL57O?^/2?_ *YM_*@ LO\ MCT@_ZYK_ "JQ5>R_X](/^N:_RJQ0 4444 %%%% !1110 4444 %%%% !1110 M!2T__CZU+_KX'_HJ.KM4M/\ ^/K4O^O@?^BHZNT %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !117SI\*?BMXJ\2?MC_ !R\"ZEJGVGPMX:L=$FTJP^SQ+]F>XMM M\Q\Q4#ON;GYV..V* /HNBBB@ HHHH **** "N7^)7@'3?BIX!\0>$-9:XCTG M7+*6PNFM7"2B.12K;6((!P>N#7444 8/@GPG9> _!NA>&=,,S:;HMA;Z=;-. MP:0Q0QK&FX@#+;5&3@.O"(\>>$=4T!]6U70A?0^5_ M:6AW1MKVW.00\,N#L8$=<&N#_9Y_9M\.?LWZ'K=EHFHZUKVH:Y?MJ6J:UXAO M!=7UY,0!EW"J" ,XXSR222:]=HH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** *.G_P#'QJ'_ %\?^TTJ]5'3_P#CXU#_ *^/_::5 M>H **** "BBB@ HHHH **** "BBB@ JEJ_\ R#W_ -Y?_0A5VJ6K_P#(/?\ MWE_]"% %VBBB@ HHHH **** "BBB@ HHHH **** "J6K_P#(/?\ WE_]"%7: MI:O_ ,@]_P#>7_T(4 7:*** "BBB@ HHHH **** "BBB@ HHHH **** *6D_ M\>9_Z[2_^C&J[5+2?^/,_P#7:7_T8U7: "BBB@ HHHH **** "BBB@ HHHH M*KWO_'I/_P!D_\ US;^5 !9?\>D'_7-?Y58JO9?\>D'_7-? MY58H **** "BBB@ HHHH **** "BBB@ HHHH I:?_P ?6I?]? _]%1U=JEI_ M_'UJ7_7P/_14=7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OE+]K;Q_P"-O%'Q.\!_ M ;X<:W)X3UOQ9!/J6M>)H0#-INE0@A_)'422,"JL,$$ C<67ZMKX]_:V36O M@C\=OA_^T-I^BWGB'PWHVGW'AWQ79Z;&7NK?3Y6,B72@?>2.0EFSCH.0"64 MMR?\$QO@K'9)/IT7B;2_&$:[H_&=OXBN_P"U%FP<39,ACW9.>(P.*X']AO3_ M !IHO[8/[1.E?$#4HM;\4Z=9Z'9RZM#'Y?VZ%(76WN&4' =X?*9@/XBU?0EY M^VW\"+/P>?$Y^*OA>73O*,HAAU&-[QL#.P6P/G;^1\FS=STKY]_8=^(FL_%; M]K[]H7Q5K.@7GA>34K'0Y;/2M04+<16?DR"V:1<_*[Q;)"O8N10!YO\ \$\/ MV7]'_:0_9]TCQ%\7+C4?%VD:7?W%KX;T.34)X+2S59C))Q \BMC]M+XM>,/"MGX%^'/PYNH=-^('Q&U5M*L=4G7:6,E1C:/E!S@-G'RAO3/VV/ OBB.]^&7Q@\&Z-/XEUSX::K->SZ%:Y\^]T^ MXC6.[6$ 9,@5%(7N-W!( (!G:/\ \$SOA!'8I=>(6\3>*/&[1_O_ !I>>(;V M/47F(YD79*$7G) *MC."6KS#X!^&/B!\._\ @HU=>#_&WBRZ\86>F_#F5=#U M:\8_:+K3SJ*-$;GG#SH[31F3JPC4]Z]PT7_@HE^SYJWA<:U+\1;#2=J!I]-U M*.2*^@;!W1M!M+%@00=FX9Z$Y&?$_@;\3M9^,7_!2R\\2WOAV_\ #NA3_#23 M_A'X=3C\JYN-.&HQA;F2+.8_,E\XJK '9L..02 8FA_"_P"&OQ\_:G^,'AWX M\ZCJ0^)<.N21>#["YU:>P6#1MBFUET_8ZH\A +,,-R,E22YK[S^'7@^7X?\ M@?1?#LNN:IXFDTVW6W.K:U,);RYQ_%*X W'MG&< 9R>:^7?CY\6_V5?V@/!' MBG3?B!XFT6RU+PS-=V8_M(FQUO3[F,E=]I&^V9SN56 0%6PH8=0/4?V&]<\8 M>)/V3_AQJ7CN2YG\2W&GL\L]YGSIH?.D%M(Y/)9H!$Q8\G.3R: />:*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** *.G_\ 'QJ'_7Q_[32KU4=/_P"/C4/^OC_VFE7J "BBB@ HHHH **** M "BBB@ HHHH *I:O_P @]_\ >7_T(5=JEJ__ "#W_P!Y?_0A0!=HHHH **** M "BBB@ HHHH **** "BBB@ JEJ__ "#W_P!Y?_0A5VJ6K_\ (/?_ 'E_]"% M%VBBB@ HHHH **** "BBB@ HHHH **** "BBB@"EI/\ QYG_ *[2_P#HQJNU M2TG_ (\S_P!=I?\ T8U7: "BBB@ HHHH **** "BBB@ HHHH *KWO_'I/_US M;^56*KWO_'I/_P!$K/748.NI6^AVR7"L,X82!-P;GJ#GIZ"NPM?#NDV&KWVL6NEV=OJU^ MJ+=W\5NBSW"H,()) -SA1P,DX'2M6B@#)\/^'-)\)Z5%I>B:79Z/ID)8Q6>G MVZ00IN)9MJ( !DDDX'))JOXN\#^'/'^DMI7BC0-,\2::S!S9:O9QW4)8=#LD M4KG\*WJ* .0\"_"/P/\ "V.=/!O@[0?"RS@";^QM-AM3+CIO,:@M^.:Y+]HS M3?BQ-X3T_4_@_K%E;>)-+O4NI]$U*&$VNMVP_P!9:M*ZEH6/575E[@D9W+ZY M10!\97/[2^BQZA'JOB+]D[XC#X@(,EK/P9!?DR@@9BOE.&0''S\$#G'3/7_L MV_#7QWX@^,'C#XY_$[18?"VOZYIT.AZ'X9CN%N)=*TN.0R%9Y%^4RR2!7('W M>(8=>U_P !^&=;UR%E:/4M0T>WGN5*@!2)'0MQ M@8YXP/2NVZ<#@4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH HZ?\ \?&H?]?'_M-*O51T_P#X^-0_ MZ^/_ &FE7J "BBB@ HHHH **** "BBB@ HHHH *I:O\ \@]_]Y?_ $(5=JEJ M_P#R#W_WE_\ 0A0!=HHHH **** "BBB@ HHHH **** "BBB@ JEJ_P#R#W_W ME_\ 0A5VJ6K_ /(/?_>7_P!"% %VBBB@ HHHH **** "BBB@ HHHH **** " MBBB@"EI/_'F?^NTO_HQJNU2TG_CS/_7:7_T8U7: "BBB@ HHHH **** "BBB M@ HHHH *KWO_ !Z3_P#7-OY58JO>_P#'I/\ ]M+7-^(-;UW3;R./2_#O\ :\#)N:;[='!M;)^7:PR>,'/O3BG+ M1$2DHJ[.DS1DUQ/_ E7C'_H1O\ RK0_X4?\)5XQ_P"A&_\ *K#_ (5K[&7= M?>O\S+V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^ M%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/ M^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ MRJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ MH1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"% M'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^ M%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/ M^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ M ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5> M,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ M/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$ M_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT M9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y M_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P M]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S# MV\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7W MK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"% M'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\ MJL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_ M\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H M1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5> M,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP M_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\ MJL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_ M\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_ MZ$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/ M_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV3 M1DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9- M&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D M=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\ M>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z M_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U] MZ_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>Q MEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP M_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^ MA&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,? M^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7 MC'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%' M_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ M "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^ MA&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,? M^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P ) M5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31 MDUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^ M1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y M';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/ M[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_ MS#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9 M=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L M9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_ MX4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ M "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5 M>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_" M5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ M E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL M/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ MH1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5 M>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#" M5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3 M_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1 MVV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L M_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S M^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/ M;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9= MU]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^ M%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/ M^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ MRJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ MH1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"% M'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^ M%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/ M^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ M ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5> M,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ M/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$ M_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT M9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y M_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P M]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S# MV\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7W MK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"% M'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\ MJL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_ M\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H M1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5> M,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP M_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\ MJL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_ M\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_ MZ$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/ M_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV3 M1DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9- M&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D M=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\ M>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z M_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U] MZ_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>Q MEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP M_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^ MA&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,? M^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y'56*LL]]D8S/D?\ ?"5!OF0*Q_P")M#WS[>U2_P#"5>,?^A&_\JL/^%'L9=U]Z_S%[>/9_<_\CMLF MC)KB?^$J\8_]"-_Y58?\*/\ A*O&/_0C?^56'_"CV,NZ^]?YC]O'L_N?^1VV M31DUQ/\ PE7C'_H1O_*K#_A1_P )5XQ_Z$;_ ,JL/^%'L9=U]Z_S#V\>S^Y_ MY';9-&37$_\ "5>,?^A&_P#*K#_A1_PE7C'_ *$;_P JL/\ A1[&7=?>O\P] MO'L_N?\ D=MDT9-<3_PE7C'_ *$;_P JL/\ A1_PE7C'_H1O_*K#_A1[&7=? M>O\ ,/;Q[/[G_D=MDT9-<3_PE7C'_H1O_*K#_A1_PE7C'_H1O_*K#_A1[&7= M?>O\P]O'L_N?^1VV3535E+6+@#)W+P/]X5RG_"5>,?\ H1O_ "JP_P"%1S^, M/&$,,DK>!OE12Q_XFT/89]*/8R[K[U_F+V\>S^Y_Y'=9-&37$+XL\8LH(\#< M$9_Y"T/^%+_PE7C'_H1O_*K#_A1[&7=?>O\ ,?MX]G]S_P CMLFC)KB?^$J\ M8_\ 0C?^56'_ H_X2KQC_T(W_E5A_PH]C+NOO7^8>WCV?W/_([;)HR:XG_A M*O&/_0C?^56'_"C_ (2KQC_T(W_E5A_PH]C+NOO7^8>WCV?W/_([;)HR:XG_ M (2KQC_T(W_E5A_PH_X2KQC_ -"-_P"56'_"CV,NZ^]?YA[>/9_<_P#([;)H MR:XG_A*O&/\ T(W_ )58?\*/^$J\8_\ 0C?^56'_ H]C+NOO7^8>WCV?W/_ M ".VR:,FN)_X2KQC_P!"-_Y58?\ "C_A*O&/_0C?^56'_"CV,NZ^]?YA[>/9 M_<_\CMLFJFK*6L7 &3N7@?[PKE/^$J\8_P#0C?\ E5A_PJ.?QAXPAADE;P-\ MJ*6/_$VA[#/I1[&7=?>O\Q>WCV?W/_([K)HR:XA?%GC%E!'@;@C/_(6A_P * M7_A*O&/_ $(W_E5A_P */8R[K[U_F/V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ M "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^ MA&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,? M^A&_\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P ) M5XQ_Z$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31 MDUQ/_"5>,?\ H1O_ "JP_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^ M1VV31DUQ/_"5>,?^A&_\JL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y M'5:3E;0@C!\V7K_UT:KF37"KXR\7O<21#P-\T84G_B;0]\^WM4G_ E7C'_H M1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_Z$;_ ,JL/^%'_"5> M,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV31DUQ/_"5>,?\ H1O_ "JP M_P"%'_"5>,?^A&_\JL/^%'L9=U]Z_P P]O'L_N?^1VV31DUQ/_"5>,?^A&_\ MJL/^%'_"5>,?^A&_\JL/^%'L9=U]Z_S#V\>S^Y_Y';9-&37$_P#"5>,?^A&_ M\JL/^%'_ E7C'_H1O\ RJP_X4>QEW7WK_,/;Q[/[G_D=MDT9-<3_P )5XQ_ MZ$;_ ,JL/^%'_"5>,?\ H1O_ "JP_P"%'L9=U]Z_S#V\>S^Y_P"1VV34-YG[ M).!U\MOY5Q__ E7C'_H1O\ RJP_X4?\)5XQ_P"A&_\ *K#_ (4>QEW7WK_, M7MX]G]S_ ,CL+/*VD /!V+_*ILFN%M_&7B^YA25? WRL,C_B;0_X5)_PE7C' M_H1O_*K#_A1[&7=?>O\ ,/;Q[/[G_D=MDT9-<3_PE7C'_H1O_*K#_A1_PE7C M'_H1O_*K#_A1[&7=?>O\Q^WCV?W/_([;)HR:XG_A*O&/_0C?^56'_"C_ (2K MQC_T(W_E5A_PH]C+NOO7^8>WCV?W/_([;)HR:XG_ (2KQC_T(W_E5A_PH_X2 MKQC_ -"-_P"56'_"CV,NZ^]?YA[>/9_<_P#([;)HR:XG_A*O&/\ T(W_ )58 M?\*/^$J\8_\ 0C?^56'_ H]C+NOO7^8>WCV?W/_ ".VR:,FN)_X2KQC_P!" M-_Y58?\ "C_A*O&/_0C?^56'_"CV,NZ^]?YA[>/9_<_\CMLFC)KB?^$J\8_] M"-_Y58?\*/\ A*O&/_0C?^56'_"CV,NZ^]?YA[>/9_<_\CJK'/VK4#C@S@C_ M +]1U<)%<]X9US5]5N;N'5-#_L9H5C9/]+2?S-V[/W1QC;^M= V:S::=F;1D MI*Z'T445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M4E "T444 %%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 44E+0 444E "T4E+0 44E+0 4444 % M%%% !1124 +1110 44E+0 4444 %%)2T %%%% !1110 4444 %%%% !1110 M44E+0 4444 %%%% !1110 44E+0 4444 %%%)0 M%%% !124M !1110 4444 M %%%% !1110 4444 %%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 4H/\ D*7G_7./_P!FJ[5*#_D*7G_7./\ ]FJ[ M0 4444 %%%% !1110 4444 %%%% !535/^0;=_\ 7%__ $$U;JIJG_(-N_\ MKB__ *": )X/]3'_ +H_E4E1P?ZF/_='\JDH **** "BBB@ HHHH **** "B MBB@ JIJG_(-N_P#KB_\ Z":MU4U3_D&W?_7%_P#T$T 3P?ZF/_='\JDJ.#_4 MQ_[H_E4E !1110 4444 %%%% !1110 4444 %%%% %*#_D*7G_7./_V:KM4H M/^0I>?\ 7./_ -FJ[0 4444 %%%% !1110 4444 %%%% !1110!1T?\ Y!EO M_N_UJ]5'1_\ D&6_^[_6KU !1110 4444 %%%% !1110 4444 %%%% %*'_D M+W7_ %QB_F]7:I0_\A>Z_P"N,7\WJ[0 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 VOFC]JK]I#Q1\$_$F@Z=X?L=+O([ZW>9_M\,LC[@ M^T!=DB_R-?2]?"W_ 4#F>V^(7@N6*/S)([1V5<9R1*"!7L911IXC%QIU8W5 MGI\CP<[KU,/@Y3IRY7=:_,OZ3^U1\<[S5K."X^'T$4$LR)(XT2]&U2P!.3+@ M<5Z%^U1^TGXF^!_B'0++0['2KN"]MGGF_M"*5FRKXPI210!CU!KBM)_:L^,- MUJEG;S?#)H899DC>3^S+P;5+ $Y)["L7]O\ MQ>?$3P/!)D++:NC;>N#*!7M MT\+3J8RG3JTE%-/1.]].I\]4QE6G@:M2C62?!?Q-J/[*WQPU#X>>([ACX:U:93;W4GR MIN;B&<=@& V/Z$=?DJ?X!X/[;WC?'3S]4_\ 1ZUR_P!GTJ;KRMS1Y>:+_KL= MBS2K56'C?EESC'H17Q MS^U-XBN_"?[6>G:U8V?]H7EC'93PVN"?-9L>']4 M\"-I5A>QJDMX4F'E 2*P/S+CJH'/K6RROVOU:I3BN5IO&]>(AB7/R+#.?W8'LDR[)--.V*Y^VB: MMEH)@( \;>X/Y@@]Z]B>64/K\'35Z;;379I/3]4>)#-Z[RZ<:DK5(V:?=-K4 M^B/CU\7?'7@/PCX7U+P=X?CUR\U(%KN,V,]RL0\M6! B<%>2>I/2OGK6/VW_ M (N>'IXH=5\*Z1IDTHW1QWFF7<3,,XR TPR,U]R>%\#POI)/_/G%_P"@"OBG MPLO_ TY^UY<:PP\_P ,>'W$D7=#%"V(<<_\M)3OQZ%JX,O^K2C4]M23C!-N M77R1Z69K$QE3=&LU*;24>FVK_4][^+GQ:\7_ L^ =AXJNK+2V\4N;9;JUDA MD^SQO)RR!1)NRO3.X\@FO!=._;$^-VL6<5Y8>!;&]M)1F.>WT:]DC<9QPPEP M>0:]F_;HX^ 5T/\ I_MO_0C7@'PG_:.^*'@OX>:-HNA?#\ZMI5I&RP7OV"ZD M\T&1F)W(=IY)''I6V!P].IA/:JDI2BNV[]3Z> MM?%7Q7\5?"SPOK.@Z5H-CXENU9]2M-;BN(8XQDA0B!]X/ ^\3UK@_@_\8/C3 M\5KRYEAT_P &Q:5INJ?V?J+;+E9L*5,AB_>$$[2<$]^U>Z?"SQ-JOC+X?:/K M.N:=_9.JW>R\MX_*;<1C:_P PX Z^M>/_ +&-K-:Z-\0%FADBW^);EE\Q M2N1M7D9KRXN"I5G*"O%JWS;^^QZ\E4E6H$==L=-M_#G]KWNC6=];12)+Y\3MY2R,TC*2RKCA1ECQ@ BG?M!?M1^(/ MAQ\0(- \,6&FWUM:BW35+F]CD?RIIR3'&NQUP=BEN<]?:O/+/P#J'BC1/CQ- M90S0ZUI/BR36M+E"$-YL$TK93U)3+_!^KM^S_ *=XNU>VDD\1>+?% ML&JW2K&VY(=LPB0#DA0"6 [!\5Z<UENIG7.-_EQD",9_O%O MPKK/^"@7B"YTWX7:1ID#F.'4M1 N,?QI&A8*?;=M/_ 17J/[-/@+3/ ?P=\- M16,$:W%]917UW.H!:6:5 Y)/<#=M'L!7O8>G0PN%6*JQYI2;23VTW;/FL34Q M&,QCP=&?)&*3DUN[[)=CYZT[]L[XB_#O6+>U^)7@EH;24@"2.VDM)BN!EDWD MI)CT&.3C(KZRTOXA:%JG@:+QA'>B+P_):F]^U3J8PL0!)+ C(Q@_TS5[Q1X0 MT;QKI,FF:[IEMJE@Y#&WNHPR[@<@CT(]17SC^WOKTV@_";1M$L?]%L[^^6.5 M(AM4Q1H66/ Z#=L./]@5$?89A5ITZ=/DDWK9Z6\D5+ZQEE&I5JU.>*6EUK?S M?8Y7Q+^VMXR\:^(;C3/A=X1>_MXL_P"D36LMS.ZYP'\N,@1KG^]N]\=*9X;_ M &UO&G@GQ%!IGQ1\(M96\N 9HK26UN(US@R>6Y(D7_=Q[$]*^@/V:O NE^!O M@YX:CTZ"-9KZQAOKJX7!::61 Y);N!NVCT %-_:6\ Z7X\^#OB2/4(8_/T^R MFO[.Y8 -#+$A<$-V!V[6]B?:NKV^!]M]7]C[E[7O[WK_ , Y/JV8>P^M^W?- M:_+96[V_X)VEQXNMKSP-/XBT:YAOK5K%[RVF&6CD 0LIXP<<>_L:>([K5/V>?&VE7# MM+!IIN!;[C]Q)(2Q0>V[ M/:Y()PK*<_C6S\#O'-_\2OA7H'B35(K>&_U")WE2T5EB!$C*-H9F/11U)KS? M]NK_ )(+=?\ 7_;?^A&NF_9)_P"3>O!__7"7_P!'25QRHTUET:UO>YK7\K'= M&M4_M25'F]WEO;SON>O-T.>.]?&?C3]N/5?#?QFO-#L[+2Y?"%EJ2V<]T\4K M7)C5@L[JPD"\$/M^4C '6OHWXZ?$!?AC\*_$'B .%NH+&2.*2WF>YD=P?E79( ><8 7->A?L@? M$7_A87P6TH3R^9J.CDZ9 MY[!\$_VQI_''C:#PAXO\/CP]J]PQC@E0NJM+C(C>-QN0D=#DY.!@9KZ \<^- M=(^'?AB^U_7+D6FG6B;I'/)))PJJ.[$X 'O7P7X(^)&F_%K]JC2O%/C22'PJ MD,D)M;4(Q5I8P!#&\A QECN+L . ..WH7_!0K7[N:^\%^&XYO+LI?.NY QPK M296-"3_L@O\ ]]&NG$9;3GC:5&,>3F5VMTN]F'O[ E=@IO8[>6W:WST,L,F3M_V@>/0U]0^!?!>E_#OPKIV@Z/ L%C M9Q!%P &=L?,['NS'DGU->,?MN> =*\1?!O4-?F@C35M$>*2WNL ,4>54>,GN MI#YQ_> ]ZPI5\#7K+#^QM&3LG?WO)F]7#YAAJ+Q?MW*45=Q:5GU:1ZS\3/&- MQX1^&7B'Q+I8M[F>QT^6\M_-!>&0JA9<[2"5/L1]:^0-'_;C^*%WI\L[.Y6&/ !(9][*IP0>3QD<5WWPY\177B3]A'73>.TLMCI5]9+(Q MR3&@;8/P4JOT45\\_!K]J"_^#?P_U?PS9>'[74WO[J6Y%U=3,%0O%''M,87Y M@/+SU&.7.V2=B%C4@$$C<1G!S@&O&?V&OA+KOP]\)Z[JVO6]N\?7HY6L16TJ-67JW9:?B=K^RM^U-JOQJ\0: MQHOB.UTZROX8%N;/^SXY$#H&VR!M[MDC%$$-T,>K*1)_O2>U??D,T=U"DL;++&ZAE9>00>00?2GCZ="C6IXBC&]. M2O;TT:#+:N(Q%"IA:\[5(NU^MGJF?!EM^V]\7K[59-)M_">D3ZG&6$EE%IMV MTR%?O903;ACOQQ7I?Q6_:>\=?#KX6^ -?.C:9;:YK@G^WVE_:3*L10KM"IYB MLO!_B)KB?@TH;]NKQ:,<>?J/_H5;O_!1C_D#^!_^N]U_Z#'7J2HX6>,HT%22 M4ES/YIZ'BPK8N&"KXB59MQ?*ODUJ?5@\2VNG^$5U[59XK*UCLUN[F9B1'&NP M,Q^@_.ODCQ)^VMXR\:^(KC2_A=X1>_MX\_Z1-:RW,[KG ?RXR!&N?[V[WQTK M;_;7\276E_ 7PGI=L[1PZI+ MQM_BCCAWA3[;MA_X#7L?[-?@72O _P<\,QZ M?!&LU]8PWUU<+@M--(@)$U&&/[1I]E-?V=RP :&6)"X(;L#MVM[$^U>*?L:^)+K4_V>O&NE M7#M)!IIN!;[C]Q)(2Q0>V[)-(T/PY:Z;>7TM MNUU>?VA'(X1"VV,+L=,$[7)SGC;ZU[+\&_B''\4OAOHGB1 B37D -Q''G;'. MI*RJ,DG 8'&>V*^,?AOX/7]K+X[>._$&I[QHB03"%F!_=[T,-J/JJ@R?[T?O M7=?L(^+KKP[KGB[X;:O^ZO;2=[N&)C]V1&$5PH_$1D#_ 'C7T6+P%&&$Y::_ M>P2#O@C:>/?":6=^+QK9[?[>CLACEYY564AAZ9X.:\"T_P#; MJ^(ECIUKJVL>!K2?1I&Q]LMX;BWBDY(PDC%USP1WY%=9^T'X)N/AS^QKHWAV M[D66[L9;1)F4Y7S"Y9@#W +$#Z5X;I/[0FOZU\$X/A1H_A-;^22/[-]JBWSR MNK2F3Y8E7ALD ')QC./3/!X.A.BY*"DN=J[=O=[FN.QN(A7474<'RIV2OKV/ MM:3XW0:]\!-2^(OAN-&>'3I[J.WO%)$A&1@CK7S-H_[>F1Q7IOAOX:ZG\+?V+_ !3I M>L+Y.IW&FWM[/!NSY)=#A">F0JC..Y/UKYJ^#7[4%_\ !KX?:OX9LM M=3>^ MNI;H75U,P5"\4<>TQA?F \O/49S4X/!TJD:OLZ:G:5E=VT]2L=CJ].5+VM1P MO&[LKZ^A]S_ 3XYZ;\=?"6#2;_*8C*LK8&589P<#D$=JX M3]H']KS3_A3JC^&]"L%U_P 3C EC9B(+8L,JK[>7-_' M7B_QKK074-9M'C:*2;#%99VD:27'9ODP#_M-7)]5PM.K6K?%3A:RONWTOV3. MWZYBZE&A1^&I.]W;9+K;NT-N/VJ/COX9A&L:YX'6'1?O2&?1[F"-5Z?ZPM\N M>Q;/XU]*_ SX_:%\=- EN=/5K'5K7 O-+F<,\6>C*>-Z'G#8'N!7ID]O%=PR M031K+#(I1T90592,$$'J#7PEX;TN'X,_MT+HF@GR=*O)Q";53PL5Q )/+^BN M00/1%J(^PS"G-1@H3BFU;9I=&:3^L994A*=1SA-J+ONF]FCU_3OVD/$VE_M- MW'PX\36>EV^D33M%975O#*DI#IYD!9FD93N&$.%'S'MC%?0FO:U:>&]"O]6O MI/)LK&WDN9I/[J(I9C^0-?(?[>GA6YT/6?"'Q%TO,-W:S+:23*.5D1C-;M^8 MDY]E%;W[5GQMM=0_9PT273) D_C%(L1JWS)"H$DP_!ML9_WS3E@H8I8>=%64 MM)>JW?W:D1Q\\(\33KRNX:QOU3V7R>AU7[+/QT\7_'(^(K_6M/TNQT:Q=(;8 MV<,@D>5LL069V!VJ%S@#EQ]*\8NOVTOBM>>*-7TK0_"^DZJ;*XECV6VG74T@ M17*AF"2_3G &37TE^S#\/A\._@KH%C+%Y5]=0_;[P$8/FR@-@^ZKM7_@-?$/ MPQ^)7BGX8_%KQA?^%/#Q\17L\MQ#+;_9Y9MD?VC=NQ&/0K.VM1-#,FG7%L7DW@;L1V,\ MJ>79V-S)*$5RH9MLIQVR<8YKVC]GGXU>//B?KVK67BSP?_PCEI;VHFAF^R3P M[W+ ;-_L5@']H+X@Y_YX7'_ *5+64*-&#KU*M)>ZDTD[K[S6I6K MU(X:E1K/WVTY-6>GDSJ_AS^W9#>>(8=$\=^'O^$;DD98S?Q.WEQ,<8\R-QN1 M>?O9.,CC'-?6L;*ZJRD$$<&OF;]NOP#I>K_"=_$[6T::OI-Q"$N5 #O%(X1H MV/<98,!V(XZG/?\ [*/B"X\2_L_^$+R\??/'!):[CU*Q2O$G_CJ+7G8JC0J8 M:.,H1Y=>5J]];7T/5P-?$4L7+!8B?/9UF>D^(]0ETGP_J=_"JM-:V MTLR+)DJ65"P!P>F17Q!H/[NIQ9WBJF'KTH*JX)IW:5^UM#[:_ M9V_:+L/CSI-^19'2=8T\I]IL_,\Q2K9VNC8&02"",9!QZ@UX+J?[9WQ,7Q]X M@T+1_"VEZVFG7=Q"D5I97,D_EQRE [;9#[9. ,D=*Z?]B/X7^(M%U#Q+XVU^ MPDTA=73R[6UDB,3.&?S'D"'[J9VA<]><<=? O#/QFF^!OQ^\=:_#I4>L//=7 M]D8))S$%#78?=D*?^>>,8[UVT<#AYXFO"E!344K*_7JKGG8C,,3#"X>=:;@Y M-W=M;='8^J_V=_VL$^+^OS^&- >>*[ MKXY?'S0O@9X?BN]05K[5+K<++38FVO,1U8M@[$&1EL'KP#7S?^S3X?\ $WQ@ M_:"N/B[J&DC1]&'FR(\:%8II&A-N$C)Y? +%F'&Y3T)Q5#Q+IT'QA_;J&C:] M_I&D64_DK:N>&C@@,HCQW#2 DCN&:N>I@,,\7)6M&$>:23O9K=7.NEF6*6!B M[WG.7+&35KI[-HLQ_M4?';Q1 =7T+P*)-%R6C:WTBYG1EY'^LW?/CN5Q^%>K M_L^_M>6'Q4U9?#GB&QCT'Q,V5B56/DW+#JJ[N4<8/RDG..#GBOHF*&.WB2*- M%2-0%5%& . .PKX=_;N\)VG@?QSX2\9Z'MT[5[UY&FDAPI,T#1M',!_>^? M!/\ LK6-"6%S&?U;V2@W?E:[K77N;8B&,RN'UIUG-*W,FM[NVG8]Q_:N^..O M_ _0=#OM"MM/NI;ZZ>&5=0BD=0JIN!78Z\Y]^'UN=. M=%?SE@N;5)%.,,KN7&"#QUZBMG]O34O[8^&'@"_*A#=3F8KV&Z -C]:^EOAO M8P7_ ,*/"]M=0QW,$NC6J21RH&1U,*@@@\$'THBL-A<'2J5:2DY-IZV>C"3Q M6,QU6G1K."BHM:)K5&-\$?CIH/QP\/R7^E"2UOK4JEYILY!D@8C@Y'WE.#AN M^#P",5YWXT_:+\2^'_VFM(^'=M::6^B7/8T(KKP[^P7HQM':* M2]TZTLV=>HC=AO'XJ"O_ *N&GA(5L+2LK2E.U_([ZN.J4,96N[QC#FMYE;Q M]^V_JFI^(I- ^%WAMO$$RD@7DT$L[3XZF."/#;>X8G_@(K!_X:Z^+WP[NH)_ M'?@95TN9L;GLIK-CR>$D)*YQV()X'UKU?]B/P%IGAWX,V&N0P1MJNM/++\ZQHFG^(M+N--U.TAO["Y0QS6\Z!D=3V(-;UL1@L-5 M>'5!2C%V;;U=MWY&-##8[%THXF6(<925TDE97V374^=OB-^T]XBNO ?A;Q-\ M+_#[:]!J9&?W _]'-6F$EA)8:M-T4^2S5WJ[M_D8XR&,ABJ,/;M<]T[+1- M);>IZ/\ '+]JG6?AS;^&=!T70X[[QKK%C!=2PS12&.!I/E$:Q [FI?VO M_@9K^OZIIOQ%\'--)KVCQH);6 9E*QN726(=W4DY7N,8Y&#L?LS_ +3FE_%R M:#2=?M[>P\=0PF-9M@5;V,VZRE%)R0"1P,UZ.7XJ.#Q"K35TK_BCRLR MPD\=AI48.S=M_)W/&=/_ &Z?AQ?WEM:Q6VM>=-(L2[K- ,L0!G]Y[UY7^WLV M[XG> CV\@_\ HX5]0V_P!^&]O-'/%X)T..6-@Z.MD@*D'((XK;\3?#?PQXSO M;6[U[0=/U>YM1M@FO+=9&C&?6P6,Q6 M&E0KRC=M6LFMGU/+_P!K#X&?\+=^'YN].@#>)M(1I[3:/FN$QEX??.,K_M = M,FOF#]A^[N=1_:#EN;R62>ZDT^Y>624DNS%DR6)ZFOT4Q\M'?$$ M^NZ;X?TZQU>?>9;VWME25]YR^6 SR>31A\T='"U,+-733MY7#%90JN,IXRF[ M--77>VWS/D;XS?\ )]?A+T\_3O\ T*OH3]K15'[//C$@8_<1?^CHZ[C4/AQX M7U;Q-!XAO- T^ZUR HT6H2P*TR%/ND-C(QVK5UW0=/\ $VE3Z9JUE#J&GW " MRVUP@>-P"" 0>O(!_"L)XZ,I4))/]VE?SL[F]/+Y1AB8MK]XVUY75M3YP_9- M\46G@G]E>]UZ^.+73IKRX=M--$\DTGSR!#&"< .N>?XA7Z P_#;PM;^%9O#47A_3TT"9]\FFK H M@=MP;)3&#\P!^H%:7AOPOI'@_2TT[1--MM*L%9G%O:1"- Q.2<#N:ZHYI[%U MJE&/O3?6SLNQR2R=UHT*=:7N05K*Z;?<_/CXX?LS_$+P'X5;Q9XA\3IXDBL7 MCB+"YGEEA5VP&!D'"[BHX/5A7T=XH^(2?%#]C'5?$!=6NYM',=T /^7A"$DX M[98$CV(KZ!UG1[#Q!IEQIVIVD-]8W";);:X0.DB^A!ZUC:?\-?"VE>&[O0+/ MP_86VAWC%KC3XX%$,I( )9>AR%7\A4U,T]O"G[9>]"5TU9:=473R?ZM.I["7 MN3C9IW;OWN> ?L5^'['Q5^SGJ^DZG MU8WVHW,$T3CAE:.,'Z'W['FOD#XU_ M#?5_A!XRO?"=[--+IT4K7=C(WW)8GP!*!T#$(%;'=,=A7ZF>%_".B^"M..GZ M%IEKI-DSF4P6D0C3>0 6P.YP/RJGXK^'/A?QU);/XAT#3]9>W#"%KVW60QAL M9 )'&<#\JWPVK:O:1:=:;3AEWQC>X]-J;N>Q*UX#^RW^T'\/O@CX+O+?5(M4FU[4 MKDS74EM:JRA%^6) 2XR -S=.KD=J^U_$WPW\+>,H;*'7-!T_5HK$%;9+R!9% MA! !"@],[5_(5A+^SU\-._@;03_VXQ_X5C0QF%CAI4*L9>\[NUEZ(VQ&7XR6 M*CB*4XKE5E=-V[OU9Y)^UUXHL_&G[+]OKM@)%LM0GL[F$3*%?8QR,@$X/XUQ MGP+_ &P/ OPY^$_A[PYJL&K/?V,3I,UO;(R9,KL,$N,\,.U?6&H> ?#FK>&8 M/#UYH=CG>(=,69;"_C\V(3J%? M&XCD G'(/>N@^E9^AZ'8>&]+@TW3+2&QL+==D-O;H$1!G. !TY)K0QVKQ)G6O$/V??VPM-\#^&;;P=X_M;W3[C2!]E@O5@9\ M(G BEC^\K)C:, \ 9P1S]L=JX'QM\#_ GQ&NC=>(?#-E?W9&#=!3',PQ@ R( M58X]SQ7KX;&4E1>&Q47*%[IK=,\'%X&NZZQ>#FHSM9I[-'A?Q&_;TT"RLUM? M NGW&N:M(ZJDUY"T5NHR/X"_@+X ^'MXEYH/A:QL[Q/N73AII MDXQ\KR%F7\#S7H(SWZ4JF*H49PEA(M.+O=O5^5EI8=/!XFM"<,=--25K):+S MUZGQ)^S[^V!8_#WPW!X,\?VE[8S:1_HL-W' 6*1J<"*6/AE9.F0#P,$ CEW[ M0'[85AX^\,W'@SX?VE[?7&L#[)->- 5+1L=IBBCY9F 2>/I_QQ\$? M WQ&N/M/B/PU9:A=D8-UM,SYK= MNVQYS\#OA#=?"#]GK6+'4U5-9U"VN+Z\C4@^4S0[5BSWVJHS_M%L>M?-?[)/ M[07ACX(Z?XCA\01W[OJ$L#Q?8X5D&$#@YRPQ]X5^A\]O%>6\MO/&LD,JE'C8 M9#*1@@CT(K@A^SS\-#_S(VA?^ ,?^%94.5K>V1H\M*[#!+CLP[5]43?#?PO<>%X?#4OA_3Y M/#\+;X]-:W4P(=Q;(3&.I)^IK$3]GOX:JX8>!M"5@ MOKF;X:^%+CQ0OB27P_I\NOJRN-2:W4S@JH53OQGA0 /85TW/ [41S6>'HPHX M=62WND[L)9+#$5ZE?$RNY;6;5EV/A/\ 95NM0^!O[0FN?#G7I8U_M!/)#(3L M>=%\R%ESCAHV?'&266J?[2/B6S\&?MAZ+KFH"5['3_L-Q,(5#/L7DX!(R?QK M[3U+X;^%M8\16_B"^T#3[K7+=D:+4)+=3.A0Y0A\9R#TJMXD^$?@OQAJC:EK MGAC2]6OV54-Q=VJ2.5'09(Z"MHYI1>)^L5(.\H\LK=7W1A+)ZT<+]6IS5HRY MHWOHM[/YGPK^TC\6M'_:2\5>%-.\%:%>/J<;/;^?/"J33F0ILC 5C\JX8Y8\ M9/09)]]_; ^!^K?$#XUW=N^YO2RB4X5EBIWE4M>RLE;:Q\B?!O\ ;F\.KX7L]-\=+=V&L6<8A>]A M@,L5R%& Y"_,K<=J*0&+,1]WL 2?JOQA^SQ\._'M]+?:WX4L[B\D.9+B'?!)(?5FC92Q]S MS6SX)^$_A#X97'7!D;+$>V<5I'&8"G/ZQ3I/GW2;5D M_P S&6 S*M#ZM5JKV>S:3YFNQYAJWPX7X3_L?Z]X;,BS7%KH5T]Q,HX:9U9W M(]0"Q ]@*^6_ /P@;XD_LHZ_JMA#YFM:!KMQ=0[1\TL/V:W\Z/WX 8#U0#O7 MZ*:II5GKFFW-AJ%M'>V-S&8IK>90R2(1@J0>H-4/"W@O0O!.FRV&@Z5::193 M2F5[>TB$:,Y 4L0.Y"J/P%94,TG1A)_;']1CT6GM]T^M?>FC_ C\%^'X[^/3/#&E MV"7\#6UVMM:J@FB;[R, .5/I6CX5\#>'_ MK/;^']%LM&AG?S)8[*%8P[ 8! M..IQ3IYC3PU2K5P\;2EM?9=R:F5UL53HT<3).,-[7NWT^X^&OBG^R;\3=+\& MZCKFN>+X_$=MI,#W7V62[N)G"@9=D$BX!"@D^RU](_L=_$;_ (3WX*Z9#/+Y MFHZ*?[-GR>2J >4WXQE1GN0:]MNK>*\MY8)D66&52CQN,JRD8(([@BL+PG\/ M?#?@1;H>'M$L=&%T5,PLH1&)-N=N['7&X_G6>(S)XO#^RK+WD[II)>J-L/E2 MP>*]M0?NM6DFVWY-'Q_\&#_QG5XL_P"N^H_^A5N?\%&,?V/X' _Y[W7_ *#% M7U#8?#?POI7B:?Q#9Z!I]MKEP7:6_C@59G+_ 'B6QDY[U+XK\ ^&_'D=LGB' M1;'64MRS0K>0K((RV,D9Z9P/RK19E#ZW2Q'*[0BE^#7ZF7]E3^IU<-S*\Y-W M]6F>4?'[X1W'Q>^ ]C8Z!@@$<_:T-NEK!'#$JI% M& JJ!@* , "N)\H7>-INMICF(Q@ R(58@=LGBLZ&-I M>R>'Q47*%[JVZ9KBS7F?,/[0'[85AX^\,W'@SX?VE[?7& ML?Z+/=M 5+1L=IBBCY9F 2>/6/@?$+GX0_L]ZQ9:FJKK.H6UQ?7D M:D'RF:':L>>^U5&?]HMCUKT3P/\ [P+\-[C[5X>\-6>GW87:+H@RS 'J!(Y M9AGO@\UVUQ;17EO+!.BRPRJ4=&&0RD8((]"**^-I*FJ&&BU"]W?=L,/E]>56 M6(Q$*76@^.X9HUEADEMD>-U!5E*2 @@]017AO[3?P?O/@ MGXVN[&Q,B^%-9?[99#)V94G,3>K1ER >NUQZFOT<$^ ?#G@..YC\/:+8Z,E MR5:9;.%8Q(5S@G'7&3^=2>*O!.@^.+.*T\0:19ZS:Q2>;'%>0K(J/@C< 1P< M$C\:ZZ>AR7[-^?^%$^"/^P9 M#_*N3_;(^(P\!_!?4K:"3R]0UMO[,@P>0C@F5OIY89<]BPKVG2=)LM!TVWT[ M3K6.SLK9!'#;PJ%2-1T Z"LGQ9\/?#7CL6P\0Z'8ZS]EW>1]MA63R]V-VW/ M3.U?R%>1#$0^M>WFKQYKV^=SVZF&J/!?5Z&[?5H4NOLL=W<0N5(RA<1K@DJ01[-6'K?@WQ5^R?\ &3PCXF\0ZE'K M'VJ=IIKV"220RQY"7"L7 );8^>_WAZ5^C5M;1VL$<,2+'#&H1(U&%50, =A MBL?Q7X%\/>.K>"#Q#HUEK,,+EXDO85D",1@D9''%>Q'/*LJDO;).$KII)7L_ M,\27#]&%./L)-3C9IMNUUY'R]_P4*N8[KP+X.GA=9(I+V1U=3D,IB!!!],5] M*?"L*?ACX2X&?[)M/_1*4_7/AIX5\2:3I^EZMH-AJ&GZ>H6UMKF!7CA 4* H M/3"@#Z"M^PLH-,LX+2VA2"V@C6.**,85$4850.P %>55Q49X:&'BOA;?WGK MT,'*GBZF)DU[R2MZ'@?[=/\ R02[_P"O^V_]"-=/^R6 W[//@[(_Y82_^CI* M](\3>%='\9:8VG:WIMMJM@S*YM[N,2(6'0X/<5-H6@Z?X8TF#3-*LH=/T^W! M6*VMT"1H"22 !TY)/XU+Q2>$6'MJI7_"QHL(_KCQ-]'&UOGN:;<:??VT=Y8W$9BFMYE#(Z$8*D'J#5#POX+T/P3I\MAH.DVFD6,T MAF>WM(A&C.0%+$#N0JC\!6^%Q[PM)P@M>9/[NGS.7&9:L964Y/3E:\]=G\CR M+]D?XL+\6OA0-/U*7[3K.CJ+&]60Y,L9!$4A]=R@J3W*,>]?..D:GKG[$?QH MU&"]T^;4/".JY5'3'^D6X8F-T8\>;'NPRD]ST!5J^X/"OPS\*^"+R>Y\/^'] M.T>XG3RY9+*W6(NN)/"^C^,-+?3M;TRUU:Q MHY%7#'4H5:GN7ISWC_EZ=":F7U:E&G[]JD-G_GZK<\$US]N_XAO=2U M*_*$QV/V4Q'=V#.WR@>XW?0]*\U_9:\$^(OB]\9+[XP>)(#!9++)):EDPL\Q M0Q*L8/5(DXW>JJ.2&Q]!V/[*?PHTZ^^UQ>#+-Y>#MGDEFCX_Z9NY7]*]2M+6 M&RMT@MXD@AC4*D<:A54#H !T%.6+PU&E*&$BTY:-NVW96)C@<57JPJ8V::B[ MI1VOW=SA?CSX!'Q*^$OB+04C\RZEMC+:COY\?SQ@>F64+]":_/'X*Z+J?QB^ M(W@;P=?NUQHVERNQ@8?+' )&GF!_WCE?Q%?J>PS7+Z!\,_"?A/6)]7T?P]IV MFZE<*R2W5K;*DCJS!F!8#H2 ?PJL#F?U2C4I6NWJO)VM?7/P!^'-WXF3RY)+.W6-G7.<$@7,L\_@G1)9I6+O(UDA+,3DD MG'4FNC#XO"475I\LN2:2W5]#FQ& QE=4JG/'G@V[V=M?(^0OCU^TA/\ M(1Z M7X$\#:)J @N[M'D^TJHFN&&=J[4+!4!.XL3_ @G !S]E?!_P#'\,/AOH/AA M)1,UA;XEE48#RLQ>1A[%V;'M6AX7^'GACP3O_L#P]INCO(,.]C:I$[C.<,RC M)_$UT9Z<=:YL7C(5:4A%8?A+P#X<\"1W,?A[1;'1DN2K3+9P+$)"N<$XZXR?SK*CBE3PU2A; M6=OP9M7P;JXNEB;Z03T]4=$_B[X;O\"&^LM41)-N3 M%(+Z$QR#W5@#^&*_0NN9T3X<>&/#>N7>M:5H&GZ=JUV'$]Y;P*DLH=@[!F R M,^JPJ);RM9]FGJ/[5/@CQ#\)/C#I_Q?\-6YFM&ECDN MV"%D@F51&1(!T21,#/J6&02N?K.X^&/A2[\4+XDF\/:=)KZNL@U(VZ^?N4!5 M._&<@ #Z"NBNK6&\@D@GB6:*12KQR*&5@>""#U%=3S*,<5]9C'XE:2Z/O;U. M-93.6$^K3GK%WBUNK;7/G30_V\/ASJ&AI%:UJFN?MN?&;3;;3[";3?".D_*TDF#]G@9@9)'8<>;)M "@_P ([!FK MZMU#]E3X4ZE?F\F\&V2S;BVV"26&/)_Z9HP7\,5Z#X:\*Z-X.TU-.T+2[72; M)#E;>TB6-IA*"#Q!HUGK,-NQ>)+ MR%9 C$8) /0XKGX?@#\-[:198_ V@;UY&[3XB/R(Q44\9A7AX4<1!RY6WH[; MFE7+\9'%3KX::BI)+57V/F?]D?P;K?Q.^+6L_&#Q!$T,7FS&SRA"RS2*4/EY MZI'&2F?4XSP:H?M333_"_P#:B\*^.KJSEN-*9;>;=&/OF)BLB GC<%VG_@0K M[AMK6*TACAAC2&) %6.-0JJ!T Z"LKQ5X0T;QMI,NEZ[IMOJMA(V#5"$_?4N:[ZR[L^)?VLOVD?"_P 8 M?!^C^&_"@O+^=KZ.[DDDMVC"[4=%C"GEF)?MQ\O?-?0=W\%;SQ1^RS8^ KS; M;:PFE6X4N?ECN4VR!21VW#:2.Q-=7X1_9Y^'G@35$U/1/"UG::A&2T=PY>9X MR>Z&1FVGZ8KT7WZ5-?'4XQIT\+%I1=[O>YIALNK2G4JXV2E*:Y;+:WS/A#]G MO]I1_@'%<_#WXA:9?6=O8W#^3,D>Z2U+'# M-)T>?_A%H;O7M592(/-@:"W5L<%RV&('H!STR.M>Y^-OA/X/^(XC/B3P_9:J M\8VI--'B51UP)%PP'MG%8/AC]F_X:>#=0BO=*\(V*7<1W1RW&^X9&SD%3*S8 M(/<W-WH.@Z?I-U=#$TMG;K&T@SG#$#GGFN"EBX4Z5:GR_' M:WE9W/0JX*I4K8>HYW]G>]]W=6/%OB_^UG)\(?BQ8^'-3\-3)H!C$MQJF[<\ MJ,O#PJ."%;@Y.3@\#C/SIXZ\1>'OB7^U!X6U'X7VDJSW%W:RSS1V[1++<+*6 M>;9P0 @!8G&<,3W)^]/&OPY\-_$735L?$FCVVKVZ-NC%PGS1GC)1AAE)P,X( MS6;X#^#'@KX8RR3>&O#UKIEQ(NQKA=TDI7^[OV>:[<-CL+AJ=XP:J6:W M]U^;_P C@Q>78S%5>651.GS)[:JW1'H **** "BBB@ M HHHH **** "BBB@ HHHH I0_P#(7NO^N,7\WJ[5*'_D+W7_ %QB_F]7: "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@"E!_R%+S_ *YQ_P#LU7:I0?\ (4O/^NJCH_P#R#+?_ '?Z MU>H **** "BBB@ HHHH **** "BBB@ HHHH I0_\A>Z_ZXQ?S>KM4H?^0O=? M]<8OYO5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP M3]I7]L3P9^RU?:!;>*],U[4)=9CFDM_['@AE"B,H&W^9-'@_.,8SWKWNOS"_ MX+%?\C)\+_\ KTU#_P!#@H&CZ*^''_!33X+?$+7K/2)+O6/"]S>2B&.37K-( MX=Y. &DCDD5 3W8@#/)%?6=?C1^VM\0OV?OB)IOANU^"_AF&S\0?;&:[N-+T MIK")HF7 A\K:N]B^TC"\ $#[V*_1_6OC!;?LR_LM>&O$?Q!>5]8T[0["TFLV MD'GWFH_9T!A4G.6+JY)YP S'I0![Q17YDV?[97[67Q&TZ?QKX.^&MN/!J.\D M,<.ER7"R1KG(WEP\V,$%HP 2#@#H/J']CC]LC3/VI-!O[:YT]="\8Z2JF_TU M'+1R1DX$T1/.W/!4\J2!DY!(%CZ5HKX:_:6_;^U[PW\47^%GP<\,IXM\8Q3& MUNKJ:&2=(YQ]Z&*)""[)SN=B%4@@@X)' 6?[87[4WPB\3:,/B5\+6UC2=5G2 MVBM[/3FCGD\U2/3%M[.14<,\4L@8EN,8A(_$5WOPT\:P?$GX>^&O%EM;26=OKFG6^HQV M\K!GB66,.%)'!(#8XKXZ_P""K>H-JW[+/@^]:VN+(W/B:SF-M=ILFBW6-X=C MKDX89P1GJ#7C'A+]KC]H>T^ 7AW4/AU\/8;;P!X1TF"PN];N+4W37!MH52:7 MEEQ&-ISL4[<'+\' .VA^JE%?._[%?[3[_M0_"^YUC4;&'2_$&EW7V+4;>V)\ MEVV!DEC!)*JP)^4DD%3R1BO"O'?[V M1)MI*[T9G2*.,D':SL2_!&.A!6/OVBO@GX=_MQ_$[X8_%;2O /[17@^U\-MJ MS(EIKEH!''&6.T/(RN\4D>X@%D8;.X/;[VH$%%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 4H/^0I>?]?]U\]_M0?L;^&/V MJ;_P_=>(-:U;26T6*:.%=,,6'$A0DMO1NFP8QZF@:/A9?"ND_L'_ +>VGG6- M,M9O &J2&33[N]A6;[%:SMA98W8$H]O*-I8?,44_WZ]U_P""NFBZIJ'P;\&Z MG:"272++66%YY:[E5I(2(I&(Z#AUSTRX'<5]&?M-?LJ>$_VI-!TC3O$=Q>Z= M<:5<--:ZAIQ03(KKB2/YU8%6PA/&(99O&&B16"Z; M,^KJIDN85X3>4 ^90%PPP#U\.>#M/:VMV?S;FZN)/,N;N3&-\KX&3CH M H[ 4!H?GK^P_KFB_"#]M;XE:-X_N8=*\17CW=C97NI$1*\YN@Y4,W ,JX93 MGY@, G<,_HOXT^-W@'X=W6F6_B7Q?I&BSZG,L%I'=7:*9&89!Z_*N,?.V%&1 MSR,^:?M(?L0_#O\ :4OXM6UJ.\T;Q'&JQ_VQI+JDLJ 8"2JRLK@#H(-8\5VT,F]-.D5+6"3!X64IEF&,?=9<_3B@-"3 M_@KA(LG[-?AET8,K>++4AE.01]CO.:]A^ .BVMC^P_X3LEMXEMI_!BRR1JN% M8RVQDK%V)]R:W/VBOV9/#?[17PXTCP3J=Y=Z!I&EWT-];#1UC39Y<,L*1 MA64J$"RG@#C:*[7PC\.;'P?\+-)\"6US<3:?IVD1Z/':I\&_C)9Z=)Y6H7#QPV\G]V1K>4(?P)%?/O[%_P '_%/Q M*U7Q-X>\.?&?4OA)XDMY4$^B02W%O+>A=P)Q'-'N:-MRE2"5W>]?IO\ LP_L MI^'_ -EC2==T_P /ZMJ6K1ZO/%/*VI&/*%%90%V*O'S=ZX3]H+_@G7\-OCMX MFN/$PFOO"7B"Z8O=W.E;##=.>LDD3@C?ZLI7.23D\T!<^:O''[#>K>.O&&G^ M#?&/[4]OXA\20JTUGHVN3RW5Q'N(#>7'+=$@G:.!R0OH*_3+1;6XL-'L;:[N M/M=U#!''+<;=OFN% 9L=LD$_C7RC\!/^";/PW^"WBJS\37MY?>,M;LF62T.I M*B6UO(,$2K$HY<'D;F8#@@9 -?7M ,****!!1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 4H/^0I>?\ 7./_ -FJ[5*#_D*7G_7./_V:KM !1110 444 M4 %%%% !1110 4444 %5-4_Y!MW_ -<7_P#035NJFJ?\@V[_ .N+_P#H)H G M@_U,?^Z/Y5)4<'^IC_W1_*I* "BBB@ HHHH **** "BBB@ HHHH *J:I_P @ MV[_ZXO\ ^@FK=5-4_P"0;=_]<7_]!- $\'^IC_W1_*I*C@_U,?\ NC^524 % M%%% !1110 4444 %%%% !1110 4444 4H/\ D*7G_7./_P!FJ[5*#_D*7G_7 M./\ ]FJ[0 4444 %%%% !1110 4444 %%%% !1110!1T?_D&6_\ N_UJ]5'1 M_P#D&6_^[_6KU !1110 4444 %%%% !1110 4444 %%%% %*'_D+W7_7&+^; MU=JE#_R%[K_KC%_-ZNT %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% %*#_D*7G_7./_V:KM4H/^0I>?\ 7./_ M -FJ[0 4444 %%%% !1110 4444 %%%% !535/\ D&W?_7%__035NJFJ?\@V M[_ZXO_Z": )X/]3'_NC^525'!_J8_P#='\JDH **** "BBB@ HHHH **** " MBBB@ JIJG_(-N_\ KB__ *":MU4U3_D&W?\ UQ?_ -!- $\'^IC_ -T?RJ2H MX/\ 4Q_[H_E4E !1110 4444 %%%% !1110 4444 %%%% %*#_D*7G_7./\ M]FJ[5*#_ )"EY_USC_\ 9JNT %%%% !1110 4444 %%%% !1110 4444 4=' M_P"09;_[O]:O51T?_D&6_P#N_P!:O4 %%%% !1110 4444 %%%% !1110 44 M44 4H?\ D+W7_7&+^;U=JE#_ ,A>Z_ZXQ?S>KM !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2@_Y"EY_P!< MX_\ V:KM4H/^0I>?]#_4Q_[H_E4E1P?ZF/_='\JDH M**** "BBB@ HHHH **** "BBB@ JIJG_ "#;O_KB_P#Z":MU4U3_ )!MW_UQ M?_T$T 3P?ZF/_='\JDJ.#_4Q_P"Z/Y5)0 4444 %%%% !1110 4444 %%%% M!1110!2@_P"0I>?]?]:YIUKX@U-))+'2I[N-+J[2,;I&BB)W.% M ))4' '-;E?'WQN_Y21_LW?]@77_ /TEDH ^P:Q=#\7Z%XFNM4MM'UO3M5N= M+N39ZA#8W<)H5%MJ1!P4M[A3M=L\8P,G !). M* /I6BO!?CM^V)X+_9Y\?:)X6\4VVI?:-6TV?4+6>RB6;S6C;8ELD8;>\TCD M*B@8)/) R1O_ X^.=YXD\$^(O%GCCP5JOPGTC1W9S)XIFA1GMU3>9V",=@ M."#WR 3B@#UNBOD>V_;TU/QM'+JGPU^!7Q \>>$XV(3Q!';)907:@D%[99#N ME7('8'KD#%>H_ ?]J7PA\?KS5M(TZ#5?#?C#1 O]K>$_$=F;/4;// 9HR2&3 M./F4G&5SMW $ ]GHKP3XZ?M>>'?@[XLT_P %Z9H.N?$/XAWT7VB+PMX7MO/N M(H?^>L[9VQ)]D9ND^5&.1U&!SN*XH ^JJ*\P^/WQXT;]GCP=I_B37;.[O;.\U:UTD+:% M8WG8JKL78 (,$GFO(+S]NR?Q)JEP/A=\'_&OQ3\.VL[6\OB;2H$M["9T.'^S M/)_K@#QD8![$C!(!]75S6O\ Q#\.>%_$WAWP_JVKV]AK7B*2:+2;*4D27C1* M'D"$/V@H]6M-*BU+0/%6BR>5K'A;Q!;&UU+3WSC]Y&2< MJ3T92>P.#Q7RO^UA\:=%_!>O^(;?3?$WB=G32-/D5RUT5P"-P4JN2<# M>1N/ R>*[ROG+7OBEX+U;XI_ :'QA\,KJR\=>*_[4DT*36+.W>[T)K:%9)A( M^XE"ZL,;"W."<5L_&7]K[P-\!OB/IOA3Q@UUIXO-'FUE=25 $6.3RQ"$!\Q MY7; 554Y)% 'NE8?B[Q=I'@/0;G6M>U"/3M-M]H>60%B69@J(BJ"SNS%55%! M9F8 D@5\SZA^W9JGA6WB\0^,/@5X_\ "/P\EDC5_$M_#"SVB.VT2W-JC&2% M!E,DDGD@ D 'T_Q1J&G>+OC5$II)[?4?#=;DL[25!&<8CZ'KFG^)M'LM6TF]M]2TV]B6>VO+602131L,JZL."".XK\]?A;X) MFT'PI\(?%D7P_P#!_AZ.;QXL,WCK1KHGQ!@6?BZ86"1\1H\EK;3W:H, ?:I;DG'\3/Z4 > MGZMJUEH&FW6I:G>V^G:?:1M/<7=W*L4,,:C+.[L0%4 $DDX%>?\ P]_:6^%/ MQ8UR31O"'Q!\/^(-7CW?Z!9WZ-.X499D3.74#JR@CWKP[_@I];ZA-^SSI-S] MCN]1\(V/BC3KOQ99V.[S)M(1G\X<$?+O\K/IP&_!7B_P5 MINFZ$FGW%OJ6C^)O J16%QMC8'RC)&G*\%2K#UL;U&N%4?Q&+.\#W(Q7HM?-'QP_8.^&WQ2T\7WAO2[7X:>/;+]]I M7BKPO +*>UG7E6=8M@E7L<_-CHRU[]X3T_4='\,Z38ZOJK:YJMK:10W>J/"L M!NY50!Y3&O"%B"VT<#- &S7$1_&#PE)\6)/AI'J_F^-H],&L2:7';3-Y=H7V M"1Y0GEKEB!M+!N0<8(KMZ^.OV'5_X6%\7?VC/BU/VH ^GY?B%X;M_'T/@F35[=/%<]@=4CTDD^U?0OCC]NSPIX!^(5QX$U+PSXCF\9?V797UEH=E;1SW=_-QUJ5)IT ?8F! M%DLSG[J ;CGI7DT_]G7XGWW@B9//76%L8_M#P=1*EKN+,I7Y M@=PR,>N: /KNBO!O@W^V/X#^/?Q*N/"7@R:XU18=!CU\ZH JP[&E$1@92=Z2 MJQ^9648Q7(>)/VZX[7Q3XHM?"7PH\:_$'PSX5O)-/UOQ'H-M&T$-S'_KHX49 M@TQCXW8QCKTP2 ?2^O:Y8^&=#U'6-3N8[+3-/MY+NZNI?N0PQJ7=S[!03^%0 M^%_%&E>-/#NFZ]H=]%J>D:E ES:7EN24FB895U]B*^>_VJOC7*W[+FMZKX>\ M%^)?%.D^+/"NHG[79V@@_LR"2S8K/=1S,CHN')X!.$/'3/&_LA_M!77AW]D7 M3;W6?AUXGTG0_!7@9=4_MBY2 6^JQV]OO9;8B0DEE4D;PH]<4 ?9M%;&DT:NJMM)&X!AG!(KF-8^/6DZ/^T% MH'PCET^^;7-8T6;6XKY-GV9(HW9"C?-NW$J>@Q[T >HT5\]^)OVGO%?A_P 2 M:KI=M\ ?B+K-O8W*-%L/AQ875UK$FH?9OFG@C>1[2,I*P:4+&V><+QDC<* /J&BN5^& M/CZS^*GPZ\,>,=/M[BTL=?TVWU."WN0/-C2:-756VDC< PS@D5S&L?'K2='_ M &@M ^$@#U&BOF[XC?MT>!?A MA\3/%?@35=-UN[\2:-'8BST_2[9;FYUF>[3=%;VD2MN9P.I;:H]>1G($?MT MP-\2=$\&?$GX9^*OA+>>()3!HNH>((T:RO)1C]UYJ\*YRHQR,L,D9&0#ZHHK MY*\1?M\,PO-7\#?![QS\1/ UC))'<>+-)M%2TF6,D226H;YKA%((WC:N0W.! MD_0/PP^+7ACXO_#C2_'/AO4X[OP[J%N;A+B0A#$%R'249^1D(96!Z%30!VE% M?)EU^WQ'XLOK_P#X5-$_&?Q:T;3[C[-<>(-(MUM].DD'WU@DDYE*^RC.1@X M()NZ'_P4&\":UKGA/P[+H?B'1O&6LZ]#X>N_#&K6JVM_I4\JDI+-&S?-"<<. MF[/' /% 'O>I?$SPSI/C[2/!%YJR0^*=7M9;VQTTHY>:&+_6.&"[0![D&NKK MXA_::^)?AOX/_MV_"CQ;XLU1-(T/3_".KM-<2 L*K739/$;_LY_$I?!,:^:=3:"W%Z(@,F0V)D\P+C)R3TYH ^KJXKX=_% M_P )?%2Z\2VWA?5_[1NO#>J2Z-JT$EM-;O:W-QC='(AP4=<\J1Z=B#7SC$[>3X?_ /!2 M+XT^&[=?+TWQAX7T_P 6"'&%$L+K:NP_WGDD)/J?:@#[$HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ KQ_QQ^UQ\&?AMK4NC^)/B5X=TS583MFLVO5DEB8 M=G5,E#[-@UY-^V%XZ\6^.OB?X%_9X\ :S+X=U3Q;;RZIXBUZV8K<:;H\;%6, M1'1I621 ?50O F_#']C7X-?"?PY!I&C_#[0[H*FV:^U:QBO+NY.,%I)9% M)).3D#"\G XH [[X>_%;P=\6M'.J>#/%&D^*+!2!)-I=VD_E$C(5PIRC?[+ M &NNKXI_:8_9'M/A=9WWQL^ MI%X#^(GAJ!]0N-.TJ/R]/UJT0;Y[:6V7"Y* MJ2-H&XC!Y*LOKI_:V\.6_P"R7:_'E]/NKK0VTR&_GT^R*-,DC2K#)$"Q"DI* M64DD?<- 'O-%?+MY^VXWB:[N(OA3\+?%7Q7MK+8+_5-),-OI\,A 9X([B1L3 M2H"=RH",X&[GCTWX!?M">'OV@_#=_J&E6NH:'K.DW36&M>'=:B$&H:73@'!*MT(!Z$,H /5:*$^.O[7'A7X*>)-.\(P:7K7CKQ_J41FM/"?A>U^U M7ICP?WDHR!$G!Y/. 2 0#7 S?MZR>![NW?XK_![QQ\+]!N)%C'B.]MEO=.@9 MSA//DA.8\\<8)!XQWH ^M**Y[6O'7A[PWX-N?%NI:U8V?AFWM/MTFK/,OV?R M"H82!QP001C&+(#K/@;X#_$KQEX-#-L\06NGI"EV@)'F6 MT3-NE4X./NGU /% 'UU7*>!?B7X8^)B:[)X9U:/5DT/59]$U$QHZ_9[V';YL M)W*,E=Z\C(YX-Z*\Q^/'[0W@ MS]G/PG!KGB^]F4W4PM=/TRPA,][J$YZ101 C<"O0_@W\6-#^.'PQ\ M/>.?#K2'2-:M1<1+, )(FR5>)\$C>CJR'!(RIP30!V]%>6:G\?-(L_V@-'^$ M=MIU]J?B"\TB76[NZM0AM]-M58HC3DMD%W&U0 ?O*3@'->IT %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %>77W[3WP![ M._MI6@GM;CQ)9I+%(I*LC*9@_''4?&W@; MPWXDO(/BCKD U#5M-AFGBA5;=@@E9=RH"[M@'&6)[F@#[QTS5++6M/@O].NH M+^QN$#PW-K*LD4BGHRLI((]Q5VOB+_@G]-8:7\7/C_X:\ 7%Q>?!72=6LU\/ M/Y[3VD%TT3F]BMI"3N3S,'@GC8?XLGO/$W[>'AO1_B%XQ^'^D^$?$OBKQYH- M]'90>']'@CEFU#=%YKSJ=V(X8QM#.^.74 -0!]0T5XGX[_:D\/\ P?\ @_HG MC;XB:7J'A;4=65$MO"BJEUJDMRPR+:-$.'?&,\@+D!B#Q7EEY^WGX@\*V?\ M;GC3]GKXC>%O!8 DEUQK:.=K6/O+<0 AHE&1G))QG@GB@#Z_HK!\%^,M$^(G MA;3/$OAO4[?6="U.$7%I?6K925#W]00000<$$$$ @BOGWQA^W-IG_"9ZUX3^ M&'@#Q1\8M8T5C%JD_AV%5T^RF!(\E[ISMWY!X4$<'!)! /J"BOD+4O^"D7@ MWPGHM^GC#P;XJ\&^,[&6W63PCK-JD%W/%-*(EGMW9@DT8+#)!!'/&!FO5_VA M/VE-/^!,WAS1[?P[J_C;QGXFFDBT?PSH48:YN1$H::1B>$C12"6.>O3 8@ ] MFKFM-^(7AS6/&>L>$K+5K>X\2:/##<7^FH3YMO'*,QLPQT8=*\X^$/[2;_%& MS\56EY\/?%GA+Q;X;A6>\\/:O9;7F#HS1_9YP?*DWE&4?,#D'C'-?)OPI_: M\16O[<7Q?UU/@UXWGO-5TG1X)]%CCMOM>G*D8 EG!FVA&'(VDG':@#]'J:S" M-2S$* ,DGH*=7Q!^T3?>(/VL?VF?^&=-%UF\\.^ -!TV/6/'-_I[[+F\$FTQ M6*/R &5T)!X.YB0?+ 8 ]O\ $7[:WP(\*ZM-INI?%7PU'>PG$D<-ZLX0]"I: M/< PQR,Y'>O2O OQ(\*_$[1_[5\(^)-*\3:=G:;K2KR.X16_NL4)VGV/-<7X M,_91^#OP_P!#CT?1?AIX9ALT383<:;%!RS'H*\^OOV&?#'A MGXP>'?B)\*=1D^%6JVMTIUK3]%@']G:Q9\EX'MLA$).,,HPO7:6"D 'TW17G M'QP^/?@W]GGP:?$?C34&M+6246]I:6\9FNKZ<@E88(QR[G'L!U) YKPV;]N_ M6M!3^V?%7[/OQ*\,>"%02S:]/8I*]K&>LD]NIW1HHP2$OVAM>\:Z?X1,UW9^&9K2-M4W(;>]6XB,J/"02< #!# $'C%>7:1_P % M#O"WC+2XH/!O@SQ1XQ\937EU;+X5TF&*2YAB@D\MKFXDW^7!"S<*S'+'@#J0 M ?65%?/WP>_:T@\??$23X>>,?!6N?"[QZ;4WMII.O&-XM1A'WVM9T.V4I@Y M'0$C.&V]Y\;_ ([^#?V>O!;^)O&FI&QLFD%O;V\2&6YO)R"5AAC'+N<'V !) M( S0!Z+17R2W[? MIXN\$ZM'J^CW!:,L%*20RK]Z*5#\R.,C@]B",@@D [NBO MECQ-^W9:WWC+5_#'PJ^&_BCXQ7NC2FWU+4=!1(M,MY@<&+[4_P K.,'H,''! M/..H^"/[8'ASXM^,[KP+JV@Z[\.?B);0_:3X8\56PMY[B'!)EMV!*RJ ,\8. M 3@@$T >_P!%?.OQ4_;8\(_"GXM:A\.K[1M=U7Q/%IMO?Z?8Z3;K<3:K+-)L M2VMXPP8R !G8MA5522>Q]2^$/CC7/B%X+@UO7_!FI> ]0FFD3^QM6ECDG55; M ?P(- '<4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 444C=#0!2@/_$TN_P#KG'_[ M-5W=[BOF#4/V=_BG?Z]J4MM\9M2M(7D\U(UCEPB,S%4_UO\ ".*9_P ,T?%O M_HN&I_\ ?J7_ ..UZ?U6C;^.ON?^1X[QN(O_ +O+[U_F?4.?>C/O7R]_PS3\ M6_\ HN&I_P#?J7_X[1_PS3\6_P#HN&I_]^I?_CM5]4H?\_X_<_\ (/KN(_Z! MY?>O\SZAS[T9]Z^7O^&:?BW_ -%PU/\ []2__':/^&:?BW_T7#4_^_4O_P = MH^J4/^?\?N?^0?7<1_T#R^]?YGU#GWHS[U\O?\,T_%O_ *+AJ?\ WZE_^.T? M\,T_%O\ Z+AJ?_?J7_X[1]4H?\_X_<_\@^NXC_H'E]Z_S/J'/O1GWKY>_P"& M:?BW_P!%PU/_ +]2_P#QVC_AFGXM_P#1<-3_ ._4O_QVCZI0_P"?\?N?^0?7 M<1_T#R^]?YGU#GWHS[U\O?\ #-/Q;_Z+AJ?_ 'ZE_P#CM'_#-/Q;_P"BX:G_ M -^I?_CM'U2A_P _X_<_\@^NXC_H'E]Z_P SZAS[U5U0_P#$MN^?^6+_ /H) MKYH_X9I^+?\ T7#4_P#OU+_\=J*Z_9M^+,=K.[?&[4W548E?*EY&.G^MH^J4 M/^?\?N?^0OKN(_Z!Y?>O\SZCA/[F/G^$?RI^?>OEQ/V:?BTR*1\<-3P0,?NY M?_CM._X9I^+?_1<-3_[]2_\ QVCZI0_Y_P ?N?\ D'UW$?\ 0/+[U_F?4.?> MC/O7R]_PS3\6_P#HN&I_]^I?_CM'_#-/Q;_Z+AJ?_?J7_P".T?5*'_/^/W/_ M "']=Q'_ $#R^]?YGU#GWHS[U\O?\,T_%O\ Z+AJ?_?J7_X[1_PS3\6_^BX: MG_WZE_\ CM'U2A_S_C]S_P @^NXC_H'E]Z_S/J'/O1GWKY>_X9I^+?\ T7#4 M_P#OU+_\=H_X9I^+?_1<-3_[]2__ !VCZI0_Y_Q^Y_Y!]=Q'_0/+[U_F?4.? M>C/O7R]_PS3\6_\ HN&I_P#?J7_X[1_PS3\6_P#HN&I_]^I?_CM'U2A_S_C] MS_R#Z[B/^@>7WK_,^H<^]&?>OE[_ (9I^+?_ $7#4_\ OU+_ /':/^&:?BW_ M -%PU/\ []2__':/JE#_ )_Q^Y_Y!]=Q'_0/+[U_F?4.?>JNJ'_B6W?/_+%_ M_037S1_PS3\6_P#HN&I_]^I?_CM177[-OQ9CM9W;XW:FZJC$KY4O(QT_UM'U M2A_S_C]S_P A?7<1_P! \OO7^9]1PG]S'S_"/Y4_/O7RXG[-/Q:9%(^.&IX( M&/W7WK M_,^H<^]&?>OE[_AFGXM_]%PU/_OU+_\ ':/^&:?BW_T7#4_^_4O_ ,=H^J4/ M^?\ '[G_ )#^NXC_ *!Y?>O\SZAS[T9]Z^7O^&:?BW_T7#4_^_4O_P =H_X9 MI^+?_1<-3_[]2_\ QVCZI0_Y_P ?N?\ D'UW$?\ 0/+[U_F?4.?>C/O7R]_P MS3\6_P#HN&I_]^I?_CM'_#-/Q;_Z+AJ?_?J7_P".T?5*'_/^/W/_ "#Z[B/^ M@>7WK_,^H<^]&?>OE[_AFGXM_P#1<-3_ ._4O_QVC_AFGXM_]%PU/_OU+_\ M':/JE#_G_'[G_D'UW$?] \OO7^9]0Y]Z,^]?+W_#-/Q;_P"BX:G_ -^I?_CM M'_#-/Q;_ .BX:G_WZE_^.TOJE#_G_'[G_D+Z[B/^@>7WK_,^H=P_R:-W^K_P#0/+[U_F?2D/\ R%+O_KG'_P"S57WK_ #/J"BOE_P#X4/\ '3_HL7_D)O\ "C_A0_QT_P"BQ?\ D)O\*/JE M'_G_ !_'_(/KU?\ Z!Y?>O\ ,^H**^7_ /A0_P =/^BQ?^0F_P */^%#_'3_ M *+%_P"0F_PH^J4?^?\ '\?\@^O5_P#H'E]Z_P SZ@HKY?\ ^%#_ !T_Z+%_ MY";_ H_X4/\=/\ HL7_ )";_"CZI1_Y_P ?Q_R#Z]7_ .@>7WK_ #/J"BOE M_P#X4/\ '3_HL7_D)O\ "C_A0_QT_P"BQ?\ D)O\*/JE'_G_ !_'_(/KU?\ MZ!Y?>O\ ,^H**^7_ /A0_P =/^BQ?^0F_P */^%#_'3_ *+%_P"0F_PH^J4? M^?\ '\?\@^O5_P#H'E]Z_P SZ4T?_D&V_P#N_P!:N5\L6/P+^.,EK$T?Q@V( M1POE-Q^E3_\ "A_CI_T6+_R$W^%/ZI1_Y_Q_'_(/KU?_ *!Y?>O\SZ@HKY?_ M .%#_'3_ *+%_P"0F_PH_P"%#_'3_HL7_D)O\*7U2C_S_C^/^0?7J_\ T#R^ M]?YGU!17R_\ \*'^.G_18O\ R$W^%'_"A_CI_P!%B_\ (3?X4?5*/_/^/X_Y M!]>K_P#0/+[U_F?4%%?+_P#PH?XZ?]%B_P#(3?X4?\*'^.G_ $6+_P A-_A1 M]4H_\_X_C_D'UZO_ - \OO7^9]045\O_ /"A_CI_T6+_ ,A-_A1_PH?XZ?\ M18O_ "$W^%'U2C_S_C^/^0?7J_\ T#R^]?YGU!17R_\ \*'^.G_18O\ R$W^ M%'_"A_CI_P!%B_\ (3?X4?5*/_/^/X_Y!]>K_P#0/+\/\SZ@&?6N3^)GQ L/ MA?X)U7Q'J1W6]E%N6)3AII"<)&..K,0,]LYZ"O"_^%#_ !T'_-8O_(+?X5YM M^T!\%?BSIGPSO]1U_P >MXLTJS>.::PCC8$#./,Z2:3U=K+SW/'_''[4_Q%\9Z_-J">(;K0X6^6.TTN M5H(XU'0<'+'KRQ/4_2OH;]D_]K#5_&7B*W\&^,IX[JZG1OL.J%=LDCCGRI ! MM.5SAN#E<');(^':]*_9MT&^\0_''P;#8*Y>#48;N5E'W8HF#N3[;5(_&OOL M=EV$>$FE!+E3L[=C\XR_,\8L;!\[ES-)ION^Q^KU%(.@I:_)C]J"BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH *^#/VS/A/H?QM_;@^ /@[Q$UXF MCW^D:TTQT^Y:WFS'"9%VNO(^9!GU&17WG7S]\1_@?XC\6?M>?"'XEV3V(\.^ M%-.U2UU!9)F6X+W$#)&8TVD,,L,Y(Q[T ,/_"BFK _X)^> M%;;X7R_M)^'_ _%<75MH?C2ZMK&*ZE,LL@C@ 16<\L3@#-?;]>#?LV_!7Q# M\)_&7QHU76WLWM?%_BZ?7-.%K*SL+=U D!4;6XZ#/UH ^5/V![/]H@_ &T\ M4^!K7X5ZC;>*]2OM6O\ 5/$MYJ2ZI=W9N)(Y&N/)A*9!C( !/&#U)KO/VA_@ M3^U'^T5X&@\.ZU'\'='FM+^WU+3]8TW4-56[L;F)P5DB9K<@$C*].C>N*ZY? M@+\7OV<_&WB'4_@5<>'=?\!^(;R74[OP+XFEDM187CD%WL9XU(5'Q]QL*O& M>H;)\$?C7^T=XHT*X^-M_P"'O"7@#1;Z'4D\%^$YI9Y=3N(FW1F[N6QB-6P= MJ<''(! 8 '.?&/PU_P )%_P47_9LCUZ*"YNK'P_J5],D>6B^TQQ2%64D X63 M#*<#E1P*Z#_@HTHUKP[\'/"&J2-!X.\4?$/2M,UYMQ5);8EW$#D$85BN<]C& M#VKT7QI\%O$/B#]K[X=?$RU:S'AW0-"U#3;Q9)6%P99L[-B;<%?4Y%=K\>?@ MCX>_:$^&>J>"_$:2I:7862WO+? GLKA#F*XB8]'4_F"0>": .[LK.#3;."UM M8$M[2&-8HH8E"I&BC"JH' %48_"NC1^)9?$2:18IX@FMULY-46V073P* MQ98C+C<4!).W.,FOE_24_:\^%>BCPY!9> _BO;V:>1I_B2^O[C3[Z6-"6)R3WG[/WPL^+6D>*]=\!O$FF?!/^R=6M MS$\T=[JQD@<$,DT9: @.C ,"1U%=1X]_9]^(_P .?C!K/Q0^!>JZ)'<>)#&W MB;P;XE\R/3]0E12JW4,D0+13\\\88DDD]#S_ (L^%G[1G[3UJ/"OQ'N/#'PO M^&]PR_VO9>%[N6^U35(@P8V_G, D4;;<%AS@X(8$B@#AOVY/ ^M:5^PC\-O" M'C[5K6XUBWUK0]*U;5+69Y(7*AHGF#NJ,,G-;NEZ%^U#\%+5/"GAR+PI\6?#%J/+TG7/$>HS6.JP0C[L M=YM4K,5!VATP6"Y;!.* ,_X^:79^$/V\/V=?$7A^)+;Q+XE&KZ1K,=OA&U"P MBM5=6FQ][RC\PS_=4?PC%O\ :H_Y/&_9)_[">O?^D45=%\!?V;_%^G_%#4/B M_P#&/7[#Q+\2;NU-AI]CI".-+T"T)RT5J)/F+-_$Y /+#+;BQW/C9\%?$/Q! M_:!^!/C/3'LUTCP5>:I<:FMQ*RRLMQ;)''Y2A2&.Y3G)&!ZT <%^TU_R?%^R M)_UV\4_^D$%8/QH\'Z;XP_X*9?!/^T[:.[BTOPM?:E#%*NY?.CDD$;8]59@P M]"H/:O6OC'\%?$/CS]I3X#>.]->R71/ \FMOJ@GE99F%W:QQ1>4H4AOF0YR1 M@>M)XH^"OB'6/VQO!'Q0A>R_X1O1_#-YI%RCRL+@S2R%E*IMP5P>3D?2@#TS MXM:3:>(/A5XRTR^B6XLKO1KR":)AD,C0."/R-?/_ .QUX+L/BE^PU\)+36)K MJ.YM+%+BPU*SE\N[L)XI94BE@DP=K*N5P0592R,&5F4_2WBS39M:\+ZQ80%1 M<7=E-;Q[SA=SH5&3Z9-><_LG?"W6?@M^SOX(\$>(&M7UG1K)K>Y:SD,D)8RN MWRL0"1AAV% &4?@9XPNM$MO"UUXR\-P>$;>=)X(]-\%PP:E%(DHE6997N)+5 M)O,&_P Q+1<,=RA6P:]4\%^#=)^'_ANST'0[7[)I]KN*JSM([N[%Y))'8EGD M=V9V=B69F8DDDFM^B@"M=VL-_:S6]S%'<6TR-'+#(H9'4C!5@>""#@@U\!_& MCP-J?_!.;Q*/B[\+I9C$]2U&*+Q;X 9BUO;&5@@NK//^K.2HQV8HO*$*GT/ M^U#\"?%_Q(N_"7C'X;>*AX9^(?@^XDN--74'D;3;Z.1=LMO<1KG 9>-X4D D M=P5\4\;?!_\ :0_:\CTWP7\6]-\+?#KX:0WD5WK,?A^\:[O=7$3!EBC)9A&C M,,@G!4@$[L8(!J?M@:Y8^"_VD/V6OBM=RHOA.UU._P!)O-0F!%O!]NME2"1C M_"/]8V3P-F>QK[4SGD'[Z!8?+@;8\!0@QR M1-@[60JI!P1Q@@@D'YB\-^!_VN_V<[%?#OAG4?"?QM\'VH":=)XBFDL=7MXA M@+$S[@C #H69SQU4 +0!]LT5\8^(/AK^U%^TQ9-X=\>ZIX;^#G@*[41ZI:>% M9WO=8OHB,O#YS9CC1ONDJ0>H(=3@_6_AGP[:^$?#NEZ+8M<26>GVT=I"UW29^U76OZG/<;C\WF&^ M *^PZ^._^":BC0? ?Q6\&3'R[[PS\0M6LGM\8*1DQE&^A(?!]J +VN_\I2O# M/_9+)_\ TY/6%X5\.6FJ?\%7O&VJW,2RSZ7X MFMBRY\N226)"X/8["Z_1S7 MK6I_!7Q#>?MK:/\ %9'LAX8M/!,GAZ1&E;[3]I:\:8$)MQLVGKNSGM2>%_@K MXAT?]L;QO\4)GLO^$;UCPS9Z1;(DK&X$T4@9BR;"_$RI-X+O+S6-4EL;@AK>]OK:U1K=)$/!VEL@'[WF,O>OK_IP.!7D/ M[2O[/-A^T1X)L]._M6Y\,>)=(O$U30?$E@/])TR\3HZ\@E2.&7(SP>"H(\NL M=5_;)T_38M G\/\ PPU/4541?$@QT .;^$O@ M_0?!W_!3_P"+ T&&*W_M/P9;ZG?PPC"I=R7,7F$CLSA5D/J7)[TS4K7XF_L* M^(/&GB'1_#R_$?X%ZOJUSXCOK'36$>L>'6F.^X>-&.V> ')V@Y &24 9FW_V M=?V2?%_P9_:>\6_$77O%'_"8Q^(O#L=O?ZQ=-LN;C4C.CR%8%7;% J(JHH8[ M54"JWBCP[^U]<:+X@\"I+J&BZMX(U*]L[E01OB>QE920>0>>0>0 M00>17EW@VU>^_P""5XMXQF2;X4W,:_4Z;(!_.O48?@&?"/[)%]\(/#MRMU<1 M^$KK0;6ZNOW:S3R6SQ^8^ =H:1RQQG /?%;7P%^&-UX"_9Y\%^ ?$L=K=W6F MZ#!I6H1P.7@D*Q!) "0"5/(Z"@#(_8RNDNOV3/A Z=!X6T^/KGE8$4_J*\H\ M<1F;_@J)\.=N"8?A[>NXSR%-S*H/YFLCP/\ "W]I7]EBPE\$_#F'PC\2_AQ; MR2OH?_"07?&V@_$[Q+\8OB_K6 MG:O\2->LDTN"PT4/_9^BZ>K!_LT)?YB2P4D^H/+%BQ +O[9?QNUGX=>$=+\% M^ A]J^*_CVX.C^';=6^:VR/WUZW]U(4.[<> Q4D$!JS]<^ FE? /]@SX@> - M!_TAH/!NL&[OG7]Y?7DEG*9;A^I)9SP"3A0J]%%>4S?!W]I^R_:9\4_%VST' MX7EO_96AP:YJMT_]CZ>K$B.(1QJ!(_!=N>2X& Q%?0/PD?XX^);[6-.^ M,GA[P+:>&KBQ>*-?#-U=32RR,0K)()>-A0OTYSB@"S^QE=)=?LF?"!TZ#PMI M\?7/*P(I_45Y1XXC,W_!43X<[<$P_#V]=QGD*;F50?S-9'@?X6_M*_LL6$O@ MGX25]#_X2"[ELM2TR-W+B"1A\LB*6;!&2?]@84=[^S?\ L\^- MM!^)WB7XQ?%_6M.U?XD:]9)I<%AHH?\ L_1=/5@_V:$O\Q)8*2?4'EBQ8@'G MGPW\$Z?KG_!5#XN^(;RTCN;K1/#&FK9R2*&\B2>&%2ZYZ-L1UR.SL.]7?^"L M&@P>(/V6;>VECW2GQ+IJPR*,O&SNT9*^^UV'XUZKX ^"_B'PS^UK\5?B5=O9 M'P]XFTK2[*Q6.5C<"2WCVR;TVX STP3GVH_;*^"WB#X\?":R\-^&GLX]1AUW M3]29KZ5HX_*AEWO@A6^;'08H ]D\-^'=-\(>'].T/1K.'3M)TZW2UM;2W4+' M%$BA550.P %?F!<:UJ7A7_@GG^TQ!HT\FGVL?Q+U'2FE@8C['8RWMG'*J@?P ME9&4J.TC5^JE?-/P#_9?G\,_"WXM^"?B%;6&IZ5XU\6:OJOV>UE:13978C"; MB5!20;">/ND @YH ]P^'G@W0/A_X'T7P[X7M(+/P]I]JD-E%:[0GE@9#9'#% ML[BW\18D]:^3_P!N+P?H*_M%?LM^*C%%%XH/C2WTP2*,236FX2$'U5'QC/3S M3ZFM'P;X%_:@_9QTD>$/"S^%?B]X*LAY6BWGB"_EL-6M(,?+#,0I214X52#G M _A&%7G_ !+^R/\ &/XG?%SX4?%3QWXHT;4/$GA_Q%!=7&@Z2\D.E:3IJ'>\ M=L'4O-.[!2[N5SM"CA10!I?'OPOH7BS_ (*0? "WUV*.X2UT+4KZRMYE#+)= M1;GC)![I@R#WC%?:=?)'[4O[(?BCX^_M > ?&.C>)!X2MO#6F7(M]8MGW7=G MJ'F"2VD6$KMECW !U9AE21WI)M2_;1739_#Z:-\+6OMODQ>,/METL6, ><;7 M:3YG4XQMW?PD<$ J_LV:=9>!?VW?VB/"/A>%;;PK);:1K-Q8VV%M[+49HB9 MB#A3*IWG']T=@,3ZMOD_X*HZ+]F^8Q_">0W7?$?]J2;1UZ[ROYBO4OV9/V;[ M/]G;PKJ<<^L7/BSQEX@O#J7B+Q->KB?4;DYP<9)5%R0JY.-S'^(UY;\(?-\= M_P#!13XU>*(!YNF>%/#FF^$UN.QFE9;J1%]=K(P;T./6@#Z[HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@#XK\8:HOPR_X*D>$]6UR5+?2?&W@63P_I5W<' M"?;([H2F!3C 8[4P.YF '+ 5]J5Y/^T9^SKX9_:5\"_\(_KYN-/O;29;S2=< MT]MEYIETOW)HF_+*]QZ$*P\%TF3]M/X0VJ:"NF>!_C-IML/+MM=N+M].U&5. M=IN SJA8 ':&/J[')H ^D?CYX\TKX8?!?QMXHUJ6.+3M.TFXD<28Q(Q0K'$ M/5G=E0#N6 KX9N/!VH^!?^"*TNF:K$UO>2:.-0\I\@K'I- M>L6W[,/Q?_:2\4:7JW[1WB#1+;P9I=RMW:?#KPGYAL[F93\CWDK\R ?W 6!S MP4RP/M'[7'PCUCXU_LW>,O 7AG['#JVK6T,%K]L#--^'GP2\"^'=(MX[6PL='M8U6-<;F,2L[GU9F+,3W+$UX3\,572_P#@ MI)\9[:V'E0ZEX2TB^NE7@231D1*Y ZD(2,FOJ#PGILVB^%]'L)RIN+2RAMY- MARNY$"G!],BO'?"_P5\0Z/\ MC>-_BA,]E_PC>L>&;/2+9$E8W FBD#,63;@ M+@<')^E 'F?_ 3\TZWU_7?CUXZU=$G\E:QI]MJFEWD9AN;*]A6:&:,C!5T8$,#Z$5\T>/\ M]FOQ]X!^,6K?%;X#ZYH^FZKK^W_A)/"'B02KI.JNH/\ I*M%EHI_<#!)8D\L M&Q?%'A_]K;XX6[>&[^;P?\%_#EP$2_UK0KZ>_P!7:/\ C6V;Y5CSZG:PXPW7 M( ?M_:/::AH'P.\ 3HFF^!?$'C_2]+U:"$B&"2U4.R6A"X 1RHP!T,:GM7US M:VL-G;Q6]O$D$$2B-(HU"JB@8"@#@ #M7F'Q@_9[T+XU?!8_#S7K_4)XXH8/ MLFNR2A]0M[N$#RKL28&90:;![!?#W]G_#?Q^;<&&V\6 M7UW!9KOQ':0 MDA9)()RD%W(O3=\JQ!O3=ZG/FGPA\1:MX1_91_;1UC0GEBU:S\>>+I;>>%ML MD+"W@S*I[%!EQ_NU]'_LY?LYZQ\-_$?B+XA?$/Q##XR^*WB:..'4-3MX?*M+ M&V3E+.T4@%8@<$D@%RJD@$,(=-U"R\9>.=8UV&VAD M,T1@]30!L?L;>#=#\"_LN_#/3_ ['$+&;0K2_DGA_ MY>;B>)99I2>Y9W8\].!T KR?_@HAIL.C:?\ "#QWI2+!XYT/QWIMII5Q&2LT M\=PS+-: CJL@4$J>RGL3F+PS\'_V@?V6HKCPU\*+CPU\1OABLCR:5H_BNZEM M-2T@,Y8P).H*RQ DD%OFYP ,<[_@O]GOXE?%#XMZ%\1_CQJVAR+X8E:?PWX) M\,B1]/L[@C NYY90&EF7^'C"D!E(Y6@#"ETZS\;_ /!3Z2#Q+ ETOA7P%'J' MARUN%W(DLMV%FND!XWC<4W>P[J,?8;*&4@C(/!%?,G[2GPW\.?%+XK>$8/#? MQ!C^'?Q_T.SEU#P]>)&)'N+-BRRQ2PM\L\)P^5!)7YC@C<#F)X7_ &Q/%<8T M/7/%GPM$Z9)^[N?$7AFTOKG4_+/4PQ3XB5R,\GH<$=* .5_X)\>&]#\'_%W M]J#1?#<4=OHEEXR6&WMXEPD.!+NB4=E1MR@=@HJW^SWJUG^RW^T%\5_@[K-P MFF>#;R*7Q]X6GFRL4%H^?MUN">BQ.N0H_A5V/6J7_!-7P'I'@^\^.\GAJ>ZO MO"O_ F3Z7IVHWUJYL8;JS;:\.C/ 1J+R8Y*!"GRG@CS!W(H [K]@_1;WQ_\ $[^ MT!KUM)%JWQ(U-FTJ&X'SVFBVQ,5I'C^$MM+''# 1M7UK65X9\.:=X/\ #FE: M#I%LMGI6EVL5E:6Z#Y8H8T"(H^BJ!6K0 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 5^87[,/[$OPX_:;A^-NM^,FUL7L7Q(UK3473=1: MWB\I?)D4F/!4L&E;D@]!Z5^GM?!?PT^#G[67P%U;Q_I_@.S^%EYX=\2>+-0\ M1QS>(KB^>X0W#(H!\DH D:'&"10?1BD1/^X*ZWX&_LQ^-[/XO2_%_XT>+K'Q=X_CLW MT_2M/T2%XM+T:!_OB . S,P+ LR@X8YW$@CJ/@3\%?$/PX^-WQR\5ZL]DVE> M--5LKW3!;RL\@CB@9'\U2H"G)&,$T > _'^U^(OC#_@HSX3L/!MOX3O-1\+^ M!GUG2+/QI+&>XB\A&;S@/+4 \8CW=0*]>F?]KV:)HY-,^!\B."K* MU]K!!!Z@CR.E;O[2W[.>J?%34_#'CCP+X@C\'_%7PDTCZ/JTT7F6UQ$XQ):7 M2@$M"_3(!*[F(!R17$:AJ'[8WBK3_P"P8-%^&W@J>8"*X\5P7]Q>^4I^]);V MS)]\K!K.N:!;^%;RXD@TE)+ M9F:.(S1(RB)U9U7YN<\Y)KV7]AOP7X>\$_LI_#2+PY#"D.I:)::K>7$0&ZYO M)X4>>20]2V\E>>0%"_PUU/P-^ VC?!'X4P^"8[BX\1I.T]QJVH:M^\DU2YG) M:XFE5B1\Y)^7GC ))R3X1X4^!OQR_93O]1TCX/W/A_Q]\+;JX>ZL?"_BF]FM M+W16=RS0VTZAE:'DG#\Y[9W,X!7_ ."J'@[0=:_9YTO7=0AA&M:+XAT\Z9<, M,2YEG6.6)3Z,A+$=/W8/85Z-^T]\$/&GB[Q9X(^)_P +M3T^Q^(W@LW*6]AK M(8V.J6DZA9;:4J%[]Q(8@XRDT$J_++"W9AZCL59O._@__P I&/V@O^Q?T'_T M374?LZ_!GQWI?Q-\:?%OXJ2Z-!XU\36UMIL&C>'R[VFF6,&2J&1QF21F(+'H M,<'!PNIX ^"_B'PS^UK\5?B5=O9'P]XFTK2[*Q6.5C<"2WCVR;TVX STP3GV MH ]YKXN^$UY!\-_^"E7QIT'57%M-X\T72]7T62Y!4W0MH?+FCB)X;!\TX':( M_P!TU]HUX5^U%^RYIO[1>E:->6NMWG@[QYXZT5\;Z=XB_;6\#0Q:1?\ @_X>?$E8<1+KUKJ3V$DR\8DFC'_&GQS\9Z?I.F>'[I=0TGP+X&DFAM5N0"%DNK M@D/(R@_=!93DX(4LK &;XLTNS\<_\%._#&E^*(UN=.\,^ 'UWP]97+!HC?O? M>6]PJGCS%0''<>4K#&T5]BLH92",@\$5X-^TY^S3=?&:;PYXK$>(7\$?%+P MI*\^A^((X]Z,K#Y[:X7^.%^XYQEN&#,K<7<7W[87B:P7PX^C?#;PA<3+Y-UX MQL[ZYNUB4@!I;:T90?,&25$A*Y !XYH P/V&_!^A^ _VAOVI=$\-1PV^C6_B M'3VAM[?B.%G@EDDC4=@KNZX[;<<8JO\ \$L?!>F:+\'?&WB&"VC&JZWXOU'[ M5=;?G:.%PD4>?[JGS& ]9&]:[']C/]E36OV8_%GQ9:_U5M?+(/@/$KWPWXE>SDU&;7=0U)6L96 MDC\J:7>F257YL=1B@#@/VTE6Q^-?[+FK0C9?Q^.A8K,.&$,\6V5,]<,%&1T. M*K>(]/M?&W_!3CP[IWB54GL_"_@!];\.VEQRGVV6]\J6X49P7" C!&1L##&T M&O2/VDO@KXA^+'C+X+ZKHCV:6OA#Q=!KFHBZE9&-NBD$1@*=S<]#CZTW]IC] MF>?XT77ASQ9X2\12>!_BCX5D:;1/$4,>]2K#Y[6X3^.%^XYQEN"&96 />Z\: M^/MO'\)_V;OBUJ_@C2[70]4CT/5-4$FEVZ6[&Z,#LUR=H&Z0'YRQY)6O,[WQ M!^V5=VD6CV_A/X66.HOF*7Q*-3NY+1?EQYB6Y42 @Y(!W"&(Y"0 9 3IRW !"@ ^8OV2O# M/[1_@S]G/P%:> =+^# \+W6EPZC;2WUYJJW4_GH)3)/LAV^:2_S8X!&!P!6K M\2O@3^TK\7OB!\,_$FO#X2Z'?^#-=BU*#4M#O]3%V\&1]HMOWEN5*2(.5.,[ M>N":V/"7P=^/G[*YO/#GPHD\-?$3X7F5Y]*T7Q1>2V>HZ1O3P.K=!X'^!/Q5^*'Q6\/_ !"^.NLZ+;6_AF9KKP[X)\*-*UG;W++M%U)/%,$Z1Z].G]FZ*C'EKV4$(P'?RU#RD=Q&1 MWKX0UKQM^SC:_L)6/PYTOXJ60^(VDA?%%IJB6UV)F\0+F5F$AB_B): ,3PNT M]10!^M58:^,M DDU>-=1_).N.PW@LO^RRGO7QY\.OV=X?V@OVUOVB;3 MQ;>75Q\-M)UG3[N\\.0RM%#JU^8/W'GE<%XXE61BF0"TB$]"* /NKPG\:OAY M\0+XV/A?QYX9\27H)!MM(UBWNI!@9/RQN3P.:ZC5M7L=!TVYU#4[VWT[3[=# M)/=7#6OX;\6:)XRTT:AH&L:?K>GLVT76FW27$1/!QO0D9 MY'?O7R3^R3^QGX.U3X2^$/&OQ5T:T^(WCC6=%LY&E\1VZW=OIUIY*FVLX+=P M8XUCB*J2%R6W'/(K'^/7PRTC]B;QEX2^,7PLMQX6\/7FMVNC>,/"MH[1Z9>V MEPQC6Y6$';'+$Q&-H ^8=/F#@'V5=>-- L=4NM-NM=TVUU&ULSJ%Q9S7D:30 MVH.#.Z%LK&#QO(V^]1^$?'GAKXA:2=4\+>(=+\3:8)#";W1[V*[A#C!*;XV* M[AD<9SR*^$OB[\(=/^-G_!4BS\.ZV\TOAA/ 4-[JVFI(R1ZE!%=L4MY<$;H_ M/\ARO0^4!7H_[5%J_@Z/X6_L_?"2&T^'!^)&KW*7=WX=MTM'LK"W19KQX5C M"R.I'S<9"L.^0 ?1M]\67W9!]J MZ?7KVWL=!O[NXGCM[6&WDEDGD<*B($)+%CP !SDUX3I?_!/W]G[2?!:^&C\, M=%O;8Q^7)?7D1DOY#@@N;K/FJQR3\K 9Q@# QYU^S6-6^#?QB^)G[-^M:I<^ M)?"FGZ(OB'PK-JCF:>'2Y3Y,EFY;[Z1NP5>V W !"J ?7FA:Q8>(-'M-1TN^ MMM2T^XC#PW=G,LL4J^JNI((]P:BU+Q1H^BZCIUAJ.JV-A?ZD[1V-K=7*1RW3 M+@LL2L07(R,A21UCC0%F9C@*!U)/I7":3^T%\+]>\0+H6F?$CPCJ.M MLYC73;37;66Y+#JHC60MGVQ7QU_P4*^-&A7GQL\ ?!OQAK.J:)\-;BQ;Q#XK M_L6&::XU&+S'2WLR(5+JA>(E_9U/!5<\WXF\=_L'>)?"+>'6\#?V9 (3%%?Z M7X0O+:^B.,!Q<+#YC,.#ERW(Y!Y% 'Z55S7C+XB>%?AW:QW7BKQ/HWABUDSL MFUG4(K1&QUPTC '&17R+^Q'^TI?2_LY_$R;7[Z]\26?PQ>\:QUO4HY(+C4]* MCADFMWE$B!@X2-E)(S@#.3DFS^RM^S'X>^,W@W3OC7\:-,M?B+XZ\:0_VI'# MKD?VJPTJRD)>WM;:WDRBH$93R"06P.Y(!TW[=WQ?BE_8=\?^,/AMXV1I8&T] M;;7O"NK M&6U&U1PD\#\$JS*<-R&(/!KZPK\U/\ @I%^R3X=^%OP \6>-_A? M;_\ "%64YL[7Q/H&F II^IVQNXC"_D?=CECG\DAD ^4N#U.?TKH \.U_X9RZ MA^UAX9\:K\6+_3EL-#FMS\.4N0(+]29%-T8_,&5!=23Y9^:)/G&W%>MGQ1H_ M]M7&C_VM9?VO;VXNYK#[2GGQ0DX$K1YW!,\;B,5\P>+O^4GO@+_LG-[_ .EC M5Y3\2_@_)\)?!7@[1/ GBSPAI[Z[I&O>'K*.QNX9;4"7F2,* M7W*A7YR>6SUYKZ6^#?C";XA_"+P/XJN0JW&N:%8ZI(%X ::W20X]LM0!X#_P M42\9>+_"7P[^&]MX+\4WW@[4?$'CW3="GU.P ,BP3PW(88/! 94;'&2HYK(O MOV.?C3'9W#-^UAXO=5C8E3I$//!X_P!;57_@J)'J-8;J4R:G K$J"P'[N0Q]^*^I/ M#=Q)=^'=+FF^*E@TTW M\VBQNEHSC5+4YC5_F VXZ^AKZY\)_P#(JZ/_ ->4/_HM: /GCPA\1_$U]_P4 M&\>^"KC6;F7PI8^#+34+;2F(\F*X::-6D QG)!(_&OIZOC[P+_RE%^)?_9/[ M'_T?%7V#0!4OKZWTVSFNKN>*UMH4,DDTSA410,EF8\ #U-7"?" MGX;Z?97VKZ+:7#Q#6M1NE$L"7!4@F)$&=H/WE/\ >^7TWQW^P?\ !?Q;X;-C MI?@G2O!6KVZAM-\0^&+5;"_L9UYCF66+:793@_.3G'/K0![?I?BG1M9@U"?3 MM7L=0AT^>2UO)+6Y21;::, R1R%20CJ",J<$9&:R-6^+7@?0?"]MXEU/QEX? MT[PY^20/(SD$D%,$8.0#[S\*^,] \=:.FK M>&=Z3=QW4#$=0'C)4G\:TKR\M]/M9KJZGCMK>%#))/,X1$4#) M9B> .YKXTC\!Z'^S5^WU\.M/\!V$/AKPU\3M%U2VU/0-/4167VJRC^T)<)" M/E1MIV?* ,;L?>.9/B5X>D_:\_:ZUWX5^(+VZB^%GPYTVROM9T:SN7B&M:A= MJ)8([@J03$D8W!0--*O^%]?VYK-_K(TWXL:_IMC_ &A=23_9;6/R/+MX MMY.R)=QVHN%&3@M,^ M)WC>W^&OPY\4^+;J/S;;0=+NM3DCW;=ZPQ-(5!]3MQ^-?)W[*_[+.@?&3P=I MOQL^->FV_P 1/'GC*%=5BAUQ/M-CI=E(3);VUO;OE @1E;D'&X@=RP!]:^$_ M%FA^,VN=1\/ZSI^NZ>RQJ+K3+J.XB)^8XWH2,X([]Z^;O^"A?QN7X9_"JPM= M \;P>'?%AU[3#);6NI)!>_9'FQ(2@8/Y94')QC KSK]H+X6Z5^P_XKTCXV_" MFW_X1;P_!J=E8>,?"UI(R:=J%C.YB$PBR5CDC8C:0 ,OGCY@^S_P4_\ A3X- MU#X5:=XNN?#.F7'B>3Q!I.GOJ\ELIN6MFGP8B^,[""1CWH ZG]N[XN[?V7;K MQ'\._&N)(_$&FVAU;POJO(W7$8DB\V!^,JPRN>0PSUKZ$\7_ !F\ ?#W4H-. M\4^.?#?AK4+@;H;76-7M[2609QE4D<$C/H*^2_\ @HM\-?#OPB_8GUK2O /A MW3_#5JVOZ==I9:5;+%&UP9XQOV 8+'8@_P" BO7_ (>_L2_#+1?"_P#Q6_A7 M1_B+XTU)//U[Q-XELX[^[O;ME_>.CRJ3$@)PJQ[0JJO<9H ^@+6Z@OK6*YMI MH[BWF021S1L&1U(R&!'!!'<5D>+O'GAGX>Z6-1\4^(M)\-:<6VB[UB^BM(MW MIOD8#/XU\O\ [#MF?A9\1/C[\'+:_GN/"W@C6K.\T9+J0N;.UO[=I_(!/\"% M#CGJ6/4FOE3X4_M!_ KXR>/_ !/\5OC\FH^*-9N]0EMO#?AVZT.ZU#3-(TM& MQ$JHL9BDD8YW$@\KG +&@#]1?!OQ)\(_$FSENO"/BK1?%-K"VV2?1=1AO$1O M0M&S 'ZU?O/$VD:=JUAI%WJ]C;:KJ"R-9V,URB3W(1=SF.,G3@' Y-?E M?\;_ (Q? 'P?=Z;\2OV=[;4?!WQ0T2[BD73=+\/7EAIVLVK2*)[6XB\H1A2F M2" O3UVE?5/VQ?#\?Q__ &GOV4=/BNKS2=.\3V&HR77V:5HIC8R6\4EQ!O&" M/,@,D1([.: /NWPE\2/"7Q :_3POXIT;Q(VGR"&\&D:A#=&V#735QWPZ^$O@OX1Z=+I_@KPMI/A>SG*M-'I5FD'G,J[5:0J 7;'\39/7GF MN0_:T^,T_P"S[^SMXV\>6<<\9QD>8RYY]*U?#?BS1/&6FKJ'A_6+# M7=/9BHN]-NDN(BPZC>A(S^-?-?P+_82\":+X;MO$/Q/T*S^)OQ-UF)+O7=:\ M51"_S<.N6BCCE!1$3.P84'"CT '4>%/V+?!7PQ^,^F>/_AW<7O@!$@DMM6\. MZ.P&FZLK [/,B8$(58YRF.@Q@Y) />KZ^MM-LYKJ[N(K2UA4O)/.X1$4=2S' M@#W-\<^&]>U-"5:STS5[>XF4@9(*(Y(..>E?+?Q(\/R M_MC_ +7?B'X5Z]>W3+##$N<99V( &2.I[UJV]S%>6\ M4\$JSPRJ'22-@RNI&001P01WK\\O$'Q9U_XK?\$N?BDGBQUG\6^%FN/#&KW" MG_7W%K-Q&,U7_X37P\6U@?V]IH.C8_M/_3(_P#0 M-_"WX"6?QY_;?_:+M_%L MLU]\/M&UC3[NY\-&1DM=3OVMR('G"X,B1*DC;"<%G0D$9% 'W3X*^+W@3XE2 MSP^$?&OAWQ5-;C,R:)JL%XT0]6$;MC\:\J_;F^+$'PP_9Q\F>$O%M]I M%RJFVU6&/4]/1H6/VI8BX0@?,16GB MSQUX9\+7Y_9__P""6/AWQU8*CZIIWA2U MBL1( 5%S,ZP1,0?O!7D5B.X4BO"O@;X]_9&\*>"X+GXB:;>?$3XAZQ$+KQ%K MWB;PI>:C+-=R#=((S+"P15)*J4 )"@DYH _3S0]=TSQ-I<&I:/J-KJNG7"[H M;RQG6:&1?574D$?0UD^,OB=X/^'0M#XK\6:'X8^V-LMO[9U&&T\]N.$\QEW' MD<#UK\[?@K\9/AO\,_VN_"6G_ F;64^'OCIY+#Q#X7N]/N[>ST^\P/L]W;B: M,;2Q^5E!QC/;;M[CXH6/P^\!_MK^-]:_:*\,VNI^#O%EAIUGX-\2:_9"\TG3 MQ%"5N+5RRLMO(TI:0,<8&6RN[- 'WQ9W=OJ%K# ;30? M<)A\+O))>VD:WLEW$%F;?^Z=V;]W@C:%.,<\DDGO"*-@:NK,^0O&'[ ?A_7? M$US+X?\ $,_AZR(24V4EL;M4W%LJC&12!\O&=U>R?!']G/PQ\#[65]-62_UF MX7RY]4NL>8R9!V*!PBY .!R2!DG QZ9#_P A:Z_ZY1?S>K?->C6S'%5J7L9U M&X_UOU9Y-'*L'0J^VITTI?U]P^BBBO./6"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \R^/'P+TKX_^ M%-,T#6+Z]TZUL-7M=826QV;VD@8LJGXFVY&%X"J% [<^M>JT4 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% 'E'QV_9M\&_M!Z;IR^(8KVP MUK29#/I'B/1;DVFIZ9*E>$O" M>EPZ/H&F1^7;6L.2!DDLS$\LS,2Q8DDDDFN:A^!&DM^T!/\ %R]U"]O]<715 MT*PLIBGV;3X-^^1H@!G>[9RQ)X)'2O3Z* "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@"E!_R%+S_ *YQ_P#LU7:I0?\ (4O/^N;)',W%YI689SA3G:,L.?\5?!._P#@+_P3-^(7AW6[M;_Q-3#'%YCF1]BA=S'JQQU)]: M\Q_:F\!ZS\3OV=OB!X3\/6Z7FMZQI$UI9P22K&KR,. 68@#ZDT ?-_[//[9F MD_ _X/\ @/PC\=X[OP5J4&B6@TKQ"UG-$OA_I=^WP7T'6;;6_$7C.^M'MHM1D@)>*RM4E"LX M8[2S8R,@X W_6GPI\*S>'_@_P"#?#FN6T1N]/T.QL;RW?;*@EB@17&>0P#* M>>G%=O0!\B:18S?\/4M;NS;R_9_^%5*@G*'9O_M*'@-TSC/%=-^V1\+_ !EK M3> OBA\.+*/6/'7PXU&:_MM%D(7^T[.=!'=VZL>CLBC'T. 6VU]*T4 ?)%I_ MP4\^!BZ&LFL:KK&A>)U0"X\)W6AWAU&*?!S!@1;"P*D9W;>F2,TG[,G@_P : M>//B1\0?C]X^T&X$7GB738]&\/>&KK_ (^;+2HOG#S]UDD?#;#@@AN,$8^L M?L\3SK/Y:F55*K)M&X*<$@'T.!^51ZI_R#;O_KB__H)H ^0/^"@WP_\ &NGZ M+X3^,7PJCF/Q%$M)I?EVL6^2ZL;Y?(*E1RYCE='4'A=SMVKWC]FCX+6O[/_ M ,$?"W@>W99KG3[4/?W2C_CYO)"7GE)ZG,C-C/(4*.U>G0?ZF/\ W1_*I* / MD_\ :A\)^*?AI\;/!G[0O@[0+SQ.?"73_ !_\6/@?K-M\8].L M]%O_ !2M[$-%L$Q+ING3JR1V\SDD23*C'+ #J 1D'/S[\$?VE4_8UT&V^#GQ M^AO/#OW94$]O'=0O%-&L ML3C:T;J&5AZ$'K0!^:'[>W[35_\ M*?LZ^*M,^$&B7VN_#JP>SE\0^+[BTEM MX)S]KB6&TLTD4/,_FF-W8#"JG?<*_3:HXXUAC"(H1%&%51@ >@J2@#Y.\66< M[_\ !3+P+)/%.D>=I8U"(V[M-%*)( MED5C\@:2$ D] :397\DO\ Q@^._P 2_P!H75-!O?#/A[Q%96NB>%[+4HO*NI[&'!>X MD3)VAV5"OKEL9 !;['HHH ^-?C7!XH_9;_:5OOCGI'A^]\6?#OQ7I]MIOC2U MTN+S+S3)+?"07R(.9$$?RL . 'R1E<;6K?\ !1CX8^(-/73OA7+J'Q0\>WR[ M=,\,Z7IMU"[RG@&>26-4AC4\NS'@ G%?6%5XK6&"266.%(Y)CF1U4 N0, D] M^/6@#X>_8%L?$UO^S[^T$OB^)1XIF\=>()-1:-3YD^'[[Q9\/?%.G6^E^, M[/2XA)=Z:]OA8+Y(QS(@0E6'8!LD97'V110!\G:M_P %&/AAX@T]-.^%F>&=+TVZA=Y3P#/)+&JPQJ3EV8\ $X.*RO\ @F?9>)['P%\8U\9Q M1Q^*G^)^LOJ;0 B%[DQ6OG-$2.4,@?:?2OKZ*UA@DEECA2.28YD=5 +D# )/ M?CUJQ0!S_CWPA9_$#P/XA\+:@6&GZUIUQIMSL +".:-HV(SQG#'K7QK\%?VH M8/V0?#EI\'_VA([KPK-X;1=/T'Q9'837&FZWIZ$I RM"C^6ZH%5E;H ,D'(K M[JJ">WCNH7BFC66)QM:-U#*P]"#UH ^#?B#\1'_X*%^+M$\!?#6QO[CX16NH MV>J>*O&EY9R6L-PD#-(EG;)*JL[.VW)*\84XV@D^D?\ !2JSGOOV>=+CMX)+ MB0>*](8K$A8X%P,G [5]1V_&J7@' \N/_P!FJ]0!\G_\%-+.XOOV79XK>"2X ME_M_23LB0LV!=)DX%?6%%% 'R=^S;:3P_MM?M:32P2)#--X8\N1D($F+"8'! M[X]JX'X4?$JW_P"">MYKGPO^)UCJ5A\,CJ=SJ'A'QK:6,EU9BVF;S&M+@0JS M1RH[-_#@Y8X"X)^[Z:RAE((R#P10!\@ZQ^VQ-\<]+-6FO(?[3 M\7ZAI4Z:)H]JL@,K2&3RVE M(_-F1#L0G3WQD]LGIDU];PPQV\2111K%$@"JB !5 Z =!4U !7F/[27PG44 ?%_PR_;PTKX5 M^';3P=^T9:W_ ,,_B!I$2VLUS=6$]Q8ZNJ+M%U!/"CJ=X4DC.-P.">@[CX6_ MMD']H'XJ:=I'PP\%ZIK_ ,.XXI'U?QUJ22:?:0MM/EQVR21[IV+ CY2,YZ# M-?2-U:PWD+PW$,<\+<-'(H93]0:EZ<#@4 ?''QB7Q+^RE^TKJWQMT[0+[Q3\ M-?&5C:6/C*'2X1+=Z5-;+Y=O>K&/FDC$9(8#I\Q)^Z*M^*/^"E'PTU;23I_P MD_M+XI>/[X>5IGAW3])NXB9B2 9WEB01HI!+)M MT;.@)1O49Z'Z4 ?)G[)BZ[\8OCU\3/CUJ/A[4/#'AO6K*ST#PQ:ZM'Y5WO ZU[[10!\)?MT:?&M25449)/V60 5Z#10!\?_#/X)CX[_\ !-/P MO\.KR0Z;<:MX4MXHI9D/[BXC99869<9P)(T)[XSBJGPY_;Z\,?#'PO:>$_C^ MFI?#/XAZ);I:7T=]IMQ<6NHF-,?:;::!)%=7"[L9ZDA=V,U]EU!/;Q7"[9(U MD4,& 900&!R#SW!YH ^;/@_^T9XN_:/^+=M?>!= N-*^"FF6LZWOB'Q!I[PS M:[=-@1+8HS*RQI@L9&!SEE*@X-4/C)^VG\&?">O>+_AW\9-*U+0K:W&R*'Q! MH4EW9:[ 4!\RW,:R*R[MR_-MY'8Y"_5-026\<^SS(UDV,'7S@]"*^ MHJ** *4/_(7NO^N,7\WJ[5*'_D+W7_7&+^;U=H **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *4'_ "%+S_KG M'_[-5VJ4'_(4O/\ KG'_ .S5=H **** "BBB@ HHHH **** "BBB@ JIJG_( M-N_^N+_^@FK=5-4_Y!MW_P!<7_\ 030!/!_J8_\ ='\JDJ.#_4Q_[H_E4E ! M1110 4444 %%%>,_M#_M0>&?V>+/2;6^L]1\2^+M%=#@,]_J+@@':H M^ZHR,L?P!/% 'LU%?(.I?MP>.?AS'#K/Q4_9Z\4>!_!,DBB7Q#9ZE!JPLXV. M!+I6RVG:@#U:BLCPIK8\3>%]'UA8F@&H6<-V(F;<4$B!]N>^,XS7GVE_ M'>'5OVE-<^$(TB2*XTOP_#KYU4W *2+)*(_*$>W((SG=N_"@#K=2^)GAG2?' MVD>"+S5DA\4ZO:RWMCII1R\T,7^L<,%V@#W(-=!JG_(-N_\ KB__ *":_.7X MK?&KXFQ?MZ?#[5$^!VJRZMI>C:M9Z;I UNU#ZK;EF!ND?&V-0,':W/-?1_Q< M_:LUWPGJ'AGP3X:^%VI>,?BCKN@#7;OPK'J<%I'I%J<([7%VX*9$I:,8&&*' MD97(![KXN\7Z1\/?!NK>)M?O/L.B:39R7U[,_"-\=2\/:JCO;7+1/$QV.T;@HX# JZ,IR.W&1S7F_A/X_ M/XZ^#/C[6/%/PUUOPQ>>%[*Z36/#7B*!3#=!+9I6CBFP8YXG3 W 8PW(P1GK M/V>_&>A>,O@3X-\4:)H%KX.\/ZAIB7EOH]L(XX+&(@ML&Q54 F5R7 MC[XI>&/A?_PCG_"3ZE_9O_"0ZU;^'],_T>67[1?7&[R8?W:MMW;&^9L*,%-:\,ZK\/?B)H_Q?\-7-_X5UQ1YOD$W"BX@E7Y9X=Q" M[U P2,@9!(!^BM%>6?M _M$>%OVM;Z_@A R7 M>Q5%=,#DAF&,'GB@#Z_HKD?A?\3?#GQD\!Z1XP\)ZFFJZ#JD7FV]P@(/!(9& M4\JZL"K*>0015[QQKFJ>&_"&KZKHFA3>*-6M+=I;;1X)T@>\<=(UD?Y5)]3Q M0!4\*?$SPSXWU_Q+HVB:M'J&J>&[I;+5K=4=3:S,NY4)90"2!GY214/A3XK^ M%O'7BGQ9X;T/5/MNM>%KB*TUBV^SRQ_999$+HNYT"OE03E"P'>OA;]CWXP?$ M7_AI+XS1_P#"F=4\OQ!XLL_[B^%=#C#W=Z4M',DA)^6*) 07D8X4'OTH _ M0JBOE;1?VS?%'A7QUX:\.?&GX.:C\)8O$]VNGZ/K"ZY:ZQ92W3?$BB3^)V/ 'U)( ) M !W%%?(,/[8GQGU#34\1:;^RGXHN/!TF)([N;7K:'4VAQG>-.*&3..BYY]:] MU^ _QZ\)_M%> X_%/A.XF-NLS6MY8WD?E7=A-/$'A+3M8MKOQ)H"P/JFFQL?-M5F0/$7&/XE( M(K:@_P"0I>?]HJ]^VEX3\2>./V5_B5H?A%9I=?NM)<006^3+.JLK2Q(! MR6>-70 =2V.]>1? 3P'^SY^UQ^R?H_A;3?#>DK96FG16-_8V\$<.IZ/>A KN M7V[UE+J6$AR).IW L* /LJBL?POX>8I&H5 M2\CDL[8 RQ))K8H **** "BBB@ HHHH HZ/_ ,@RW_W?ZU>JCH__ "#+?_=_ MK5Z@ HHHH **** "BBB@ HHHH **** "BBB@"E#_ ,A>Z_ZXQ?S>KM4H?^0O M=?\ 7&+^;U=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** *4'_(4O/\ KG'_ .S5=JE!_P A2\_ZYQ_^S5=H M **** "BBB@ HHHH **** "BBB@ JIJG_(-N_P#KB_\ Z":MU4U3_D&W?_7% M_P#T$T 3P?ZF/_='\JDJ.#_4Q_[H_E4E !1110 4444 %?'WPHL;?Q%_P4B^ M.6H:_P"7)J_A[0=&LO#LX!(''F$9YY^P:^>OVB/V9=1 M^(WB[0/B1\/O$G_"#?%CP_$;>TU1HO,M-0MBVYK2\C'+Q$[L$9*[B<'C ![Q MJ>FVNL:?=6%];1WEE=1-!/;SH'CEC8%61E/!!!((/4&OS.$QO)_P2]^/FCV M$[W7AK1=>U>RT"5G+AM-CNH9$*DYXW&7N:]\\2_#/]K/XR:3+X3\7^+OAYX" M\+7A^SZGJG@>.^DU2Y@/WUA\_P"6(,N%)R&'S'D<'WWPU\"?!GA'X)Q_"FPT ML#P8NER:3)9NWS30R*RRL[#&7"O@U^U3^SWX? MC\"_#GQ1\//&7@BS+0Z->>-H[V+4;" L2L;^1\KJ@.T=3TP%4!:]8_9C_9SU M3X-W7BWQ7XS\3GQK\3/&5Q%<:WK*P^5 J1*5AMX$_AC0,0.F>. % !POQ0_ MY22_!3_L4M8_K6[^TC\"/&]U\0K#XR?"36+&Q\?Z9H[Z+>Z/K2DV&M:=YAE\ MAF7YHY%": MW&\LP8Y#G''?Y0H!S^E_M$1?'C]F?XS6NH:#=>$/&WAC1=2TSQ#X#K.%F1BI\B2>))^1 M_P!,FD^O2O9?A9^R_P")] ^&/Q@^'_ S$O!VF>$XX(_#=OI-L+ 6X 1X3&K*_'4MG<6Z MDL2//V8]%[EKWP]XFLXUD>TE9=KQR(W$D+@ ,G? ZC(/F5]X=_ M;.UZQ_L&;Q3\*/#MNRB.;Q3I5I?37X4X&^.WE'E"0 $D'"_,,8Q0!N?L2_ G MQC\#-+^($'BG7?#NKP:YX@EU:"U\,O-]DL9WR+F)4D'[L;E7Y03C!!Q7TW7F M?P!^!6A_L]_#Z'PSHT]SJ$TEQ)?:GJ]\VZZU.]E.9;B9N[,<#V"J,G&:],H M^2?V.?\ DXK]JO\ [&VU_P#2=JQ_V3?"NGR?MJ?M5^))($EU6'4M-L(9V'S1 M0O SR*#Z,R1Y_P"N8KV#X$_ W5OA;\4OC+XGU"_LKNT\;:U#J=G#;;_,@1(B MA63H.UV&1V)KBO^"B MFG^*O%/QD_9I\-:!-.6ZRJHYR7(Z9S[[ M^V/\#=6_:._9Y\2_#_1;^STW4]4DM&BNK_?Y*>5-F).4OBR^M+Z*^*C M(WO;H##YIR",#9P00:]0_9Q_9WM_@5IFN7NH:W<^,?'GB2Z%]XB\57T:QS7T MP&$14'$<* D)&"0N3] >LP?\A2\_P"N[>(K@*"RD'&' )^5?NE00 :W[?\R0_L:_% M=I'$:G1V4$G')D0 ?B2!^->B_ "%X/@1\-XI$:.1/#6FJRL,$$6L8(-?,OB; M]GC]H+]J6ZTO0_CEKO@WPU\-;6XBN[_P_P"!_M+3ZQ)&0RI+)-G9'N&?E;MT M)"N/IWXP^&_%NM?"7Q%HOPYU6T\+^+)K(P:3?W$>8;5^ . K;1M!4$*=N0<' M&* .VFFCMU#.RHI8*"Q &XG 'U)('XU\;_M>?LW7G@>XU;]H7X,WG_"'_$KP M_;2ZCJUO;I_H?B"TC4R3QW$(X:0JI.[&6(Y^;:Z^@^+OV9_$'QK_ &8_#G@C MXD^+6?XBZ6(+^/Q=HZE&MM3A),4Z#";P =IX4MRPVM@CRKQ-\'_VP?BWX1F^ M&OC#QC\/=(\)7L9L=7\4Z/!&-:T[2%T[0]1OQY@A=0!OD.UOF8;LL%.&;,/#OP MM\-:;X_UFW\0^,K6S6/4]3M$VQSR@GD?*N<# W;1N()P,XH [BBBB@ HHHH M**** *.C_P#(,M_]W^M7JHZ/_P @RW_W?ZU>H **** "BBB@ HHHH **** " MBBB@ HHHH I0_P#(7NO^N,7\WJ[5*'_D+W7_ %QB_F]7: "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "L_5-8LM%B@DOKN&TCGGCM8FF< M*'ED8)&@SU9F( '([[X2> /"W@R1T\7^(/&EA#IOEOL<21) M+,CANQ61(CGM0!]G5%)*D$;.[*B*"S,QP !U)->4_LM_'&W_ &B/@CX<\9(B MVVI7$1MM5L@"IM;Z([)XBIY7Y@6 /.UE/>O+?^"AWQ.UCP[\'X?A[X+5[CX@ M?$2631M-MX3ATM0F^]G]E6'*ENH\P'M0!]/Z3JEGKNEV>HZ?0I<6]Q M"VY)8W4,KJ>X(((/O5ZO!OV%?%7_ F/[(/PFU#=O,>@P6!;.>;;-N?QS%6+ M\4OVS(/#OQ&O/AS\-_ ^L_%SQWI\?FZGI^BR);VNF@XVK<74@*(QR. #CH<' MB@#Z3KC_ (F_%CPK\&_#L6N^+]4_LC2I;N&Q2X^S2SYFE;;&FV)&;D\9Q@=R M*^;-:_X*$#X7Z7JJ?%WX6>(/AGXC@L9;W3[&[N8KJRU9HUW/!;WJ 1F7'\) MSQCD@',_X*!>,K7Q?^QSX/\ %87^S[+5-:T#5-EPX_<1R.LF&;I\H;D].* / MM:BOEFX_;"\8^-KRXN?@]\#M>^)OA:WD\O\ X2:;5;;1K.["G#O9_:!NN%!! M 8 D''')[GX _M3>'?CIJ6M>'6TS5/!WCW0<'5_"6O0^5>6RD@+*I'RR1G* MX9?[RY W+D I:A^W7\ M)U"YL;SXI:#;W=M*T,T+R/E'4D,I^7J""*Z#P5^U M5\)OB1!K;&21G9(JLO(/! -='7Y_?LF_M2:GI_[-OPZ\%_"WX; MZM\7/%.DZ-&-56SO8=.T[3G8LRPS7LWR>:5(/EJ"0.N#Q7T;\ _VGH?B]XDU M[P9XC\*ZC\.?B/H4:W%[X7U:9)7>W; 6XMY4PLT62%+*."1Z@D ]THKQ/]H3 M]J;P_P# .YT;11I.J^,_'.NEAI'A/0(?.O+D#.9&[1Q C!4W?[= M/B_X<36][\8O@'XF^&_A*:98F\1V>HPZQ;VHOWCR, DB@#["H MKQWX]?M+>'?@3\);#XB7$9\0:!>7-G##/I]PGEM%<$;)PY^4IM.[(ZCI69\' M?VBM?^-?C /H_P ,=7L/AE/;RSV'CG5+R.!;\*0$:*S(\W9)G--:\,?!?X7ZS\9;S0YOLVIZE8WL6G:7;W&2#"+J4%7<8. M<#'<$BL#Q!_P4@T;X?Z3>6GCSX>>(O!/CNVFMU7POJ;1@WD,LJQ>?:W(_=S* MA8;@,'@X! ) !]+^./B=H_@.;3[.Z6[U+6]2WBPT72X#<7EWLQO94& J+N7= M*Y6-=R[F&17/V7QTAMK^SM/%_A#Q)\/!?3K;6=UX@%G+;33,0J1F>SN+B.)F M8A5$S)O8A5W$XKP;]HRSCU/P%^TQ=7]K;W6NQ'2]-MXKG SI?EVTL*?Q8C>X MEO,G;RP;@[:7PG\.]+\,_&SQ9X;\3> /!WPW\+ZQX N'O-%\&W'VC3-0B2Y" MS3W.;6U"RQ)(%7]RV5E?Y^ M 'V37$?%3XS>"/@CX?36O'7B6Q\-:;))Y44M MXY#2O@G;&@!9VP"<*":K_ /4M6UCX'^ +[76D?6+G0;&6[DFSYC2M A9FR!\ MQ)R?_'S29]2\ ^*['Q);VY"SK;EDF@)Z>9$X6 M1,X.-RC.#CI7>7%S%9V\L\\JP0Q*7>21@JHH&223P !WKR/P[^R[\-M"^,EI M\6/#.EKH>OOITEE*NARBVL+Z.3:1)-#& LC #ANAR"02J%? ?CXNL_M@?M22 M_ "TU:\T7X8^$["#5O&DNGOY*]8^&OQ>\$_&/13JW@GQ1 MIGB:Q7'F2:=!M!TK3%3RVAB ML(V,H(P?,=@6D)P,ER2<I(+;60 ^C***\V_:.^($GPJ^ OQ \76[[+O2=$NK MFV8''[\1,(N?]\K0!-$_C?X7^.$'B.Y\*RW5W9:#J\^B7%Y- 8XI;B+'F>4 MQ/SH-R_,.#D5W&H:A;Z3I]S?7DRV]I:Q----(<*B*"68^P )KY5^ .I6'[(_ M_!/+PSXFN]-FOTTWPZGB&]M8B$FFENB)W4LW\0,P7GLH':NA^%_[6FJ?'CQ% MHB^!_A;JVM_#V^(@U#QI>WD5K9V\GEEI4BB<%[E48&(LH"EP0#CF@#UCX.?& MOP?\??!]>0_ /XTZ/XO\ V5['X@_# M'X8/9V4[7#67@S21;6CR.ETT,FTC;$I)5G).,_6OG[]A'XK^,E^*'QDL1\*- M:-GKGQ'OKC5-0^WVOEZ'(^W?#,N_=(R8Y,8(.>* /T*HKR[X(_':P^-MS\08 M;'3+C3#X/\57WA6!8?C1%$WUQ1X[EL/[3 M32_(DYAY.?,V[-V 6V[MV!G&*]$KQ6;XB>$H_P!KRV\!-X/MF\;OX-.O+XK\ MB'S5L_M;0?9?,V^9C<"V,[>>F:XWXD_MV>%OAG\6O%7PZN_#^L:KXGTN.Q&F M:;I*+/]88(A@C8.7=CM ]R 0#Z; *QRRQA1$YR!CYL$\XY-5-8_;D\4ZM:W7B+X;_ ; MQ5\0_AW:O(K>*(;N*S%TB$AY;2V96DN(\@@, N<'TH ^NJ*X'X3_ !J\*_&; MX6Z9\0?#VH*?#U];-:IY/BS6K2:^L-/\ L\K>=#%_K'\P(8UQZ,P)[ U\^:/_ ,%#/#&H M>*O"7@[4?"6O>&_'FL:]!H-[X9UA%@NM.:4$I<\\30''#IZC(&1GDOVG/B9X M=^$/[=WPE\5>*]173='LO"6K;Y-I=Y'8[4CC106=V8A55022: /M^BOD^Z_: MZ^+4-B_B ?LN>,#X+1#+]K;5[-=5V#G)TWF4''.-V:]S^#/QJ\)_'[P%9^+_ M 7J7]HZ1<,T3;T,71-5M;R PR0W$?4@'[R'G:PX.TUZ#7QY\*[5_ 7_!2KXPZ% /)L/&'A M'3_%)B&0OF02+:%A]6>0GW)K[#H **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ KP/QW^W5\!OAMK+:5KWQ-T:*_C?RI8+'S+TQ-D#:Y@1PA M!/(;&.%_!6D6=NL?ERW$UHDUS<\8+33, M"TA/N<=@ .* -?X5_'3X?_&W37OO OBW2_$T$0!F6QN 98<]/,B.'3/^THKO M:^-/VK/V2;#PW87GQH^"UM#X$^*GA6&35!_8\0AMM8AC!>:WG@0!7+JK?VA](_:!T+59(-,OO#'B?0KLV&N>&=60)>Z9/R5#CNC@$JXX8 ]" M" >N45X)\;/VMM%^%7C*S\!Z#X0<8(->?W_P"W+XK^&4D5W\9/@-XH^'/AAY$1_$5G?P:U:6H.-3U^RMO",%F-0;6/.#P&W8 JZLN=P M8%=NW)8L ,DBOFO3OVW?'_C:U37O /[.'B_Q3X'?%;PM\5H_$$GA;4_[430-8N- U(_9Y8?(OH-IEB_>( MN[;O7YERISP37,?L^_M'^$OVCO#-WJ7AQKNQU/391:ZOH.J0&"_TNXY_=31G MI]UL$9!P>X('D/\ P3O_ .07^T!_V6#Q!_Z#;4 ?6M%?*>O?MP7?B7Q;K'A_ MX*_"W7/C*^C2_9M0UBQO(M/TJ*<9W1)=2@B1ACG P>,$@YKJ/@K^U_I/Q,\> M3_#WQ3X8UCX8_$F&+[0GAOQ H)O(0NXR6TR_)*HPV<8/RD@$!L 'T)17E'[0 M'[1_A']F_P ,V>I^)I+N\O\ 4K@6>DZ)I,'VB_U.X.,1P19&3R,DD ;E&N ">V* M /K*BOGWX9?M>Z)\9M'^*.H^"-'N/$=OX)VFW:TN$(UG= TR" D?*2%VX;G< M<''->A_ _P",&B_'KX4^&_'F@;TT[6K83"&1@7@D!*2PL1QN1U93CKMR* ._ MHKR6_P#C[80?M&:7$+#2;K4]8ET:37-2U"*0"'3+<,4C\P8R6=\ *,8# ]# M7K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5&'5+.X MU*YL(KF-[VUCCDFMU8%XU?=L8CL&V/CUVGTJ]7P!K7QPU?X<_P#!07Q9K]QN M_P"%<--I7@W5KHM^[MYYK8S6\C>@242@L> KMZB@#[_JE=ZG:V-Q96]Q<1Q3 MWDIAMHW8!I7"-(54=R$1V^BFKM? 7Q-^.FK>+/V[OAY-II;_ (0'P?XA'A-[ MM6_=7&K7MO*DRC^\4&(_]DJ?[] 'W[17F_QL^-%E\%--\,7E[IUQJ2Z[X@L_ M#\:V[*IBDN-^V1L]5&PY YYKTB@ KD_AK\2O#?Q>\&V7BKPEJ7]K:!>M(L%Y MY$L.\H[1O\DBJPPRL.1V]*Q/A?\ &:R^*'BKQ_H=KIUQ8R^$-6_LF>69U9;A M]N[>H'0?6OGS]B'Q9K7@O]A;P5J.@^$K[QI??:[V/^R]/GBAEVF]N,ONE8+@ M8'&<\T ?3W@_XH>%O'WA.;Q/H.L0ZAH,+3+)>JKHBF(D2YW 'Y2#GCM53X3_ M !@$?&_PG_PDG@O5/[7T?[1):FX\F2$K(F-RE9%5AP5/3H17RU_P3E\=^(K MCX:6?AN7P!J2>'YM3U.63Q,UU ;5',KL8C'N\PG=\F<8S[5[7\!?BYX4\2_L MVK\0/"GA&+PKX>6"_O5T.SABA ,#RA\",!,N8BXT5\JZ1^W-'\0M' MTH?#3X.N,8KI/A[^ULFI^ M/=/\"_$;P3JWPJ\6ZFN=,AU25+BSU!N\<-R@"LXXX(&20.I (!ZWX@^)7AOP MKXR\+>%=5U'[+K_B@W*Z1:>1*_VDV\8DF^=5*IM5@?G*YSQDUU=?,'[0W_)X MW[+?_7;Q)_Z10UZ!\=/VD=#^"5QI&D?V9J7BSQEK3$:7X8T2'S;NX ZR-V2, M'JQ]#@':V #U^BOE.\_;-\6_#V2&^^*OP0\0> O"TDJQOK]K?Q:K#;!CA6G6 M) 8QGKU// )(%?3NDZM9Z]I=GJ6G745[I]Y"EQ;W4#!XY8W4,KJPX((((/O0 M!G^-O&FC?#GPGJ?B3Q%>?V=HFFQ&>[NO*>7RT! SM168]1T!-7]%U:UU[2K+ M5+&7S[&]A2YMY=I7?&ZAE;! (R".",UX]^VY_P FG_$W_L$O_P"A+7GW@7]J M/5=4\$^'=#^$_P -]4^*UQI.DV=MJ.H6VH0:;IL$ZVZ;X%NIOEDD7C(4$#(Y MS0!]95RK?$SPW'\2D\ -J6/%SZ5_;:Z=Y$O-GYIA\WS-OE_?!&W=N[XQS7F_ MPE_:BL?'WCFY\!>*/#6J?#KX@11&YCT'6"KB[A ),EO,GR2@8;./[I(R V.2 MNO\ E)79_P#9*S_Z=7H ^GZ*\1^,G[4&D_"_Q59>#=%T'5/'WQ O8_/C\-Z& MH,D,.,^;/(?EB3ZY/(.,'-(#RR1ZCCG. "0#L?3M%8OBCQ5I7@GPWJ.OZY?PZ;H^GPM<7-Y.VU M(XQU/O[
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end GRAPHIC 14 slide3a57.jpg begin 644 slide3a57.jpg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�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end GRAPHIC 15 slide4a18.jpg begin 644 slide4a18.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1HF17AI9@ 34T *@ @ !@ + ( M F (8@$2 , ! $ $Q ( F (B $R ( 4 (KH=I M 0 ! (PNH< < @, 5@ $48'EZ@X2%AH>(B8J2DY25 MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08' M" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*! M"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*C MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S M]/7V]_CY^O_: P# 0 "$0,1 #\ ]^;.T[?O8XS65 FMB>7SY+8Q,A*;1RK= MOJ.OY4 6%74?,CW/$4R-_'./:EQJ 7.Z(MD\8XQ0 W;J>[.^ #/3'2A4U++; MI(>GRG'?/^% #/\ B;%P,P!>[?C_ (5>A\WRAYV-^3G'3KQ0!)10 54N!?>9 M_H[1!<=&'4T 0(NK! &: L,9/K4ML-1\P?:3#LR<[/3'^- %VB@ HH ** "B M@!K@E2%.#V..E1>5/_S\_P#C@IIH31';0W4=U.\UR)8FQY:;,;?7FK1^Z:&T MWH$4TM1:0]12&+2#O]: ]*6@!&)"D@9(' ]:Q+36K^>X1)]*:!&.-YE!QP2 M?U&* +7]HW& #9,7/& XZ_X58%S,S2XMR%0X4EOO>_TH CDO9U)"64KX/7( MIIOKH!2-/D.1TW#(/O0 2ZA<1.RFPF;!(!4C#<\5-;7,TS8EMGAX)^8Y],4 M6J* "DW#=MR-V,XSS0 O?%% !10 44 %% !10 AI: $'4_6@_=- "TAZB@!: M0=_K0 'I2T -?[C<9XZ5A"$N5\S3L%FR6\_J0.!]* )(8Y"S%K (Z@[29-V# M@^_7H*LP:;#)#^^B*MD@A93C@]?\_P#UJ 'MH]FRL"LGS#!_>-S^M6H($MX_ M+CSMSGDYH EHH ** "LK48M]TI^RM-P>DNWL?U_QH SI(%QN&GS8P,.ER2>G M8?\ UJV=, 2Q1/+>(Y/R2/N;K_G\* +M% !10 44 %% %34+6.ZAC$GF?)(K MJ(WVDD'@=13_ +1+_P ^DWYI_P#%56Z)M9W0RTN;B>:X6:S>W2-@(V9U/F#' M)X/&*M'[II-)/0<6VM1:0]12&+2#O]: ]*6@!" RD'D$8-4FTFT8@E#D$G. M[J3WH 'TBT<$,K<^C8JU# D"%8Q@$Y- $E% !10 44 %5KBPM[E]\J$MC'7I M0! NC6:J%"-@8Q\U26^F6UK('B5@P)/+9YQB@"Y10 44 %% !10!7O+*"]2- M+A-RI(LB\D88=*L4[NUA)).X@ZGZT'[II#%I#U% "T@[_6@ /2EH #TXKG/M M^L*/FN=,*N<*P+=WIC/FSVBOG*[ <8]\U<7^TL?,8"=I['K0 M'^T5 P8&^504S\S# M.<5=H ** "B@ HH ** &R$JF54L?0&HO.F_Y]F_[Z%-(39';7,TMS/%):20K M'C:[$$/D=L>E6C]TT-6>@1;:U%I#U%(8M(._UH #TI: #J,5%]E@SGR4_P"^ M: #[-#G/E)^52T %% !10 44 %% !10 44 %% !10 44 (:6@!!U/UH/W30 MM(>HH 6D'?ZT !Z4M !5+[5*LI5O)*@CY@_O@_KQ32N2W8C-Y<[F CC' Q\P M_P :47ER$.Z./=CS=S ?ZM,JH+9;OCI_.FB\N-H+1H,H;I1RH.9A]HN]I'V8 M;QCOQ2F>\VY%LN?]ZBT1WEV$%Q>$_P#'L ,\G-.2:ZR0\ Z<$'VHM$+R!9KK M)W6X'!(P?RH,UVJ#]P&8C) /0TK(+R'/+OUH)X- !FC/( MH ,T _SH ">*6@ JM]BML,/*7YAAO>FG835QG]G6FXDP@DC'))I3IUH2/W(X MZ>/_ *YIIL32)S96[+M: M($8(Y)IOV"UV!/)7:.0.?;_ 4KL=D-BL+9=K"+Y@, [CD4\6-L""(@,?6AM@ MDAO]G6FUAY"_,,'KR*FA@B@&V)=J^@-#;&DB6BI*"B@ HH ** "B@ HH ** M"B@ HH ** /_V0#_X3'H:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \ M/WAP86-K970@8F5G:6X])^^[OR<@:60])UG)E4WI.5&-Z M:V,Y9"<_/@T*/'@Z>&UP;65T82!X;6QN&UL;G,Z'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ _5.BBB@ HHHH **** "BBB@ MHHHH **2B@!:*3-+0 4444 %%)FEH **** "BBDW#UH 6BBB@ HI,TM !111 M0 44F1ZTM !1110 4444 %%%% !1110 44E+0 4444 %%%% !129HH 6BBB@ M HI,]^U+0 44F1ZTM !1110 4444 %%%% !1124 +1110 44F:6@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDS1F@!:*** "BBDS0 M M%)2T %%%% !1110 4444 %%)2T %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52C_Y#4_\ MU[Q_^A/5VJ4?_(:G_P"O>/\ ]">@"[1110 4444 %%%% !1110 4444 %%%% M &5K;LDFF;6VYO%!^FUJU:R->_UFE_\ 7ZG_ *"U:VX>M "T4FX>M% "T444 M %%%% !1110 4444 %%%% &5X@D:.SM]K8)O+!/\ M>OO_ $MGH&>GZ5^T-\.M=^*E[\.+#Q59W/C2R#--I:JX(*C+J)"OELZC.45B MPP7_ +"/_)?OVH?^OFZ_]*[J@#[;^#_QX\#?'O2+[5/ NM_V[86- MQ]FGF^R3V^R3:&QB9%)X(Y Q7H-?F%^P#\4-1^#/[(_Q5\::=X8^_8_P!U26(QT4U]W_ OX[:/\;O@UI7Q"ME72;*XADDO;>:< M/]B>(L)49\#(&TD,0N5(; SB@#T[H>,)M.\'2:+X7T M2Z^RVFM37_FM?N6) $7E+Y9V!7(W-C>HYZU]#4".07XI^%F\>:CX+&J#_A(M M-T]=6O+8P2B.VMF;:KO-M\I2<$[2V['S8QS6'_PTW\'O^BK^!_\ PH[/_P". M5YE^RU9P>,OB%\??&UU$ES_:OBM]!0R(K*]K8PI"J].5.]LCG.*Y#QO\"?AM M:_ME?#/1(?AYX5@T:[\.:K/,)M9ER<$@D<\B@#ZS\-^* M-&\8Z-;ZOH&KV.N:3<;O)OM-N4N()=K%6VR(2IPP(.#U!%:>1S7E?Q#^(G@3 M]EKX>VC_ -E1Z7I[W L])\.>&[%%FO;F1B1#;6Z;069BS'H,DDG)KS"\_:R^ M)'@^Q/B'QM^SUX@\/^!XQYD^K6.LVVHW5K%_STELT >-5'+9/R@'K0!]1YKF M_ /CW0?B9X9M_$/AN^_M+2+B26*.X\F2+F^+/A=X7B^*!U+RY+:U@U>'3U>W=6)E$LHQD$*"A&H?#/2M$U'X=?V5X/B?4IH/%7]N03>=.;^4M#]E51(N&:1=Q.#Y>$/%WPRU7PCXZUK6['2SI-]?(]N;>=RC75M M=1HR7 C;8"F$R7 SUH ^AI_B%X?M_B%;>")+_;XGN=/;58;'R9#NMED$;/YF MW8/F(&W=N[XQ73U\XZU_RD"\-?\ 9/[O_P!+4KZ.H 3-%>4_&[]H/1O@JND6 M#Z=J'BCQ9K#BO-IOVNO&'@"6VO/B]\% MM7^'GA6XD6'_ (2*SUBWUFWM68A0;E85!A3) W'/)QB@#Z*\2>)-+\(Z#J&M MZS>PZ=I-A"UQG>N2^$'QZ\"?'O2[_ %+P)KO]O6=A,+>X MD^R3VYCD*[@-LR*W3N!BO&/^"AGBK7K;]F/7$\/>'D\0Z%JULHU#68=3BA73 MX?,B:.4(03.')VX0]\]*]8^ 'B3QAXF\&A_%_P .D^'5Q;K#;VEK'J\&H"YM MUC&V0-" $') 0\B@#U'-<'K?Q^^&'AK5KK2]7^(_A'2M3M7,=Q97VNVL,T+@ M9*NC2!E/L17<7%Q':V\DTC;8XU+LWH!UK\Y?V;_C!^R[K&CZC=?$C_A%+SQO MXG\0ZEJLS>(] %P;=);AS%&UR\#1HH0*V"^ 7)[T ?H9X;\4:-XRT:#5] U: MQUS2;C=Y-_IMREQ!)M8JVV1"5.&!!P>""*TMP'4UB>$]"T#P[X=L;#PQIVG: M7H*KYEK;:3#'#:A7)?=&L8"X).[(ZYS7(_M"?%X? 7X/>(/'1TD:X-)$)^P& MY^SB3S)XXO\ 6;'VXW[ONGI^- 'I5)FOF2W_ &K_ !SXZ#ZC\+?@=K'CCPFK M%$UZ^UFVT>.[ )!DMHY@6E0GHWRYQT%>B_!']H+1OC/_ &KIO]F:AX6\7Z*R MIJ_A?6HO*O+0D JX'1XV!!61>"".F10!ZM1FO!/B1^U#/HWCRZ\!_#GP+J7Q M2\:V*)+J-K8W45G9:<&Y5+B[DRJ.0"0F#G'4'BF?#S]J*YU/Q[8^!/B7X"U+ MX5^,-35Y-,@OKN*]L=1"8)2"\CPCR@0REHMSDIYK948R1BO=V^-;^!_@U-X] M^*V@K\.9K4/]ITG^T8M1=#O*QHDD0"R/)\I"@=3@]": /5LT9KYD3]J'XL30 MC6XOV;/$S^#F'FB[.LVHU4PXSG^SL>9O[>7NS[UZ>GQVT#6O@;J_Q.\-$ZWI M=CI=WJ"VKDV\C20([/ ^X$QN&0J(6\1U.ZNM9ATJSMKED#26\,TZ W#1L2K,JJ!@'H17K/PM^.Z?%SP M7X@U#2_#>H:?XMT"26SO_"FK,MM -(\1V][XOT9"]_IJQ2*T84J&PY4(^TL 0K$@GFOECX._%#XNR?M6?$R> M7X)>3>:DNA0ZW:?\)99M_8L"I*J3[]N+C>C.^Q.5V8SDU]#>&?%/A_\ X:<\ M8>%K'P5IFG:[!HEIJ5YXGMTC6ZOEED*"*3$88A?+!R7/T&* /8LCUHKPOXE? MM-R^'_'5UX%\ >"M4^)_C>SA2:^L--N([6TTX/RBW-U)\D3L,E5()P.V:\V^ M('[=FN?!KPQ>S?$?X/ZMX/\ $>Q7TNPDU6*ZT_4CYB*T:WT,;*DJHS2;"G1" M,\B@#Z6\1?$+P_X4\2^&_#^JZA]EU?Q'-+!I=OY,C_:)(H_,D&Y5*KA>]NY N7V@' 1/XG)P.O- 'JF1ZT;AZU\RS_ +5GCSP.!JGQ0^!FL^"? M"&Y5DU^PUJVUA;12V/,N(80'BC&06;YL>AJ&X_;"+&T74+'5M:U2&2>ZMB&9GEMD&ZW*JH)5F)^8 9Q7$6O[57 MQ#\;6ZZU\./@'KOBKP?("T.LZIK-KH\ERF>)(+>4,[QL.5;C/' H ^G,T9![ MU\Z_!S]L;3/C1\9I_A]8^%]4T2^L-%EU+4QK.8+FQN8[A8FM7AV$'Y71Q('Q MA@,=<:/Q&_:>N-(\=7O@7X<>!M2^*/C/3TCEU*VL;N*RLM/5^52>[DRJ2$M5))YMS,VV*/Y%.W)_ MB; 'I;SI<5Y=1WUAJ.T%FCAO(@$,H4 M;BA (&,$DXKRC]N+QU\1+'7/!&F:?\+_ .U/#UGXQT:\T[7/^$@MH?[0O%?< MEIY#*6BW.2GFME1C)&* /LW-%>#>+OVCO$/P]^&/AW5?$GPUO;3X@>(M2_LG M3?!-AJL-X\EPQ;9NND'EJA5=S/@[=W(ZUT_P=^+VK_$*ZUC1O%?@35/A_P"* M]*6*:ZTV[E2\MGBEW>7)#=1CRY02C C@@J1CB@#K? _Q \/_ !*TFXU+P[J MU&TM[R>PG/E21/%<0N4EC='565E/J/0C@UTU?-_[.\?_ BW[1'[0?A-%5+$ MZKI_B*!%(QOO;;,Q]<[XL_\ ZZ^D* "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M S?$?B;1_!^BW6L:]JMCHFD6JAKB_P!2N$MX(02 "\CD*HR0.3U(J_%*DT:2 M1NLD;@,K*<@@]"#Z5\X_\%%C_P 87?%#_KRA_P#2F&O?O#/_ "+>E?\ 7I%_ MZ * &^'_ !9HGBRWNI]#UC3]9AM;F2RN)-/NDG6&XC.)(7*$[74\%3R#U%:M M?&?[)WC0_#;]GGX^>+?L7]H_V#XT\5ZG]D\WRC/Y!,FS?@[=VW&[!QUP:?X+ M_;N\9?&[PSIVK?!_X":UX^A%O"VJ75UKEOH]C:W31JTEM!/<(/M+1L2C,J+C M /1A0!]D9%&17E7P!^/FG_'CP_JD\6BZEX7\1:)>G3=;\.ZS'LN=/N0H8*2. M'5E8%7'!!Z Y%>=^+/VP-8U7QGK?A?X-?"O5OC#J.@SFTU74+?48-*TJUG'W M[<7DV5DF7CKZI;Z+9-Y$DHFNYVVQ M1X16V[F_B;"CN17/WG[1/PZT_P",EK\*;CQ1;Q^/[JW^TQ:*8I2S)L+@&39Y M88J"P0MN(YQS7R;\?OVB)O'TGPD\'^,_!>K?#+X@P?$?P]>'0M6D2XANH5N= MK2VEW'^[N%0LBMC!4D9 '-?1GBGQ=X9T;]K/P/X;E\!Z3>>*=;T._NXO&+QQ M"]LXK.OVO/$EE\3O$_A3X>?![7/B9:> M#S$/$NJ66H6]F+1WC\T16T+XI:WJ$VB M>$FL(M0\[4;9X9U20 I&8B-_F,2%" 9)( R* /2*R_$&N67A?0=1UC4I_LVF MZ=;27=U-L9_+BC4N[;5!)P 3A02:^9E_:P^,>M6\6N>'/V7/$VH>#)4$R7VI M^(+&PU-XL9+#3VW29_NKNRWM757?QV\+?M _LL_$?Q!X8>[A%OHFJV-_I>IP M&WO=.NH[:3?;W$63M=<\@$CG@T >R^#/&&D?$+PGI/B7P_=_VAHFK6L=[977 ME/%YL+KN1]KA67(QPP!'>MVOFCX'_%CPS\%/V$?AQXP\7:BNFZ)I_A73VDD( MW/(QA4+'&O5G=L*%'<^@)K!_X; ^,$EC_P )+'^RSXL;P'CSOMS:U:#6#;_W MQI>/-WXYV;OQH ^MJ3->3:1^TUX"\0? .]^,6FZF]YX.L[":_G:./-Q%Y2DR M0M'GB4,-NTG!)'."#7#?"']JKQ9XX\2^'K/QA\%?$7@'1?%2%_#FM27<6HQW M(\HS!;I(EWV;-&I8"0'[K9/% 'TE1D5X7\;OVI+7X8^+['P)X6\*:I\2_B7J M%LU[!X9T5TC$$ ( GN[A_EMXB> S G)'&"#7,>%_VO/$VA^*M)T3XS_"#5OA M"NM7266EZS_:D&L:7))9+J8W%PECI^EZ="9[[4KJ0XCM[>($%Y&[#(X&2:\:C_:N^+6DG^VO% M/[,GB?1? PQ(^JV.MV>H:C#$<8DDTZ,"48&2R@EE Z&@#Z \%_$;P[\0KKQ! M#H&H_P!H2:!JDNBZDOD21^1=QJK/%EU&["NOS+N4YZ\5U5?*?[!/BC2O&T/Q MQU_0KZ+4]&U+XCZA=6EY 3MFC>VM&5AGGD$=>0<@U]64 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 51C/_$ZG_P"O>/\ ]">KK5DWBW#7&H"U(6Z-FOE,W0-F3;G\::U= MA/17-7FCFOE[_A'/VI/^AD\,?]\+_P#&*/\ A&_VI/\ H9/#'_?"_P#QBO3^ MHK_G]#[_ /@'C_VC+_GQ/[CZAYHYKY>_X1O]J3_H9/#'_?"__&*/^$;_ &I/ M^AD\,?\ ?"__ !BCZBO^?T/O_P" ']HR_P"?$_N/J'FCFOE[_A&_VI/^AD\, M?]\+_P#&*/\ A'/VI/\ H9/#'_?"_P#QBCZBO^?T/O\ ^ ']HR_Y\3^X^HJ* M^7?^$=_:D_Z&3PQ_WPO_ ,8H^P?M26(V"_\ #-_GG> @Q[?<7^5/Z@O^?T/O M_P" ']HO_GS/[CZAS1FOE[_C*3T\,_\ CE'_ !E)Z>&?_'*7U#_I[#[Q_P!I M?].9_GAG_QRC_C*3_J6?\ QRE]0_Z>P^\7]I?].9_<=_\ MM#?'/1?@KI.EW%[&^H:I+.7M=/B(4R!5;+,V,*H+ 9P22> >YW'*M]-HKQG]I=_';?$8+\0_LYUI;2,1"TQY/D M_,1MP>/F+9]\UY17V^7Y)A'AU*M[S?5/3Y'Y_F7$&,6)<:5X*/3K\S]??AS\ M0-&^)WA*R\0:%.9[&X&-LB[9(G!PR.O9@?P[C((-=1W-?'O_ 3KDO\ _A'/ M&22[O[,6ZMS;CG E*OYN/P$5?82_2O@\=AUA<3.C%W2/T;+<5+&86%>:LVOR M'T445PGIA1110 4444 %%%% !1110!D^)/\ CSMO^OVV_P#1R5K5D^)/^/.V M_P"OVV_]')6M0 4444 %%%% !1110 4444 %%%% !1110 5D^'?]7?\ _7[- M_P"A5K5D^'?]7?\ _7[-_P"A4 :U%%% !1110 4444 %%%% !1110 4444 % M9$?_ "-5S_UY1?\ HR2M>LB/_D:KG_KRB_\ 1DE &O1110 4444 %%%% !11 M10 4444 %%%% !5'6/\ CQ/_ %TC_P#0UJ]5'6/^/$_]=(__ $-: +U%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/W[?!_P",1?B/_P!> M47_I1%6/_P $X#_QAUX%Y_BOO_2V>O9OBY\+],^,WPZUKP7K5Q>6NE:M$(9Y M=/=4G4*ZN"C,K*#E1U4U\Q^&?^"5?PG\*^)-)UJT\0>-)+K3;N&\ACFO;0QE MXW#J"!; XR.@(X)Y% ^AP7PG_P"4LOQ(_P"P9)_Z3VE9W["/_)?OVH?^OFZ_ M]*[JOK;P_P#LL^%?#?[0NM_&.VO]9?Q/JT!MY[6::(V2J4C3*((@X.(EZN>I M]L0?"7]DWPE\'/%_CSQ'HVHZU96^\6Z"@ M9\S_ /!)K2;77_@3\1=,OHEGLKS5S;SQ,,JZ/;(&&/H:^8=:^)'B_P#98T/X MR_L[V\=W<3:OJ<=OIT\:EG6&0XJZ)X M6O\ 5[^UU&[%Y-)K$T4CAPBIA3'%&,84=03[U\??"?3[;]L#_@H'XB^(2VT+ M^#O WEQVDR1@K=2Q%DMG+<@DN))0?[J(*!'V)^RO\%8?@#\#O#7A(1C[?'#] MJU)QCY[N0!I?J <(/9%KUVBB@1\Y?L.Y_P"%;^,O,"_:?^$WUSS]N,[_ +4< MYQWQC\,4>/O^3Z/A1_V+&L?^A14_]FN5/"?Q=^.W@1U$4L'B-/$EN.1O@OX% M.0KQN#CH3BO5-9^$^DZW\5O#_ ,0)[B]36M$L+G3[:&-T%N\J6.FW%P!Y,.JR"+RPS-PK.@*I MW+#BOHK6M0T_2=)O;W59[>TTRW@:6ZGNV"Q)$%)8N3P% SG/%8GQ&^&?AOXM M>$;SPSXMTB+6=&NL%[>8E65@)))],X.5!B55)"X& 6[J M7>B6[(4V:>]TYB '& ?F(X P1Q3/V+X;NX_9'L([!BE\\VM+;L#C$AO[K:0> MW)%?0UAI\&F6-O96D$=K:V\:Q0PPH$2)%&%55' '85R_PE^%NE?!OP-9 M^%-$N+RYTZUFN)DDOW1YBTT[S-DJBC :0@<= ,YZT >3?L$:AI,G[-N@:59E M8=:T>6XL]=LW/^D0:@)G,PF&2=Y)W9/4$8K!_;;U[PY%XB^!>D7YQCIQW/Q(_9#\'_ ! \7W/BNPU;Q-X \4W:JEYK M/@O56T^>\4=!+A65C[[<^IX&,.Q_80^'-K?Z+J]S>>(M8\4:;K-KK3>)M6U$ M7>I74EN24BDDD0@0DGYDC5-VU>>* #6O^4@7AK_LG]W_ .EJ5]'5P]U\)M)N M_C!9?$=[B]&MVFD2:(ENKH+8P/*)2Q79NWY&,[L8[9YKN* /F6"XL=%_;^U M^(&CBO=7\&6\'AF2X "N([B1KN&-CUDZ.0.=N>U>M?';6/#GA_X.>,KOQ;); M1^'DTN=+I;O;LD5D*B,9!RS$A0,')( &:=\6_@GX3^-^@0Z5XKTYKM;:87-G M>6\K07-G,.DD,J$,C# ]C@9!KS+P_P#L0^#[/7+#4?%/BGQS\3$T^59[+3_& MVO-?VEM(N=KK$%56..SY'M0!Y;XZTW5M'_X)7QVFMK(E_'X8L@\<@VLB&:(Q MJ0>A"; <\\'ITK[,\._\B_IG_7K%_P"@"N=^+7POTOXS?#O6?!FM3WEKI>K1 M+%/-8.J3J%=7&PNK#J@ZJ:ZNSM5L;."W0LRPQB-2W7 ']* .*^,GQ0T+X/^ M!Y?$'B:TNKK0?M,-E=M:P+,L"3R"+S959A^Z!8;L9.#P#6SK'AOPO?>"[C2M M4TW2I?"AM2LUG<11_8Q;A7_A031033W'AV#7=2@\/27#,Q.FK<,(,,W++][!]/I4__ 4% M:)/V1_';7"&2 ?83(HZE1?09 _"O>=#T.Q\-:/9:5I=E#I^G64*P6]K;1A(X MHU "JJC@ 8Q7@G_ 4,Q_PR#X^_W;(?^3L% ^I[1\/-;T#Q)X%T'4/"T]O/ MX=GLXFLFM,>6(=H"J .F -I7J",'D&O!M2O++7/^"@.@Q>'C')?Z+X/NH_$U MQ H(6.66-K6"1@>'W9D"G)PP..]:FL?L6^$]2U";4/#GBKQQ\-X[]S<7VF^" M]?>PL[J5A\SM"595)Z$(%'->E?!WX&^$/@7X?GTKPGIGV9;J7S[V]N)#-=WL MO.9)I6^9SDGV&3@"@1Y+^Q--86=C\3]#NVC7QQ9^,]3GUZ*10L[^9,6MY2.K M1M'C8QXX8#I1^W)<6=YX9^'VA6C1/XWOO%^F2>'X@ UPDL$?BQXAA\2/=ZYX1\70Q"W7Q+X3U)["_,((/ELX!5AP/O* M3QP13/A/^RSX1^%/B23Q/]MU[QEXP:(VX\1^+]1;4+Y(>?W:,0%0#Q''X0TNU\86[76NS MV"7D.GS-%(+:>6)R$*"0A27.T%P37O?Q*^%NE_%.V\/P:M/>6Z:)K=IKMO\ M8W12\]NY>-7W(V4)/(&#Z$5M^*O"FD^./#]_H&OZ;;ZMHU_&8KFSNDWQR+Z$ M=CD @CD$ \$ T > -\#/VADC+']J-0JC.3\/]- _P"^^EGP)>+:/%F$7P?\ \)1*=*$(_P"6(C*[_+]M^?>O9KCX3>&_^%5WWP]T MVP70O#%UIL^E"VTT"-HH949&*$@C?\S'?3]%L(-.MY;HJTK1Q1A%+E54%L*,D #V%8 MWA?X1Z1X1^)GC;QQ9W-])JWBQ;)+V&9T,$8M8FCC\H! PR&);2ZKXGBLH;R&9T,"+;(Z1^6 @89#G.YFS@8Q3--^$^DZ7\6M:^(<5Q>MK6K: M;!I4T#NAMEBB=G5E79N#98Y)8CI@"@#QK]BR\M-/D^*_AW476/QW:^,M0N]7 MMYW!N)(Y6#6\W7)C:+:%/3BJO_!2#7O#FE_LM>(;/79(/MM_/;Q:5!)@R/@7(/7!]&^+G[,'A#XP:]:>(KF?6?"_BZTC\B'Q+X7OVL-06/ M^X9%!#KZ;E..@QDYX#5/^"?/P[\2Z'J=IXEUOQAXNUF]C2%/$OB#6!>ZE:1K M(KA8&DC,<>=NTD1YVEAGF@"U\>O^3BOV9_\ L):I_P"D%?2M<+XN^$6C^,_& M?@;Q->W%]%?^#YIY[".W=%BE::+RF$H*$D!>1M*\][[_D_C2?\ MLG5S_P"G&*L>6\M/#_[?Q?Q&ZP'6/!L=IX:FNF C>1+EFN88LG D(*,1C)%> MT3?"W2YOBY;_ !%-Q>?VW!HKZ$L =/LQ@>=9BQ79NW[D SNQCMWJ#XM?!;PE M\09'DMJ\X"G\"!7TGI_[#/@^74+:7Q7XN\>_$C3K659;?1?&7B%[ZPB= M3E6$(50V.F&)&.H-=#8_LE>$=-^#GAKX:PZAK7]@^']6CUFTG::$W+31W+7" MJ[>5M*;W(P$!QWSS0!@_M[6,EW^SCJK2PRS:);:GIUSK,-NI9Y-/2[C:? !Z M ,?93GCFO>/#NI:7K&AZ??:+<6]WI%Q;QR6=Q:,&A>$J-A0CC:1C&*Y_P"+ MB^*?^%<:\?!EAI6J^(5MF:WTW6XFDMKT#[\#;73!==R@D[06&X8S7P8NM?L^ M>&VBL;_QU\7O@)?R$R7?P\L;K4K>!9&/SJJ+!("C'=@HZ@@] , 'N^CZQH& MK_\ !2+5HM(DAFU"Q^'[6^JO"00MP+V)E1L?QB,QYYZ$#C%>:_L]?"[XKZYJ M7Q/@\,?'./P+JEOXOU!M9T)O"-G?S+*\I,<[2RN'9)(PI4_=P"%Z&O0?V4_A M5HS?%/4OB)X8\"ZAX$\&V^@IX?TB'6(FAOM49KAKB>]E1R9,,?+57D.Y@">! M@#U7XJ_LM^$OBKXC3Q/]KUWP=XP6'[,?$GA'4GTZ^>'C]V[KE7& !\RDX '0 M8H*/%O'_ ,$_B#-X@\#:7\0?VG;6^DFUZWN](TN3P396\US=P$R+Y;1RAUPN MY2V=N'PV=V#Z5^V1_P @;X5?]E%T+_T>:V_A1^RIX.^%/B:3Q2;G7/&7C%HS M"OB7Q=J#:A?QQGC9&Y 5!@D950<$C)!Q7:?$KX6Z7\4[;P_!JT]Y;IHFMVFN MV_V-T4O/;N7C5]R-E"3R!@^A%!)A?';X1Z9\8M'T;3I-?N/"WB73KX:IH.L6 M+K]IM;F-2"ZHW$B[6(9>A!YQ7,_!'XH>-%^)&O?"GXCKINH>*-&TZ'5;7Q!H MX\N'4K.1S&'D@/\ J9@RG('RGDJ -W7?&;X#>&_CAI^GIK,FI:7JVE3&XTO M7M"NS::CI\A #-#, <9 P000< XR 14^#O[/_A?X%KK.H6%[JVMZYJQ5]3\2 M>);\WFH700$())2 J@] /7.!@ XSX6S?;/VROCA)$K&.UTO0;65R,#S#%, M^ >^%8&OH>OG']CS=XR3XD_%%@&A\:>))Y=.E(&Y["U'V:W.<=#LDS:S^QS\58(8I)G32#<[8QS MMBD25C],(<^U>N^ ?$>FZ_\ #WP_KEC>0W&EW6F0745U'(K1M$8U;=N!QC'> MMV]LH-2LI[2Z@CN;6=&BEAE7H([5\L77_!-_X=22WEC8>+/B)H/@ MF\F:6Y\!Z5XFDAT*8,=SHT&W<%8]0'';!% 'GOP/>+4OV!_V@]?M',^E^(+S MQEJMC/C E@=9E5QZ@[#7T7^QMI%EHG[*7PEMK"UCM('\,V%PR1#:&DE@621S M_M,[LQ/J?"?P]?_ EOOAQ:6G]B^%KK2)=#2WTW;&;:V>(Q8CW!@&"D MD$@\\D&M#X=^![+X:> _#GA'3)KB?3=!TZWTRVEO"K3/%#&L:%RJJ"Q"C)"@ M9Z 4 ?-7PFAO9OVP/VN+;3)&BO7L?#WV;:P7;.VG2[6'8'.WGV]JV?\ @G+J M&@_\,K>&-"TM([36=!>XT_Q!IS,/M%MJ2S/YXF7J&9LL,]01Z5[!X0^"^B^# M/BOX]^(%E=A61SQ][;D]R<# !Y_^WWX@ M\,0>)OV>]&O9+=_%D_Q'TBYTZ'@S1VZS@32=EW>E:K/>>)=<\6V6LV6LR>+-;U/[;JMV]K)YD<,DTJ M$"$MC-T%L\=P5+LZE M"Q8;!@AP/4&@#QKXC_!GQCX/\>^*_BQ\#?&%A#J][A_$?@W60LVE:M/;Q[<^ M8K![6X"!5W X)"[L#=GS?X[?&K1_BG\*?V9_BWJUC+IWP]N?&%E?:[:W#K)# M9,8YHHWG;&&BBG7[Y !X/!(QZK\0/V"? /CWQ;K>LPZ]XT\(6?B"0RZ_X?\ M"^NO8Z9K3D89[F *=Q8<-M*YZ]22?:4^%?A*/XW^SJH4(5.<]!R><\]>: .F@FCN(8Y876:&10Z2(P964C(((X(QTQ7B_CKQA MX*\8? [XTMX+OM,OC866K6FKMIJJ +];1O,$A4 ,X&P%N>F,Y''!2?\ !.WP M;"CZ=I/Q$^*GA_P>P,?_ AVF>+IDTGRC]Z+RV5GV$=M]>UZ'\"_!_A/X177 MPT\.:2OAWPG/83Z?]FT]CYBI,C)(^]]Q:0[B2[[B3R M*U/1YM:DG4-# S63K;33$_*(EE(RS#'(K]"A+&81*'7RL;O,R-NW M'7/3I7"^'_@GX8T3X,Z;\+[JS.O^$[/2X]':WU8+(UQ B!%\W:JJ6P!R .1D M $"O#_\ AW+X(6/^S$^(/Q2B\$_<_P"$'3Q;-_8WD=/(\O;YGEX[>9GWH YO M]FOP_P"$OB;8?M/I*UJ?A%XI\63VMO+$XAMKAFMHXKR:*3A"_ACXXTSQ9=>)/&GCW5]&C>+0_\ A--;;4(M'5E*L+5-BA,K MA"\^'> MG1FXF>5?*2,I*'W[]K H0R[=V1MR/I;XV_LR>"_CQ<:9J6M)J6C>*-)##3/% M'AV]>PU6Q# @B.=.WS'Y6#+DGCDUR/PY_8=\#^"?&MAXOUW7?%_Q1\3::0VF MZE\0-:;5'T\CD&%=JHI!Y#%20>00: .)^-R6W@?]K']FW6?'%VMUH-M8:GHU MMK5V5B@36I(H@CN#PC2JCA>?O=.E?6]Q<0VEO+//+'##$I>221@J*H&2S$] M!US7-?$SX6^%OC%X/OO"WC'1+;7=#O /-M;D=&'1T8?,CCLRD$9X(KP"/_@G M9X+N?+L=;^(7Q2\3^$H\*/!^L>+99=)V+]V/RU57*#L-_% &=_P3GU;P[K^A M?&S4_"0C_P"$9NOB5JUYM\%_@-X8^ ME MXDL?"D4UMI^N:O)K#V;B(0VK-%%$(8%C1=D2K"@53DC)Y/0>DT %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 52C_Y#4_\ U[Q_^A/5VJ4?_(:G_P"O>/\ ]">@"[1110 4 M444 %%%% !1110 4444 %)2T4 >)_M'? 32?C5I>EK/*VFZS#-Y5K?H@;"LK M'8Z_Q+D#Z+7U8)J7B31[?3-W,UKYLDV/\ <**/_'J^X=>' M[S2_^OU/_06K6Q7K8?-<7A:?LJ4M/R/$Q638+&5/;58:_GZG)?#7X;Z/\*?" M5GX>T*$I9099I),&29R MU.HH CVD#I4E%% !1110 4S;VQQ3Z* (]I'3BI*** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "J4?\ R&I_^O>/_P!">KM4H_\ MD-3_ /7O'_Z$] %VBBB@ HHHH **** "BBB@ HHHH **** ,C7O];I7_ %^I M_P"@M6O61KW^MTK_ *_4_P#06K7H **** "BBB@ HHHH **** "BBB@ HHHH M R?$G_'G;?\ 7[;?^CDK6K)\2?\ 'G;?]?MM_P"CDK6H **** "BBB@ HHHH M **** "BBB@ HHHH *R?#O\ J[__ *_9O_0JUJR?#O\ J[__ *_9O_0J -:B MBB@ HHHH **** "BBB@ HHHH **** "LB/\ Y&JY_P"O*+_T9)6O61'_ ,C5 M<_\ 7E%_Z,DH UZ*** "BBB@ HHHH **** "BBB@ HHHH *HZQ_QXG_KI'_Z M&M7JHZQ_QXG_ *Z1_P#H:T 7J*** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "J4?_(:G_Z]X_\ T)ZNU2C_ .0U M/_U[Q_\ H3T 7:*** "BBB@ HHHH **** "BBB@ HHHH R->_P!;I7_7ZG_H M+5KUD:]_K=*_Z_4_]!:M>@ HHHH **** "BBB@ HHHH **** "BBB@#)\2?\ M>=M_U^VW_HY*UJR?$G_'G;?]?MM_Z.2M:@ HHHH **** "BBB@ HHHH **** M "BBB@ K)\._ZN__ .OV;_T*M:LGP[_J[_\ Z_9O_0J -:BBB@ HHHH **** M "BBB@ HHHH **** "LB/_D:KG_KRB_]&25KUD1_\C5<_P#7E%_Z,DH UZ** M* "BBB@ HHHH **** "BBB@ HHHH *HZQ_QXG_KI'_Z&M7JHZQ_QXG_KI'_Z M&M %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ JE'_R&I_\ KWC_ /0GJ[5*/_D-3_\ 7O'_ .A/0!=HHHH M**** "BBB@ HHHH **** "BBB@#(U[_6Z5_U^I_Z"U:]9&O?ZW2O^OU/_06K M7H **** "BBB@ HHHH **** "BBB@ HHHH R?$G_ !YVW_7[;?\ HY*UJR?$ MG_'G;?\ 7[;?^CDK6H **** "BBB@ HHHH **** "BBB@ HHHH *R?#O^KO_ M /K]F_\ 0JUJR?#O^KO_ /K]F_\ 0J -:BBB@ HHHH **** "BBB@ HHHH * M*** "LB/_D:KG_KRB_\ 1DE:]9$?_(U7/_7E%_Z,DH UZ*** "BBB@ HHHH M**** "BBB@ HHHH *HZQ_P >)_ZZ1_\ H:U>JCK'_'B?^ND?_H:T 7J*** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3(]:-P]:\-_;8\0:KX M4_9=\?:KHNI7FCZI:VD307UA.\$\1,\8)5T((."1P1P37Y^:9K7QS^''[,WA MOX_Z?\;]>U5+R_-M-X=UJ:6[C11/+$IW32NLF2F2-BD!C@_+F@=C]=/6OA;_@F/^TE MXL\3?&36_"7C/QAK/B--6TW[18#6M0FNS'/"P)6/S&;;N1Y,[>NP>@H"Q^H6 M0>]&X>M?G7_P5._:(\2^ =8\&>"_!_B35?#E\T,FJZA<:1>RVLKHQ,4*%XV4 MD964E2<<+QP*^G/AS\9+S_AC+2/B.X?6=3L?")U&;SI&9KFX@MSOWN26YDC. M3R>O6@1[Q1N'K7Y7_!-?CU^U-X5\0?$;PG\?;N'QUI=\3_P@ZRM!:A,!D^0O MY0##<%W1,A*X9\@D?I;\/[?Q-:^#-&B\976GWOBE;=1J%QI<;);/-CDQAN<> MYQDY("@A0 =)24;@.IKY-_97\'I\6/AY\5/&<^I:CI%]\1?$%\8M9T:X$%[! M902&WMUAEVG:4"/@\_>^M 'UE2U\(Z!^S[J^J?M+>*_AY+\(DT'PSX\L;O5Y"%AM M;J">S:5CP%C,\:!V_P!E6P.>O% 'M^:*^=/V)?C=X*^)GP;\+>&_#>M_VEK?AG0-.M M=7M?LL\7V:00!-NZ1 K_ #(XRA(X^E=/\3OVP/@[\'M:;1_%?CJQL-51MDEG M;137DL3>DBP(Y0^S8H ]DS1FO,_#O[1WPU\77OA:UT/Q;9ZM/XH>YCTI;,22 MB5X(A+,CE5(B98V5BLNTX(P.:\[^%/\ R>K\=#CG^R=!_P#1,O\ 7^5 'TC1 M17&?$[XO>#/@UH(UCQKXBL?#]@Q*QO=/\\S 9(CC +2,!V52: .RHS7DWPG_ M &J_A1\;M2DTWP7XSLM6U*,;OL,DOPFLS\'V8^!WN9VM]QNCMEWXEQ]I_>_>SUXY..*]4O+>2ZM988YY+ M621&19X0N^,D8WKN#+D=1D$>H/2@"U29%?+O[/WAO5OAQ^TM\1/!D_COQAXS MTFVT'3;^ ^+-7:^DAEEDF#;/E55!"CHN>.IKZ9O+>2ZM988YY+621&19X0N^ M,D8WKN#+D=1D$>H/2@"U17RY^S]X;U;X,])MM!TV_@/BS M5VOI(999)@VSY5500HZ+GCJ:^HZ $I:Y?QM\1?#OPY717\0ZC_9RZSJ<.CV/ M[B27SKN7=Y?%&T?'^]0![W16?H/B#3/%.CVFK:-J%KJFEW:>;;WME*LL4J^JNI(8> MX->07BA1V52.A8 &@#U>C-< M7\,/C'X)^-6AMJ_@KQ'9>(;)"%E^SN1)"3T$D3 /&3@\.HKY4_:&_:Q^%>B_ MM._"L7GBGR?^$*U/5HM?']GW9^QM)9M$@XB/F9?C]V6QWXH ^WZ6N5T_XE>% M]0\ 6OC==:M;?PG<6BW\>JWC&VB$# %9&\T*4!!'W@#S7F'AG]N;X%>+O$T6 M@:9\1+!M2F?RXA,T >\9'K1FN9^(7Q"T#X4^ M#]0\4>*+_P#LS0K#9]IN_)DFV;W6-?EC5F.691P.,YZ5YKXW_;4^"?PY\3-X M?U[Q_86VJA@DD%O#/="%B<;9'AC98V'<.01WH ]PW#UHS7'>(OBUX1\*_#F; MQ]?ZY;_\(?%;I=-JUH&NHC$S!5=?*#%@2P^Z#UKY9_8Y_:=^&FM_$+XB^'++ MQ+Y^M>+/&U_JFBVWV"Y7[5;-!$1)N,>U!B*3Y9"I^7ITH ^UZ*\"_9K^%_PX M^&OC3XI0^!]?UO6-7FU=#X@M]6GDD6TN65I52/=&@;(D/SY=B, MQ75_%G]I MSX7? ^ZCM?&WC&QT:^D4.MDJR7%R%/1C%"K.%/\ >(Q0!ZEFC9%NV/AI%5>#S7'ZUG_ M (> >&_7_A7]U^/^G)_]>@#Z/S1FL[7-:L_#NBZAJU_+]GT^P@DN;B;:S;(T M4LYPN2_;"^$=Y^U9\2]0B\7%K/Q1!F0*/F],T ?=5)D>MA_VQXQ\0V/A_3\E4DO)<-(V, ME8T&6=L=E!->=^#_ -M3X*>/H-5DT3Q[9W1TRUEO;B":WN+>?R8D,DCQQ2QJ M\NU%+8C#'@T >XT5YUJW[07P^T'1/".L:EXFAT_2O%47VC2+RZBECBGC\GS] MS,R 1#R_FS+M_/BIOA;\=? WQHT#4];\':ZNKZ/IUPUM=WC6TUO%'(J!V&Z9 M%# *025R ".: /0*3(]:\#U#]N_X"Z;XD_L.;XD::;X2"(R0PSRVNX_]/*1F M''^UOQ7I?A'XL>$O'WB+6M#\/ZW!J^I:-%:SWJVZ.T:1W,9D@99<>7('0$Y1 MFQT.* .QHKRCXL?M3?"KX(:A'I_C3QG9:3J,@#"Q1);JX53T+Q0H[*I'0L # M72?#'XP>#/C1H#:SX+\0V?B#3U(21K=B'B8C(62-@'C8CG#J#0!V>:6OA_\ M:&_:Q^%>B_M._"L7GBGR?^$*U/5HM?']GW9^QM)9M$@XB/F9?C]V6QWXKZ.\ M6?M,?#+P/\/=%\;Z]XLMM.\-ZW&DVFW,T$QEND< J4@">:W#*2-G (W8H ]1 MW =3BC-5;G!5@".]>2? ML.:EU'PPTLK99H[>8F('/0".1% ]%% 'T31110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %4H_\ D-3_ /7O'_Z$]7:I M1_\ (:G_ .O>/_T)Z +M%%% !1110 4444 %%%% !1110 4444 9&O?ZW2O^ MOU/_ $%JUZR->_UNE?\ 7ZG_ *"U:] !1110 4444 %%%% !1110 4444 %% M%% &3XD_X\[;_K]MO_1R5K5D^)/^/.V_Z_;;_P!')6M0 4444 %%%% !1110 M 4444 %%%% !1110 5D^'?\ 5W__ %^S?^A5K5D^'?\ 5W__ %^S?^A4 :U% M%% !1110 4444 %%%% !1110 4444 %9$?\ R-5S_P!>47_HR2M>LB/_ )&J MY_Z\HO\ T9)0!KT444 %%%% !1110 4444 %%%% !1110 51UC_CQ/\ UTC_ M /0UJ]5'6/\ CQ/_ %TC_P#0UH O4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110!\_?M\?\ )HOQ'_Z\HO\ THBK\[?#_P"R7XT\TMM4U>W2*":_=T@5EE1R7**S8PIZ*><5\::'^P_\ M16OPQA^ M%TOQ4\*Z9\.V$D4UCI_F-+Y4DC22*'^R)(P9G8E3+@@[>G%!2.C\9_M,#XG_ M /!,[Q'XG?3;71-1D@'AN>QL5\NV5_-CB(B4YQ&87!V_P\CMFOF:/P+-^S;X M _9J^.5A;F*2:ZD.KM&N/-5IY)(\^I>V:1,^BCZ5]D?&+]AG6+[]E+PQ\'/A MSJFF0FPU)+_4-0UR22 7;;92[8BCDP3)(I"_PJH&3CGT#XP?LM2_$3]D:R^$ MUE-91:OINFV,%A=W+L($N;<(-Y8(6PP#C.TGYC0!\2W_ (=B_;2^,W[0_CU4 M_M'0/#GAVZ@T-F7^'_ !1<++:R>';N M99XOEPS,7B3#92(@?.IP0.T6\N !)"_L+3O!^SIH^@3LY MOO#5_J&A722 @I)!=R@+_P!\%/SH#H5?!Q_XSR^(O_8FZ9_Z/DK(U_PMI_QC M_;8FTGQ=!'J6A^"?#5OJ>E:)=;7MYKNXF='NFB/$A145!GA2 1SS7I.@_"?6 M-+_:5\5_$.:XLVT75= L]*@@21S) M-"\<>"O$3>#OB-HD;6UMJ9@\^VO+5B6:TNHLC?$6Y!'*DE@,] 1I_M%_"+PK M\6/A7K6G^(K.%?L5G-"KEKJ>;[\S+;2)YA]WV[_\ @58>L?!W]H/XT6+>&OB9XQ\' M>&_!=P5&HP^ 8+O[;J4.F3@4 >-Z=XRU/X=_\ !/C2?$NBX75=-\ 6 MMS:N5R$D%FF'Q_L_>_"NW_9A^%?AKX:_"+PX^AV\,]]JMA!?ZCK3 /PT*VTB_6'+P3[(%BD + M%E.&Z@$CJ*\6T?X)?'7X'0/H/PE\6^$==\$JY.GZ7\0(KLSZ5&23Y$4]N%?!?[&_V@_B3X M[N9[.32/$EEIEM:00R.9T:W1UD,BE H!W#&&/?.*"CUROEKX5^$].^*7[57Q M:\6^*H(]4U+P?>VNAZ!8W@61-,@,"2M/'&1A7E%? \%RL&JNA#(+J:X._RP>3&O#8!X(!'HO[1'PDU?XM:#X0L M=&GL;631_%.FZW-]N9D4P6\A9U3:C'>1T!P/4B@H]:*^E/HHH)/GWP3_ ,GN M?$W_ +%31_\ T;<5]!5Y7X>^%VK:5^T-XP\>S3V9TC6=%L--@@C=S<+) \K. MS*5VA2)!@AB>#D"O5* /GWP3_P GN?$W_L5-'_\ 1MQ7T%7E?A[X7:MI7[0W MC#Q[-/9G2-9T6PTV""-W-PLD#RL[,I7:%(D&"&)X.0*]4H ^6/\ @H#X7LO& M_@OX8>']2NFLM/U3Q]I=G/.CA&1)$G4[6)&UL' /J17T#X<^'?AGPCX3B\,: M1H-A8^'HXC -.C@7R64\$,I'S9[ELD]\U\^_\% /#MMXP\&_"W0KUYHK/4OB M%I-E-);2&.54E$R,58=&P20>Q%7W\$_M2>&85T+0O&_@'Q#H\:^5#X@\26%V MFKHG0;DB)AD=1CYS][!) - &+\);:#X(_M ?&CP5X1A9O"EOHMMXGMM%A;,& MG7T@D$D,29_=B4*C[.@P,8'%;W[#/@/28?@WI'Q!G$>K>-O&2/JNL^()B);F M>61SF+?C*HF OEC !4\9KO/@-\!H?@W8ZU>ZAK%SXL\:^([A;S7O$=Z@22]E M (5%0<1Q("P2,<*"0., ><+\!?BS\%-4U-?@?XE\,MX2U*Z>['A/QM;W#6VF M2.=SFUE@.$S'/ED!5Y/)))"B#XQ>%=-^%?[3_PB\:>%;==*UCQ9JDV@:[9V M(6*/5+9H7D$LR 89XF56W_>Z#G QT7QT_P"3G/V<\\?Z?K7?_J'-5CX7_ 7Q M9)\1K;XE?%KQ+9^)O&%G;O:Z3IFC0O#I6BI(,2M '.^21P-ID?!VG'88ZGXE M?"_5O&'QA^%/BRSFLX].$W.HS7L4[N)I%N+1H$\H!2"0Q!.XKP.,GB@D$_ M;3N/$WBCXS?"CP7IG@AOB+HHBO-=N_"[ZM#IL&IR0F-8_-DERK)$7WF,@[M^ M"#5_Q5XN^,/C?PK-X9U[]D&PU7098S$=/G\NW/A'QIX=N3>Z'XBLXA*]I*R[71XVXDB=?E=#PP ^A\TU# MP-^U-XTC;0M9\;^ /"FAR?)-KOA6RO'U9X^AVI.?+C9A_$K94]#Q04>7?%W1 M?''A_P#X)G^)=#^(&E3:/K>FB"SBM[F^AO9?LBZA#]GWRQ$JQ6,JF>,[,D#. M*^KOA%\&?"WPD^&MAX1T+2;:'2EMECN085S>N4Q))-UWLW.2<\''0 5Q'QF_ M9QG\4?LJWWPC\'WD<4WV2TM;2ZUVXD8$0W$4K/+(BLQ8A&/"XR0, =/=+>,Q M6\2'JJ@'\J"3YO\ V(E72M!^*GART18-'\/_ ! U;3M-M8Q\MM;[DD$:^BAI M&P,=^*T/V3,?VS\<\?\ 11M1_P#1%L*Z?]G_ .$FL?"F?XE2:O<65P/$OC"_ M\06?V-W?9;SB/8LFY5PXV'(&1R,$U9^!_P +=6^&NH?$F;5)K.=/$OBNZUVT M^R.[&."2.%%63./&1FU35]>D4/ M>R_ +XI_!SQ!J]S\#_$WAU/#6K7+WLGA'QI!<26=C/(VZ5[:6 ^8BL23Y9&T M$]^P!S7[9?PC\*6WC[X.^/;6TM],\3GQWH]C/-;@1F_C:;=B51C>Z;% MY]$DMV=_M)F>Y656"[-NS /);.3TQ04>LLN[/%?/OPE_Y/ ^/9P?^/#P]_Z( MN/RKZ&KRKP/\+=6\,_'CXF^-;F>SDTKQ-;:5#9PPNYG1K:.5)#("@4 F1=N" M>ASB@D\M^&OAW3OBW^U=\6/$/BN"'5[WP1/9:+H%A=J)(M.B>$327"QMD"61 MO^6F,X7 -=C^V%$/"OQ0^!?BV?Q!9VZWNDZ7SECC9P5DX.TD89 M.3;K9ZA;ZA TVF:S A.Q;E%.Y73/R MR+E@./<>>?$3X"_M#?'_ ,%ZQX>\?>-O!_AK2I;601:9X)ANE6_FVDQ+0%'G_ (P\$Z5\1/A_^Q5X?UJV6[TF[%HUS;, R3+'ITL:;X%\.:3X77PU9:#IMMX>6$P?V5':1BV\L]5,8&T@]P1SWKY3_ &:_ ^C? M [X]_M-Z5X0LQ_9NGP:5?6NFQL6$3O;W$QA7)Z;F( [ @9XKI=.@_:4.@P+: M_$GX5ZGX3,&1XXDLKG[<8L?\? B5_LK-C_:V]:R?V(/ UOI/Q&^-7B32_$MQ MXUT'5+^QM(_$MTRN=4NH87:\F1U&TQ^;,5782H"X!.T&@#S7]E/Q-\7?#7@& M+Q=H_P"SPGC?6_%3OJE]XTN?&EA;W.IF1B5.QT+Q(HPHBS@8)QDFN]\*Z3\6 M]4_:1\*>-A\ 8?AG%)YUCXFU&S\4V%VFHVDBY4S0Q!&:2*1497Y;'RG(QMZ^ M/X%_%WX+7VI6_P $_$OA>7PA?W4EY'X6\<6UP8-*DD8O)]EFMOG\MF)(C;Y5 MYQR23U'PE^#'CN'QW_PG_P 5/&<>O^)H[62ST_1M"1[?1],CD*F38K?/*[;5 M&^3D#UP" #/^.G_)SG[.>>/]/UKO_P!0YJ/VB/AWXP7XE^ _BMX+T&R\9:CX M3AO+:?PY>SK;R3PW"J#);2L"J3+LQSP0Q'U['XE?"_5O&'QA^%/BRSFLX].\ M)W.HS7L4[N)I%N+1H$\H!2"0Q!.XKP.,GBJ'QB$_%^;Q)IWB+X6>+-%MY(K M!/'^F^)-7\'Z')X9U> M;5&/B/2;RS^RWUOJ 1587"?WMJKRI(/)SG=CE?V4]B^,OCVD39C'CVZ8*&+# M<;>#<>O7=UKH/@3$]9^%5MXP\4^./$-MKGC#Q/=KJ.L7EE$8;*W2*()%%"I MYV1H#\Q^8]^02>=_8?MY-0^%&M>,9(6@;QKXGU3Q$B, /W@"[1110 4444 %%%% !1110 4444 % M%%% &1KW^MTK_K]3_P!!:M>LC7O];I7_ %^I_P"@M6O0 4444 %%%% !1110 M 4444 %%%% !1110!D^)/^/.V_Z_;;_T-I9IYG"1Q MHHRS,QX !))X %?,=G^T-\6/CI)-=?!'P1HT7A&.1H[?QCXZGFAM;_:<-Y% MM$!,5R"!(>,]0""* /J.EKY=O?V@OBU\#WCO/C9X'T6X\(-(JW'B_P !3S3V M^G[C@&>UF'G; 3@NO [ D@5ZM\;OBE-X!^ OBCQ[X;>QU66PTEM2L'F)EMI_ ME#(Q*,"R$$'*L,YZT >EYHR*^7?#VO?M;:QHVFZR+3X-75G>6T=TMM')JL,S M*Z!E7<=R@\]\BO0OA7\>)?B;\-_$^K7&B/X;\6>&IKJPUC0;N03"UO(4W;0Z MX\R-@58,N 02!TS0![!D>M&:^0_AI\0/VK_B=X!T#QAIEK\'1I>L6L=Y#;W MU6.X\MN=K89E#8]R/K78>$?VE?%?AGQUH_@OXS^"8O!6IZU*+;1_$.F7OVO2 M-2N#_P L Q&Z"0_PH^2V.HXR ?1ETM[)]*\4PZI)>33(YGC- MM"KIY9#A0"6(.Y6]L5!X/^+>MR_M#>,OAIXEM+*UC@L8-9\-W=K'(AO;)B4G M$FYV!DCEPN5VY#9VB@#V*DS4=Q<1V=O)//(L,,:EWD<@*J@9))/0 5Y#^S9\ M7M;^.?AW7_%UU96=GX4N-6GM_#7E0R)<7%E$2GVB8LQ!+L&P%5&/%_A6$>9?7OP[NKC[3I\0QND:"Z^:8# MG(0C R2< T ?46117E^L?%JV\6> _"^I_#_4;349?&%Q'::/J$B%X8@R/++, MZ<$F***8^6VTET",5))'S5!\5[./Q=UT &11N'K5'5X[Z?2;Q--FBM]1>%UMYIHR\<%#MDJ/O$X[8KVW(]: .8\;?#?P[\1%T5?$.G?VB-&U. M'6+#]])'Y-W"28I/D8;L9/RME3GD&NHI,BB@!:*2C(]: %HI,T9H ,BBO'OV MMO'>N_#/]G?QIXG\,WW]FZYI]M&]M=>3'+Y;--&I.R0%3PQZ@]:]3T6Y>ZTB MQEE;=+)!&[''4E03^IH OTE&1ZUXG\./B+XAD_:,^*'P^\07RWMG9P6.MZ 6 MACCD2SF4I+$2@&Y4E7AFRWS')/& #VVBBB@ HHHH **** "BBB@ HHHH *IZ MAIMMJ]G/97UM#>65PACGMKB,21RHPP593P01P0>*N44 ?/EU^P'\ ;S76U=_ MAO8K=-)YABBNKF.VSC&!;K*(L?[.S'M7N6BZ%IWAO2;;2])T^UTK3;5/+M[. MRA6&&)0?NHB@!1]!6C10 4444 %%%% &3XD\.67B[P_J6B:I')/INHP/:W,< M4TD#O$X*NH>-E9<@XRI!]Z3PSX9TWP9X?TW0M%M%L=)TVWCM+2U4EA%$BA57 M)))P!U))]ZUZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*KZAJ%KI-C%4 $DG@ 5\FV'[37QD_:#DN+OX!^ -!A\%QRM';>./ MB%<3P6FI%#M_P#VE/C-^SZ\5[\>O &A M77@II$6Z\:_#J>XGM=,W' :XM)@9]@)YD7@< D@5]6Z7JMGK>F6FHZ?=0WM MA=PK/;W5O('CFC8;E=6!PRD$$$<$&@"W1129'K0 M%)G%&: %HI-P]:,B@ W M#UI:\#U7XF^);7]MO0/ ,6HE?"=UX(N=7ETTP1G==I>)&LGF;=XPA(QNP?3O M7O>X>M "T4F11D>M "T44E "T4F1ZT4 +1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 52C_Y#4_\ U[Q_^A/5S@ HHHH **** "BBB@ HHHH **** "BBB@#)\2?\ 'G;?]?MM_P"CDK6K M)\2?\>=M_P!?MM_Z.2M:@ HHHH **** "BBB@ HHHH **** "BBB@ K)\._Z MN_\ ^OV;_P!"K6K)\._ZN_\ ^OV;_P!"H UJ*** "BBB@ HHHH **** "BBB M@ HHHH *R(_^1JN?^O*+_P!&25KUD1_\C5<_]>47_HR2@#7HHHH **** "BB MB@ HHHH **** "BBB@ JCK'_ !XG_KI'_P"AK5ZJ.L?\>)_ZZ1_^AK0!>HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YW_ &\]0N+/]FO7 M((9GM;74+VPT^^N(R08[6:[BCF/T*DJ?]ZO=M#T:R\.Z+8:3IEK%9:;8P);V MUM;J%CBB1=J*H[ #BLGXD?#[2?BGX'UKPGKT3SZ1JULUK<+&VUP#]UE/9E( M# \\@9!KY\\-_$KXN_LYZ8GA?QU\/]>^*.A:?&L&F>+O!%NEU=W4*@!%N;,N M'615 !<'#>YRQ /IK5]*L]>TJ]TW4+:*\T^\A>WN+>=0T3R?\$T_B)8F5[C3]+BUG3=-FD;)>TBN76+GT ^4>RBO1-?\ BA\8/VA] M/F\-> /A[KWPLT:^7R+_ ,8>.(%M;NUB/#BWL@Q9I"N0KYP/]DD,.I^,_P ( MHO!G[&/BKX?>"]*O+Z.R\/26-C9VT1GN;EL==J+EY';+' Y)/%!1R7P_^,O[ M0)\'>';.S_9SA-JNG6\<&I77CFR$;*(E"RM&L98 C!VCD=,UVGPN^$^O_#7X M6_$/4_&&H6FI^-/%#]=AAC>::2PG1(XU+, MS&-@ .I)H)/-/V-_P#DUKX8?]@*W_\ 0:R_VX-#T_6OV6_'[:@ G]GV!U&S MFR0\5U"P>%E(Z$L N?\ :]Z\B^ O[36I?"OX+^#_ CJGP)^,MSJ>C:;%9SR M6GA%FA9U7DJS2 E?J ?:MCQ/9_$S]LBZT_P]JO@6_P#AA\(H[V*[U=M>D5=5 MUI8G#I;+;KGR4+JNYF/. 03@J0?4U?%]]WA)N[G1M8FGRN#YC6 M,18X[W(R1'B0$] M/+-2_%+PKJMW^U7\"=3L=(O)]&TNUUN.ZO;>V=K>TWVT:QB1P-J;B,#)&2.* M]VU'3[?5K"YLKN%9[6XB:&:)QE71@0RD>A!- CYB_;0^)EQK7@;PM\,O!5XL MWB3XI3I86UQ;X?RM-8!KFYX_A,9"Y[J[D?=-=[\9]-/P=_9)\7:?X1C:T&@> M%Y[:Q,7#QK' 5\S/]X %L^HKQ_\ 96_9=\2> /CMXM\1>+[B[U'3?"MNOAKP M5)=@873CF4,N.NQ)%CW=R91_#7U[JVEVNN:7>:;?P+(OB):KI=MIV>/-6'<[7! .0! MWQD, 10!S?P+\'WL.H?%?2/!L=N(/!'Q!DU#P_932-':YDM\75F,?ZM"L\J@ M@$*SJVT[<'<%G'-X%U+PO'I/C6'Q/<>*SXICM6\*7 6&8Z@M[]F%WN%F1P8O M.%R%PQ;VKV7X$_!VS^!_P]MO#UO>S:O?R2R7VJ:M<*%EU"]E;=-.P[;FX R< M*%&3@D^BT <1\,/"^JZ+::SJNO\ DC7]?OVU&\@MY#)%:KY:10P(Y W;(HHP M6P S;V (%<]^U9JTNA_LU_$V\@D\J9/#]XJ-W!:)E'ZFO6*\N_:@T&7Q1^S MK\2=,A7?//H%[Y:^KK"S ?FHH Y+6M$B\.?L+ZCID"A$M/AY)$-O/(TXY[#. M>>:\<_9Q_8R\/_%CX&^"M>^,5UJ?CJ[N=)MFTO39=2GMK+2;/R@((X8X'3YS M'L+,0(T4#)8L< 9S MQ78_LYZ7>Z'\ /AOIVHV<^GZA:>'=/@N+2ZB:.6&1;= R.C %6!!!!&010!Y MC^RW/?>#/B+\6?A))JVHZ[HW@ZZL)]'N=5G\^>"VO+@..U M8'[+O@'3/BE^S?\ $3PGK,7F:9J_B?7K68#JN;E@'7T93A@>Q45V7P@\,ZQI MG[67Q]UB\TF^M-)U*+018W\]LZ071CM9%D\J0C:^TD!MI."<&I/V,?#>K^%O MAIXBM=:TJ]TBYE\6:O[7XB^*O'W[1&M*Z:7 M>1RZ5X860$&'1;5F+S 'D&>57<@]-OH:QOVM/V?_ !QXH^(>EZM\.+F33H_' M%NOA+QE+!&&VZ?N\P71]&6-9HMQY(=5&-U?4.B>#=)\.^$+/PO86:P:'9V2Z M?#:KT$*IL"^_RB@#Y/\ A3^S_9_M>>%;?XH?&JXU#Q%#KY>ZT;PI#J$]KIND MV98B'"1,A:5E&6#+1;ZZ^RLQ98+JWWJRO'G;O!PPP ,@D[?A?2_'/[1_Q>\*^./$WA*^^'_@ M'PBTMYHVD:T%75-1O9$,8FGB!/D(BDX0_-GG)!X"C0^%W_)Z7QX['^R-"_\ M1,M)_P $\_\ DTOP;V_?ZC_Z7W%:GPU\,ZO8_M=_&?6+K2KVWT?4-,T6.TU" M6W=;>X9(I!(LV>I^ =7^%OBSQOX0@U*ZNO# MFM>!M.6_/V6:5IA#<0AE:-T9V&[H>@!QDA)ULP/_ \2MO\ LF;<^O\ Q,QS M7C7P2_9QL/V@/B%\:6\=WU[J'@+2_'>JQ6?A>UNY+6WGO&<&6XG,3*S%5,:H M-P ^?CGGVSX'>&_%_P 0/C7XB^,?C#PU+X+MY](B\/\ A_0[[8;Y+02^=+-< M;<[&>3 "9R ,'H"VS^ROX]M?MEN\/GP.T>R5-P M&]& .&&0<<&@#P>Q^$.L> _VC+KX!>#/%>LZ#\+M>T6/Q-<6T%W(UWID,5N8_,%W ')R=_P ;?!/PS^R+\1/A=XK^&?V[PW;:_P"*;;PW MKFDOJ%Q=6NHQ72R 2.LKN1(C*"&!')Z5Z;-X9U@_MY6WB :5?'01\.WLCJGV M9_LHN/[1#^3YN-N_;\VW.<.K<>;:ZQ9ZKNF:;89&TS;][&;:>0BC+<8]* /$M'@N+?_@DIJT-P@%S'#>)*BG(#C5W# M ?C_ /6KVG1/V(_#?Q&\.Z?J?QGOM5^(?BFX@2203ZE<6MCIS%1^YM+>%T5$ M487)R6(+'KBO-M'^'/C(?\$N]0\*W7AO6CXODAN@=(>PF-Z[MJCR B$KO.5. MX<=#GI7H7A;]H?XD?"+PW8^'/B3\'?&WBC6;.%(8=>\"::NI6FHQJH"RNH9& MMW(P"C#J"1@$* HM_"FWUK]GCX^6?PENO$>H>)_ WB32Y]3\-OJ\QGO-,FMV M3SK0R=6BV,&4G&,!<=2=G4[<6/[?&A7$6 ]_\/[F*8#(R([Z-E/7!.6(Z5#\ M(_!OC?XH?&,?%_XA:#_PA\.G:>^E^%_"TLRS7%M'*09[JX9>%E< *$[+P0", ME^G-_P )-^WGK%Q$YDM_"W@>"RE7=Q'<75V91QCDF.,=Z"3Z,HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** /F7_@HIJ5W9?LK^(;:&>2TL]3O].TS4+F,X,5G/>1).3CG!0E3CLY MKZ'\/Z#I_A?0=.T?2;.*PTJPMX[6TM;=0L<$**%1%'8!0 !6-\4/AKHOQ@^' M^O>#?$<,D^BZU:M:7*Q-M< \AT/9U(#*<'! X-?-/A?XJ?&G]E_2XO"?Q$^& MWB+XN^']+C6VTGQIX MDO+V[A4 (MU8LX=)%7 :0'#?[1!8@'UCK6BV7B+2+ M[2M4MHK_ $V^@>VN;6X4-'-$ZE61AW!!(P>N:_-/Q!>7_$7Q:^-G[3FG7'A3X<_#3Q#\(- M"U!/L^H^-_B!;I9WEG$W$HM; ,7>0KD*Y8 ?[)(86?VM/@7_ ,(A_P $_/$' MPR^'>@ZEJXT^RL+2QT^PMGNKNYVWL#R2%(UR[MAY&(7NQQB@"KX9_P""=_@W MQSX7T_6OC-?Z[\0_B9=0+/R!KK48;0*]OYCC&6VR(A8^F>:^O M;-2MG K @A%!!'3@5\D_ 7X(WGC#P'^TYX.\6Z1J6AZ?XN\>:\+::ZM'A:6U MGBB6.ZAW@;USEE<94E<9XH J>!_V(]'^.GA'3?&'[0FH:I\1_%NM0IJ)T]]4 MNK/3-&\U0PM[2"&5-H52%+$DL06ZG)],^"/[.NO? /Q_J%MX>\9WNH?"2YL< MVWA77)Y+R?2[P.,?99W)*VY3=E&)(;ZDUYCX&^.GQ6_9I\*Z?X&^)WP>\:>/ MWT>%+'3?%?PXL%U:+4[>,;8Y)X2ZO!)M"YW9R02,9KT_X'^-OC!\4_'FI^)/ M$WA/_A6WPV2S^SZ5X>U<))K%[.7R;N;8?]' 4;?).222,^#_A6O[>W MBCQAXO\ B7JNI7?PMTO7+K0O#?@G3K^:TL[B.UD:-[RZ,15I)'<$KAAMP1DC MBF^.OA-%^P+K?A;QY\,-3U+3_AG=:S:Z/XG\#ZAJ$UW8I#=2K$MY;&0LT+K>T^'VO?%'X0>(-5GUS3W$PK=:MHES*/"FFW/P[U_X8?"'1-5@UO59_&-NMKJ MNKSV[[X;2.UW$QQ;\,TC?> &"",, =3KW_*2;PK_ -DUO/\ TX)7 >#_ (5K M^WMXH\8>+_B7JNI7?PMTO7+K0O#?@G3K^:TL[B.UD:-[RZ,15I)'<$KAAMP1 MDCBO4]:\*ZW+_P % O#7B)-'OW\/P_#Z[LI-66U_A&%;K5M$N;A]\]JUJ74RPER M65EQMR%--N?AWK_ ,,/A#HFJP:W MJL_C&W6UU75Y[=]\-I':[B8XM^&:1OO #!!&&VOC;:^)/AW^TM:_$;X9KIWC M;7VT%-/\6?#F+4H8=3N=-69V@U"W1VSOC=V7YAAP=J\G- %;7O\ @G/X#\(: M3=:M\&KS6OA=\08$,UIKEAK%U+YD6./OC((R*]GU+]J MCXD_%/3[SP]\./@9XZ\+^(IHVB;7OB)IZ:1I>F @C[1NWNUQL.2$09/!Z5H? M\$TM/N]+_8M^'\5XC1S.;^8%A@R*]]<.CCV8,"/8T 7/B1^UA:?\,=VOQ4$ MQ22ZSXELH+3P_IP3?*=5N3Y4<&.C-'*6R.G[IL=J],_9Y^$,/P-^#OAGP='( MMS>6-L'U"]&\9:):ZK]M^%/PYU M>3Q/8::L8\FUUS48$8P9Z,(1YTBA?N&49P37W[0 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 ?(?[97[2FJ^"-2C\%^%;MK'46A$NH7\>/,B5Q\L<9_A8CYB MW497!SFOB^V\=>)+35CJD&OZG#J1.3>)>2"7KD?-G/X5]!_MW_#/4=$^)7_" M8I&\VDZU''&TR@D0SQ1A"A] 40$9Z_-Z&OF"OU?)\/AE@X2II-M:O?U1^,YY MB<5]>FJDFDGHM5IT/T4_9!_:'O\ XO:7?Z)XAD6;Q#IB+*+E4"?:8"<;B!QN M4X!P!GPEMCIMIYF09CYBM(RC^ZI15S MW.1V-?;'2OS[-J=&EC)QH?"?I62U*U7 PE7^+\QU%%%>2>X%%%% !1110 44 M44 %%%% &1KW^MTK_K]3_P!!:M>LC7O];I7_ %^I_P"@M6O0 4444 %%%% ! M1110 4444 %%%% !1110!D^)/^/.V_Z_;;_T!- NMFSQ%XE\-M M;Z:LD9#*RXR"".HQ M7)?"3XI:%\:OA_I7C#PZ\QTG458QI-_AMI7CBVD>QT M#4-/74T>^VQF&$IN)DPQ5<#.?F(&* .MI:^9K?\ ;Z^'YN+6[O/#_C;2_!UW M,L-MXXU#P_+%HDI8E4(G)W;68$ E,<$G KZ4MKJ&\MXKBWFCG@E021RQL&5U M(R&!'!!'>@"3(]:*R?$_B;2O!OA^_P!7XUN/#,R:,R'I()<[]I['90!],9'K16'+X MTT&'PA_PE;ZO9KX;^QC4/[5,R_9S;%-XEWYQM*G.:\";]O?P2J_VE'X.^(=Q MX-^^WC.+PQ,=(2/O*92=^P>H3\* /IG-&1ZUFZ#KVG^*-&L=7TJ\AU'3+Z%; MBVNK=]R2QL,JRGT(-4F:CC8M&K%2A8 E6QD9]<5XYX._:?TCQE\7I?AU_PAWC M/P_JJPW-S;7VOZ1]BL[V&!U1Y(2[[W4EQ@[![XH ]GS4-Y:Q7UK-;SQB2"9& MC>-AD,I&"#]036'X^\7'P%X1U'7_ .Q-8\1_8D#_ -F:!:?:KV?+ 8BCW#<> M&/B+\' M#\3WAU#PIX3"S2_:/$210-Y4;;3+A)'&TL"%YR2.!R,^=+^WMX& BU"X\)?$ M"S\&2L/+\:W'AF9-&9#TD$N=^T]CLH ^F,TM4='UBR\1:39ZGIEU#?:=>0I< M6]U;N'CFC<95U8<$$$'(]:O4 %%%% !1110 4444 %%%% !1110 4444 %%% M% !7F?PI^#S?#GQ-X^\0WVKC7=:\6ZO_ &A-)/B7 MXOLO^/S0O .D/JEQ:C.#YA!6,$'@KO++CD"@#Z(S2U\[?#O]N/X>>./&%EX1 MUFP\3?#/Q=?8^PZ'X^TA]+GN\G \LDM&22'YECN8D?&Z&5 M6!6:$D F-AV." S9]AI,T ?*DG[)?Q:\;))I7Q*_:5\0^)_"DV5N=*\/^'[/ M0);E""&CDN8"SF-A\K(,9!(SWKZ4T#PS8>#_ S8:%H%G!I>FZ=;):65K$G[ MJ"-%"HH7(R .^3ZUKT9H \M_9X^!\?P'\#W>DRZN_B/7=5U6[UO6=W$FYY/++OL 4(H&X\(.:]3I,CUHW#UH 6BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@#/U72++7+&:QU&T@O;*8%)+>XC$B./0@\5Y-9_LI_"NU\2272>#[5 MI41)522>9X@Q9O\ EDSE,<#C&*]FYJI'_P AB?\ Z]X__0GK:G6JTTU"32?9 MG-4P]&LU*I!-KNA]K9QV-O';V\*001J$2.,;550, < >E6?6BBL=]6="22 M22LD.HHHH&%%%% !1110 44F11D4 +129%&X>M &3KW^MTK_ *_4_P#06K7K M(UYAYFE^UZA/_?+5K;AZTQ76PM%%%(84444 %%%% !1110 4444 %%%% &3X MD_X\[;_K]MO_ $'[;5M)@T>Z\4>+]!E MMM(LH7B6-KK?'YK2 9W+A1U!]C]-_MF?\FK?%#_L"3_R%8>C_M3?!GPK\']( M?5_B+X6N4M=&MX[G3[;4H+JX;$"AH_(1F=CG*E0/K0!TNNZQIG@/]E>^U'2M M7CU72='$.;35+>4.MRD5H1'(K9(.[:"#D]:\'_8OTNZ_9[\4:1\-K^6Y.A> M-/#=GXHT9K@@"*_6!%U"V7G.3E)0HX50?>N?N+76_!?_ 3/UZWO-/;0GUN6 M6/2])NCM>UL[[4 (86]/WV,GBWX<#:=N<=NE;G[+5]+\8=8\4_&Z\M;BUB\2,FE^'K:Y8;[;2K9B.@X!DN/.D/ M7.%[5R'P=\=7?P;\$_'^6U\.ZEXID\,^.M1NQI=DRB9K>?RIRRENNU7=\#). M.F302;/P5^,5GH']D_ KXMZ);^&O%MG9Q:?8_:%632?$,$:B-)+:0C:68*I, M3@,"0!SE5^G%4* , =J^+OVMOCA\$/C7^SC>BQ\3:5XB\1W,:R^&;'3YM^K M1:B2!"$A7]]$Q;Y6! X)'/%>NZG^S'X5^/'P^\ R?&;P]_PD/BK2='ABN)/M M]S;E+AXHS/GR9$#9=.^>G'6@#/\ VZM!U#6O@2;BTTR?7--TC5['5M8TBW&7 MO;"&8//'C^+@;B#V0GM5K7OVQO@/)\,+K69_'/A_4-(FL6#:,MPC7F7-Q]KFA^USW&Z0JJEMTS MN1PBC ('%?,WAGX;^$_VK/CY=^)](\+:-I_PI$WWS7]EI\4+^+=71CEY)$4 M-);PD]\J['/S D* 7?"_P>O[K_@G!)X3\1:K#X0DN=+FU))M6?9%I\;7)NX( M9V;D)C8C9&0"1M)&*SX/^"@DR_!X:I_PI?QD[K9^7_:,>DR?\(X0%V^:+K&[ MR"/F_P!5G:<=:]2_;CT&[U?X0Z9?'3;C7= T3Q%I^KZ_I-HN][S389"9T*?Q MJ,JY'HA^M;[?M@? V'PC_; ^)?AEM-%OO%HEZAN=F,;!:_ZW./X-F?:@!G[+ MOAW2_@_^R_X4MI?$^G:QI.GZ=+?W&MVDV;$*[R3R&-S@^4F]E!(!PG(7D#Y4 MT/\ :.+SX?Z()+/PE=67A^2?2=-B+8EU&XE) \Y]H V! MMJ\Z+!XFU;4-;\.>'6B*3P:6T\<@MEBZK MYB1R[4'42#'6OVP1 I@^Q_P"L M)7[N%4@XR,CF@#VKPGXJTCQUX0?P((/((( M/->,>,/^3WOAQ_V*.K_^C[>F?L/>'=1\/?!%YKW39]"L=6UK4-5TG2;F,1/9 M6$\Y>&,H.%X);'HU/\8?\GO?#C_L4=7_ /1]O0!] 9'K7SO^U1K]]XPF\/?! M3PY>O::[XX9AJEU"N6L-%3/VJ8]@7'[IZ^(=>L/"NAZAK6JW*66F:? M;R75U#_LIZ'J'CBZ\1?&[Q);M'J_C1@-%MY0-^GZ(C'[+ M%[&3_6M@X.Y<\T 4_P!LGP*]E^S98:?H&B27_AKPQ?Z;=W^@V(_X^-*M9%,D M 7/S (JL0>T?M6SKW[8WP'D^&%UK,_CGP_J&D36+!M&6X1KN9&4KY!M,^:"0 M=NTJ ,\X'->]-C!SP.]?%?AGX;^$_P!JSX^7?B?2/"VC:?\ "GPG??-?V6GQ M0OXMU=&.7DD10TEO"3WRKL<_,"0H![+^Q7X1U;P3^S/X+TW68);2Z>&6\CLI ML[[2&::2:*$YYRJ.O!Y'3'%>Z5'M*\ ?E4E !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110!X)^VU\2-:^&?[.OB&]\-3O M9^(M3FM=$T^[1MKV\MW.D'FJ01AE5V82!BL%U%(LL+L!U7>BYZ\$\&O,/A'^W!X2D@'A+XPWEM\)_BAI$*1ZMI?B: M=+2WG8 #[1;7#D121.067#9[QD13; M09K.;&$GA;^&13R#WZ'()!^2+C]H[X@>'?\ @FKXB\96^N/#\0_"-R= FUJ2 M%+AII+?4H[4RLLJNK,\1Y)#?,Q/7FO5OBM^W)X0MU;PK\(;NW^+?Q/U*(QZ5 MH_AF9;NWC9N!/<7*$PQ1(2&;+YZ [1EAY7^TE\&I?@+_ ,$N_$WA&[NUU'5X M8K2ZU2\C^[<7L^IP2SLI('R^8[!>!\H'% '9^&_#_P"U7\;/#=EXV_X67H?P M=6^A6ZT_P9#X:AU7]R5W1+>74Q#K(W&[RU^4'@!LJ/1?@1^TD_BSX)^)_%/Q M!2QT'6O ][J&D^*18NS6L5Q9WL!7P MW$OAW>?%WX*_MB>#=-D2+4M9^('B.TM6D;"^&=PD;,,.%C' 8!NF3Z M'\$?$'QJT'Q_J'@3XIZ;9>)M/AL?MVF?$+0[?[+;W0#A#;W5N3B.XYW#R_E* MCIP37)_L^_MG?#JY^'^F>'O'WB#2_AEX]\.VT6FZUX?\574>FO!/$@0M$965 M9(VQN4J3\K#-=Q\*?VJ/#GQQ^)^M^&_ =G=^(_#6BVVZ^\96N!IBWA? M(V; M!F'O@[KFF_#?P+X5OWTB_\ '.H:6NI7 M=_J$>?-AM+>0B,QH<*S/U)&T]J;:_$KXR_LQ^/\ PKHWQ?U[3?B9\/?$^H1Z M1;^-;#2ETV\TV^E.(4N[>,F+R7;Y0Z\CDL>@.1^S_P#%KPU^RKXI\:?![XHZ MA:^"9FU_4-=\/ZYK$HAL-9T^ZF,H87#G8)HRQ1U8CMC/-1_M'?%OPQ^U5K'A M+X+_ NU6V\;7MUK=CJ^O:SHLPGL-'TZVG69G>X0[/, M_P"4DWA7_LFMY_Z<$K(U3XF_&#]I;XC>*O#WP=US3?AOX%\*W[Z1?^.=0TM= M2N[_ %"//FPVEO(1&8T.%9GZDC:>U:VO?\I)O"I[?\*UO/\ TX)7(?L__%KP MU^RKXI\:?![XHZA:^"9FU_4-=\/ZYK$HAL-9T^ZF,H87#G8)HRQ1U8CMC/- M&O:_$KXR_LQ^/_"NC?%_7M-^)GP]\3ZA'I%OXUL-*73;S3;Z4XA2[MXR8O)= MOE#KR.2QZ ]E\=OCIXSMOB;HGP@^$NFZ9?\ Q!U2P?5K_4]1 M4YDD=\JB ]0"W!KS+]H[XM^&/VJM8$?!?X7:K;>-KVZUNQU?7M9T683V&CZ M=;3K,SO<(=GF.4"HJ-G.02,C.S\4O%MM^S!^UV_Q+\6VTT/PY\;Z%:Z#<^(U M1I8](U"WEIWU_ O@3JOQ5^U17_AVWT@:M M:R1R +=JZ!H%0GO(711[N*3]GE?'+_![PU=_$>_:_P#&E_;_ &[4%-M%;BT> M4EQ;!(P!B)66/)RQ*DDU\3^ O!'B77OC/I?[*^K6)N/AW\.M=D\5S7TD@;[; MI&5FTNS;CYB)IF#@XRL/'0U^D..W2@!:*** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** &]JHJ<:Q/SC]Q'W_ -IZN\UX[\8OV?--^-7B*SGU#7-6TIK"U"HNG2*H M?<[P^8G]_]:/,3^_^M?,7_#!O MA[_H<_%'_@1'_P#$4?\ #!OA[_H<_%'_ ($1_P#Q%>C]7P?_ #__ /)6>=]8 MQW_/C_R9'T[YB?W_ -:/,3^_^M?,7_#!OA[_ *'/Q1_X$1__ !%'_#!OA[_H M<_%'_@1'_P#$4?5\'_S_ /\ R5A]8QW_ #X_\F1].^8G]_\ 6CS$_O\ ZU\Q M?\,&^'O^AS\4?^!$?_Q%'_#!OA[_ *'/Q1_X$1__ !%+ZO@_^?\ _P"2L7UC M'?\ /C_R9'T[YR_WA2^8O]X5\P_\,'Z"O,?C7Q0D@Y1OM$?!]>$'\Z/^&(C_ M -%,\3_]_/\ [*CV&$_Y_?\ DK']9QW_ #X_\F1].[AZBCN##-( 2JOENA.!GMUK2GAL'SI2 MK:7_ )695<5CU"7+0UMW1\F_$KXX>+_BIK$UYK&L7 MR^Z*QMY&CMX5R2 J# MC(!^\,X(\&OK&XTV^GL[N&2VNH)&CEAE0HZ,IP00>00>"*ZCX2_#O4/BEX^ MTGP]80N_VB56N)!TAA!!D=CV 7\S@#K7Z77PN$^JN,HI02_IW/RG#XO&_6XR M4FYM_P!:'Z\*LB/_D:KG_KR MB_\ 1DE &O1110 4444 %%%% !1110 4444 %%%% !5'6/\ CQ/_ %TC_P#0 MUJ]5'6/^/$_]=(__ $-: +U%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 9^L:'I_B+2;K3-6L;75--NHS%<6=Y"LL,R'JK(P(8>QS7&Z3^S M[\+=!U&VU#3/AKX0TZ_MVWP75KH-K%+$W]Y&6,%3[BM_Q]X\T/X7^$=1\3^) M;TZ=H6G(LEU=^5)+Y:EE4';&K,>6'0'K6Y;7"7EO'-$=T4BAU;&,@\B@"AKW MAO2?%5FMGK6E66KV:RI,MO?VZ31B1&#(X5@1N5@"#V(R*T984FC:)T#QL,,K M#((/4$=P:YWP-\1/#_Q(LM1N_#FHG4;?3M0GTJZ?R9(O+N86VRIAU7.#_$.# MV)KIMP]: *.DZ/9:!IMKINEV5OIVFVL2PV]G:0K%##&H 5$10 H X &.E0 M:7X9TG1;[4KW3]*LK"\U*43WUQ;6Z1R7<@7 >5E&78#C+9.!6M24 7$>M:U::%;?8T1RL]P^R-GW,N$!^\1D^@-&--_:"L?@]+I^ MMMXFO+,WT=W'8YL0FQFP9-V[HA^8+LS\I;/% 'K+*'4@C((P?"'P+?^)E\27/@KP[<^(@XD&KS:5 UV M&'1O-*;P1ZYJW\/?&UC\2_ N@^*],BN+?3M:LHKZWBNE59ECD4,H<*Q ;!Y M)%=+0!&JGKC%9\WAO2KK6K;69]+LY=8M87MX-0>W0W$4;D%XUDQN"L0"0#@X M&:TZ* *.KZ19:_IESIVJ6-OJ.G749BN+2ZA66*9#P59&X(//!!%6+6UBL;6& MVMXD@@A18XXXUPB* .@ P,5-D>M% #64.I!&01@YJCH^B6'AS38-/TK3[ M73=/AR(K2SA6&*/)).U% R23TZDUH;AZBC6T4\)WQ2JLBG&,@\@T 87@WX<^%/AS M9R67A/POH_A>SE;=);Z+I\-I&Q[$K&J@FKOB3PKHWC30[G1O$.C6.NZ/<[1/ MI^IVR7%O+A@PWQN"IPP#)%7=M;^(<'L3764 (JA5 P!T%96A^$]%\+'4#HNCV&DG4;N2 M_O38VL3:!OD; RYR3CDFM>DR/6@#C_&OPA\"_$N2WD\7^"_#WBJ M2W&(6UK2H+PQCT7S$;'4]/6N@T70=-\-:9;Z;H^GVNE:=;KLAM+*%88HEZX5 M% "CZ#O7*_%7XN:/\(+7PW/K-M?7*:_KUGX>MOL*(Q2XN7*1O)N=<1@CYB,D M#H#7(ZA^U1X3TO\ :4T[X(S:=KS>++^Q_M".\CL,Z>$V,^#)NW=$(W!2@/RE MLY% 'I7B[P+X<^(.E?V7XI\/:7XDTS<'^QZO917<)8'@[)%(R/7%-\'> ?#/ MP[TMM-\*^'-)\,Z<7\S['H]C%:0[C_%LC51GWQ70;AZT9H R)/">C2^)H_$; MZ/8/X@BMC91ZLUJANDMRP8PB7&\1EOFVYQGFH/%W@7PW\0-*_LOQ3X?TOQ)I MFX/]CU>RBNX2P/#;)%(R/7%;V:QO%_B2U\%^%-9\0WT#O /AGX=Z8VF^%?#FD^&=.9_,^QZ/8Q6D.X_Q;(U49 M]\5Y'\?/AO\ $Z;Q;IWC7X9:I9ZLT=F^G:UX#\47%(VSN*PV,*.\@ M^\H<[,XSWKZD^#_PQT_X(_"GP]X*T?S;RTT2R6W61E59+F3EI)". &=RS'ME MJ[FDS0!X'^RC\+/$WA:S\:>./B#8K9?$/QSK4FI:A:^9',UC:1YCLK/S(V96 M$40R"&.#(1GBO?:3-&>W>@!:*3-&X>M !FEK@_AE\6]'^*UYXR@TFWOK>3PK MKT_AZ]^V1H@DN(DC=FCVLV8R)5P6P>#D#%=Y0 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!5*/_D-3_P#7O'_Z$]7-P]:HQLO]M3GJ*Z6Y?HI-P]:,BD,6BB MB@ HHHH **** "BBB@ HHHH \L^*/P-\"_$+4K"\U[P[;WEW+<)%)<(SPR.H M5L!GC92<8'4G@8[UU'@7X9^&?AG8R6GAK1K?2H9"#(85)>3&<;G)+-C)QD\9 M-:FO?ZS2_P#K]3_T%JUL5LZ]64/9N3MVN=M_U^VW_HY*UJR?$G_'G;?]?MM_Z.2M:@ M HHHH **** "BBB@ HHHH **** "BBB@ K)\._ZN_P#^OV;_ -"K6K)\._ZN M_P#^OV;_ -"H UJ*** "BBB@ HHHH **** "BBB@ HHHH *R(_\ D:KG_KRB M_P#1DE:]9$?_ "-5S_UY1?\ HR2@#7HHHH **** "BBB@ HHHH **** "BBB M@ JCK'_'B?\ KI'_ .AK5ZJ.L?\ 'B?^ND?_ *&M %ZBBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** / /V]/^31_B+_UYP_^E$5>V^&_^0!I MO_7K%_Z *\I_;*\/7?BK]E_XCZ?8VK7ET=*>9(8_O-Y;+*<#N0$) [XQ71_# M_P"+_@_Q'\']-\;VWB#3QX9CL$FN+][A5BMMJ#>LI/W&4\%6P0>#0,$_9U\ M57?@7]GOXZ^)+".&:^T?Q3XGU"".X5C$TD69%#@$$KE1G!!]"*A^&/[0'[0/ M[1'@?2/$?P^\%^#?#VG&WC2XU3QI-=+'J-R%Q/\ 9(;1CD>X(%' MX0P2W7[#'Q@\1&VN+6U\4?\ "3Z]9K<*5Y.>] RK\ ?C-J?Q.A\2:+XHT%/#'CC MPK>K8ZSIL-P)X001SC-< WQ\^*'QHU;58_@9X:\-S>%]- MN7LV\8>,KB=;*_F0[94M8H!YCJ#QYN=I(..E0?#/3Y-6_:L_:@L89!%-9#(N]?DD'(R0>,5]&>)_BQJ^B_M(>"?A_#;6+Z/KFC:AJ%Q-)&YN4D M@*! C;@NT[CG*D\#!%>,_ME_%OPM<>//@YX"M+RWU+Q/_P )WI-_/;VSK(UA M$DX7=+C.QG,@ !P2,G'KV?C_ /Y/H^%'_8L:Q_Z%%0!2\0?&[XP>,/BIXST' MX5^%?"U]HO@F:&UU.3Q)>S0W.I7#Q"4PVOEC;&0#MW2C:20>F17I'C7XZ:?\ M-_@]:>._%&BZEI4]U#;K'X=\M9;^2\FP([-54X:0L<=>,$GF'Q*\"^%/% M?B#Q?\3OAG\2X? _CWP^K6NN7]M=))I\SVZ$"'4K=\J0 -H? 9<9&2HQQ?Q, M^)VH^-O@G\ ?CEJ^ALNFZ-KEMK&OVMG'(XMH7CD@:Z1?O%$8JXZG:PY(R: . M]7Q9^U7K4,>N:?X+^&^AZ9(@E'AO5]2O)M5"XSL,\2B .>G3 [UMQ_%R3XO? MLW_$>^O?#6I>$=O:3XZ\.Z MYX53Q-8:YIUUX=>+[0-5CND-N(P,EB^=H [Y/%>7ZO\ &#PY\:/@'\4-5\+S M7%[I5C8:IIZW\D+)!=-';L&D@<\2QYR-X."5- '*?#KXRZ-\"_V*?AMXDUB* MXO6.A:?:6.FV2;KB_NI(@(K>)>[,0?P!/;%0?$I^UB]I_PD2^ /AZFF_P"N M_P"$2;4[G^V"G_//[3_Q[B3WQCVKSC59#X9_9G_9<\?7MM/>>&?!]QIM_K*6 MZ&1H('M6B%T5 )(B=E)P,_,:^QX_'_AF3PB/%*^(-,/AKR?M']K?:X_LOEXS MO\S.W'XT >7Z'^U5X>U[]GOQ#\4K;3KR-O#]O<#4]!N?W=U:WL*Y>TDX^5MQ M4;L=&!QU%97PA^)'QRU/5O#EUXZ\#^'3X7\2Q>=;7'A>\E>XT?=$98Q>K,0K M@J-I>(D;L<%M3\-_'+XE>*'M],^%GC'7F6U?5T\F"[L_*2U>&/"\_A"\N8[63Q3X'N+@ MP:7)(X2,W4-Q\_ELS &13A>,@Y%>42?!_3-6_:X^)^A>)/BEX\^'.N^()[75 MM#C\-Z\NF6^LVIA"$+\A\R6%T=-O4+R 1DU<^,W[/_@#P3:66@>,?C]\9=7G M\0W,6G6WAH>*5O+B_P#-<)C[,83NC'5BPQA>[8! /I'XZ?'"T^#&DZ3%:Z7< M>)_%NO7/V'0?#=BX6:_GP"?F/"1HI#/(?E4$>M>>P^+OVH]%8:YK'@CX?ZUH MBCS)/#NA:E=)K"H>JK+*/(=U&>!@,1@$9K)^.UQ9?!/XX?!7QWK[N_@K2[.\ M\-7.KW1+MIT\\:"&XE(& '\LJSX &3G&17T3K?C[PWX=\*OXEU+7=.LO#ZQ^ M=_:_>OJF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH ^;O^"BW_)E_Q0_Z\8?_ $IAKW[PS_R+>E?]>D7_ * * M\<_;F\,WGC#]D?XHZ;I]J]]=MH\EPD$>2S>2RRG '4@1D@#J1BNH^&_QL\$^ M*/@CI7C^U\2::/"L>FQSW.HR7*+%:[8UWK*Q(V.A^4JV"",'F@#YW_9A\87G MP[_9G_:'\5:;%!-J&A^+O%NI6\5TK-$\L.9$5PK*2I*C."#CH14?PF_:2_:3 M_:<^'NB^*/AKX$\#>&=,-M$ESJWCN:\6+4[H+B@95!'J"".M?1W[(L M$5O^RQ\(DB1(E_X133'VQJ ,FUC)/'*="\7^' M8_"?C_PA?)8:YI4-R+BWR\8DAN('SDQ2)RN>000$M*NWL3XW\=G8Q!QTJO\*=-EUC]L7] MK>P@E$$]WIWAV".0Y^1GTZ4 \>A_E5W_ ()\^/M"A^"^F?"N=K?1?'_@4S:1 MKGAV1MEPDJ2O^_53@O'("'\QX^)'_*0CX-_]BEKG M_H4- %'Q)\?OC;XV^+_CKPY\'_!_A'4-!\ SP6NK2^*;Z>&ZU6YDB$IAL_+^ M6(@';NF!4D@],BO4O'G[0VF_"WX'V/Q#\6Z%JVD7-W#;K%X9V+-J4E]-@1V2 M*APTI<[>HP 2<8(KR7XJ?#WP=XP\1>-?BS\*/BM!X ^(OAM7L_$&H6EXDFF3 MO;J<0ZK;/E2 5$F R]1N*C'!_%CXM:IX\^ 7[-_[0.N>'Y$TG0_$%KK?B2R MLHY'%I;O'+ UXB?>,:,5D Y.UQR1DT >C+XP_;"UZ&/7].\!_"WP_I,B"9?" MVMZK?3ZP%QGRVN(E%N'/;(P.]=!'\:)?C;^RW\4=1O\ PKJG@KQ!I.EZKI6K MZ'JJY:VNH[5BZQR@!9X\,"LB@!@>@KVG1OB%X8\0^#X_%>G^(-,O/#+P_:1J M\5VAM1&!DN9,[5 YSD\=Z\FUOXW>%_CO^SC\6M8\(3W5[HUAIVKZ8-0DMVCM M[QX[9P\ENYXEBW' =3@E3^(!QOPQ^.6A_L]?L%?"SQ7K<-Q?LWA[3;+3M+L$ M+76I7DD($-M$HZNQ!_ $XXQ5;_A//VR9+$>)4^''PS32L>?_ ,(8^K7?]N&/ M_GE]I_X]1)_M=/:O+=8D/A+]E/\ 9$^)&H6MS>^%?!,^E:AKJV\9D-K;26;1 M"[*@%B(G9&. 3\WY?(_V9_$WQ=M-+O8CX;MKH:MX=NOW5Y9WUNN9+.3(^5MVWYL= M&!QU%8_P6^*7[0.L:QX8N_B%X \+GPAXKB\ZTN_"-[,]SH8:$S1K?K,=KA@- MIDA. ^!CYA7!?L[^(/"&K>%?V@_BIXO>WTKX0>.?$;"S?6XS#:WED(4M'N2K M:C_9EKX-UFY%Y=Z7&8BZ M7=A.,N;5 HW*^5 ;@Y?< #TKXP?M&>+E^)S_ J^#?A2R\7>/;6T2]U?4-:N M'@TC0(I!F$W+(-TDD@Y6)"&VG=T!QSL/QY^-WP/U*QN/CSX2$W'@J^N8K.3 MQ;\/[FY,&D22N$C-Y!0" QK0^.O[-GPV\!6- MAX:\<_M'?'/6I_$US#IEMX57Q@E]%_!\GBK5O$6F6'AI(A,=6FNT6V*$9#+)G#9[8//;- 'SC_P3W\8 MV/Q!TGXU^)-+2YCT_5/B-J%S#'=Q&&:,-;6AV.C#Y7!R&'8CBOK2OC__ ()P M^,].^(WAOXS>*M(M7L])UGXBZC?VD4D?EL89+>U9'*]MP(;'^UWZU]@4 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110!\A_ME?M*:KX(U*/P7X5NVL=1:$2ZA?QX\R)7'RQQ MG^%B/F+=1E<'.:^+[;QUXDM-6.J0:_J<.I$Y-XEY()>N1\V<_A7T'^W?\,]1 MT3XE?$BD;S:3K4<<;3*"1#/%&$*'T!1 1GK\WH:^8*_5\GP^&6#A*FDVUJ] M_5'XSGF)Q7UZ:J2:2>BU6G0_13]D']H>_P#B]I=_HGB&19O$.F(LHN50)]I@ M)QN('&Y3@' &=P]R?I'I7Q1_P3]^&NHVNH:SXVNXGM["6V.FVGF9!F/F*TC* M/[JE%7/_UNE?\ 7ZG_ *"U:] !1110 M 4444 %%%% !1110 4444 %%%% &3XD_X\[;_K]MO_1R5K5D^)/^/.V_Z_;; M_P!')6M0 4444 %%%% !1110 4444 %%%% !1110 5D^'?\ 5W__ %^S?^A5 MK5D^'?\ 5W__ %^S?^A4 :U%%% !1110 4444 %%%% !1110 4444 %9$?\ MR-5S_P!>47_HR2M>LB/_ )&JY_Z\HO\ T9)0!KT444 %%%% !1110 4444 % M%%% !1110 51UC_CQ/\ UTC_ /0UJ]5'6/\ CQ/_ %TC_P#0UH O4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110!&RENW KPW6/V'?@9KWB] M_$U]\.=-EU5YO/?;+-';.^>K6RR"%LGKE#GOFO=J* ,;6?">E:_X7OO#E[9( M^B7MF^GS641:)#;NA1HQLP5&TE?E(P.F*=X7\,Z=X-\-Z7H.CVOV/2M,M8K. MTM_,9_*AC4(B[F)8X4 9))/B@#E]%^''A[P[XR\2>*]/TXVVO^(A;#4[ MOSY&^T"W0I#\C,43:I(^4#/?-J44 >1>'?V4?A1X3T73M*T?P59:;:6&I6^KPM;RRB8W M4#%H9))M_F2[2S?*[,O/2NWU'X=>']6\*O%'@:QU775VEKKS)8A,5Z&5$ M=4E( _>!L@ =.*]4ATFS@TQ--BLX(M.CB%NEHD86)8@,",(!C;MXQTQQBKM M% '@.I_L&_ 75O$1UJ?X;Z%(&4J8T6/&P;21\N,9[5NT4 8'AWP3HOA7PA8^ M%M-T^.+P_8VBV$%C,6G18%4((R9"Q8;0!\Q.>]>0-^P;\!&\2_VZ?AMIOV[S M?-\L37 M=V.GV;S/)VX_AV;?:O?J* ,FZ\,Z3J'A^30;K2K.?1)+?[(^G20( M;-NS'&W&,5YQ\+?V4?A1\%_$$VN^#O!=GI&KRAE^V-+-<21AAAA& M97;RP1D'9C(XZ<5Z[10!Q?Q.^#O@SXS:*-(\:>'++Q!8JQ:-;I")(B>ICD4A MXS[J0:YCX4_LJ_"GX(ZE)J7@SP59Z5J;@K]NEDENKA 1@A))W=D!'4*0#WKU MNB@#.UK0]/\ $FDW6EZM8V^IZ;=1F*>SNXEEBE0]59&!##V->)Z/^PA\!M#\ M1+K=K\-].:]5O,"W$]Q/;ACW\B21HOPV<5[[10!S/@_X>Z!X!;6VT#3_ .SS MK6HR:I?!99'$MRZJKN S$+E8T&U<+QP*Z:BB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C*E^"/SKY]US_ ()__L^> M(_&K>*]0^&&ERZP\_P!H?RYKB*U=\Y+-:I((6R>2"A![YKZ&HH P]<\&Z/XC M\(W_ (6O["-_#]]82:9/80DPH;9T,;1 QE2J["5^4C Z8IWA+PKIG@7POI'A MS0[4V6C:19PV%E:^8\GE0Q($C3^?*WVD6Z&.#Y&8HFU21\@&<\YZUQGQE_9+^$?[0%]#?>/ M? UCKNH1((UOEDEM;HJ.BM- Z.RCLK-@?B:]@HH \6\,_L<_!OP9H&EZ-H?@ M*PTRRT[5;76H#;RS+.;RW8M!+)-O\R4(Q)"R,R\X(Q7?:E\,?#6K?$+1_&]W MIOF^*-'M)["QO_/E7RH9B#*FP,$;.U>64D8X(KJZ* /$/B3^Q7\%/B]XZ3QA MXN^'VGZMXB4J7NS+/")RN #-'&ZI*< #,BMD #H,5[#!H]C:Z3'I<%E;Q:9' M"+9+..)5A6(+M$80# 7;A=O3 QC%7J* /F_5O^"=?[.>L^)FUZX^%NF)?,_F M&.VN+F"TR/\ IVCE6''/39@U[>? ?A__ (0J7P?#H]K9>&)+)]..E6,?V:!; M=T*-&@CQL4J2/EQC/&*Z&B@#G/#/@'0?!_@G3O"&EZ8D7ANPLETZ#3YF:=!; MJFP1L9"Q<;>#N)SWS7B;?\$Z_P!G-_%7_"0GX5Z7]O\ .\[R5GN19[O3[)YO MD;?]GR]OM7T?10!CWGA31M1\,R>';K2+*XT&6W^QOI-NS'& MW&,5Y=\(OV.?@W\"?$D_B#P/X%LM%UJ963[\3)KU MG\+=,.H(YD5;FYN;BV!_Z]Y)6B_#9Q7T=10!RO@GX9^&_AQ)K[^'-,73#KVI MR:QJ.V61Q-=R*BO)AV.W(1!M7"C;P!75444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G MZKI%EKEC-8ZC:07ME,"DEO<1B1''H0>*\FL_V4_A7:^))+I/!]JTJ(DJI)/, M\08LW_+)G*8X'&,5[-@YZ54C_P"0Q/\ ]>\?_H3UM3K5:::A)I/LSFJ8>C6: ME4@FUW0^ULX[&WCM[>%(((U")'&-JJH& . /2K/K116.^K.A))))62'444 M4#"BBB@ HHHH **** "BBB@#(U[_ %NE?]?J?^@M6O61KW^MTK_K]3_T%JUZ M "BBB@ HHHH **** "BBB@ HHHH **** ,GQ)_QYVW_7[;?^CDK6K)\2?\>= MM_U^VW_HY*UJ "BBB@ HHHH **** "BBB@ HHHH **** "LGP[_J[_\ Z_9O M_0JUJR?#O^KO_P#K]F_]"H UJ*** "BBB@ HHHH **** "BBB@ HHHH *R(_ M^1JN?^O*+_T9)6O61'_R-5S_ ->47_HR2@#7HHHH **** "BBB@ HHHH *** M* "BBB@ JCK'_'B?^ND?_H:U>JCK'_'B?^ND?_H:T 7J*** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J4?_(:G M_P"O>/\ ]">KM4H_^0U/_P!>\?\ Z$] %VBBB@ HHHH **** "BBB@ HHHH M**** ,C7O];I7_7ZG_H+5KUD:]_K=*_Z_4_]!:M>@ HHHH **** "BBB@ HH MHH **** "BBB@#)\2?\ 'G;?]?MM_P"CDK6K)\2?\>=M_P!?MM_Z.2M:@ HH MHH **** "BBB@ HHHH **** "BBB@ K)\._ZN_\ ^OV;_P!"K6K)\._ZN_\ M^OV;_P!"H UJ*** "BBB@ HHHH **** "BBB@ HHHH *R(_^1JN?^O*+_P!& M25KUD1_\C5<_]>47_HR2@#7HHHH **** "BBB@ HHHH **** "BBB@ JCK'_ M !XG_KI'_P"AK5ZJ.L?\>)_ZZ1_^AK0!>HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I1_\ (:G_ .O>/_T) MZNU2C_Y#4_\ U[Q_^A/0!=HHHH **** "BBB@ HHHH **** "BBB@#(U[_6Z M5_U^I_Z"U:]9&O?ZW2O^OU/_ $%JUZ "BBB@ HHHH **** "BBB@ HHHH ** M** ,GQ)_QYVW_7[;?^CDK6K)\2?\>=M_U^VW_HY*UJ "BBB@ HHHH **** " MBBB@ HHHH **** "LGP[_J[_ /Z_9O\ T*M:LGP[_J[_ /Z_9O\ T*@#6HHH MH **** "BBB@ HHHH **** "BBB@ K(C_P"1JN?^O*+_ -&25KUD1_\ (U7/ M_7E%_P"C)* ->BBB@ HHHH **** "BBB@ HHHH **** "J.L?\>)_P"ND?\ MZ&M7JHZQ_P >)_ZZ1_\ H:T 7J*** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "J4?\ R&I_^O>/_P!">KM4H_\ MD-3_ /7O'_Z$] %VBBB@ HHHH **** "BBB@ HHHH **** ,C7O];I7_ %^I M_P"@M6O61KW^MTK_ *_4_P#06K7H **** "BBB@ HHHH **** "BBB@ HHHH M R?$G_'G;?\ 7[;?^CDK6K)\2?\ 'G;?]?MM_P"CDK6H **** "BBB@ HHHH M **** "BBB@ HHHH *R?#O\ J[__ *_9O_0JUJR?#O\ J[__ *_9O_0J -:B MBB@ HHHH **** "BBB@ HHHH **** "LB/\ Y&JY_P"O*+_T9)6O61'_ ,C5 M<_\ 7E%_Z,DH UZ*** "BBB@ HHHH **** "BBB@ HHHH *HZQ_QXG_KI'_Z M&M7JHZQ_QXG_ *Z1_P#H:T 7J*** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH *3(I:\3_ &E/VK_!O[+>GZ)<^*[75K]]7ED2VM='BBEEQ& 7 M=A))& HWJ,@YR: /:\TM8?@OQ;IGCSPGH_B/1YO/TS5K6.\MI.,E'4,,X[X/ M([$5XGXX_:R_X0W]JSPK\^V'7K:.X.M_VCL$&X3';Y'E'=_J>N\?>]N0 M#Z(HI*6@ HI,CUHW#UH ,TM?.?[2G[7G_#._CSP7X&8CJ>H7UL MDIB6Z\HK%L!97)7)V@9R: /?**^6=+_;^TC7+_4;+3O@S\8KZ\TV407UO;>% MDDDM9"NX)*JSDHQ!!PV#@YKZCCD#J&P5SV;@B@!])D>M&1ZUY_\ 'CXJ'X)_ M"7Q#XV&F?VR-(A27[#]H\CS=TB)C?M;;][/W30!Z!2U%#-YL,;XQN4-^=24 M+2;AZT9KS;X1_%\_%/6/'UC_ &1_9G_"*>()M"\S[3YWVK8B/YN-B[,[_N_- MC'6@#TJBBDR* %I,CUHR*\A^/WQTO_@\/"FFZ#X1F\<^+?$U\]CIFC0WT=D' MV(7D9II 0H50.2._.* /7LTM8'@C6-8\0>%-,U#7]!;PQK,\0:ZT=KI+G[+) MD@IYJ *^,<, :WZ "BN2^)GQ(T'X3^$;KQ%XCNQ::?$5B4#!EFE<@)%&I/S M,QX ^I. ":ZV@ HI,TM !129HS0 M)FC(]:\\G^*_D_'JT^&O]E[A<>'9-?_ M +4-Q]W9B44F1ZT9'K0 M%)D>M+0 4E(QVJ37F/P M>^,4WQ<^#L?CFWT"6TGD-\L>D07(GDD:WGEB"JY5%+.8N,@ %L9[T >GY'K2 MUY?^S]\5O$7Q@\$S:UXE^'NK_#>_CO)+==+UAF,DB*%(E&Y$8*P;-NWKN.?:@#TJDW#UI:\Z^$OQ8_X6E>>.H#I?]F'PQXCN- W?:/-^T^4D M;^;]U=F?,QMYQMZF@#T6BDR/6CK3X:_V5N%QX=DU_P#M0W'W=ERD'D^5M_VMV[=VQCO7H>X>M !F MEKDOBEXNN_A_\.?$GB>QTG^W;G1[":^73O/\@SB-=[*'VMM.U3CY3R,=ZN^ M_&5C\0O!.@^)]-+?8-8L8+^!7^\J2(& /N,X/N* .@HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $S2U MY]\;_C)I'P#^'E[XU\06&IWNB6,L,=XVE0I+);QR2+'YS*SKE%+#=MRP!X!K MN[6ZBO+:*X@D66&5 \X(H ES2UYS\9/C9H?P5L_#TFK6NH:K?> M(-7M]$TO2M)C26ZNKF4G&U7=%"J 69B0% [G /HN10 M%)D>M&10 9'K17F7 M[0_Q2\0_!SX9WGB7PQX U7XEZM#/%$N@Z.S"=U=L&3Y4=B%ZD*C'D=!DCL?! M>N7GBCP?HFLZAHUQX>OK^RANI])O2#-9R.@8PR8XW*3@^X/2@#=HI,T4 +12 M49'K0 M%)N'K2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M4H_^0U/_ ->\?_H3U=JE'_R&I_\ KWC_ /0GH NT444 %%%% !1110 4444 M%%%% !1110!D:]_K=*_Z_4_]!:M>LC7O];I?_7ZG_H+5K4 +1110 4444 %% M%% !1110 4444 %%%% &3XD_X\[;_K]MO_1R5K5D^)/^/.V_Z_;;_P!')6M0 M 4444 %%%% !1110 4444 %%%% !1110 5D^'?\ 5W__ %^S?^A5K5D^'?\ M5W__ %^S?^A4 :U%%% !1110 4444 %%%% !1110 4444 %9$?\ R-5S_P!> M47_HR2M>LB/_ )&JY_Z\HO\ T9)0!KT444 %%%% !1110 4444 %%%% !111 M0 51UC_CQ/\ UTC_ /0UJ]5'6/\ CQ/_ %TC_P#0UH O4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 @XK\L/B]X/OOV^OVS/%WA[2M1D@\ M.>#M*N+.WO(]K1B:+-/AKXU\,^$;'Q<%NI5UB,3 M7=PJ,XC=M]I-M4[F( ;HV2,F@:[GN_\ P2[^*EWJGPUU_P"&&N+);Z_X+OI( MUMIAATMY';*$>L//A]X' M^!$TWA>_O(%N?$>I7&GQ72V1P/-7$R,OEQZ*SW*VRQB W,JA<.V,*HV@,YX!"L!\I?"G2?& M_P#P39^*/A'7_&]BL_A'QEI\=MJTELF\V#E@S1%AG][#PQ53M==^W.,@!'TY M^V5\=?B%\%?BA\#O#?AGQ3-!9:Y="UU=[BQM97OPL]M'N8F(A"P=\^6$'S< M<8VOVL_VN/$OP_\ B!H7PD^%6B1:]\2M;1'\RZ7=!9(Y8+\N0"^%9R6(5% ) M# \>1_\ !134K76/CC^S9>V-Q%>65U?":"X@!-0BCM[^YM$#&UD^SFV:,\@!BH21=V QW#.>@! MI>,?B=^UI^RC8P>-?B/J/AOXE>#/.CBU"VTZ..&2S5F !#I;PE220H;$BYP" M.'_V5?!_Q-^%>MMI#:]J5LL=Q):P3.(7@G9XF25'4,K1@-@9 M!0X.,Y\\_:^_;@\ ?&/X.WOP[^%TE_XW\3>*'BM!;VNF7,9@42(Y^5T5GD.T M*H0'J,$<$(9-N M1P=N>E R]XA^,'[82_ O3/C.-:\.:1X7M[.WN9=(BLHFO+R#*K]JE62(@+)D M,1'(N%;*J*^T_P!F'XS2?M ?!#PUXVGL4TZ]U".1+JVB)*)-'(T3E<\[6*;@ M"20& ))&:\M^)?\ RC@N>./^$!MB.?\ IUC-2_\ !-'_ )- \)?]?-]_Z52T M"Z'KW[17B*7PC\!?B'K%OG[19Z#>RQ;3@AQ"VT_G@U#^S3X8C\&?L^_#O1XX MQ']GT*S,@"XS(\2O(2/4NS$_6LS]KK3Y=5_9A^)\$(+.= NY ,\+&6(_)37 M7_""^CU+X4>"[R$DPW&BV4J;A@[6@0B@.AY%^S-_R6W]HO\ [&>V_P#2-*9\ M1OBE\1?B-\5]4^%_PBDT_0FT.&*3Q)XRU6V^TQV#R@-';VT/W9)BA+'?\N.# M@\T_]F;_ )+;^T9_V,]M_P"D:5SNE^/-+_9A_:,^(-GX\D70_#'C^\@UC1?% M%UD6AN%@6*>TGE/$3 IO7=A=I.2,@4"(?$WBKXW?LMK;>)_''BRQ^+_P[$T< M6LW<&B1Z9J6DQL0OGQQPDI+$I(+ Y;D=!DB#_@H5X:\8:[\"O$7B#1/B"NE> M#8-,B^W>'%TB"X&I,UPA6073'?$/F3A01\OO5G]ISX_>$_BA\/=1^%?PVUC3 MOB#XU\90G3+6TT*YCO(+6)R!++=' M25IUT_2+.T$K\EQ'- FX^YQ04;T'B37_ -F?X*>(?$_Q2\>O\1FLR+BWFAT: M#3)"&54CM4CC)#LTAX8\_/SP*Y+3?!G[3?Q%L8/$5[\3]$^%LMPHFA\*Z?X; MAU184;YE2XN)F#>8!A6\OCKBNQ_:L^'6M_$OX"WMEX:A%WKVGS6FKV-FPQ]K MDMI5F\G.1@N%('(YQ4?@;]L[X1^,/#2:E>^--)\*7\8*WNB>(KV.QOK.9<^9 M$T4C*6*D$94$$CB@DX#X,_&/XN:G^U?=?#;XBPV.GQ:7X4DO'CTJ-39ZG,+M M%CO8F8&5 8WV&,M@,K?*.W2?LB_\C=\?O^R@7G_HF&O/?A'\<-,^.7[>5UJ? MA^UNO^$:LO L]MI^I7%N\*ZDOV^$O-$' S'O+(&P,E&]:]"_9%_Y&[X_'M_P ML"\_]$PT ?1]?+FH?$3XK?M!^/O$NA?"G6=/^'_@OPU>MI=[XQOM.6_N;R^C M/[V*U@_9I\2>+OA3\1[ZW$3'6[[6M#UG M591#9:K8W,ID#"=SL$J%BKJQ';&>: -.V^(7Q8_9U\;>'-*^*>MV'Q#\"^(K MZ/2[?Q?9::NG7>G7LIQ$ES!&3'Y3M\H=>G)8] >._:P\#_$'5_VGO@V^B?$S M^P(=2O;V/1HO^$?MKK^QY4L\S2[G8&?S!D;7P$SQ6W\??BAX>_:6U;PQ$/A MQJ5OXOO+C6+/5-;U;2)5FLM)L+>82.[3KE?,8J%55.>N2,C/6_M"_P#)RO[- M_P#V%=6_](304>Z>#=+U?1?"NEV&OZU_PDFM6\"QW>K_ &1+7[7(!S)Y*$JF M3_".!6K=7D%C:S7-S-';V\*-)+-*X5(U R68G@ #DDU-7D?[2WP:\0?'CX;W M'@W1O&G_ A5G?MMU&XCTXW# M[SXIFXNM+^&?AO6K&R\)V.-G]LS/=QPSZA*#G]W@LD70D$GCY@WZ45^>'[4_ MP-^+GP]_9]$&J_&^+Q!X8L;S3+2'0;?P98Z?'&!-B0L9VD+T.T"ON3 MX:>'?$OA?PA9Z=XO\5?\)OKT32&;6O[-BT_S@7)4>3&2JX4A>.NW)YH&>&?M M8_&;XA?##XH?"'1O %FFLW'B275+:;19EC$5W(L,8@:21E+I'&[F1MC+E5() MI9?AC^U!;VIUF'XT^&[K5@/,'A>?PM''IF_KY7VI3Y^SMNQFL3]L#X@3?#'] MH#]G_P 1)I%YK<%I)K9NK.PB,D_V?[-#YTB(#\QCCW28ZD*1WKTZZ_;,^"-G MX5/B!_B;X=:R$7G?9XKU9+S&.GV4?OMW^SLS0(;\*_VDK'Q9\)O$_BKQ5IDO MA/5O!SW-KXGTJ4[S9SV\8>3RS_&C(0R$==V.>I\Z\+Q_M%?M!Z3#XQL/'.G? M!7P[J">?H^AQ^'X=5O9;9LF.6Z>=MJ.PVL G9AD9%8W@#X4^)?C1\$?CSKM[ MID_AF_\ BE<3W&C:9??NI(K>. 1VC3*#\C2%06]5(/-=Y\%?VM_AW>>!K'2/ M%VOZ7\//%VAPII^K^'_$=W'82VUS$H5@@E8!T)&5*D\$9YS0!=^"GQ>\:P?$ M;4OA1\5;2P3QA:V7]J:7KFD*RV6M608(\@5ON2HS ,@XY) &3X=JOPG^,LG M[8EIIT?QW\K7Y/!]Q=PZW_PA]DWDV?VZ,&S\DOM;YB&\T_-QC&":](\ ^)[; M]I#]JBS\=^%8Y;GP%X)T>[TJ/7RACAU/4+ATWI!D9DCC1.6Z;B,#!4GI;[_D M_;2?^R=7/_IQBH*)OC%\6O&B^/-$^%/PS@L+KQO>6']IZGKFK1EK/2+'<8_. M:-2"\KN"$0<>H(Y',:MH_P"T7\$].G\5W'Q TOXRZ58QF?4?#MQH$.DW7D*- MTAM)8"=TH SM<8(! &<"N!_:B^$OPTL_VE++QC\9O#\VI_#WQ!I,.EPZV+F[ MB@TC48Y&PL_D.NR.:-QAV) 9#D 9:N6^(/PR_8H\(Z4@T#0+'X@^([QO)TWP M[X4\37VH7-Y.?NQXBN6$8)QEFZ#G!QB@#VK]K#]HS6_ OP9^'7C_ .',K:A% MKGB#356T2)&;4;2:*60VV61_+,FU5W*-RGI23^!OVI+S26\5'XG^&]+UE8OM M*^ XO#LQ8=^AQS67^TAX/TSP'\-_V>M T72FT+3+'XA:#% M!IKW#3FU7,K&,R,S%L$D9W'..N*^M9O]6_\ NF@D\-\.^+?%/[3?[//AGQ/X M$\6CX9ZUJ86>XO%TR+5!"T;/'/ (Y<*1YBGYNORUYA_P3S\%^.[#X8Z5K>I? M$7^UO!\KZE!!X5_L2"'R9Q?2JTWVH'S&RRR-L(P/,QT45V?_ 3U_P"32/" M[^=J7_I?<5?_ &#_ /DV7P]_U_ZK_P"G&YH 7]GKXSWVK_!OQAXQ\=ZPLT&A MZYK$!&\#V'A[QOKVG?#SQKX?@CTW5]#\2W M:6+QSQ*$+1M(P62-L;@5)X(S0!QNG_%?XW^#_P!ISX6?#'QS M+CCKZ=\*?^3UOCK_ -@K0?\ T3+04>V>/M%U[Q!X1U'3_#/B+_A$]=G0+:ZU M]BCO?LK!@2WDR$*_ *X/KFODO]CCX>_$RU^(7Q&O[SXL_;]&TWQM?6^M:3_P MC=M'_;-R+>(&X\X-NM\EH_D0$#R_]HU]KU\^?LE_\AKXZ_\ 91=0_P#1%M02 M8VJ?$7XG?'OQYXF\/_"?5]+\$^$O#=T=+U#QG?6*ZA<7-\HS)%:0$^65C) 9 MG/)/%>9_M%>.?VD/V8?A9JNHW/C#3?'VG7'DQ1>*(-&@L;[2)VFCQYEMAX9( M77?'G!(9U.1QGK/@O\3-#_9@\8^,/AA\1[Z'PNMYKEYKF@>(-2(@L-2M;AQ( M5\YCL26-MP8,1VQ7(_MY_M6>!]:^!_B+P7X,U>V\;ZKJ20F[FT-_MEIIUL)X MR99IH\HN6"HHSGX*69<@UT'C7XE>._@CX9\&>!(=6@^*WQA\4W4\&GWE M]9)IMH(D)>2YGB@X2&%"@*J=S\D'L(-?_P"3ZOAUZ?\ "#:AC_P(BY_SZU'^ MTC>3?"3XQ_#WXRW>GW.I>$M(M;S1-?DM8S++IL%P4,=V$')173:Y'(5NA-!) M'/\ #?\ :=T&W?7;/XP>'?$NI1J9?^$3O/"\5KI\C=?*2Z1_. [*S=^M5_V6 M_P!HWQ!XN^%/Q4\;_$UFTI?#?B+4$>Q:./=IEK!#%(;;*(AD9"9%#-EF.!FN M_P!7_;"^#&D:!_:H^(_A_4491Y5EIE\EU>S,?NHMM&3*6)XQMSGKBOGG]G_P M_JWQ^_9S_:1TS^SYO#^M^)?%FLF/3[L>5);3O! 4BEQT(8*K9_VNM '?>&K? M]HCX_:/;^,+'QYIWP7T#4$^T:3HO9WDTA(FMX(YY3Y M@0!27QU/&/E+ '&ZK\)_C+)^V)::='\=_*U^3P?<7<.M_P#"'V3>39_;HP;/ MR2^UOF(;S3\W&,8)KT_XE>,OB;XT_:&B^%/@SQSIOP[73= BUJ;5;K28KZZU M61I&0QQPRD*(UVY8KR">I[;U]_R?MI/_ &3JY_\ 3C%65\?M:^ OC_Q?=>$_ MB3K$'A3Q7X>@COM/UJ\N&TFZA60;EELKIBHD(*\JI8;E^Z<&@H]D^'MOXLU; MX?QVGQ"M=-C\0LLUK>?V3*SVTZ!F194W#*>8@#[3DC=C/8>8?L&S3_\ #,'A M>PG=I)=*GOM-W-_=AO)D4=3P%"C\*M_L>_$#7?''P-76/$6J3ZW!:ZA>VVG: M_>6_D2ZII\,A6&ZD3LS*#G/)VY.3R:O[!\<[_LR^'+ZX3RVU.[U'4%CP>$EO M9G4#/4;2.>X-!)]"4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% &)XP\)Z;X\\*ZQXY$_BWX9Z@?#UQ+P#=604/87( ) MPLEN4&3S^[;OFOI"OA[]O;4O&7[/.J'XO_#FS^U7WB32V\%ZO#$VPI<2,?[. MO@,'?)$YE09Y_>(,XH U_AK?)^U)^VMXE\;,!=>!/A*C^'M!8L#%<:Q*/],N M5&.J+B,'H1Y;#GIZ)\>OC=XRM_B-H?PC^$MCIE[\0M4LWU6]U/6BQL=#T]6V M>?,B$-([O\B(._)XKI/V2_@7#^SM\!O"_@S:AU."'[5JMQ&<^??2_-,Y/\6& M.T'^ZBUY)\7?$T?[,/[6D?Q8\46]P?AOXNT&#PY?ZW! TJZ+>0SL\+3[>1#( M'*[L<,!GB@"75_"7[5/P=L)O%5O\4=&^-4%H/.O/!][X8@T>26$?-(MI/ Y) MEVYV^9P<=">#Y/!/BQ;ZLVH^/-1\1I9SO\ 8K93>0_VA/%] MG\L1;$+)&B;E7=WSGFOHGXC?MS?!WP7X4EO=&\:Z-XYURX7R],\.^%;R/4KV M^N6!\N%8H2S*6; W, /QXKY"\,7TFI?\$W?@G=S)Y4]Q\1;661!D!6;6[@D8 M)SC)(H ^C/&=Q\>/@W^S?\5OB!XS^)UEJ?BD:&;[3-)TO0+:"T\/W"ABZ1R, M':Z7)1091_"<@[LCNOBM^T5??"/X!^$?$$>E2^+/'7B:.QTW1='AQ&=0U*XB M#*&VX"(,,[$8&!CC(Q/^W5_R9_\ %O\ [ %Q_(5YK\?-#UK3_@[\"?B;HVB7 M'B4?#NYL-9U'1[0;YY[!K,PW#Q)D!I8U8.H]F]\@%K_A5?[7LEC_ ,)$?CAX M3CU[_CX'@H>$XSH^[_GA]MS]IV_[6,^^*W/#O[3>L_$+]ECXG^)SIC^"_B5X M+T[5+/5M,E591I^IVULTBNFX,)(CE'4D,I!QE@"3T,?[=GP!?P6/$X^*_AH6 M/D>?]E:^47^W&=OV3/G;^VW9FO,?@/\ #?7OBQ\*?V@/%U]I5UX8/Q?FO'T; M3+_$4\5D;(VUM-*O(C>3+,1SQM.3D4 ?07[._BK5/'/P%^'/B36[G[=K.K^' M=/OKVY\M(_-FEMXWD;:@"KEF)PH '3 KSKX>_&#Q/J/[2O[1'AS4;R34_#O@ M^TT6XT?2X[>-6B:>RDFF4.J!W+L@(WEL=!CI7&_LJ?M8_"_P_P# 'PGX7\7^ M,=(\ ^+?".F0Z#K&@>)K^*QO+>XM$$+821E+AO+W#;G[P!YR*9^R_P"*[3Q3 M\0/VA_CW9V6I/X(URXLK;2)DM)'EU*WTVU:*2X@B WNKN6"8!)QC@@B@#)_9 MQ\:_M$_%SPOX8^+MMX[\)>(_#^NWH2]^'L>G);QZ7:&;RW,=^I,IGB7YVCD4 MC[PY.*^UJ_-_XA?$+X.^']6\+?$W]F[QI;V'Q'\4:W907'@?0KC='KRRS!98 M[W3L_P"CNJM(WFE4(()!)8-7Z04 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %4H_^0U/_P!>\?\ Z$]7*I1D?VS/_P!>\?\ Z$] %ZBDS1F@ M!:*3-&: %HI,T9H 6BDI: "BDHS0 M%)FB@#(UW_ %NE_P#7ZG_H+5J_C7DG MQV^.OACX.V^F'6)WN=1:83Q:=; -,Z ,I?GA5R<9)&><9Q7F'A+_ (*!>$]9 MU9;36M%OM!MI'VK>;Q<(H_O.% 8#Z;J]"EE^*K4_:TZ;<3RZN98/#U51J5$I M'U92U5T_4+75;*"[LYX[JUN(UEBFA<,CHPRK*1P01R"*LUP/31GIIJ2NA:** M*0PHHHH **** "BBB@ HHHH R?$G_'G;?]?MM_Z.2M:LGQ)_QYVW_7[;?^CD MK6H **** "BBB@ HHHH **** "BBB@ HHHH *R?#O^KO_P#K]F_]"K6K)\._ MZN__ .OV;_T*@#6HHHH **** "BBB@ HHHH **** "BBB@ K(C_Y&JY_Z\HO M_1DE:]9$?_(U7/\ UY1?^C)* ->BBB@ HHHH **** "BBB@ HHHH **** "J M.L?\>)_ZZ1_^AK5ZJ.L?\>)_ZZ1_^AK0!>HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@# \7>!O#OQ TN/3?%'A_2_$FGI*)EM-7LH[J$2 M%0X216 8!F&>N&/K6EINFVVDV%M8V5K#96-M&L,%M;1B..&-1A%50 %4 8 M '2KM5[S4+7381+=W,-K$72(23.$4N[!$7)[LS*H'( MK%!%:ZQ+I\37=N@SA4F*[U #-P#_ !'U-=-D>M4)O$6E6^N6VBRZG9Q:Q]P@N)8D(#NL>=S*I8 D# R* &:]X=TOQ1I<^FZSIEIJ^G3#;+9WT"3PR M#T9'!!'X5C^#_A9X,^'TLTOA;PAH7AJ28;96TC3(;4N..&,:C/0?E73W%Q%: MPR33RI##&I=Y)&"JJ@9))/0"J/A_Q+I'BW1[?5M#U6RUG2KD$P7VGW"3P2@$ M@E70E6P01P>H- &-JGPM\&:YXHM?$NI>$=#U'Q':E&M]8N]-AENX2AW(4F92 MZ[3R,$8[5>\6>"_#_CO2_P"S?$N@Z;XBT[S!+]CU6SCNH=Z]&V2 KN&3@^]6 M)O%FB6_B.W\/RZQI\6O7$#7,.EO=(+J6)3AI%B)W%0>"P&*NVNH6M]YWV:YA MN/)D:&3RG#;)%^\C8Z,.X/- '*7'P;\!7D&B17'@?PY-%H?_ ""HY-(MV6P^ M8,/(!3]U\P#?)CD ]JZF^L+?4K6:UO+:*[M9E*2PS('1U/4,I'(/I4UQ<16L M,DTTB0PQJ7>21@JJH&223T %5=#U[3?$VDVNJ:/J%KJVF72>9;WMC.LT,R_W MD=258>X- '/^$_A'X&\!7\M[X9\%^'_#EY*FR2XTG2X+61USD*6C0$CV)J_X ML\"^'/'VF)IWB?P]I?B/3TE$RVFKV4=U$L@! <)(K#=R1GKR:K:3\4O!>O>) M[KPWIGB_0=1\16I<7&D6FIPRW<)0X>&V\/ M7&CV%QH!@%J=*EM4:U,( C\H@KL &W&..E+X9\*Z+X+T>'2?#^CV.A:5"6 M,=CIMJEO F3D[40 #))/ [UD7WQ@\!Z7XF3PW>^-O#MIXB=UC72)]6@2[9F^ MZHA+[R3V&*ZZ@#,\2:'!XF\/ZII%T,VVH6LMI*!W1T*,/R8UYS^R[X;\4^#? M@1X4\.>,M/\ [/U[18&TYT6>.99(HG*0R!D)!#1!#@\]0>:['2?BEX+U[Q/= M>&],\7Z#J/B*U+BXTBTU.&6[A*'#AX58NNT\'(X/6NGH R]-\,Z3HE[J-[IV ME65A>:E*)[VXMK=(Y+J0# >1E +L!@9)SBG:]X>TSQ3I<^FZUIMIJVG7 VRV M=] D\,@]&1@0?QK%C^+O@6;Q0?#4?C7P[)XC#F,Z.NJP&[W#DKY._?GVQ764 M QW">%?"NB^&DN"#,NCZ?#:"0CH6$:KG ]:T]>\.Z5XJTFXTK M6],M-8TRX $UE?VZ3PR@'(#(X*GD#K6G10 U5"@ # P!7&^(O@UX!\8:LFJ MZ]X&\-ZYJB[<7VHZ1;W$PQC'SNA;C []J[2B@#%A\(Z);:Y'K<.BV$>LQV@L M4U%+6,7*VP;<(!)@,(]W.W.,\U)I/AG2?#\^H2Z7I-EILVH7!N[R2SMTB-S, M>#+(5 WN0!ECD\=:UJ* "L/Q5X+T#QQIAT[Q'H6G>(-/WB3[)JMI'#L M=2,CUQ6Y10!A>%? _AWP+IIT_P -:!I?AZP+[S:Z59QVL6[^]LC4#/X5/J/A MK2=8U/3M1O\ 2K.]U'3'=[&\N+='EM6==KF)R"4++P<$9'!XK6HH **** ,G MQ!X9TGQ;IIT_7-)LM9L&D20VNH6Z7$1=&#(VQP1E6 (/8@$'_%KX M;^(O$W[1?P0\4:9I_P!IT+PW)K#:K=>?&GV<3VBQQ?(6#/N<$?*&QWQ7>?\ M"F? #>)#XA_X07PW_;[2><=5_LBW^U%\YW&79NS[YKM** (U4]<8KEO%WPE\ M$?$"ZAN?%'@SP_XCN84\N.;5M+@NG13V4R(<"NMHH J66GVVEV<%G96L-I:0 M*(XH((PB1J,8"J. ![>E5V\.:4WB!==.EV9UM;8V2ZE]G3[2("V\Q>9C=L+ M-MSC(!ZUIT4 5;ZPM]2M9K6\MHKNUF4I+#,@='4]0RD<@^E7)<:3I4%K(Z]E+1H"1[$UUU% &5K?AG1_$JV0UC2;'518W M4=]:"^MDF^SW"?ZN:/<#LD7)PXY&3@UJ-@C!'%+10!D^'?#&D>$=)ATK0M)L MM%TN$L8K'3K9+>%"S%FVH@ &6))XY))ZT[0/#>E>%=-BT[1=+L]'T^)G:.TL M+=((4+L7$8CDU?3(+MD'H#(IQW_.N MLHH YZ'P'X;AGT6:/P[I<4^BB1=,E6RC#6"NNV00''[L,H (7&1C.:N6OAG2 M;'6K[6+;2;*WU?4%C2\U"&W1)[A4X022 !G"@G&2<=JU:* "LO1_#FE>'VOV MTO2K/37O[EKR[:TMTB-Q.V TLFT?.Y &6.2<#-:E% &+XE\':%XTTUM/\0Z) MIVO6#')M=3M$N(B?7:X(_2L>U^#W@33_ S=>';7P3X=M?#]VP>YTF'28%M) MF#!@7A"!&(8 Y(/05V5% &3)X7TB77+?6WTFQ?6;>!K6'46MD-Q%"3EHUDQN M"G&2H..!Q7GGQT\ >./$BZ'KWP[\1KH_B;0YWD&FZG-,=)U:%UVO!=1(>3T* MR;25(.,9R/6:* /CO1[+XLVOB%KGP]^REX \&>)WR@\87&M6+PJQP#(4MX1< M%3UVYSCK7OWP-^%4GPE\$OIU]J"ZQKVI7UQJ^LZFL(B6YO9W+RNJ#HH.%4?W M5%>C44 9C=L+ -MSC(!ZUF>+OAOX3^('V0>*/"VB^)%M&+V_]KZ=#=>2Q M(R4\Q3M)P.GH*Z:B@#S/X_:;XGG^!_BG2/ >D#4/$-[I[:;8VD47 MS(RJ%C1F;'^SP#TKI/ACX'MOAI\.O#7A2SYMM&T^"Q5O[WEH%+?4D$_C7444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 53OM-M=4MUM[VTANX%DCE$<\8=0Z,'C;![JZJP/4%01@ M@&KE% !52]T^WU*SGM;NWCNK:=&BE@G0.DBD8*L"""".,&K=% '$>$_@G\// M .K2ZIX8\!>&?#FI2J5DO-)T>WM9G!.2"\: D$^IJY#\*O!=OX;L?#L7@_08 M_#]C6FDIID(M;><2&02QQ;=BN'8ON SN)/7FNKHH S=>\/Z9XHT>[TK6= M.M-7TN\C,-U8W\"S03H>JNC AE]B,59L[*'3[6"UM8([>V@C6**&)0J1H!A5 M4#H . *LT4 <&WP'^&LGBK_A)W^'GA1_$OF_:/[8;1+4WGF_W_.\O?N]\YKN M I7''3_/^%244 <3XM^"?P]\?:Q%JOBCP'X9\2:I"H2.]U;1[>ZG11T"O(A( M /O776MK%9PI!!$L,$:A4CC4*J@=@!V JQ10!R.C_"?P1X<\57GB?2?!GA_3 M/$MX6:YUFSTN"&\G+'+%YE4.V3UR>:ZZBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@!M?._CSXC?&S1_'NL6OAKX>V&K:/%L6WNIIL-+&,G M<1YHQR7'3L*^B!5)/^0Q/_UPC_\ 0GK>A5C2DW*"EZG+B*,JT>6$W'S1\U_\ M+:_:._Z)7IG_ '_'_P ?H_X6W^T=_P!$KTS_ +_C_P"/U]0_YZ4?YZ5W?7*7 M_/B/X_YGG_4*W_01+\#Y>_X6W^T=_P!$KTS_ +_C_P"/T?\ "V_VCO\ HE>F M?]_Q_P#'Z^H?\]*/\]*/KE+_ )\1_$?U"M_T$2_ ^7O^%M_M'?\ 1*],_P"_ MX_\ C]'_ MO]H[_ *)7IG_?\?\ Q^OJ'_/2C_/2CZY2_P"?$?Q%]0K?]!$O MP/E[_AF #[DY[UPE???[5?[*LGQ(UJ#Q3X8DAMM>N"MO<6DWR)L);ZO96WAZRWXDO)KF*<[>Y5(V8L?0 M$CW(K[_!YM@OJR;DHV6Q^:8[)L>L7)*+DF]SZ8_85US4-7^!Z1WS.\=EJ$UM M:O(228MJ/U] SN!Z8Q7T3WKF/AUX!TWX9^#]-\/:3&5M+*/;O;EY6/+2-ZLQ M))^O&.E=17YMBZL:V(G4@M&W8_5\#1G0PT*4WJDKBT445R'<%%%% !1110 4 M444 %%%% &3XD_X\[;_K]MO_ $IMI, M/^3WOAQ_V*.K_P#H^WKS3X6>&_%W[+7[22Z;XU\8IXQT7XJ!W&L+I4>FI'K4 M(X1HHV9$,L60&!!=@.,@D^E>,#_QF[\./^Q1U?\ ]'V] CW[;N&,<5\?2>+- M/_89^+NO6.NS26WP?\9?:-:TJ9(RR:1J:J7N+0 #A9@-T8'\0"@?>:OL2OC3 M]H7PS??MJ?$G4OA)HNJ-I?@KP?$;S6];AC$@DUAD=;:T7/!$88O)@YY*_*P! MH&CO?V4_ NL:]=:Y\:_'-C]E\;>--OV.Q?DZ1I"X^SVJY'!8 ._]XE20&!%> M$67C;QU\&_VC/C;\0M+2;Q!\.K#Q%!:^*O#]NA>>W@:TC9=0@!/+1XPRCJN, MY #1_2_[+/Q>U#XC>#;WP_XJ5+3XC>#[C^Q_$5BN!F5,B.X4#K',B[@1QG=C M@"N=_9KA2X^-'[1T4B!XF\36RLK#*L#9ID8[@\T"/6]1\4:5XV^$FH:]H=]# MJ>D:CH\UQ:W4!RLJ-$V#^N"#R""#TKA/V(_^34/AE_V"5_\ 0VKQOXAZ??\ M[$=UKUYIEO/?? GQ0)X[K3[>-I&\*WTL;!98E&?]%DO)R>:]5_:*@\=WGP>U^R^&T+/XPO$CM;259HXFMUDD5)9@SNH# M)&78^''_8HZO_ .C[>OH#- '@VF_L3_!C3?A__P (S>^! MM'U!6MS%0*^HRN1\\QNB/,5RP+95@ >@ XJK^PSKFIZS\!;:._U677;' M3=4O]+TC5;AMTEY803M'!(3@9X4KGT45A>./%6L?M5^*-2^'?@+4[C2OAYIT MYM?%OC*R8*UTP'S:=9-CYF(.))1\J@XR%M7FN_[ M+L8K;[1)Y]N2\FQ1N/7DY/-=/^V1XMUS0/A38:)X9O)-.USQCKEEX8MK^'/F M6PN7(DD4CH1&KX;MG(Y JOXP_P"3WOAQ_P!BCJ__ */MZJ?MN2OH?@3P/XL* M;M.\*^-=)UC47"%O+M5D:.1^.1CS0 ]+A3R!$NL MI HU17 XF%WCS-^?FSG&>,8XH_8U\9ZYXD^%%[HGB6_;5/$/@[6;WPQ>7TC% MI+C[,X$]MTTQ(#-*HA$07<9"^<; M=O.[.,)_ZZ1_\ H:U>JCK'_'B? M^ND?_H:T 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X3 MXP_"'2?C9X13PUKUYJ$&BM>P7=U;:?(D8O5B<.()2R-F)F"E@NT_*/F%=M#& MMO&L<:".-0%5%7 4#@#CL/Z5+10!P7QA^#^C?&SPG'H6M37EB+>]@U&SU'3' M2.[LKF%]R2PNZ.%;JN2IX9AQ7+?&3]F/2_C)XGT+Q#-XS\9>$M:T>TELH;WP MGJ26,LD2TEM5M? M$GB!;VWCW@ 2K&80/,7'RDY R<@UV'P:^#>A? [P7'X;T%[RZA-S->7%_J4H MEN[NXE!D*.%%=[10!YZWP6T6/XR)\2[.ZU#3=>DT_^S+^WM)(U MM-2B!S&;A"A+/&?NLK*0.#D<5;\#_";2?A_XI\::_I]S>S7GBS4(]1ODN71H MXY$B6,",*BD+A1]XL<]\<5V]% &?K6C67B+2;W2]2M(;_3KR%K>XM;A \2!NP"\36-)TZXTR"%'3[.T4S([LZ[-Q8&,8(8# MDY!JQ\2O 0^)?@G4_#4FMZMX=M]0C,,U[H*O&?GW377V[Q=J?VZYCRBKY:2;5VH-N=N.K,>]=Y10 M!QFH_"W2]4^*FB>/I9[Q-8TG3KC3((4=/L[13,CNSKLW%@8Q@A@.3D&NCUO1 M[+Q!I-[IFI6<6H:=>PO;W%K<)OCEC8%61E/!!!-:%% 'S+'^P+X$0C3G\3^/ MIO!>_WM;= M D4,:@!451P *OT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5*/_D- M3_\ 7O'_ .A/5VJ4?_(:G_Z]X_\ T)Z +M%%% !1110 4444 %%%% !1110 M4444 9&O?ZW2O^OU/_06K7K(U[_6Z5_U^I_Z"U:] !1110 4444 %%%% !11 M10 4444 %%%% &3XD_X\[;_K]MO_ $/\ ]">@"[1110 4444 %%%% !1110 4444 %%%% &1KW^MTK_K]3_T% MJUZR->_UNE?]?J?^@M6O0 4444 %%%% !1110 4444 %%%% !1110!D^)/\ MCSMO^OVV_P#1R5K5D^)/^/.V_P"OVV_]')6M0 4444 %%%% !1110 4444 % M%%% !1110 5D^'?]7?\ _7[-_P"A5K5D^'?]7?\ _7[-_P"A4 :U%%% !111 M0 4444 %%%% !1110 4444 %9$?_ "-5S_UY1?\ HR2M>LB/_D:KG_KRB_\ M1DE &O1110 4444 %%%% !1110 4444 %%%% !5'6/\ CQ/_ %TC_P#0UJ]5 M'6/^/$_]=(__ $-: +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !5*/_ )#4_P#U[Q_^A/5VJ4?_ "&I_P#K MWC_]">@"[1110 4444 %%%% !1110 4444 %%%% &1KW^MTK_K]3_P!!:M>L MC7O];I7_ %^I_P"@M6O0 4444 %%%% !1110 4444 %%%% !1110!D^)/^/. MV_Z_;;_T/ M_P!">@"[1110 4444 %%%% !1110 4444 %%%% &1KW^MTK_ *_4_P#06K7K M(U[_ %NE?]?J?^@M6O0 4444 %%%% !1110 4444 %%%% !1110!D^)/^/.V M_P"OVV_]')6M63XD_P"/.V_Z_;;_ -')6M0 4444 %%%% !1110 4444 %%% M% !1110 5D^'?]7?_P#7[-_Z%6M63X=_U=__ -?LW_H5 &M1110 4444 %%% M% !1110 4444 %%%% !61'_R-5S_ ->47_HR2M>LB/\ Y&JY_P"O*+_T9)0! MKT444 %%%% !1110 4444 %%%% !1110 51UC_CQ/_72/_T-:O51UC_CQ/\ MUTC_ /0UH O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M4E&: %HHHH **2B@!:*** "BBB@ HHHH **2C- "T444 %%)2T %%)FB@!:* M** "BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BDS10 M%%% !1124 + M1110 4444 %%%% !1110 444E "T444 %%%% !1110 4444 %%%% !1244 + M1110 44F110 M%%% !1110 44E% "T44E "T444 %%%% !1110 4444 %%)1 M0 M%)FB@!:*** "BBB@ HHHH **2B@!:*** "BBB@ HHHH **2C- "T44E " MT444 %%%% !1110 444E "T444 %%%% !1110 4444 %%%)F@!:*2B@!:*** M "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HI,T4 +1110 4444 %%%% !124M M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4H_^0U/_P!>\?\ MZ$]7:I1_\AJ?_KWC_P#0GH NT444 %%%% !1110 4444 %%%% !1110!D:]_ MK=*_Z_4_]!:M>LC7O];I7_7ZG_H+5KT %%%% !1110 4444 %%%% !1110 4 M444 9/B3_CSMO^OVV_\ 1R5K5D^)/^/.V_Z_;;_TI:CHUHM[74[...2ZLXY5:6 .#MW@'(S@XS M6JS!5))P!ZTK-:,I235T)D4O&*YGP#\0-%^).@#6="NUN[$S2P;^A#(Y4Y'; M. 1Z@@]ZZ7(-$HN+LQ1DIKFCL.HI-P]:-P]:10M%)1N'K0 M%)N'K1N'K0 < M4GY4?Q5Q7Q2^)5M\+=#L]3NK.6]2XOH+$)"P4J96VAN>PJHQE-J,5JS../%GAUO#^I:8NA2I&+ZZCVPW6[.2GY9'7((/&<4>RGKI MLD_O_P"'!5H.UGNVOFM_R.^HI,CUHW#UK,W%HI,T;AZT +12;AZT;AZT ':D MSZF@'WKB_B%\2K;X?7OA>WN+.6[.O:M#I,31L!Y3R9PS9ZCCI51C*;Y8[FM>HV:^:,H M5H5':/9/[]BW129'K1N'K69N':DSZFC=ZFN+^(7Q*MOA_?>%[:XLYKMM>U:+ M2HFC8#RFDSAV]0,548RF^6.YG.I&FN:3T.VHI-PQFC:7- "T4FX>M&X>M !2C=[UQGB#XDVV@?$CPMX/DLYI;G7HKJ6.X4 M@)$(4WD$=3D57\&_$M_%OCCQ9X=;P_J6F+H4J1B^NH]L-UNSDI^61UR"#QG% M:^QFH\UM+7^5[?F8*M!RY;ZWM\[7_([ZBDW#IGFC'M1O4UB*23^U+=,V]OL#'#'\.>>,KUS7><9//UJG%Q2OU,XSC- MM+IN/HI,CUHW#UJ306BDR*,CIWH ;QFCWKB_$7Q*M_#_ ,1_"W@][.:6YUZ* MYEBN%("1"%-Q!'4YKM#5.,HI76YG&<9-I=-Q01ZT?2N-7XDV+?%1O 8M+C^T M%TC^V/M'R^3Y7G"+9USNR<],8KLM&1ZTBQ:*3$YK:XEO?$8N MC;S1A?+C\B/S&WY.>1TP*[$]LU3C**3:W(C*,FTN@HZ4GZUQ/Q<^(TOPN\)_ MVW'H=_KY%Q'!]DT]-TGS$C<>.!V^I [UU]GM&:DT$SFCMTKCO /Q&MO'FH>*+6WLY;5M"U632Y&D M8$2N@4EAZ#YJ['/O52BX.TMR(2C-*_#S>'M2TQ=#E2,7UU'MANMV>4_+(ZY!!XZ52BY)M=#.52,6 MHRZ['?T4FX=,\T;AZU)H+129'K1N'K0 M%)N'K1F@!*/RHXKEOB5XX@^&O@? M5_$MS;27D&GQ>:\,3 ,PR!@$].M.,7)J*W9$I*$7.6R.JHQ5#1M276-)L;]% M,:74*3A&.2H90V/R-7]U+;0I/F5T+129%&X>M Q:*3M.47"3C+=$0E&<5*.S'44FX>M&X>M(L6BDW#UHW#UH 6 MBDW#UHR/6@!:*3YG&I&4>=/0U M/YT"N?\ OBR/QSX-T;Q!#"]M#J5K'=)#(060.N<$_C6^2%RXXR M4HJ2V8^BDW#UHW#UI%BT4FX>M&X>M "T4F1ZT;AZT +12;AZT;AZT +129%& M1ZT +12;AZT9H 6BDR/6CBN8^(_CK3_AKX+U3Q+J:N]II\7F,L8! M9V)"JH]V9@/QK+^%_CW6_'5O=S:OX/O_ H$6.2 7LJ2?:$<,01MZ$8&5/(W M"M%3DX>TZ&#K0C45*_O'>T4F:-P]:S-Q:*;N'3(I*?'GB_P +V]K<0W?ALVHN)I OER^?&SKLP<\; M3G-=@#[8JI1<7:2(C*,U>+_I:#Z*3:7- "T4FX>M&1 MZT +129'K1N'K0 M%%% !1110 4444 %%%% !5*/_D-3_P#7O'_Z$]7:I1_\ MAJ?_ *]X_P#T)Z +M%%% !1110 4444 %%%% !1110 4444 9&O?ZW2O^OU/ M_06K7K(U[_6Z5_U^I_Z"U:] !1110 4444 %%%% !1110 4444 %%%% &3XD M_P"/.V_Z_;;_ -')6M63XD_X\[;_ *_;;_T6'J*I$Y<1AXXFFX2/+O@S\.]4^'7]K6%Q%I-SITAC MEMM6M8&BO[PG<6-WG.^0++@:1IZ*< M%5? FD)[*J'&[^$N#VKV3<%'/%?*,/A_Q3^T3\9]<\8>&O%*^%M*\*RG1](O MCIZ7RS/M(N'178*,[OO8.05]*[,._;577JO2.OSZ+[S@Q*]A16'HJ[D[?+J_ MN_$UOA/H/_#.'QF_X0#SY9/"_BBR2[TN>8Y_TZ% LZYZ NJAC_VS KW7XD>( M[GP?\/O$VNV2Q27>EZ9=7L*3@F-GCB9U# $$KE1G!'U%?//Q?^!?Q1N/#0\0 M7/Q,'B74?#;_ -K6%H- @M',L?S';)&Q;[H.%.0QP#V(]+\2>.K/XD_LM^(_ M$MEA8=0\,WLA3.?+D%O(KH?=6#+^%:5H^V<*U[W:4O7_ (*,!_BA\3OC9X9T[4_"=CHOA_3S;1B[U;58I7%S=;!YJVT(;B-'W+O< MG)7 Z&NK^%_Q/\0W?C;5O GCBSLK7Q396ZWT%SIF\6M]:LP7S$#G(*L=I'KG M'2M?]G>S2Q^!G@:.-%16TFWE(7H2Z!R?J2Q)]S7(:Y@_MB>', !O^$5G!/\ MVW_QJ9.G.=2FH))7MWT+A[2G3I57-MNR?;4]UKQ[XF?&'6;'QE;>!/ FDP:[ MXPEB%Q'O%?AZ$;[V#05EBO;:, EI(U<[9%7J5^\>V.M=%\"/B[/\3/AG M<>+-9-G910W5ROF0JT4:P1GAVWL<';R3G'M7I&JZA:Z5IMU>WLR6]G;Q-+-) M(<*B*,EB?0 &OE3X5V =.T?P]X25VCM=4 M\11RO<7V#CS(HUP%3C^+/USD#SOX]>.O&MOI.@^$_'^CV<&HRZY97-AK.BN[ M6=VJ2 .A#?,D@W X/!R<8QS]#_ _7-(U_P"$OA6YT1XFL5TZ&$1Q-GRG1 KH MV.C!@0:\X_;$U?3+?POX4T^YEC.IW/B&SDM8=P\SY'^=\?W0#@GIE@.];X>< M?K2I*FDD_FK&.(IR^JNJZK;:^3OY'H7Q>^+%K\*M#M)A93ZQK6I3"UTS2+4_ MO;N8]AZ*.I;'&0.I%<:K_M"-:+JNSP2)-N\Z%_I&[;UV>;G'F?PYSLSSTJ'X MK75MH/[1GPIU?666/1VAOK*"XEXBM[MT4+N)Z%Q\H]P?2O>..W2N1R6'A!J* M?,KZ^KT.R,7B*DTYM*.FCMT6I\R_ GQJ_CS]HOQUJ4^FW&CWR:3:6]WI]T 7 MMYHV*NF?X@",AAP00:]%^%?Q$\1?$GPSXUF2+2[;5=+UB_TK3LQR" ^4 (FF M&XL?F;YMI''0"N1^&VL:7K'[6'Q,DTN6.=(M-M(+B2)]RM,F XR.XX4^ZD5I M?LH?\@3X@G_J[G?Y,X'X3Q_$]?C]\3Q M%/X3^WK-I0UHM#=>44\E]GV8;\AMF<[SUQ7LWP_^(NI^*OB=\1O#MU#:QV7A MR>SCM9(482.)8F=O,)8@X(P, ?C7+_"#!_:0^.9_V]'_ /29Z/@QQ\?/C>/^ MGK3?_2=Z>(2J>TNM5&/X\O\ F&%O25-)NTIRW=]N;_(F\4?%WQ5XF\Z60-5US6'86-FY&1$ AW/)U''W2,$'G&5J7Q0^)GP;FM[[XC:;H^L M^$7=8KC6O#HE62Q+$!7FC?[RY./E'XYP#/\ LISP6>F^.=%N<+XAL?$MY)J$ M3\2.78%)L==K <'OM.*[;]H'6-,T7X+^,9=6DC2UDTR>!%D;&^1XV6-5_P!H ML5QC^E9ODA65!4TUHO-^=S9>TJ47B'4:>K\E;HT8_P ?OC3+$?"WAGQ!9+: M76G:AK-M:W*:6Y=,<"X=" C'KM49' )SFO/?B9H5W#\!_@)I6JQM]I_M[1;>>"92K* M#!(NQAUR =I^AKZO4'9@#MQ42<,/3CRQ3;;6NNQ5/VF)J2YI-)).RTW1P7P9 M^*2?%3PC)?S63Z5J]A(]4L/ MAAI^E0:#IDK6USXEUP2-%/,"05MUC/S8/.XY!!Z#(W5_@;;W%SJGQP@LW$-U M)XBNTA?^ZYB&&_,YK9_9%O+&3X%Z#8VR"WN]-::TOK5AB2"X65RX<=F.X-SV M854Z<*7/4C&]FK+>UU?_ (!$*E2O[.E*5KIWMN[-(Y#XA?&SXH? _P -W]QX MNTC1=5,J;=,UK2DE-L)\\1W,18,NY0Q#*<9P.><:7QSU"75H_@??S!5FNO%. MG3,L8(4%D+'&3TYK;_:^U;3=-^ /B5-0= ;I8[>VC)^9YC(K*![@*6^BDUS? MQ@_Y!'P$_P"QCTO_ -%&MZ/+*,*O)RMN2?G9&%=RA.=)SYDE%^EV?1O89KS> MU^(VI3?M WG@=H+4:3#H"ZJLP1O/,IG$>"V[;MQGC;G/>O2?2O"G9=)_;.5I MW$4>I>#2D)PI,"49XXF=0P!!*Y49P1]17FOBSXU:WH/[+L'Q' MM[73VUR2QLKHV\D;FVW321(XVAPV './F],YKKOC]?V^G_!+QW+9629=(TG&?#DJ[K&37(99;J^0? M=E**0(HW[ Y;!SW%=)\&OBCJ'C>;7M"\1Z?#I?C#P]<+;ZC;VI8PR*P)BFBW M$ML8 D \_F*[[P_8QZ?H>FVD:"..WMXXT1!@ !0 !^5>.^ E_P",K/BCC'_( M,TW/UV&B\*T:D5%+E5UWW2U[[E?O*,J4G-MR=GVV;T^XL>*?C#XH\2>/+[P7 M\,]+L+^_TP@:KK>K,_V"S8C_ %0"?,\GL#\I!R#@XYGQ]XR^*7PY$ZP_CC3 M]&\0>&KJSFMY=3\/K)'/8LZ%5>6)S\T>Y@,KR.2>PK7_ &6;FVL?^$^T*Z94 M\2V?B6\GOHY.)91(P,B_&75M+T7X6>*KG698XK#^SIXW\Q M@-Y:-E5!GJS$@ >I%:UC$=ZC-&1).$8X5E.0&R.>W>O2/C5\2-:\&KX;T3PS:6= MSXF\1WILK.346*VT "[GD?'+8&,*.3R><8/A_C#_ ),*\/>OEV/_ *5+7T7\ M3OA=I/Q4T"'3]1EN;.YM9ENK'4;*0QW%G.OW9$;U]OZ@$:552C-3FOM2O^%C M.C*M*FX4W:T8-?C/>V<>4\+Y.[J= MP(7&!R37.>*/BWXH\2>-M0\'_#/2;&_OM+VKJFN:O(RV-D[ XC 0[I).#G'W M3P>^(_AKXQ\6^&?B1NG$?B2R\1WDU_#)Q))O8%)L=2K <'VK)T^1RJRBG:UK;:] M?ZZFL:KFH4HR:NW=O?3I_70?JOBCXU_#:$:IK.D:#XXT.,@W,&@1S0ZA&"+["41SQF.1VC]4=)\7/B]<>!]0TKPWX>TAO$?C76 QLM-5 MPB(B]9I6_A0<^F=IY&,UR]]JW[0'A:U;6+O3O"'B:VC_ 'EQI&DFXBN=@/*P MN_#'&3SDGH :;:W$.C?MA:A_:Q$&HX]*DEP%8)+F6)">K?*6QZ"O=YID M@@DEE=4C52S.Q 50!G)/I2DXT%"*@G=7N^MQPC+$.65O:O*;20A)%F!V^4_7:=Q )YX.1FL;P;K'QJDN=#U'6+# MPMJFBZFR-%?B@9K5+KPE MXA\37[6L;*1'<0,%5I$/]TD$ CH5/I46/$_[,>M>';'^V)/%'PZU748=)A@O MQF^TMY,B,+(/]9&,8P1P !GD[>SIQUJ25.M-M1MK;U M[=F=O\7?B]?^#]8TCPMX5TA?$'C36 TEM:22;(8(ESNGF/78#G R,X/(QSS= M_?\ Q_\ "=O_ &O<6WA+Q5;1C?8U:98Y#YL +JP)_C(&#@?2N_;X'ZY'&S/\6_ M%ZHHR29+?&/^_55RT:,(+2[5W=-[]B7.O6G-J]DVE9I6MY'8^!/B5HGCSP#: M^+K.9;?2YH6EE,[!3;[,^8K\\%2#GZ9Z5Y?H_P 2_B;\9&N-2\ :=H_A[PDK MM%:ZIXBCE>>^P<>9%&N J^$OA6XT22)K)=/AB$<;9\IT0*R M''1@P(-92C3HJJ[FT9U:\H4ZDK:7TZ]-&?._P >?'/C6WTG0?"G MC_1[.#49M(;.2TAW#?\C_.^/[H!P3TRRCO7T"O^K SS4XB2E0IR4;:O M]"L)'DQ%6/-S*R]>NYXU\>OCE=?!WQ)X)@2P34+#6)+N.XACB>2Z=D1/*2'# M !F=PO(/4=,54CF^/^K0G5(8?!>C!@7AT.\\^9U4\A994X+^Z?+S6;^T3JVF M:%\9O@G>:S)'#I\=_>J\DC;41V2)8V)/ B9YM\'_C!_PLB'5--U73)/#WB[19!#J>D3-N*$C*R1 MM_%&W8_S!!/F/PT^,WQ3^-^EW/\ PCECX?TNH/$/[7WB"]T>19;/2_#$>GZE+#\R?:VN-ZHQ'&X(/K\I M':C]B^U%O$)Y H7S]8O)"1U;]YM!/X+C\*VE&G3A.HH*_NVOTO>YS0J5:U2 M%-S=O>U76UK&M\0/BWXDC\:0> O 6EV>L>+?LRW5_?:@S)8Z=&2 &<*=Q9LY M"@Y *GG)K"UOQA\:/A7:OKOB.Q\/>+O#-N/-ODT198+RVB&2TBJ_RLJCZDX[ M#+5ROAGP)>:U^T)\5;%O&.M>%M7DGMKR)=-:)?MEH8\(_P Z,6"$[>#@%N:[ M[7_@S>Z=H=_EQ0.]T]Q);>6(\$ONS%TVYJW&A1<8.SNDW=-O5=& M1S8BLI35U9M+5*UGU_4]9\.Z]8^*M#T_6--G6XL+V%;B"5?XD8 CZ$9Y'8UI M_=ZFO%/"GPUU"V^#?AC2/AG\0KC2--B+W,.JW.F0WCW,$C.X7:X4* 7R#C. M*T_#_P /?B-H\.N-KOQ)_P"$JCN--FM[:S_L2"R\JX8#9+YD9).,,-O3YL]A M7F2IPN[2TO\ /<]:-:HHKFAK:[[&$WQ:\;?%/7=2LOAAINDQZ%IL[6MQXDUX MNT,\RD;D@CC.6QG[QX^G&7?$I\6_AWJ]@GB[0M,\7>'[J=+5M1\+Q3"[M2Q M"B26$YW*3UV=.3GH#:_9%U73[SX%Z%I]F1'>:69;2_M&XEM[@2L65UZ@G.>> MQKU[4-0L]-C22]NX;6)W6-6GD5%+DX503W)Q@=S715G&G4=)032T\_4YJ,95 MJ<:SJ--I/R]+'C7Q(Y_:E^$/_7GJW_H@5T_P^^(VI^*OB=\1O#UU#:I9>'9[ M..TDA1A(XEB9VWDL0<$8& /QKF/B2O'?C[Q1XO\)>&M$TN37- M(UNZM/[1NUECLK.RC?9$\V&)DF=A( J[0=A. :W(OB1X]^&/C/0-+^(BZ/J M>A:_G8_[Z85;]FZWL(P5G]][?YD1=7ZO]8=1W M7W6O_D=3XN^(VIZ'\9O GA*WAM7TW7H+Z2YDD1C,GDQ;TV'< .>N0<^U1_%G MXO3>"-0TKP[X>TEO$?C/6 QL=+601QQHN=TTKG[J#!^NTXQC-KY&[ [#WK.- M&'NR:^RW;OJU_7H;2K37-%/>25^UTBU-'^T%IL!U!9/ ^IR ;GTF..YBR!SM MCE)^\>GS8 P/>N\\ ^/G\6>!_P"W]9TB[\)S6_FB\L]44Q_9S&2'.Y@ R8!^ M<#IGTKM&; ZUYO\ &P2>*_@?XUBT"XCO9I-.N8U^R,)=[*I$D8V_Q'#+CKDU MS$E( MHY9+B^VG'F11K@*F1_%GIUSD##\:?'[XB_"DZ9HWBO0-).LW]_!#9ZO8K))I M]U"S!95VEP\:_MB:MIMKX5\(Z=1N&QCO8#T"MC/JXKLHN$\0J# MIJU[>9PUHU(8;ZPJKYK?+7R-'XCG/[4GP@/_ $Z:K_Z(%>YG[O'6O#/B-_R= M)\'_ /KTU4?^0!7NG\-3=?8OLOVM>-N_?YF_OG&.V:]D^*GQ@N_ DVB>'='TH>(_'6LJ1;:= M"Y6*/ ^::1NJQ@YZ]<'D8)KGXV'_ VI-Z?\(,/_ $N%,CEBT7]L*X;4_D;5 M?#"1:5,XPI,1Z5URY:LDY1VC>RZG!!2I1DHSWE:[Z?\$DN+SX^ M>'8_[5N;;P?XC@C >?1=.\^"8KW$,CY!;_?]Z@^&?[0E_P#$3PG\2=>AL;>" M#P^93I\,L#I(0L!D G&\_-N&#MQ_6O>6(4X9LD'T(J*?)6ISU:7B+X MQ>+/%OCK4/!_PQTNPNYM);R]5U[62_V*VD[Q*$.6D'Z$'C'-;O[,-HMG\ ?! MB*NS=8B0CW9F;/XEJY?]DNXAL=$\7^'[DK'XCT_Q#>/J43<2.7?*3$=U8+@' MH=O%54]FIU)1@O==DOF]633=1QI4Y3=YJ[?HEHBMXO\ B=\5/@OH,^I^+M+T M3Q%H_E,HU+0XY5>TGVGRVGB8_-&7V@LA7 .>N >[\,_%J'_A1NG_ ! \3F&T MC;35OKI;12%W'^&,,Q.2<*H)SD@9JS\>->TSP[\'_%]UJS1BU.FW$(60C]X[ MQE$0>[,P%>"^.-.GU#]A?PP4$K6=O;Z?/>B!0S^0)%WD @],ACD8 !ITZ=/$ M0C*4;7DDVM-!5*E3"U)QA/F2BW9ZM.YW>C>(?CG\1M,CU[1[3POX2TNX436- MAJXFFN9(R,J92HPN00> ".XKI?A;\6]9UGQ5?>"?&^D0:#XRM(!=I]DD+VM_ M;EBOFPEB2 #_ DD_D0M'2_@[J>K:;:7EE\7_%EQ97$2S0RPRVS(Z,,J5/E= M"".E9NC?"W1-*^-WA^XU+XBZUX@\7Z;:37-MI^H&$DV[JT;EMD0^7+=SG(XH MG[":E'32]K)W^80^L0<):ZM7O)6=SC_BPGQ);]I#X<".;PN+HRZN=!+0W/EK M#Y W?:AOR7\O&#'@;L]N*^F?#ZZJ-%L_[;:S?5_+'VHV"NL&_OL#$MCZFO'_ M (J8/[3WP2'^QK/_ *2"O#I\M6L[M^]^B/-_C_P#$ M34OA7\,K[Q#I4%K@0Z?J,MQ:7-K,MU8ZC9R&.XLYU^[(C>O7(_J 15.-*,*N%T[^T]-UZWB\I[B 2 M>6RSH. X/<<8]25E^8EF5@$7DX)Z"N[\1^,_B[\*K,Z_P"( MK'0?%WAJW.^_CT*&:&]MHSU=%=BKHG4YYQU( +"C^SAK>F_\+2^,>CEXTUC^ MWY+K83AW@SM!'J%;.?3>/6O;_%6MZ9X;\-ZEJ6LS10:7;0-)I%5E#V:>B]7HMCS<-3E*@ZGM&K-^BU9D:E\3O#VF_#F3QNUZ)?#Z MV0O5N(QGS$(^4 '^(DA0IYR<'FO+=&\0_'/XC:9'KVCVOA?PEI=PHFL;#5Q- M-H>']2_X8-TE;F*>*SCNDOIH%4M*MDUXS \YR & M#YQC;[5[7I?P=U/5-.M+RP^+_BRXL[B)9H989;8HZ,,JRGRNA!%5[*EATVVK M\S6JNM+$>VKXF<8V=N5-V=M7_D7OA;\7-9UCQ5?>"?&^D0Z%XRLX!=I]DD+V MM_;EBOFP$DD '^$DG\B%T?A_\1]2\5_$WXB^';J"TBL_#L]G':2PHPD<2Q%V M\PEB#@CC 'XUQVC?"W1-*^-GA^YU+XBZUX@\8:;:3W-MI]^823;.K1N6V1#Y MHJ4Z7+.4%]E/YW2T-J=2LG3C-_:: M[W5F]3!\._'KQUX^\4>+_"7AK1-+DUS2-;NK3^T;M94LK.RC?9$\V&)DF=A( M J[0=A. :W(?B1X]^&/C30-+^(BZ/J>A:_3CCQ7I MV/\ OIA5-4W65",%9_?>W^9G'VJP_P!8=1W7W63_ ,CKOC)\7H/A5I-B(=/F MUGQ#JLWV72M(MO\ 674O&>>RC(R?<>M0KO_ +#'VA7 MZ[!-G;O_ ('_ 1^/FH_ M%CQ_XHT:ZT9=%MM)MK=C:7$;"ZAN&++,DA+88!U.TA5)&,U[BWRU\\?"'7-, M\0?M2?%JXTMDF@CMK&WDEC/RO*BE7/\ WTI7_@%>\Z];W%YHFH06DGE74EO( MD3_W7*D*?SQ4XNG&%51BN5-1?WI%X*I.5%RF^9IO\&>*M\7?''Q4\0:GI_PO MT_2H=#TR5K:Y\3:YYCPSRCAEMTC(W8Z[CD$>F1NX#]H#QK\1/"GPI\0Z%\0- M+TR_T_5+?R;+7_#^\1I,'#".>-^5+!3AEX! '.7,[QJ$C7W)_( GG&*Y2WN/V@]8L5U:*/P9HA?\ M>1Z)=BXED"GG;)*O&\?[. !_@W>7-_/I6CVNIV7VK4+?;NM M&:$".ZOLQN5:K4Y M%>R2V=NF_F:/PC^+%S\0/[8T?6=+_P"$<\9:(RQ:CIDC!T&Y M/4@@E/@C\3=2\?6>OZ=XBM[.R\5^']0DL=0M[)66(C),H6]\8B8HG97CW%(U^;Y!CG(!K,^* MEY%\%?C1H?Q%8F#P[K\?]B:\RK\LB;OZ;7]5U^9VGBSXF:I!\8O"_@3P_!:SR7$$FI:S<7*, M_P!EM%.U-FUEP[OE03D#(.#FK7QC^*X^%^DZ>MII\FN>(=7N19:5I,#!6N9B M,DEOX4'&3T&1G .1R?[-.DW'B&'Q%\3=6@,6I>+KKS;:.1*[(&$W.K*"X.T C)[=*<: M-+ZPJ3VBG?S:5W_D$ZU589UE]IJWDFTE_F;DO_#0]O:KJ@_X0F[D WOH<:SH M2O7:LI.-_;D[<\YKK_A]\4+;XI> ]4O5LY=*U6Q,]EJ.EW)!DM+A%.^,^HZ8 M/?V((K)_X4;KBC/_ MKQAC_ *Z6_P#\:K-^$?@?PYX;G^(FH:+XMO?%>HW4 MGV;5I+OR_P!WU.3I5(-Z75K6377J3!5ZSO>[3Z;H MI?LW>*].\#_LGZ!KVK3_ &?3[&WNII9.^!TWPSX4T*?]Y86FO>=)=SQD J\GE\(&'8 ,.>O!KRUK62X_8+\-3&)[BQM; MM+B^AC7<7MUOWWCZ="?I7V%H^I6>L:9:WMA-'FESS'X8_=8\677@CQOH\7A[QG M;0?:D6VDWVNH0;B/-@))/']TDG@GL0O,>)/V@/%-C\8O%/P^T'P[;:YJD,=J M=*1=T00/"'FFNI"V!&A9>% )W =3FK7Q.N(-6_:;^$UAIK"35M-CU"[OFBY, M%J\(4"3'0,V0,]R/6JG@/5M+M/VP/B;8W,L<6JW=AIYM-[ %U2!#(J^IY0X' M92>U5&E3LZG)O"]NSNE?]12JU;QI*>T[7[KE;_KS+>IZQ\>/!-B^M7]GX5\6 M6<($MWI6D)<1700?>$#-PQQS\P)/0"O2_!?Q*T+QOX!@\7V5TL6D/ T\TDWR MFWV ^8LGH5P<]N,C(-=->7<%C:3W%U-';VT2%Y)96"JJ@9))/0 =Z^4O".FW MWB#]FOXRW6B12?V?K&KZK>Z3%'&O%<\5'$J\DHM-+31:F\ MY3PD^6+>05. M:E\1?!W2+;QOX+C\3_$_Q!J6KIJ2WFCV-ZT#&6:'#D#;%G;@:5X=T#26\1^,]8)%EIBO MM5$'!FE;^&,<]>N#R,$CG+B[^/WA^#^U[BV\'^(XD&^?1=/\^"X)R1Z@BO6?BH?\ BV/B[_L$7?\ Z)>GB?\ >M%_ M+^2)PG^Y:O\ F_-G@WP-\!=,TS2M'TO3X;.XUW7TD87,ZH MZV\2$;@K#!=C@G(QQ78V_P 6/&/PU\6:7HWQ-L=+DTK5Y1;6'B711(ENDQSB M.X1R=C-Q@@X^N"1J?LI:YINM? ;PI_9KQG[+;?9;B-#RDZGY]P[$D[OHP/>L MC]LB^M#\&+O1R%FUG5[NVMM+M4YFDG\]&R@ZY !Y'J!WK>4HU,5*BX63;7GO MO>WJ;U,1 M4I2E2W]D8?)"2I$9#HFHM<2S[2>%ED3@-C^[CKR!BN MK^$/Q>?X@2ZKH>MZ5)X=\9:*534=)D=7'S#*RQL/O1MZ]LCJ""?2T=9$#*P9 M&&0P/!'M7@UC<1:Y^V+=SZ0RR)I?A7[)JLT7*"5KC?'$Q'1\?-] 1VKHC*-> M,TX)65[KR.6498:4&IMW=FGK\T97AWX]>.O'WBCQ?X2\-:)I*].Q_WTPKH?LW6]A&"L_OO;_,YX^U^K_6'4=U]UD^WH M=?\ &+XL+\+]*TY+33Y-<\1:OL[B"\ MLK74[(H'ANR!A=SJR@N#M&1D]NE=K_PHS7<<_%GQAC_KI;__ !JE&-*C3@VU M>2OJK]6ASE6KU:B5[1=E9VZ)G1_"/XH6WQ3\-R7JVDVE:I97#V.I:9<$&2TN M$^\A/<=,'O\ 4$5W8S7C?P'\$>'?#7B#QM?:+XMO?%>HW5W';:M)=;/W=S$& MXRB*"V'.<9&1[5[(<[3Q7G8B,(U'[/8]3"RG*BG4W/$_%'Q=\5>)O'-_X.^& M.E:??7NEL!JNN:R["QLW(R(@$.YY,9''W2,$'G&5J7Q0^)GP;FM[[XC:;H^L M^$G=8KC6O#HE62Q+$!7FC?[RY./E'XYP#/\ LISP6>G>.=$N<+XAL?$MY)J$ M3\2.78%)L==K <'OM.*[;]H'6-,T7X+^,9=6DC2UDTR>!%D;&^1XV6-5_P!H ML5QC^E=SY(5505--:+S?G<\Z/M*E%XAU&GJ_)6Z-'G7[:<^MWGP+U*YTFXTN M3PW*D#W[2>8UQ(&N(/),#*VW!/WMV,5ZK\,X/&EOI+1^,9-"D=!&MI_8< ML8NWJV)?7T.FV<]W=31V]K; MQM+--(<*B 9+$GH . --T3P_P"$MY2TU+Q&)6N+X \R M1QQ\*A(Z,,G@YZ@=[^T)I]]JGP2\:6NG!VO&TV4JD:Y9P!EE '))4$?C5[X+ M:MI.L_"GPK<:-)&VG_V;!&BQL#Y95 K(?]I2"#[@UC3M3I.KRW=[:ZI:&];F MJUU1YK*U]-V<9X/^,'B;0_'5IX*^)FDV.E:QJ09M+U?279K"_P!H!9!O.Y'& M1PW4D<#*[NAM?B/J4W[0%YX&:"T&DPZ NJK,J-YYE,XCP6W;=N.VW.>]H? M$CQ%=>$?A]XFUVS6.2[TS3+F]A2=249XXF=0P!!(RHS@CZBO)?''[06L>$/@ M'X,\>M9V3W>J267VZ%8G,:QRH7D\M?,!#8'&6/OFN^_: U"WT_X)>.I+B=(8 MVT6[A#.P +O$R(.>Y9E '7X6*QM6I"4U3>T?QN>T_#>\^)6N:B=7\41Z-I&A7=OYEOH]NDCW MD#$@J)920NX+D-@=0.G->F!ACDTU%PH':L_Q-:W-YX=U2WLG\N[EM94AK;9XVWQ:\;?%/7=2LOAAINDQZ%IL[6MQXDUXNT M,\RD;D@CC.6QG[QX^G&7?\)I\6_AWJ]@GB[0=,\7>'[J=+5M1\+Q3"[M2Q"B M26$YW*3UV=.3GH#:_9%U73[SX%Z%I]F1'>:69;2_M&XEM[@2L65UZ@G.>>QK MU[4-0L]-C22]NX;6-W6-6GD5%+DX503W)Q@=S7;5G&G4=)032T\_4X*,)5J< M:TJC3=O3TL<%XL^(VIZ#\9O 7A&""U?3==AOI+J61&\U##%O380P R>N5/X5 MZ2QVJ2.:\,^+3#3?VD?@QJ$S".VD.J6;R,< .]N/+7/JS' ]:]IU'4+?2]/N M;RZF6WM8(GFEED(5411EF)/0 5C6@E&DXK=:^MV;T*CGI9'@FD?M" M>(]0_98O?B7)9:6NNP^9MMUBD^S';<"+E?,W=/\ ;Z_E5C0_B1\3/$GAFX\> M1VNAZ-X133I[VWT^ZAEDO;E4A9HY6(<*BLRJP4'(0]2>:\PT6QEL?^">-YYH M9#-'+,JL,':;[@_B,$?6OH;6K5-/_9YO;9%")#X8>,*.@Q:D5Z-:-*G?E@M9 MM?+0\RC4KU;.4VK03]6[G!?"7XG?$_XU:3HOB#3K70=!\/*Z1WLEY!+)+?.I M G,"!ODC!W*N6))7)/:M/Q!\6O&/B[QYJGA+X9:7ILK:,RQZKKVM,YM(92"? M)C1#N9Q@Y]""".AK<_9ALUL_@#X+15V;K 2?BS,V?Q+5X[\!_AQJ&O3>.+)? M'NO^&M9LO$5T-0T_3VA569V!2?#QEL.!P,(P^?"#!Y'/ M0US'Q&^#MOIW@S4I?%_Q<\3IX<,?EW?VR2W,;*Q"X($.3DD8QSDBLS]H3PO: MZ5\-?@[X?@G?4-/A\3Z19)+=?>FB$4B M@#DKUX[U,8T*LZ;?5ZV5E8J4\11 MIU$G:R5KN[3_ ,CIEU+XW^*K,ZWI5KX9\,VD@\VTT;5XIIKITQP+AT(",>NU M1D< G.:Z3X9?%"_^*OP[U"^L+.'2?%=B\VGW5A?AFBM;^-<;7VD,8]Q4\'." M1G(S7I:XVCZ5X;^SA\OB[XP]!_Q5&_"#_DY#XY_P"_H_\ Z3/7N7>C'2YJJT2TC^2'ET.6B]7\4M_\3/"? MBM\?=8^'_P 7M/\ "%CH::[_ &CI N+*T@4BYFO&F9%0R%MJ1A5+$E> I.>U M+--^T%8VY4.H]2P%?0I8#.2 *TJ3C1C3M!:K6_4QIQEB)U.: MHURO2W31'#?";XIZ?\6/#3:C:V\^FWUM,UKJ&EW8Q/9SI]Y''\CW![$$#@6^ M+7C?XJ>(M4T[X7Z?I4.AZ7*UM<>)M<\QH)Y1U2W2/&[!_B.1[#(S0^$I/BKX ME?'/5_#DR_V3>S6ME9W47,3W<=LRRLIZ'#,IR.NX&M[]D6\L9/@9H5C;Q_9[ MO36FM+ZV88DAN%E MZ01,#^8%;48TZD83G36KE?SM&YA6E5HSG3A4>BC;RN[,[5+?XV-H-Y/<7?@M M-0F=7CM7M[IHK>$H_F(75P6?=Y>#T^][5QG[%Z>,Q\)O#K32:$?!WEW?D)'' M-]O\S[3+G<<^7MW;N@Z;:^C;W_CSG_ZYM_(UXU^QK_R;;X2_[?/_ $KFKG]K MS8:?NKXE^3.IT>7%P?.W[LNOG$Y'X4_';XD_'+PI:'PQI.BV&H0,ZZMK%_', M+&%][;(8(@Q:1_+V,Q+8&[W%=GX/^)GB[PW\2;+P+\0X=-FNM6@>?1]9TA'C MAN#&"9(I%XN+J5RO\ $?.=03Z\*!^ MJ?XX?\EJ^";=&_M.\Y_[8+6]2-.6(G0C!):V[Z)LYZ3JQPU/$2J-MVOVLVEL M;WQ<^+U_X/UC2/"WA;2%\0>--8#26UI))LA@B7.Z>8]=@.<#(S@\C'/-W]_\ M?_"=O_:\]MX2\56T0WW.D::L\%P5'40NW!.,GG)/0 \5S/C#PE<:U^UK<6\W MB;4_"T^H>'4.F7>GF-3.L6C1A!:7:N[IO?V>T M4DNHW$"QLRR@[@B[B RKSA3SD\UYYXJ\)^&O"O[)'Q ?PKXBN?$FEZA=M=-> MW 4?OO.B20+M11C*=ACDD=:^D?!>FPV_@+0[%XE,"Z=!$8R,KM$2C;[C%14C M2I4VX1O>35WO:R_S+INM6JI3E:T4]-KW?^1XYX-\>?&GQAH>G^,]/TOPO>:% MJ++)%H'G21W0MRV ?//R!\?,<@C';/ ^@USM&[@]\5\V^*O#^O\ [*NGW'B3 MPKJ+:K\/H)U>^\+W_P S6<;R %[67J,%Q\AXY)Y-?1UMUOU]#JP;DKTZC?,K7O^GJ6:*2EKA/3"BBB@ HHHH **** " MJ4?_ "&I_P#KWC_]">KM4H_^0U/_ ->\?_H3T 7:*** "BBB@ HHHH **** M"BBB@ HHHH R->_UNE?]?J?^@M6O61KW^MTK_K]3_P!!:M>@ HHHH **** " MBBB@ HHHH **** "BBB@#)\2?\>=M_U^VW_HY*UJR?$G_'G;?]?MM_Z.2M:@ M HHHH **** "BBB@ HHHH **** "BBB@ K)\._ZN_P#^OV;_ -"K6K)\._ZN M_P#^OV;_ -"H UJ*** "BBB@ HHHH **** "BBB@ HHHH *R(_\ D:KG_KRB M_P#1DE:]9$?_ "-5S_UY1?\ HR2@#7HHHH **** "BBB@ HHHH **** "BBB M@ JCK'_'B?\ KI'_ .AK5ZJ.L?\ 'B?^ND?_ *&M %ZBBB@ HHHH **** "B MBB@ HHHH **** "BBB@!*6H9C)'&?*19&[*S;1_*H//OO^?.+_O_ /\ V- % MVBJ7GWW_ #YQ?]__ /[&CS[[_GSB_P"__P#]C0!=HJE]HO?^?.+_ +__ /V- M'VB]_P"?.+_O_P#_ &- %7Q+I,VN^']1TZWO9=-FN[>2!;R%09(2RE=ZY_B& MV'PM\#Z7X:TW_\^D1_[;__ &-7S24.7H]3+DBY\_5:%F10 MX(/3&.:\N\._ >P\,^"_&WA:SU.YCT7Q(UR8K?8N-/$\91UB_P!D9! /0CWK MK['QK::IJ6L:?:RVLU[I!07\"W!S;[UWKN^7C(!_*I?#?BN#Q?HMMJ^C-;:C MIMP&,-U#.2DFUBIQ\OJIJTZE--+9V_X!G*-*K)-[V?W=23P3X7B\%^$-%T"& M9[F+2[.*S2:0 ,ZQJ%#''D7_ '__ /L:S=%\50>(_MITN2SOQ97+V5Q]GNPWE3)C=&V% MX89&0>>:E3G=R7S^9?)3M&#Z;?(WJ\]^)OP8TGXF36.H/C(>ZGU.,9-=J;B]'_+I$/\ MO\ _8T?:+SK]DB_[_\ _P!C4QG* MF^:+*J4XU(\LUH>1+^SUJ>OR1Q>-_B!K/B_2(G#C26BCM+>7'($PC&90" <' MN*[7X3_#&S^$_A:30K&YDN[=KN:Z#2($V^8V[: .PKJ?M%Y_SZ1?]_\ _P"Q MI&FO>AM(A_VW_P#L:WGB*M2/+)Z;V,*>%I4Y*<8Z]_(\BO\ ]G%](US4-4\! M^+]3\"'47\VZL;2*.>T>3/+K$XPK'VX[# XJG??LIZ5KD:7NN>(M4USQ-]JM M[AM,+;PG9Q7>L2 M6NGV\LR6Z237!PTC'"K]WJ35QQ5>]HRU_KJ8RP6&2?,M!/'GP_T3XF>&KC0O M$%DMY838.,[6CE3MR*V]OGN,O%, M5W+//XE-HTMNZC;#Y$9C&T]3N#9YH$_#6V$>-_&/B2&[EGG\22V\LL+J L M/DQE %QUR#GFNG\^]_Y\XO\ O_\ _8T?:+T?\ND7_?\ _P#L:7M9RO=[V^Y6 ML7&C3C:RV=UZO<\\\?? NR\6^)HO%.DZOJ'A'Q7&@B;5=+89GCP $FC;Y7 P M.OH.N *Q]+_9T;4->L-6\<^+M4\=2Z<_FVEG>HD%G'(#D2&%!AF'J?UKUO[1 M>_\ /I%_W_\ _L://O?^?2/_ +__ /V-:+$UE'E4O+T_4PEA*,I>?:NTQMJG]HO?^?2+_O_ M /\ V-'VB]_Y\XO^_P#_ /8U@Y-I+HCI4(J3DMVC_39--VO;W;=G MDA;Y2W)Y]R>I)KN=/\86^IZYJFBVDEK/JNE^5]MM5N#O@\Q=\>X;>XK7^T7O M_/I'_P!__P#[&M55JPES?TS#V%&I#D2NKOY/J>)ZQ^RS;^,=,OE\8>+-6\5: MQ/ 8+:_O%016()&6A@ V*Q P6.3QQBNY\4_".T\4VO@B"6^F@3POJ%M?P^6H M/G-"NT*WH#[5V7VB]Z_9(O\ O_\ _8T?:+W'_'I%_P!__P#[&G+$U7:[VO\ MCH3'!T()\L=[7\[:E[MQ7 ?%7X/Z9\5+6P>XN[W1]8TV0S:?J^FR^5<6KD=>_P#/G'_W_P#_ +&LKP[XN@\7Z6FHZ,]MJ%B[O&)X9SM+ M*Q5A]WL0?RK.+G%\\3>I&%1>SGU/*I/V9]1\47=D/'?Q UCQEI%G(LJ:3)"E MK!*Z]#*$Y.J M?C73?:+TL7_ '__ /L:TEB*LI1DWML8QPM&$912 MTEN6HHQ#%'&.0H"@_05Q^A_#:VT;XF>(_&274(RM?IJCSOXA M? K3_&7B2U\3Z5JM_P"%/%D*>5_;&ED;IH^FR5&RKCZ\\#J !6 _[- M.O&6K>-&B1Q:074<<%I [*5$OD)P\BY."QXKTWP_XRM_%<=Y+I$EK?QV=S)9 M3M%<$^7,F-Z'Y>HR/SK6^T7H_P"72+_O_P#_ &-="Q%>FE&^WX?,Y7A,/5?- M;?\ $\VU3X V&J?!.Q^&[:KU=CY][_SZ1?]_P#_ .QI?M%Z M?^72+/\ UW_^QJ/;U+IW[_CN:O#4K./+T2^2V. ^&WP97P7XAO\ Q)K&OW_B MWQ5=P"T;4KX+&(H =WE11K\J D GU(SQW;\0/@3IGC#Q);^)]-U+4/"GBR%! M%_:^DR!7FC P$E0@JX^HSPHY KT$3WN?^/2+_O_ /\ V-#7%[G_ (](O^__ M /\ 8T_;U>?VBEJ'U:ER>S<=/Z_$\7E_9IO_ !5/$GC[X@:WXPTN-UD&D[$L M[:5EY'FB/[X'X'/>NZ\;?"JP\9/X1"S'3(/#>IP:E;06L:A&\H$+'C^%<>G3 MM77?:+WK]DB_[_\ _P!C2?:+SM:1?]__ /[&E+$59--OT%'"T8Q:2]>YS'Q. M^$^B?%72;>UU59[:[M)?/L=1LI3%$(0596'<, >$EDV?ZQEZ@GH?8D'UOSKSI]DC_[_P#_ -C1 MYU[G/V2/C_IO_P#8U,:]6*:3W'+"TIM2E':QS'Q,^%.B_%32[>WU/[1:WMG) MY]AJEC*8KJRE_OQN.AZ9'0X'< C@+S]G/7_$48T[Q+\4O$6L>'R(JTU: M+"IA:-1WE'^O,@T'0+'POHMII.E6D=EIMG$(H((A\J*!@#W^I/\ C7E%]^SB MVCZ]J.J>!/%^I>!&U%_-NK&SBCGM'DSDNL3\*3[<=A@<5Z7>>*X=.UK3]*NI M;.WU+4/,-G:270$D_EKN?8-N3@15B8L(8DQMBC).2!U/->ZA<<53\^]_Y](O\ O_\ _8TIN+T_\ND7 M_?\ _P#L:BI5G4LINZ7X&E+#TZ-W36KW\SP?]HKP[IWB[XP?![1M6M([W3KV M?5(I[>7[K+]F3\B.H8,; M4N&&X # '4@"O3=4\.6VLZMI6J7VC6MS?Z2SM97$DQW0,ZA7*_+W _2M;SKW M_GTC_P"__P#]C73];G&G"$'HD_/JVXF??-1S]WT(./0BM_P"T M7O\ SZ1?]_\ _P"QKGG.KJIO?5_H=5.G25G!?#=?YG$_$KX,Z5\1KJQU,7=[ MH'B33_EL];TJ3RKB-2>QSCFO9OM%[_P ^D6?^N_\ ]C1]HO?^?2+_ +__ /V- M7#%5H1Y8O3^MB)X2C4ES2CK_ %N6+6UBLK>.""-8H8U")&@PJJ!@ #L*FJE] MHO?^?.+_ +__ /V-'VB]_P"?.+_O_P#_ &-(;P'[9<:9M>&[/9I87!5B#SD8SDGJ+Y+R6*YT"*YBBME M4;)?.3:Q8]1CVH$_#.V$^-O&/B2*[EGG\2RV\LL#J L/DQE %QUR#GFNG^ MT7HZVD7_ '__ /L:/M%[_P ^D7_?_P#^QK+VT^7EOIM\M_S-O8PYN>VN_P"G MY'+_ X^&=O\.)/$[VUW+=_V[K-QK,@E4#RGF*Y1<=5&.]+\4/AG;?$[2]*L MKF[ELEL-2M]25X5!+-$20ISV.:ZC[1>_\^D7_?\ _P#L:3[1>]/LD7_?_P#^ MQH]I+GY[ZC]C#D]G;0YCQ!\-;?7OB1X6\827DL5SH,5S%%;*HV2^!P00<#C@5T_VB\X'V2+ M_O\ _P#V-+]HO?\ GSB_[_\ _P!C3]K.Z:>JV)=&FU*+5T]_4\:N_P!GWQ=J MD8L+_P",/B2;1B/+>"&&&&X9,8*F<#)/N0??->F^ ?A_HGPU\,VV@Z!9+9Z? M#EMO+,['[SNQY9CZGV X K8^T7N/^/2+_O\ _P#V-'VB]Z?9(O\ O_\ _8U5 M2O4J*TGH33PU*D^:*U/([_\ 9TDTC6;[4? 7C'5/ BW\AENM/LTCN+)I#U=8 M7&$8GJ1Z <#BJ.H?LIZ7KD<5UK?B+5-=\2"[AN&UN_97D58WW>3$F-L49/) M[FO6+WQ5!IVLZ?I5W)9P:GJ/F&SM)+L"2?RUW/L7;DX')QT%4M3^(.EZ/XFT MWP[?7=E;:WJ2,]I927!#RA M(/AK;:]\2/"WB][R6*YT"&YBBME4;)?.382QZC'M7:KBJ7VB]_Y](L_]=_\ M[&C[1>?\^D7_ '__ /L:XY3E)+F>VB.Z$(P;<>N_K_2.8'PSME^+S>/OM?8ZE9R&*YLY>SQ. M.0>G'0X'< CJ/M%[Q_HD7_?_ /\ L:/M%[_SZ1?]_P#_ .QJO:334D]42Z-- MQ<6M'N>.M^SYXAU>/^S_ !'\4?$6M>'SA9-/CCBMGF3H4DF0;V4C@CC(K=\) M_ 31_!>C^-=*TR=X+'Q)O'DQQ@+:*T1CVIZ@ YYKT4W%[_SZ1?\ ?_\ ^QH\ MZ]_Y](_^_P#_ /8UM+%59)Q;T?R,(X.A%J7+JOU,GX?^#H?A_P"#-'\.V]P] MU#IMNMNLT@ 9PHX)Q7B6NV?@+XJ_$S5+6>]U;X<_$72)/(%Y:W:6=Q>PX&UT M8$B:,J!U&['!P.*^@OM%[_SZ1?\ ?_\ ^QKF/&7P[T/XA6Z0^(_"^FZNL61& M]RV9(\]0K[=R\=<'FBC6Y)N%?A[X4U* M]\2^+]6\?>+)[66TT33=6NUN"+F5#&KPVRCA@3G<0<8]<5[Q\-?!1\/_ E\ M/>&-6@BF:WTJ*SO(& =&;RPLBG^\,[OK67X,^!_@_P"'^H"^T#P;IEC?#[MT M9&DE3C!VLX8KD<'&,UWOG7O/^B1@G_IO_P#8UI7Q/M(J,6WUU_1(RP^$]G-U M)I*ZM9?C=L\;C_9QU7PR);7P3\1=<\+Z*[LZZ24CNXH-W58C)\R#TY//.2:[ M#X7_ 9TCX9&^O(KF]UK7]1(:^UK59?-N9\=%ST50>@'H,DX%=KY][_SYQG_ M +;_ /V-'VB]_P"?2+_O_P#_ &-93Q-6I'EE+3^MSHIX2C3ESQ6O];',>)OA MK;^)/B)X/\72WU=E]HOD7_ '__ /L://O?^?2/'_7?_P"QJHU9P2L]OU,Y MT*O\ Q9XHNX!:-J5\%C$4 .[RHHU^5 6 M)]2,\9Y],JG]HO>UI%_W_P#_ +&D^TWG_/I%G_KO_P#8TI3E-WD73IQIQY8' MD-]^RWH=WJ.M:M#J^I:;XAO=5FU6WUC3W6&YLVD"AH@0/GC.WD-ZG&,G,"_L MU7?B:XL_^$_\>:UXUTVT?>FE2*EK:R,.AE5.7P?4Y[9QD'V;[1>_\^D7_?\ M_P#L:/.O?^?.+_O_ /\ V-='UJLE;F.;ZE0WY?Z\QMUI-I=:7)ITMK')8R1& MW:WV#88R,%-OICC'I7CD?[..J^&O-M?!7Q%UWPMHDCLZZ28X[N*#=U6(R?,@ M].3@\Y)KV7SK[_GTCQ_UV_\ L:/.OC_RZ1_]_P#_ .QK&%:=._*]S6IAZ56S MDMCBOA?\&](^&)OKR*XO=:U_465K[6=5E\VYGQT7/15'H/09)P*N^$?AK;>$ M_&WC'Q)#=S3S^));>66%U 6'R8R@"XZY!SS74^=>_P#/G'_W_P#_ +&D\Z]' M2SC_ .__ /\ 8T2K3E>[^+]-?T''#TX\MEMM^7ZG+_#CX9V_PXD\3O;7TES\]]2O8PY/9VT/+OV M@=>\(6.DZ9HOCW1I[OPUK$Y@?5-H,%A-CY&=\[HR/)?7(Q#Y6#\AGQG9M.,9Z=Z]QO[-]6L9K.]TNUN[29#'+!.X> M.13U# K@C\*\U_X9C^'/V];S_A7^E>:#NV^:WE]/^>?W<>V*[*.(C3ARW:^Y M_GL<%?"RJ3YK)_>ORW.5_9ET72+KQU\0/$WABPCL?!TK6NDZ1Y<919U@C/FR M+GDJ7(.X\LU6O/O? M^?./_O\ _P#V-JZT^;T7W:'7AJ"P]-0]7]^IY?XK_ &?H-0\67/BGPIXB MU+P/K]XNV]GTX+)!>>C2PO\ *6'KQU/,M,O?^$P\5ZKXIUJ:W M:WMM0O$18K%206:" #8K, 6.2<5[89[[_GSB_[_ /\ ]C2^=>_\^!]+UCP6/"^J6JZCI36J6DD4PXD55 !. M.AR 01R",C! KR^+]G;Q)I-F-+T/XL^)--T$95+*2.*:6)#T1)R R@#@>F*] MF^T7O_/G'_W_ /\ [&CSKW_GSC_[_P#_ -C6<*]2GI%Z?J:5,-2J6-/90Y/9\NFUA=-TVVT?3;:QLX5@M+:)888E'"(H"JH]@!6+X^ M^'NB?$OP[-HFO6GVFSD(=2K%9(I!]V1&'*L.Q_ Y!(.UYU]_SYQ_]_\ _P"Q MH\Z^_P"?./\ [_\ _P!C4J4HRYD]2G3C*/*UIV/&)/V>O%4UJ-,D^,'BAM#" MB/R%6);DIW!N -Q..,D5Z3X1^'>B> ?!Z>&]"LQ9:68]R M?8>@K=\Z]/\ RYQ8_P"NW_V-'G7O_/G'_P!__P#[&MJF(JU%:3T,:>%I4VY1 M6NQRWPY^%]E\/?AO9>#?..K:?;Q30L]W&/WR2.S,&4<8^KW_P Q2PM&44G';;N<7\,?@SI'PP^W7<-Q M=ZQKVHL'O];U.7S+JY()PI/15'8#T&64.DW% MCJEA*8;JRE^SD;XG'()[]C@<< U]*F:]Z?9(_P#O_P#_ &-9-CX9M]-\0:EK M=MHUK%JNHK&EU=+,=\RQC" _+V%:4\5.,IR;]YJU_FO\C&K@X3C"FDN5.[7R M?^9Y=>_LY:UXIB&G^+_B9KWB+P]YBL^EK#%:B=5.0DCH-S+P,COC/!Y'L>C: M+8^'](MM,TZUCL]/M8EAAMXUPJ(!@ 5)YU]C_CTC_P"__P#]C1YU[_SYQ_\ M?_\ ^QK"=:I4LI/]#>EAJ5*[@M_O/(;S]G.;1-4OKOP'XSU7P-!?2>=-IMK' M'<60D/5TB<80MGG'T& !C<^'7P+L/!.O7'B/4=6U+Q7XJGC\EM7U>0,T46<^ M7$HXC4^@SWY .*]#\Z^_Y\X_^_\ _P#8T">^_P"?./\ [_\ _P!C6DL35E'E M)/BAXAUGPZPV2:=??\^(JTURQ>@ZF%HU9O:CXV\2PKLM;S5& BM ?O>3$ORH3D_TQR3Z@9[ M[_GSB_[_ /\ ]C2>=>_\^U#6-0E\FQL;>2XF?T15)/X\5X]^R3X'30_ ]]XJFL(]/O_ !;>2:J;:->( M;=F8P1K_ +.UBP]GKU;Q)H,?B[1;K2=6TJ"^TZZ $]O+,=K@," <#ID#\JNV ML=Q96\=O!80PPQ*$CC27"JH& H&W@ 5$:O+2E3CU:OZ(J5'GKQJRVBG;U9IU MD>)/"^G>,=#O-'UFRCO]-NXS'-;S#*N/Y@@\@CD$ C!&:M^???\ /G'_ -__ M /[&CSK[_GSC_P"__P#]C7.KQ::>J.II27*UHSQ>W_9U\1:)9KI6@?%7Q%I? MA]8KE%QU48[T[XH?#.V^)V MEZ597-W+9+8:E;ZDKPJ"6:(DA3GLM/M-G(0ZLK%9(I!]V1& M'*L.Q_ Y!(KS*3]GOQ7-;#3)?B_XH.AA1'Y"K$MT4[C[0!N)QQG%>S&:]_Y\ MX_\ O_\ _8TOG7W_ #YQ_P#?_P#^QK2GB*E-6B]/ZV,ZF&I5'S26ID>!? >C M?#?PW:Z%H-F+2PM\X7EF9B=?'_ESC_[_P#_ -C6$I.3=^/O@79>+?$T7BG2-7U#P MCXKC01-JNEL,SQX "31M\K@8'7T'7 %8^E_LZ-J&O6&K>.?%VJ>.I=.?S;2S MO42"SCD!R)#"@PS#U/ZUZYY]]_SYQ?\ ?[_[&D\Z^_Y](_\ O_\ _8UT+%5H MQY5+R_KJNF:]_P"?./\ [_\ _P!C2_:+[_GSB_[_ /\ ]C5T MZLZ+?(]S.K0IUK>T6VW<\]^'?P-T[P3KUSXDU'5-0\5^++A/*;5]6<,\<7>. M)1\L:DC.!Z]AQ6A\5/@_I?Q3M;!Y[N]T;6=-D,VGZQIDOE7%JY S@]U.!D=\ M=1UKLO.OO^?./_O_ /\ V-'G7I_Y M*2?LSZAXHO++_A//B!K'C/2;-UE329(4M8)77H9=G+CZ\^_)!]!^)?PQM/B3 MI.DZ?/=26$6G:E;ZE&8%!W&(DA"#V.?TKJO.OO\ GSB_[_\ _P!C2>?>G_ES MB_[_ /\ ]C52Q%6;4F]5MT(CA*,(N*6CW+PX %%4_/OO^?.+_O\ _P#V-'GW MW_/G%_W_ /\ [&N8[#R[Q1^SW:7GBJ[\4>%?$&I>"/$-X#]LN-,VO#=GLTL+ M@JQ!YR,9R3U.:S],_9I74M>+M4\>R6,OG6ME?*D-DCC&':%.&88[G& M.""*]?\ .OO^?2/_ +__ /V-'G7W_/I'_P!__P#[&NGZU5MRW_KU.+ZG1YN; ME\SG?B9\,M&^*OAPZ/K*S(BRK<6]U:N$GMIE^Y)&V#AAD]01R:\RO/V9]?\ M$=G'I/BCXJ>(-<\. @2Z=Y4<+7"@\+)*,LPZ9SU]CR/:_KS.3\;?"O3/%GPNNO L!.D:5 M+;QVL9M4'[F-&4J%!X_A K;U+PO%JG@NZ\//,ZPW%@U@9@!N"M&8]WUP(X_$VC:SJ/A#Q2L?E/ MJFE,!]HCQ@+-&V5<# Z\\#K@8]"\Z^[6<7_?_P#^QH\Z^_Y\X_\ O_\ _8TX MU9QDYIZO\294*E=K\2/AG;?$F/PXES=S67]B:S;:S'Y*@^:\.X!#GL=W7VKJ/M% M\/\ ESC_ .__ /\ 8T>=??\ /G'_ -__ /[&KE7JSDIMZK;H1'"THQ<5'1[^ M9<"X&/;%<9X!^&MMX!U7Q5?07)C:-+;NHVP^1&8QM(Y.X'/-=IWJEYU[_SYQ_\ ?_\ ^QI?M%]_SYQ_ M]_\ _P"QHE*4W>7]?T@A"--6CMO]^Y\[?$SP)I'Q'_:FLM#UVV^TVDG@]W4J MQ22*079VR(P^ZP[$>XY!(/17?[//B;5+232;[XN>)KKP[(OE-:>7"MR\?]UK M@+ELC()QSGGTKU!_#5O)XG3Q$^BVIUJ.V^QI>>[;L M\D+?*6Y//N3U))]/\^]_Y\X_^_\ _P#8TOG7W_/G%_W_ /\ [&N>-6I"3FGO M^)URH4YQ46M%_6AXEJW[+-MXRTR^7QAXKU;Q5K,\!@M[^\5!%8@D9:& #8K, M!@LLZQX"OWOIXV\),S0*JC$^8A'\WIP,\5V7G7O_ #YQ_P#? M_P#^QH,U[_SYQ?\ ?[_[&K^LU7:\N_ROHS*.$H1VC_F[:HLS1B:%XSP&!7\Q M7(?"?X<6WPH^'^F>%;6[EOK>Q\[;<3* [^9*\AR!QP7(_"NG\^^_Y\X_^_\ M_P#8TGGWO_/G'_W_ /\ [&L%*2BX=&[G2Z<7)3>Z5OD$->FNY;>7PYF,=JZ?S[W_ )\X_P#O_P#_ &-+Y]]_SYQ_]_\ _P"QJO:SYW.^K_ID M^QAR*G;W5;_@'+?$SX4Z+\5-+M[?4Q<6M[9R>?8ZI8RF*ZLI?[\;CH>F1T.! MW (X"\_9SU_Q%%_9WB7XI>(M8\/DX?3XHXK9IT_N2R*,NI[\#^M>T>?>_P#/ MG%_W_P#_ +&CSK[_ )\X_P#O_P#_ &-:T\15IJT695,+1J.\H_UYG'^+OA'I M/B3X4W'@*T']BZ1);1VL7V1 3"BLK#:#U/R]3SSGK717?AFWU#PM)H%R\SV< MMG]BD>*1HI"A3:2&4@J2.X-7O/O?^?./_O\ _P#V-'GWQ_Y???\^<7_ '__ /L: MQ.DNT52\^^_Y\XO^_P#_ /8T>???\^<7_?\ _P#L: +M%4O/OO\ GSB_[_\ M_P!C1Y]]_P ^<7_?_P#^QH NT52\^^_Y\XO^_P#_ /8T>???\^<7_?\ _P#L M: +M48_^0U/_ ->\?_H3TOGWW_/G%_W_ /\ [&JZB_6]DG^R18:-4V^=Z%C_ M '?>@#5HJEY]]_SYQ?\ ?_\ ^QH\^^_Y\XO^_P#_ /8T 7:*I>???\^<7_?_ M /\ L://OO\ GSB_[_\ _P!C0!=HJEY]]_SYQ?\ ?_\ ^QH\^^_Y\XO^_P#_ M /8T 7:*I>???\^<7_?_ /\ L://OO\ GSB_[_\ _P!C0!=HJEY]]_SYQ?\ M?_\ ^QH\^^_Y\XO^_P#_ /8T 7:*I>???\^<7_?_ /\ L://OO\ GSB_[_\ M_P!C0!5U[_7:5_U^I_Z"U:]8VH07]XUF1:Q+Y$XE_P!=UP&']WWJYY]]_P ^ M<7_?_P#^QH NT52\^^_Y\XO^_P#_ /8T>???\^<7_?\ _P#L: +M%4O/OO\ MGSB_[_\ _P!C1Y]]_P ^<7_?_P#^QH NT52\^^_Y\XO^_P#_ /8T>???\^<7 M_?\ _P#L: +M%4O/OO\ GSB_[_\ _P!C1Y]]_P ^<7_?_P#^QH NT52\^^_Y M\XO^_P#_ /8T>???\^<7_?\ _P#L: +M%4O/OO\ GSB_[_\ _P!C1Y]]_P ^ M<7_?_P#^QH K>)/^/.V_Z_;;_P!')6M6-JD-_?P11BVC7;/%+_KO[CJW]WVJ MYY]]_P ^<7_?_P#^QH NT52\^^_Y\XO^_P#_ /8T>???\^<7_?\ _P#L: +M M%4O/OO\ GSB_[_\ _P!C1Y]]_P ^<7_?_P#^QH NT52\^^_Y\XO^_P#_ /8T M>???\^<7_?\ _P#L: +M%4O/OO\ GSB_[_\ _P!C1Y]]_P ^<7_?_P#^QH N MT52\^^_Y\XO^_P#_ /8T>???\^<7_?\ _P#L: +M%4O/OO\ GSB_[_\ _P!C M1Y]]_P ^<7_?_P#^QH NUD^'O]7?_P#7[-_Z%5GS[[_GSB_[_P#_ -C5+38; M^Q6X!M8V\R=Y1^^Z;CG^[0!M452\^^_Y\XO^_P#_ /8T>???\^<7_?\ _P#L M: +M%4O/OO\ GSB_[_\ _P!C1Y]]_P ^<7_?_P#^QH NT52\^^_Y\XO^_P#_ M /8T>???\^<7_?\ _P#L: +M%4O/OO\ GSB_[_\ _P!C1Y]]_P ^<7_?_P#^ MQH NT52\^^_Y\XO^_P#_ /8T>???\^<7_?\ _P#L: +M%4O/OO\ GSB_[_\ M_P!C1Y]]_P ^<7_?_P#^QH NUD1_\C5<_P#7E%_Z,DJUY]]_SYQ?]_\ _P"Q MJFL-^NK2WGV:+:\"1;?.]&<_W?\ :% &S15+S[[_ )\XO^__ /\ 8T>???\ M/G%_W_\ _L: +M%4O/OO^?.+_O\ _P#V-'GWW_/G%_W_ /\ [&@"[15+S[[_ M )\XO^__ /\ 8T>???\ /G%_W_\ _L: +M%4O/OO^?.+_O\ _P#V-'GWW_/G M%_W_ /\ [&@"[15+S[[_ )\XO^__ /\ 8T>???\ /G%_W_\ _L: +M%4O/OO M^?.+_O\ _P#V-'GWW_/G%_W_ /\ [&@"[5'6/^/$_P#72/\ ]#6E\^^_Y\XO M^_\ _P#8U#=+>W4/EFUC0%E)839Z,#_=]J -.BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** $Z4UG"Y)Z"D]:\;_ &HO'5YX7^'HT31%:?Q1 MXGF&D:;!$P#EI,"1\GA<*>O8LIK6E3=6I&"ZF%>JJ%.5271'A>M_$C7[CXJ7 M/QMM'=_ >BZHGAHQ1Y/FV1R)9QV*^8R,/5B@_AK[6@GBNH8YHG26*10RNA!# M*>00>XKY8T6U^(ND_"&+X?'X%F?2/L#64K#Q19JTA93OEQMX9G)?V)KM/V2_ M%VI7G@F[\%^)(6M/%'@^5=/N;>1PS^21F%LC@C;E01P0@.>:]7%Q56GSPM[F MFEMNC^_\SQ,#4E3J\DV_?5]?YNJ^[\BO\,?^2Q?'_P#W[#_TE>MK]C__ )-R M\'_[EQ_Z4RUB_#'_ )+%\?\ _?L/_25ZVOV/_P#DW/P>.^RX_P#2F6EBOX4O M^W/_ $@K"?QH>D__ $I'I'B[Q$_A7P]=:HNE:EK30;?]!TJ$2W,NYE7Y5+*# MC=D\\ $U\Z_LK_$:7^UO&FF_\(GXDVZIXOO[HWHLT^SV6Y4/E7#>9E)%V\@ M@;EY.:^I7Y4CVKPO]E?'V?XI'/3QSJ?\HJY*+BJ$U*.NAUXA3^LTVI66I+8_ MM6:)XDM4'AGPUXB\2ZEO<3Z?8VJ-):JLC1[Y2'*H&*L5!.2!T%=A\2/C-X?^ M%]M8+JJ7MUJVH,%L]%TZ+S[V=L@86,''!/4G'H37G'[$NBVUC\+]5OHXU%S? M:U=-))CDA2J!<^@VGCU)J[\*]/M_$G[1'Q2US54%QJVCRVFFZ>DQW&SMS$6R M@/W0YR>.?O>IKIJ4J$:DTE[L/QU2.>E6Q$J5.3E[T_+1;LOV?[35G8WUM!XM M\'^)?!-I=2"*#4]8LP+7#7F7QP^-6B_$?P9INE)9ZCH/B*S\0:=)<:+K5O]GND0RG MYPI.&3I@@]QD#(KW+X$^%M)\(_"?PQ::-%$EO+80W+S1@?OW>-6:0GN3G\L# MH!7F_P"V)X8TR^T#PGK42?M3RV\ U.Y^&7C6W\.D;O[3;3A\J?\]&3/RICG<3TK#_:$CUO7/CI\ M,]'TRRT_41;PW6J06.J3-%;7%PB@ L54DL@PPX]:[9M6^-A5E/ACP:4/\/\ M:EQR/3_55$*-*-.,IV;>NKMI>Q<\15G4G&%THZ:*^MKZGHGA'Q?I/CKP_:ZW MH=\FH:9=+OBFCS@\\@@\@@@@@\@UY18_M8>'O$>BZ=<^&?#_ (@\1ZI?1R2K MH]C:H\]O&LC1[YRKE(U)4X^8D@CCFK'[/OP[\6> =3\:OKD&EV&EZO>+?V>G MZ7ZVG?3LUMZW.L\-_M->$M8T7 M7+S54U#PO>:$$.HZ7K%L8KJ/><)M09W[B0 !SR,@;A69;?M16-MK.GP>(O!O MB?PEI&HS+!::QK%F([?>V=HD.[Y,X[YQU. ,USGCSPAIVO?MF^#)+JT240Z$ M]XXV AY(Y)!&S_[K$,#ZJM=[^U):PW7P"\9I+&LBI9>8 P_B5U*GZ@@?E5^S MP_/"/*_?MUVOIH1[3%41_M2;K5=5;X:^-D\.,GF?VI_9HP$_YZ; V?+QSNSTY MQ7-^(K>/QO\ $CX':'KW^E:,^DRZH;>C%,>>/,WYVLKM?H=,:E;$SDZ\,:G<:1;Z[XALX3)+80FT&S&#E Y+*7'W3CUP?KC MX;^#?#?@7PA8:=X5@@CT?RQ+'- X?[1N /FLXSO+#!W9],<48NE&G&-2>KE& M-K=-%O\ Y"P-:=20:YI'B[X%^-/$OBO0=*_X2[P=KDXO]2TRW.W4+*0+AY80>)5 M.-VWKV&,$GU_P3XQTGX@>%=.\0:+/]HTR^C\R)B-I'.TJ1V(((/N*Y:].$:: ME37;6_EJFCMP]2I*K*-5ZZZ6\]&GU-]C\I^E?*OP"^-6D>!/A7I6AQ6.I>)/ M$EQ=WTR:/HEOY]P(_M<@\UQD"-/=B/I7U4V-I^E?._[%GAW2=/\ AOJ&KVT, M9U2^U2Z%W-CYQLD*JF>N /FQZN:N@X+#U'-75X_KN3B/:/$TU3=KI_H=7X?_ M &BM.N?$5EH'BCP]K7@?5+X[+3^VH56WN7./DCF4D%N1P<'<_+JEMI_$J_P!^-"';S[5;;C% M+&ZE)8)!UC=3RK#\B#D9%<7%JWQJCB5$\+^#4B4;0JZG/C'_ 'ZK(^$_P[\< MZ#\7_$7BG6;/1=)TC6[)5NK'2;MY0UW&R[)L-&N/D+@X/).>]74I4N1M637G M>YG3K5^>*E>2?E:Q+^RB0-%^(&>O_"9ZE_..KFO?M-Z1%KU[H_A;P[K_ ([N M[%@EU-H%KYMM"W.5:4D#=P>G&0>:\T\'ZS>^'_V?OCCJ.FLZ7\/B'6!'+']Z M,G8I8'U4$G\*]U^!_A72_"/PI\,V6D1QK;/80SO*A_U\CH&>0GN6)S^0Z#%. MO&G"%OA_XQF\.Z[+<6-Q%I/]K_ &HH&A>, MS>4(U .]I2W10ISZUQ?[2]C#H_B#X9>*[$"'Q%!XEM=-CDC.'N+>M9?B;PW:>(OVW/#DE[ MQ_9OA47T2.,J)!M1"C1FU M-W46F[>:+J8BO!>S33DI)7\F=#-^T]!I4UO=Z]X%\5>'/#MQ(D*:UJ-FJQ1% MV"JTJAB8U)(Y///2O:)+ZVALVO9+B)+18_-,[. @3&=V[IC'.:Y/XQ:?;ZI\ M)_&%K(47!)_&6G6\ACDU32[(?9B1G<$9B"Y&.@'<5IZ+^TUX0\0:SH.CVT>I)JVJW MM>#_&CPUI%C^TA\']:@@CAUF^N[F&X>, &:-(AM+>I7=@'N&Q MV&+IQPU:3AR-63:=^R;U(JRQ-""J.:=VDU;NTM#Z+/3/6OE[]JCQ]-;^)_ F MF_\ "+^(95TKQ=IUXMZEHAM[TA2WDV[[\O(=VW:0HRK#/%?45>%_M1?\?7PF MY_YGK3/YO6&#:5975]_R.C'QE*@[.VWYGHVC_$*SOO!\GB75K&_\*640=IHM M?C6WEA5#CL>'KY;RV)V2HPVRP2 QSD9!S76YP,FO ])L8O"G[7V MH6FDCR;77O#0U+4[6,X0SI/L28KTR1E?Q7/6IQA)..S5SHPU652+4 M]TVF?*OQ7^*$D?[1WPVG'@SQ2YT276($A6P0OJ(,'E[[4>9^\48W9.WY3G': MMOXL>,K*/XO? OQ'JLHS M7L4W"4J2<;>Y+7_P(\2JJD8UFI7]^.GG[IMW_P"U%#9VKZPO@'Q=+X20%FUS M[ %C\L?\M1&S!O+QSN(''.*]BT76['Q!I%IJ>G7,=W87<2S07$1RKHPR"/K4 M]Q9PW-G-;S1+)!(C(\;C*LI&"".XQ7RO\.-:O] _8E\23:<\GGV2:E#;LI^: M)/.<$@G^Z&8^V*X(TX5X7IQY=4OO_P"&/1E6JX>=JDN9.+?W6T_$]'UC]IS3 MIM6OM-\'^%]>\>26+F.ZN]&M]UI$PZIYI/S-_N@@]B:Z'X9_'30?B;J%YI,5 MMJ&@^([-0]QHFM6YM[M$.,,%)PR].AR,C(&17G'PAM?BEX3^&?AW3_#WAGP> MVD_8XY8ISJ4ZM/O7>9&Q%]Y\Y/N?2GZ]X#^*OB[XC>"_$UYI7AG1KK0[U3+= M:?J$KRS6KD+-"08QD%=V 3P3[UTRH4/>A=*U];[V\O,Y88G$^[4=W>UU;37S M\OQ/1+74O"!^.][IL>A%?&PT5;R75O(3:UKY@C";]V[=G'\/0#GH*P]0_:=T M"/6=7T/3=%US6_$6GWLMC_9-A:K)-,8\;YAAR%A!8#<^TY. #@U1T_Y?VS-3 MQR/^$-C_ /2L5E?LV:+;?\+8^-.K&)3=MKYMA)CD(I=L#Z[QGUP*S]E347.> MMHI_>:>VJN<84VE>33T[+\SW?0-2EUK1;*^GL+C2YKB%96L[L*)82PR4;!(! M&<=:X7XA?'SPS\-?%4.@:RE\MY<6)OH#;PB03'S/+6%%#;FE9N H7'E MXKYW\<:+;:Q^V=X$:YC606N@SW**PS\ZO(JG\"^?J!7)AX0J3?.M$F_N.W%5 M*E*G'V;]YM+7S9Z9X=^*D5[X1U/Q'XAT74?!6G6+G?\ V\B1.T8 (?:K$\YV MX]>!FN"7]JAM0A74='^&_C/6?#N'5?C7%&D:>%_!J1J,*J MZG/C'M^ZKLIT:7LU4:7O7T;M9(X9UJSJ.C%OW;:I7NWJ=K\.?B3H'Q2\/IK' MAV[^TVV\Q2QNI26"0=4D4\JP_(@Y&0)/V6&U2.ZTIO$WPRFO);Q;ZP'^FZ4) M&W,)(_\ EI&"?O \#)/I1&C1]I*,?>T5E?[]>X2Q%=TXRFN75W=NVVG1'JOB M_P",&A>#?#WA_7+M+NXT_6[NVL[62&,*5,P+([K(4*I@<]QGI7&S?M.VVI7$ MS>%?!'BGQCIENYCDU;2[(&V8@X(B9B/,P>N!TYK _:T72_'7PV\![+E)=&U? MQ+IV+N,X4P2I(-X/IM;.>U>_Z5IMMH^G6UC8P1VUG;1K%%#&NU40# 4 =@!6 M/+1ITHSE&[;?7L;\]:K6E",K)):V[G*_#/XN>'OBMI]S/H\DT5U:2>3>Z;?1 M>5=6DF2-DL>3@Y4\@D<'G@U5^)WQIT'X6R65K?K>:GK=_D66BZ5 ;B[N,=U0 M8X]R>QQG!KA?&6G0>%_VK/AYJ.E1K!>>(K/4+75DAX\^*&)7B=P.X;C)ZA0. MU<=X=/C?5/VBOB=KF@:1HFJ7]A+;Z7&=:NY(7M(!&&41A$;A\;B2>WOSM##4 MI/VGV>6]KVZVM?U,9XNM&/L_MWH=U:_M2V.FZE;6WC'P?XC\#VUU M((X=2U6U_P!$W'E0\@^XWM@@=R*]M:YA2W:=ID6!5+F0L H7&2<^F*\.\6V/ MQ>\:>&]2T/5/"G@V:QOH&MY1_:DYP&!!()B^\."#V.#VKD/B5I7BGX?_ +(^ MG>&_$%_&NH&>WTF]OK64LL=FUQM'S$#@1[$/MD=ZF6'I57'D:3;M9._S''%5 MJ7/[1.22O=JWR.XN/VGK+5KRYC\'>$/$?CBTM7,"R,1O/L!@ M\8ZUTOPW^.F@?$K4KK28[?4=!\1VBB2XT/6[8V]TJ.-OO*KXR ?;U/J:YISH6<8P?D[_F=E.&(NI2FGW5OR/FCXK?%"2']H_P"& M]P?!GBACHJW7BCPEJWQ*^'[:MX M4O+?Q;JMI7;J&EE9F"JB*6&6R>F1QFO,_VCK&;P3K'A?XK:;$[S^';@6V MJI'UFTV8[9,@=2C,&'H6)/ JIXRNH?C7\=/"_ABSE6[\,>&8H_$.IR1D/%/. MX_T2(]CP=_H58US0P\)\M1?#:[\K;KY]/4ZYXJ<.:D_BNDO-/9_+6_H>X1ZM M$NC+J=XK:9!Y GF6]*HT QN82$$J-HSGD@8ZUXW)^U/;ZM+/+X2\#>*?&.E6 M[E7U33['$#X.#Y6>7/M@5)^V+?7UG\#]1MK&7R/[0NK:RFF+;1'$\@#9(!PI MP <#H34FA_\ "W_#VCV>F:;X1\%6EA:Q+#!#'JDX5%48 '[KTJJ-&G[/VL[. M[LDW;;_AR:]>K[;V,+JR3;2OO<[/X8?&+P_\6+6[?2&NK:^LG$=[I>H1>3=V MC^DB9/IC()'!YKNMWO7S]X?^'_Q(N?CMH_CC5=.T#1[9;.2PU1-+O9)&NXB" MT>5:,&](TG6/&?B*!-\]CX?MOM'V M;H!YS9PG)]\<9QD4_P !_M#:'XR\3+X;U'3-6$^)67S(M,U^V^SO<+SDQ') M#@ 'T)YP#@UF_LD:'9V?P7TG5XV%UJFN/+J&HWS'=)<3M(VXLW4D8V_@?4U5 M_;"TNV_X4W>^(0PM=:\/W-M>Z9?*<203>?&ORD<\@].F=I[5U>SHNK]7Y=;V MYK]=MCC]IB%1^M.6EK\MNF^_<]%L_B1IUU\1]0\$M;W5MJ]I91ZBKSH@AN8& M;:6B(F15CQYX_T;X;Z-%JVN7/V6SDNH;0-QG?(X4'GL 2S=PJL M1G&*\O\ CXESX6;P7\4X+=XKGP[<1IJT2C+&PN,),,#[Q0E2/3)-<[\4/#\/ M[3'Q6?P8ERQ\,>&],:\N[B!OD:^N(R+<9'78IWCU^8'(XJ:>&A-QG)VAU?:W M^>EO4NIBZD%*"5YW7*O7_+6Y]+Y 7.>*\JF_:*\.1_#+7O'HLM4E\/Z3>M9" M2..(O>8F2'S8/WF&CWOU8J?E;CI7EO\ PN75Y/V=!X?!;_A8C7O_ AGDEL. M+LGR_-SU_P!7\^[INK;_ &C/!]I\/?V.]5\.6(_T;3[>P@5L8+L+N'G74D2\*TIC.7QZG)R>^34.%*I&:A&W+K?O MJE^IHJE>E*G*I*_,[6[:-G4?$3X^:)X#UR+P];6.I>)_%$J>8-%T.W\^>-3T M:3D!!WYYQSC%9'AO]I;3+SQ'9^'_ !1X$OBW\5?!E[X>U/PWX1@CG"O'=1ZG.9()%.5="8N""/7H2.]=3P MU&$E2G;S=];^AQK%8BI%U87\E;2WJ>F_$SXS>'?A->:'#XB>:VAU1IE2[1%, M4(B3>Q?+ \C 4$DG&*P(_VB+"T\,ZSXBUSPSK_AO1;)8FMYM3M5CDOS(<(L M4>[=N)'0]B"2*\\^,GAV]U3Q)^SUI7B@Q7NI+?8U$H=\P?&CX:S?%#P3)I=E?#3=4M[B*_L+IEW(EQ$VY-P_N]1QTSGGH$::GU MW=^S:.CVN)J2J.#MRVLK=TG^%S*\$_'B/Q3XFM-!U7PCXB$ZG>(TUF-7LBL M=PB@%@'7.U@I!(8#'3.:]5_G7D'P_P#C)JD_BJ#P5X]T+_A'?%TD3R6DT!\R MRU)%&7:!^H. 6*') ')[5Z_QZUQXB"C*RC9>MU\CNPM1U(:RO\K/YCZ***YS ML"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHI* &#M7D:?#76O$7[0C^,=?2+^P="LA;:!;B3<3-(/WT[+V;[R_ M0KZ5ZY2U<*CIWMN]#"I2C6Y>;9.X5Y%KWPWUG3?CYHGCOP]'$]G>VCZ;K]N[ MA"\8(,4R_P!Y@0,]$ .M>N?Q&EQM&.M.G4E3NUU5F%6E&JES=&FCR?P7\.M M8T/XB?%C6;E(19^(FM38%9,L?+A9&W#MR16E^SUX(U/X=?!_P]X=UE(X]1LE MF$JPOO4;IG=<'OPPKTBDK2=>51-/K;\%9&=/#0IR4ETO^+NQ,9!%>8? OX?Z MMX#M_'*ZLD2MJWB>]U6V\IPV8)1'L)]&^4\5ZA1NK)3<4XKK^AK*G&4E-[J_ MXGF'[._@'5OAO\.5T;6DBCO1>W,Y$,F\;'D++SZX(K,^(7PM\1VOC@>/?A]> M6EGXAD@6VU+3=14BUU.-?NEV7E9% PK#T R!G/L/MFDQ6WUB?M'5>[W\S%X6 MG[*-+HMNZ/#[Y?C-\1+>71;O2])\ Z9.#'=ZI!??;;IHSPP@ "L1QN;H#D< MBM+]G_X1W/@#X3W7A+Q#;03Q375T&AWB59+>1L ,<#DKUKUZEZ=ZJ6*E*#II M)*Z>GS/ M#$_%+X)PR:+X6M=-\<^$HBQTZWO[PVE[9J6 MSY1<@JZ '@]>W' KG?B-\'/BC\76TC6=?N-.L)-/U"WFL_#>GW!,$,8?,DLT MK#]Y+C"C SCJ<_3[=O2C\:TCC)QESJ*YN]M3.6 ISCR.3Y>U]#SKXO_"F3 MXBV6EWNE:D=$\5:'/]KTK4PF\1OC#1N.\;X 8>PX/(/)2>(OCU):#3D\(^%H M;\H%.L'4W-J&/!;R=OF>_4_C7N2D;>E'&[IS6,,0X+E:3[7-YX6,YW M4X/X1_#:X^'?A^[BU'5IM=UW4KE[[4M0DRJRSOU")T1 /3MT&9^S=X"U; MX9?!_1/#NMK%'J5JTYD2%]Z#?.[K@C_985Z?0/7M4.M.2E%]7?[O^'*CAX1E M%K[*:^\\PU3P!JUW^T/HWC!$B_L:UT*6PDVGS1E_+^FH_80Y91_FW^9Y)XP^#-SX MN\ ^%((-0_L/Q?XR[3K7]IO]E#?WS#M\PCVS_A7MQXXHV@MFM(XAI6DD_7H8RPD;W@VMMN MMCPCX-?!/Q'\/?BMXK\0:SJG]MKK%G#YFI2%5>:XW9D C'W$' 4>@KJ?V=_ M6K?#?X;IHVM)$EZ+ZYGQ#)O78\A9>?7!%>GX-&,4ZN*J54U/K;\-$.CA*=%I MPZ7_ !U9Y/X6^%]Y;?%[XIZUJ]K:W6@>)HM/BMXI"LGFK%;F.19$(Z9.,'.1 M6?X/^&_BCX.^+EL?"[+JWPYOG+MI=Y/B?2)">3 S??B.<["<^ASG=[,?6EQV MS4O$U'=/71*WHK(:PE.-G'1W;OZZL\6UV^^-NBZMJMKIVC^'?$NGW,[OI]]) M<&U-HC'Y4FC_ (]OJIR<=W<)DFN;A%VI)-([. MY4>F6(']M)^RM'-IMY:J UC-%_JI(P,?=Z8 MXX)&1UKNLPR?F(R?U/IPHQ1/$.2:44K[V0Z>&46FY-VVNSR3X/_"V]\.>&?&^ MC>)K6WGM=V:$_ZIG(*NB\8/7J. ![_BD[4_K4N9N23OT\Q?5(*,5%M-=3Q3PU M\,?%WC;Q[I_C+XCSV,(TDLVC^'=,9G@MI",&:5V^_(!P,# P",=*W9/A_J[_ M +247C4)$=#7PQ_91??^\\_[49,;?3:>M>G]>E'.<4OK$Y._E:W9!'"TXJVN MZ=^[1A>.M)N/$'@K7],M INKW3[BWBWG +O&RJ#[9(KSFU\#Z-X?_9NL?"GQ M$FM;#38=/ALKZ:2<+'%)E0C*Y& 0^T@^H%>R5F^(- L/%&CWFDZI;1WNGWD; M0SV\HRKJ1R#_ )XJ*=5P2C?2Z?GH:5:*FW.UW9KRU/$]%T?XW^!]/ATK2+[P MOXUT:-%6RU+57FANA&!\OF[,A_E &X9)ZDFN+U3P9K\?[1OPLOO%&N1ZUXNN M9+VXN;?3T,=EIUI'$2B1J1N(+LPWN&^6W7KLC:0;E4= ,UU'PW^"^F> =4OM;GU'4/$GB>^3RKG6M6EWS&, M'/EH!@(F0/E'H/08]/ZQ"G>2:NTUHK-W5M3QUAJE1Q@T[)IZNZ5G?0]&SFO+ MOCAX U;QU-X!?2DB=='\3V6JW7FN%Q!$6WE?4_,.*]2I.U>3";IRYD>[4IJK M'DD<5\5OAG9_%7PC+H]U/+87"2)'?#?B.Z13&NN_P!HM;HX'"O+#MW;B.2%('IBOYY;\(?A/?^$;[5_%'BG4H];\:ZT5%W=1(5AMHE^[;P \[ M >YP6P">E>I;L#UHH]JSJ3E4E>1M2IQHPY(['E_CKP#JVN_&WX9^)[2.(Z7H M*ZD+UG?#CSH-D>T=\MU]*=\0? .K>(?C%\+_ !'9I$VF^'VU$WS.^'7SH%1- MH[\@_2O3=W6G=:U6(FK>2:^^_P#F9/#0ES?WFG\U;_(&72_ WX6W?A7 MX2W'A;Q/:V\YNKF\,\"OYD;PRR,<$^ZGD5ZY31C%9QJ2C%PCUL_N_P"'-948 MSFIRZ)K[SP#0?#7Q7^"UFV@^'+/3?'OA6 _\2Y;Z]-I?6L9.?*=B"KJN>#UP M,<< :_A+X?\ CCQ9XZL/&'Q"O+*R321)_9?A[1Y&:*-W&UI9I#_K&QP%Z#@\ M<@^S&BMY8J4EK%)O=VU.:.#C%I86OP_P!6A_:,U#QBR1?V+-X< M33%;?^\\X7'F$;?3;WH^#O@'5?!?B+XA7FI)$L.M:[)?VC1ON+0LH W>AXZ5 MZCTZT5FZ\FG'NDON-(X:$9*79M_>+WKRW5/ .K77[1&C>+T2+^QK;0I;"1B_ MS^<9=PPOI@]:]2I.]9PJ.FVUU5OO-JE-5$D^CO\ <<3\6/AC9_%;PG)HUS.] MA=1RI=6.H0C,EG<(1UK@H=:^/&C6@TR3PQX;U^[0%%UI-1:" M)@.CO"5W9QU"D#/3%>YX]^:0@FM(5W3CRM)KSZ&-3#1G+G3:?EU/,?A-\-== M\+SZSXA\4ZTNL>+]:*&X>$,+2U1!A(8DR/E7G)X)_4\7X@L_CGJ_AW4_!]UI M?AO4(]0CEM&\3?:#&@@D!4LUMC.\*V,#C([]_H*EJXXB2DYM)_+8B6%BX*"D MU;SW]3Y?_:0^'UIHWP7^&O@H7,TEE#KVF:8URN%D9?+D1I!G(#'D]ZZZPN/C M9X'MXM&72-'\>6\(V6^MRZ@;.=H_X?/C8-N?W4\@9/)KO?B;\-;7XE6NB6]S M>360TG5;?5T:%0=[0YPASV.:[,'@5L\5^ZC%I-W;=_,YXX.U:4XMQ5DE9]$> M2_#/X4Z[;^,+SQWX\U"UU+Q7<0?9;:VL%(M--@W$F.+=R2>['GDCG))A\>?# M#Q+IOCP^/OA[=6<.NW$*6NJZ3J.Y;74HE^ZQ9>5D4!Z'8_&CX6Z2FAVMAI/Q$TZU_ M=V.H37WV.[6(# 68,"K$= 0>G4FND^'WAOXF7_C!O$OC;6K33K-(&@MO#.C$ MO;C./WDTC#+,,'&/S RI]8I*J6(,O .K:W\>)A]Y&!4C\C7FW[.GP3_ .%*^$KRQNKA;_5;R[>2>\&27B0[(%R> M<", X[%B!Q7K)XYHK.-6<8.FGH_T-)482J*JU[RO;YG/^.O!>F_$+PCJ?AW5 MHO-L-0B,3X.&4\%74]F5@&!]0*\GT?\ X7;\/]/30XM)T7QW:6V(+/5Y+\VE MQY0&%,Z,#N8=/E/.,Y.2_#/X< M>*_^$NN?&WCW4X+C7YK;['::9I;.+.P@+;BHR?G" M*(_"%[*]TGA[4KA MK62PE8Y*V\H!7RR23AAQQ[DN?X;^.OC%X@TNZ^(B:;H?A;3)DNXO#6FS&X:[ MF7E3<2$ %0?X0,$$@CO7O%%='UN>]ES=^IR_4H?#=\O\O0S/$6@VGBC0=0T> M_B\VQO[=[:=/[R.I5A['!KS[]G;X.M\&? CZ5ZM=74EQ=W:Y/F<[(P"> M<"-4X['->IFE'S5SJK-0=-/1NYU.C3E455KWDK?>>-_\,^VG_#11^(H9?LGV M+=]DY_X_L>5YV.F/*X]<\UL?M'>!-5^)7P;\0>'-$2-]3O#;^4LSA$.RXCD; M)[?*IKTSO036GUBIS0FW=QM;Y&7U6DH3@E93O?YD5JABMXD;JJ@'\J\U\*> M=5TKX\>.?%-PD7]DZM9V<%LROE]T:8?([5Z?_%1W-9QJ./-;[6GZ_H:RHQGR MW^R[_A8\0UCX:^,OAYXWU;Q-\.3IU]8:W+]HU7PYJ&0?==C][(P M??C;0U?PM\5OC1Y.E>*+?3? OA(NDE];Z=>&YOKP*P/E"0 *B$KU'/3KR*]] M[48K=8J2L[)M=;:G,\'#56?$7X6/%=%\2;?QDV@P2>"9]/35+>X262WU-&,5S$ =T6Y3\A)(.['; M'&:[+M1MK+VTGRW2?+_GS:?8W^WJV MWS_/P^,<;LY\O&#C&[(SBO1*6KEB)2=VE:UK=O\ @D1PL8JRD]TV[[V'4445 MS'8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9 end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2018

Oct. 30, 2018

Document Information [Line Items]

Entity Registrant Name HALOZYME THERAPEUTICS INC.

Trading Symbol HALO

Entity Central Index Key 0001159036

Document Type 10-Q

Document Period End Date Sep. 30, 2018

Amendment Flag false

Document Fiscal Year Focus 2018

Document Fiscal Period Focus Q3

Current Fiscal Year End Date --12-31

Entity Filer Category Large Accelerated Filer

Entity Common Stock, Shares Outstanding 144,557,543

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Current assets:

Cash and cash equivalents $ 55,019 $ 168,740

Marketable securities, available-for-sale 309,347 300,474

Accounts receivable, net 27,656 22,133

Inventories 18,285 5,146

Prepaid expenses and other assets 19,619 13,879

Total current assets 429,926 510,372

Property and equipment, net 6,790 3,520

Prepaid expenses and other assets 7,291 5,553

Restricted cash 500 500

Total assets 444,507 519,945

Current liabilities:

Accounts payable 3,331 7,948

Accrued expenses 43,020 39,601

Deferred revenue, current portion 4,247 6,568

Current portion of long-term debt, net 88,521 77,211

Total current liabilities 139,119 131,328

Deferred revenue, net of current portion 5,507 54,297

Long-term debt, net 57,940 125,140

Other long-term liabilities 2,203 814

Commitments and contingencies (Note 9)

Stockholders' equity (deficit):

Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding 0 0

Common stock - $0.001 par value; 200,000 shares authorized; 142,301 and 129,502 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively 145 143

Additional paid-in capital 769,382 731,044

Accumulated other comprehensive loss (478) (450)

Accumulated deficit (529,311) (522,371)

Total stockholders' equity (deficit) 239,738 208,366

Total liabilities and stockholders' equity (deficit) $ 444,507 $ 519,945

X

- Definition
Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669686-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=75030427&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82896770&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
shares in Thousands

Sep. 30, 2018

Dec. 31, 2017

Statement of Financial Position [Abstract]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 20,000 20,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 200,000 200,000

Common stock, shares issued 144,522 142,789

Common stock, shares outstanding 144,522 142,789

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Revenues:

Product sales, net $ 6,269 $ 13,589 $ 17,553 $ 37,803

Royalty Revenue 18,710 17,119 59,643 45,839

License and Services Revenue 577 33,023 14,434 43,407

Total revenues 25,556 63,731 91,630 127,049

Operating expenses:

Cost of product sales 626 8,332 4,514 23,664

Research and development 35,540 33,993 113,602 109,267

Selling, general and administrative 14,864 13,329 42,773 39,045

Total operating expenses 51,030 55,654 160,889 171,976

Operating income (loss) (25,474) 8,077 (69,259) (44,927)

Other income (expense):

Investment and other income, net 1,910 790 5,561 1,512

Interest expense (4,286) (5,538) (14,286) (16,526)

Income (loss) before income taxes (27,850) 3,329 (77,984) (59,941)

Income tax expense 0 580 220 970

Net income (loss) $ (27,850) $ 2,749 $ (78,204) $ (60,911)

Earnings Per Share, Basic $ (0.19) $ 0.02 $ (0.55) $ (0.45)

Earnings Per Share, Diluted $ (0.19) $ 0.02 $ (0.55) $ (0.45)

Shares used in computing basic net income (loss) per share 143,949 141,190 143,396 134,633

Shares used in computing diluted net income (loss) per share 143,949 143,236 143,396 134,633

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=96948231&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Statement of Comprehensive Income [Abstract]

Net income (loss) $ (27,850) $ 2,749 $ (78,204) $ (60,911)

Other comprehensive income (loss):

Unrealized gain (loss) on marketable securities 256 24 (17) (40)

Foreign currency translation adjustment 2 1 (11) (6)

Unrealized loss on foreign currency 0 (17) 0 (1)

Total comprehensive income (loss) $ (27,592) $ 2,757 $ (78,232) $ (60,958)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e557-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Statement of Cash Flows [Abstract]

Capital Expenditures Incurred but Not yet Paid $ 2,345 $ 266

Operating activities:

Net loss (78,204) (60,911)

Adjustments to reconcile net loss to net cash used in operating activities:

Share-based compensation 26,684 23,268

Depreciation and amortization 1,798 1,668

Non-cash interest expense 2,000 2,378

(Accretion of discounts) amortization of premiums on marketable securities, net (2,166) (94)

Deferral of unearned revenue 3,000 422

Recognition of deferred revenue (2,333) (4,192)

Recognition of deferred rent (78) 125

Other (10) 38

Changes in operating assets and liabilities:

Accounts receivable, net 13,962 985

Inventories (13,139) 5,292

Prepaid expenses and other assets (7,477) 8,998

Accounts payable and accrued expenses (4,155) 3,077

Net cash used in operating activities (59,962) (19,196)

Investing activities:

Purchases of marketable securities (272,643) (198,748)

Proceeds from maturities of marketable securities 265,917 184,494

Purchases of property and equipment (1,590) (490)

Net cash used in investing activities (8,316) (14,744)

Financing activities:

Proceeds from issuance of common stock, net 0 134,875

Repayment of long-term debt (57,099) (10,988)

Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement 11,656 7,686

Net cash provided by financing activities (45,443) 131,573

Net increase in cash, cash equivalents and restricted cash (113,721) 97,633

Cash, cash equivalents and restricted cash beginning of period 169,240 67,264

Cash, cash equivalents and restricted cash end of period 55,519 164,897

Payments for Tenant Improvements $ 1,322 $ 0

X

- Definition
The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense attributable to debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(8))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(8))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).
+ References
No definition available.
+ Details

Name: us-gaap_OtherOperatingActivitiesCashFlowStatement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.
+ References
No definition available.
+ Details

Name: us-gaap_PaymentsForTenantImprovements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=82896770&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=SL79508275-113901
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=82896770&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_RecognitionOfDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfSecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfCashFlowsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Difference between actual rental income due and rental income recognized on a straight-line basis.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_StraightLineRent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 22 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1

Organization and Business
9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Business
Organization and Business
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.
Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds.
The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex^® recombinant, and it works by temporarily breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE^® Drug Delivery Technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.
We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”) and Alexion Pharma Holding (“Alexion”).We receive royalties from two of these collaborations, including royalties from sales of one product from the Baxalta collaboration and two products from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.
Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is Pegvorhyaluronidase alfa (PVHA), also referred to as PEGylated recombinant human hyaluronidase (“PEGPH20”), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause increased pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. Through our efforts and efforts of our partners and collaborators, we are currently in Phase 3 clinical testing for PEGPH20 with ABRAXANE^®(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (HALO 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA^® (pembrolizumab) in non-small cell lung cancer and gastric cancer (HALO 107-101), in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq® (atezolizumab) in patients with previously treated metastatic PDA, in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with gastric cancer and in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX).
Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
Basis of Presentation
The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on February 20, 2018. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated statement of cash flows within operating activities to conform to the current period presentation. There was no change to net cash used in operating activities. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.
The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.
Cash Equivalents and Marketable Securities
Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of September 30, 2018, our cash equivalents consisted of money market funds and commercial paper.
Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.
Restricted Cash
Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. At September 30, 2018 and December 31, 2017, restricted cash of $0.5 million was pledged as collateral for the letters of credit.
Fair Value of Financial Instruments
The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.
Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.
Inventories
Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
We capitalize inventory costs associated with our drug candidates prior to receipt of regulatory approval, based on management’s judgment of probable future commercialization. We would be required to expense these capitalized costs upon a change in such judgment, due to, among other factors, a decision denying approval of the drug candidate by regulatory agencies.
Bulk rHuPH20 formulations manufactured for partner use prior to our partner receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries and with no alternative future use are recorded as research and development expense. All direct manufacturing costs incurred after the partner receives marketing approval are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in any stage of development or in commercial product, and ENHANZE drug product used by our partners in clinical trials, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.
As of September 30, 2018 and December 31, 2017, inventories consisted of $2.4 million and $2.9 million, respectively, of Hylenex recombinant inventory, net and $15.9 million and $2.2 million, respectively, of bulk rHuPH20.
Revenue Recognition
We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, Revenue from Contracts with Customers (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted. Accordingly, the reported revenue amounts for the three and nine months ended September 30, 2018 and 2017 are based on different accounting policies.
Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.
Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018
Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services.
We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.
Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers.
Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE^® technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.
When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).
We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements representations and are not obligations to provide goods or services.
We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.
Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals and successful completion of clinical trials. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.
When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target if the exchange right is exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.
Because our agreements only have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.
We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners.
Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner.
Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups.
In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.
Refer to Note 4 Revenue, for further discussion on our collaborative arrangements.
Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other differences in revenue to be recognized under the previously existing authoritative accounting literature and ASC 606 applied to our collaborative agreements.
Product Sales, Net - as reported under ASC 606 beginning January 1, 2018
Hylenex Recombinant
We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders. We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.
Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.
We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.
Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.
We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.
Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustments.
In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of a practical expedient allowed in ASC 606.
Bulk rHuPH20
We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
We recognize revenue from bulk rHuPH20 formulations as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.
ENHANZE Drug Product
We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
We recognize revenue from ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.
Revenue Presentation
In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms and sales of bulk rHuPH20 that has no alternative future use. We report royalties received from collaboration partners as a separate line in our statements of operations.
Revenues from sales of Hylenex recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.
In footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront amounts, event-based development and regulatory milestones and other fees, sales milestones and royalties).
Cost of Product Sales
Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 and ENHANZE drug product that has alternative future use. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any. Prior to bulk rHuPH20 and ENHANZE drug product having alternative future use, all costs related to the manufacturing of those products were charged to research and development expenses in the periods such costs were incurred. During the three and nine months ended September 30, 2018, sales of bulk rHuPH20 and ENHANZE drug product included $1.7 million and $2.3 million, respectively, of cost of sales that were previously expensed as research and development. Of the bulk rHuPH20 and ENHANZE drug product that has alternative future use on hand as of September 30, 2018, approximately $2.0 million in manufacturing costs were previously recorded as research and development expenses. We expect to sell this inventory by the end of 2020.
Research and Development Expenses
Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. The manufacturing costs of bulk rHuPH20 for the approved collaboration products, Herceptin SC, MabThera SC (RITUXAN HYCELA™ in the U.S.) and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in any stage of development or in commercial products, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.
We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.
Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred. We currently have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.
Clinical Trial Expenses
We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.
Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.
Share-Based Compensation
We record compensation expense associated with stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and RSUs with performance conditions (“PRSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.
Income Taxes
We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to zero, with the exception of the alternative minimum tax ("AMT") credit carryover of $5.5 million. Under the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017, the AMT credit carryover will either be utilized, or if unutilized fully refunded in 2022. For all other deferred tax assets the valuation allowance will reduce the net value to zero until such time as we can demonstrate an ability to realize them.
The Act reduces the U.S. federal corporate tax rate from 35% to 21%. As a result, the Company evaluated and adjusted its deferred tax assets to reflect the new corporate tax rates as of December 31, 2017. The Company is still evaluating other potential impacts and planning opportunities related to tax reform. As of September 30, 2018, the Company believes that its disclosures in its financial statements as of December 31, 2017 are still reasonably accurate.
Net (Loss) Income Per Share
Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. For the three and nine months ended September 30, 2018, approximately 13.8 million shares of outstanding stock options, unvested RSAs, unvested RSUs were excluded from the calculation of diluted net loss per common share because a net loss was reported in each of these periods and therefore their effect was anti-dilutive.  Outstanding common stock equivalents totaling approximately 7.8 million and 14.3 million, respectively, were excluded from the calculation of diluted net (loss) income per common share for the three and nine months ended September 30, 2017, respectively, because their effect was anti-dilutive. A reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Numerator:

Net (loss) income

$
(27,850
)

$
2,749

$
(78,204
)

$
(60,911
)
Denominator:

Weighted average common shares outstanding for basic
net (loss) income per share

143,949

141,190

143,396

134,633

Net effect of dilutive common stock equivalents

—

2,046

—

—

Weighted average common shares outstanding for diluted
net (loss) income per share

143,949

143,236

143,396

134,633

Net (loss) income per share:

Basic

$
(0.19
)

$
0.02

$
(0.55
)

$
(0.45
)
Diluted

$
(0.19
)

$
0.02

$
(0.55
)

$
(0.45
)

Segment Information
We operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Our long-lived assets located in foreign countries had minimal book value as of September 30, 2018 and December 31, 2017.
Adoption and Pending Adoption of Recent Accounting Pronouncements
The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters

In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.

The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.

January 1, 2018

We currently do not hold equity securities. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.

In October 2016, the FASB issued ASU 2016-16, Income Taxes; Intra-Entity Transfers of Assets Other Than Inventory.

The new guidance removes the current requirement to defer the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) until the asset has been sold to an outside party. As a result, the income tax consequences of an intercompany transfer of assets other than inventory will be recognized in the current period income statement rather than being deferred until the assets leave the consolidated entity.

January 1, 2018

We adopted the new guidance on January 1, 2018. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.

Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In March, April, May and December 2016, the FASB issued additional guidance related to Topic 606.

The new standard superseded nearly all existing revenue recognition guidance. Under Topic 606, an entity is required to recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. Topic 606 defines a five-step process in order to achieve this core principle, which may require the use of judgment and estimates, and also requires expanded qualitative and quantitative disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including significant judgments and estimates used. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.

January 1, 2018

We adopted the new guidance on January 1, 2018 using the modified retrospective approach. Refer to Notes 2 “Revenue Recognition” and 4 for additional detail regarding the impact of this adoption.

Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In July 2018, the FASB issued additional guidance related to Topic 842.

The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.

January 1, 2019. Early adoption is permitted.

We plan to implement the guidance on January 1, 2019 using a modified retrospective transition basis for leases existing as of the period of adoption. In order to adopt the new standard, we will be using available practical expedients and newly implemented processes and internal controls for lease accounting. The practical expedients allow us to carry forward our historical assessment of whether existing agreements are or contain a lease and the classification of our existing lease arrangements. We expect all of our real-estate and automobile operating lease commitments will be recognized as lease liabilities with corresponding right-of-use assets upon adoption, resulting in an increase in the assets and liabilities of the consolidated balance sheet. We anticipate that the adoption will have a material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).

The new guidance removes, modifies and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement.

January 1, 2020

We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our condensed consolidated financial position or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurement (Notes)
9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]
Fair Value Measurement
Available-for-sale marketable securities consisted of the following (in thousands):

September 30, 2018

Amortized Cost

Gross Unrealized Gains

Gross Unrealized Losses

Estimated Fair Value

Asset-backed securities

$
39,721

$
—

$
(24
)

$
39,697

Corporate debt securities

74,699

—

(181
)

74,518

U.S. Treasury securities

99,716

—

(248
)

99,468

Commercial paper

95,664

—

—

95,664

$
309,800

$
—

$
(453
)

$
309,347

December 31, 2017

Amortized Cost

Gross Unrealized Gains

Gross Unrealized Losses

Estimated Fair Value

Corporate debt securities

$
117,427

$
—

$
(235
)

$
117,192

U.S. Treasury securities

66,601

—

(201
)

66,400

Commercial paper

116,882

—

—

116,882

$
300,910

$
—

$
(436
)

$
300,474

As of September 30, 2018, all of our available-for-sale debt securities were scheduled to mature within the next 12 months and 27 available-for-sale marketable securities were in a gross unrealized loss position, all of which had been in such position for less than 12 months. Based on our review of these marketable securities, we believe we had no other than-temporary impairments on these securities as of September 30, 2018, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.
The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):

September 30, 2018

December 31, 2017

Level 1

Level 2

Total estimated fair value

Level 1

Level 2

Total estimated fair value
Cash equivalents:

Money market funds

$
55,271

$
—

$
55,271

$
142,091

$
—

$
142,091

Commercial paper

—

—

—

—

15,700

15,700

Available-for-sale marketable
   securities:

Asset-backed securities

—

39,697

39,697

—

—

—

Corporate debt securities

—

74,518

74,518

—

117,192

117,192

U.S. Treasury securities

99,468

—

99,468

66,400

—

66,400

Commercial paper

—

95,664

95,664

—

116,882

116,882

$
154,739

$
209,879

$
364,618

$
208,491

$
249,774

$
458,265

There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the nine months ended September 30, 2018. We had no instruments that were classified within Level 3 as of September 30, 2018 and December 31, 2017.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue (Notes)
9 Months Ended

Sep. 30, 2018

Deferred Revenue Disclosure [Abstract]

Collaborative Agreements
Our disaggregated revenues were as follows (in thousands):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Royalties

$
18,710

$
17,119

$
59,643

$
45,839

Product sales, net

  Sales of bulk rHuPH20

$
2,402

$
9,748

$
6,350

$
26,825

  Sales of ENHANZE drug product

186

—

322

—

  Sales of Hylenex

3,681

3,841

10,881

10,978

Total product sales, net

6,269

13,589

17,553

37,803

Revenues under collaborative agreements:

  Upfront license fees

—

30,352

1,336

31,054

  Event-based development milestones and other fees

—

329

11,000

988

  Sales-based milestones

—

342

—

1,028

  Research and development services

577

2,000

2,098

10,337

Total revenues under collaborative agreements

577

33,023

14,434

43,407

Total revenue

$
25,556

$
63,731

$
91,630

$
127,049

During the three months ended September 30, 2018 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $18.7 million. This amount represents royalties earned in the current period. We recognized revenue of $0.5 million during the three months ended September 30, 2018 that had been included in deferred revenues at December 31, 2017. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.
During the nine months ended September 30, 2018 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $70.6 million. This amount represents royalties earned in the current period, development milestones of $1.0 million from Roche and $5.0 million from Alexion, and $5.0 million of variable consideration in the contract where uncertainties have been resolved and the development milestone is expected to be achieved. We also recognized revenue of $2.3 million during the nine months ended September 30, 2018 that had been included in deferred revenues at December 31, 2017. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.
Revenue recognized during the three and nine months ended September 30, 2017 was determined in accordance with the accounting rules applicable prior to the adoption of ASC 606 on January 1, 2018.
Upon the adoption of ASC 606, we recognized an adjustment to increase our accounts receivable by $19.4 million, decrease deferred revenues by $51.8 million, and decrease accumulated deficit by $71.2 million. The impact of applying the provisions of ASC 606 in the three and nine months ended September 30, 2018 was to decrease revenues by $6.4 million and to increase revenues by $2.6 million, respectively. Under the previously existing authoritative accounting literature, at September 30, 2018 our accounts receivable and other contract assets would have been $18.7 million lower, and our deferred revenue $48.7 million higher, than the amounts reported in our condensed consolidated balance sheet. ASC 606 did not have an aggregate impact on our net cash used in operating activities, but resulted in offsetting changes in net loss and certain assets and liabilities within net cash used in operating activities in the condensed consolidated statement of cash flows.
Accounts receivable, net, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):

September 30, 2018

December 31, 2017
Accounts receivable, net

$
22,656

$
22,133

Other contract assets

5,000

—

Deferred revenues

9,754

60,865

As of September 30, 2018, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $9.8 million. This amount has been collected and is reported as deferred revenues. Of the total deferred revenues, $3.0 million represents pre-payment of bulk rHuPH20 that we estimate will be delivered in 2019. Of the remaining deferred revenues, for which the timing of when these goods and services will be provided is controlled by our customers, $4.5 million can be used by the customers at any time through 2022 and the remaining $2.3 million at any time through 2019.
We recognized contract assets of $5.0 million related to collaborative agreements as of September 30, 2018, for amounts considered probable to receive for development milestones that relate to intellectual property licenses granted to collaboration partners in prior periods. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of September 30, 2018 (in thousands):

Upfront
(1)

Development
(2)

Sales
(3)

Royalty

Total
Collaboration partner and agreement date:

Roche (December 2006 and September 2017)

$
70,000

$
25,000

$
22,000

$
211,613

$
328,613

Baxalta (September 2007)

10,000

3,000

9,000

22,438

44,438

Pfizer (December 2012)

14,500

2,000

—

—

16,500

Janssen (December 2014)

15,250

15,000

—

—

30,250

AbbVie (June 2015)

23,000

6,000

—

—

29,000

Lilly (December 2015)

33,000

—

—

—

33,000

BMS (September 2017)

105,000

5,000

—

—

110,000

Alexion (December 2017)

40,000

5,000

—

—

45,000

(1)
Upfront and additional target selection fees
(2)
Event-based development and regulatory milestone amounts and other fees
(3)
Sales-based milestone amounts
Through September 30, 2018, our collaboration partners have completed development, obtained marketing authorization approvals for certain indications and commenced commercialization of the following products:
•
Roche, for Herceptin SC in the European Union (“EU”) in August 2013; and MabThera SC in the EU in March 2014 and its equivalent RITUXAN HYCELA™ in the US in June 2017; and Herceptin SC in Canada in September 2018;
•
Baxalta, for HYQVIA in the EU and in the US in May 2013.
The remaining targets and products are currently in the process of development by the collaboration partners.

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-URI http://asc.fasb.org/topic&trid=5833765
+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1

Certain Balance Sheet Items (Notes)
9 Months Ended

Sep. 30, 2018

Balance Sheet Related Disclosures [Abstract]

Certain Balance Sheet Items
Certain Balance Sheet Items
Accounts receivable, net and other contract assets consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Accounts receivable from product sales to collaborators

$
1,980

$
18,475

Accounts receivable from revenues under collaborative agreements

451

2,142

Accounts receivable from royalty payments

18,777

—

Accounts receivable from other product sales

1,949

2,075

Other contract assets

5,000

—

     Subtotal

28,157

22,692

Allowance for distribution fees and discounts

(501
)

(559
)
     Total accounts receivable, net and other contract assets

$
27,656

$
22,133

Inventories consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Raw materials

$
625

$
377

Work-in-process

15,401

2,131

Finished goods

2,259

2,638

     Total inventories

$
18,285

$
5,146

Prepaid expenses and other assets consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Prepaid manufacturing expenses

$
8,844

$
2,337

Prepaid research and development expenses

9,195

7,793

Other prepaid expenses

2,344

2,585

Other assets

6,527

6,717

     Total prepaid expenses and other assets

26,910

19,432

Less long-term portion

7,291

5,553

     Total prepaid expenses and other assets, current

$
19,619

$
13,879

Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations. Such amounts are reclassified to work-in-process inventory as materials are used or the CMO services are complete.
Property and equipment, net consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Research equipment

$
9,528

$
9,268

Manufacturing equipment

3,979

1,702

Computer and office equipment

4,811

3,725

Leasehold improvements

4,160

2,715

     Subtotal

22,478

17,410

Accumulated depreciation and amortization

(15,688
)

(13,890
)
     Property and equipment, net

$
6,790

$
3,520

Depreciation and amortization expense totaled $0.6 million and $0.5 million for the three months ended September 30, 2018 and 2017, and $1.8 million and $1.7 million for the nine months ended September 30, 2018 and 2017, respectively.
Accrued expenses consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Accrued outsourced research and development expenses

$
19,786

$
18,757

Accrued compensation and payroll taxes

12,914

13,384

Accrued outsourced manufacturing expenses

4,743

2,504

Other accrued expenses

6,142

5,396

     Total accrued expenses

43,585

40,041

Less long-term portion

565

440

     Total accrued expenses, current

$
43,020

$
39,601

Deferred revenue consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Collaborative agreements

License fees and event-based payments:

Roche

$
—

$
39,379

Other

2,265

15,999

Total license fees and event-based payments

2,265

55,378

Product sales

7,489

5,487

Total deferred revenue

9,754

60,865

Less current portion

4,247

6,568

Deferred revenue, net of current portion

$
5,507

$
54,297

X

- References
No definition available.
+ Details

Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-URI http://asc.fasb.org/topic&trid=2122208
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1

Long-Term Debt, Net (Notes)
9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Long-term Debt
Long-Term Debt, Net
Royalty-backed Loan
In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (“Halozyme Royalty”), we received a $150 million loan (the “Royalty-backed Loan”) pursuant to a credit agreement (the “Credit Agreement”) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the “Royalty-backed Lenders”). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (“Collaboration Agreements”). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the “Royalty Payments”). The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of September 30, 2018 was 10.25%.
The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first to pay interest and second to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps.
Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050. Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan.
As of September 30, 2018, we were in compliance with all covenants under the Royalty-backed Loan and there was no material adverse change in our business, operations or financial condition.
We began making principal and interest payments against the Royalty-backed Loan in the first quarter of 2017 and therefore had no capitalized interest in the three and nine months ended September 30, 2018. In addition, we recorded accrued interest, which is included in accrued expenses, of $0.5 million and $0.7 million as of September 30, 2018 and December 31, 2017, respectively
In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of $1.5 million and incurred additional debt issuance costs totaling $0.4 million, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of September 30, 2018, and are being amortized over the estimated term of the debt using the effective interest method. For the three months ended September 30, 2018 and 2017, the Company recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of $3.1 million and $4.2 million, respectively, and $10.5 million and $12.4 million for the nine months ended September 30, 2018 and 2017, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of September 30, 2018 was $101.0 million, net of unamortized debt discount of $0.4 million.
Oxford and SVB Loan and Security Agreement
In June 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (collectively, the “Lenders”), providing a senior secured loan facility of up to an aggregate principal amount of $70.0 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we had the option to draw during the second quarter of 2017 and did not exercise. The initial proceeds were partially used to pay the outstanding principal and final payment of $4.25 million owed on a previous loan agreement with the Lenders. The remaining proceeds are being used for working capital and general business requirements. The senior secured loan facility carries a fixed interest rate of 8.25%. The repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provides for a final payment equal to 5.50% of the initial $55.0 million principal amount. The final payment is due when the Loan Agreement becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the Loan Agreement in full, subject to a prepayment fee of 2% in the first year and 1% in the second year of the Loan Agreement.
In connection with the Loan Agreement, the debt offering costs have been recorded as a debt discount in our condensed consolidated balance sheets which, together with the final payment and fixed interest rate payments, are being amortized and recorded as interest expense throughout the life of the loan using the effective interest rate method.
The Loan Agreement is secured by substantially all of the assets of the Company and our subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any of our intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our subsidiary, Halozyme, Inc.
The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of the Lender’s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan. In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition.
As of September 30, 2018, we were in compliance with all covenants under the Loan Agreement and there was no material adverse change in our business, operations or financial condition.
Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.2 million and $1.4 million for the three months ended September 30, 2018 and 2017, respectively, and $3.8 million and $4.1 million for the nine months ended September 30, 2018 and 2017, respectively. Accrued interest, which is included in accrued expenses, was $0.3 million and $0.4 million as of September 30, 2018 and December 31, 2017, respectively. The outstanding term loan balance was $45.5 million as of September 30, 2018, inclusive of $2.0 million of accretion of the final payment and net of unamortized debt discount related to offering costs of $0.2 million.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1

Share-based Compensation (Notes)
9 Months Ended

Sep. 30, 2018

Share-based Compensation [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Share-based Compensation
Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Research and development

$
4,407

$
3,060

$
13,107

$
9,891

Selling, general and administrative

4,460

4,702

13,577

13,377

Share-based compensation expense

$
8,867

$
7,762

$
26,684

$
23,268

Share-based compensation expense by type of share-based award (in thousands):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Stock options

$
4,645

$
4,973

$
14,026

$
14,971

RSAs, RSUs and PRSUs

4,222

2,789

12,658

8,297

$
8,867

$
7,762

$
26,684

$
23,268

We granted stock options to purchase approximately 0.4 million and 0.1 million shares of common stock during the three months ended September 30, 2018 and 2017, respectively, and 2.3 million and 2.5 million shares of the Company’s common stock during the nine months ended September 30, 2018 and 2017, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (“Black-Scholes model”). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Expected volatility

58.6-60.6%

70.5-70.8%

58.7-70.1%

70.5-71.7%
Average expected term (in years)

5.4

5.6

5.5

5.6
Risk-free interest rate

2.75-2.87%

1.73-1.93%

2.25-2.87%

1.73-1.94%
Expected dividend yield

—

—

—

—

Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):

September 30, 2018

Unrecognized
Expense

Remaining
Weighted-Average
Recognition Period
(years)
Stock options

$
38,966

2.45
RSAs

$
2,743

1.09
RSUs

$
26,434

2.24

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-URI http://asc.fasb.org/subtopic&trid=2208855
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stockholders' Equity (Deficit)
9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Stockholders' Equity (Deficit)
Stockholders’ Equity
In May 2017, we completed an underwritten public offering pursuant to which we sold 11.5 million shares of common stock, including 1.5 million shares sold pursuant to the full exercise of an option to purchase additional shares granted to the underwriters. All of the shares were offered at a public offering price of $12.50 per share, generating $134.9 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. We intend to use the net proceeds from this offering to fund continued development of our PEGPH20 oncology program and for other general corporate purposes.
During the nine months ended September 30, 2018 and 2017, we issued an aggregate of 1,280,996 and 1,020,028 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $11.13 and $8.71 per share, respectively, for net proceeds of approximately $14.3 million and $8.9 million, respectively. For the nine months ended September 30, 2018 and 2017, we issued 438,536 and 375,906 shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered 138,986 and 96,069 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $4.2 million and $1.9 million, respectively. In addition, we issued 67,959 and 98,945 shares of common stock in connection with the grants of RSAs during the nine months ended September 30, 2018 and 2017, respectively. Stock options and unvested restricted units totaling approximately 13.4 million shares and 14.7 million shares of our common stock were outstanding as of September 30, 2018 and December 31, 2017, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1

Commitments and Contingencies
9 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies
From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1

Subsequent Event (Notes)
9 Months Ended

Sep. 30, 2018

Subsequent Event [Line Items]

Subsequent Events [Text Block]
Subsequent Events
In October 2018, we entered into an agreement with Roche for the right to develop and commercialize one additional exclusive target and an option to select two additional targets within four years using our ENHANZE technology for an upfront payment of $25.0 million. We will receive potential milestone payments of up to $160.0 million to $165.0 million per target, subject to the achievement of specific development, regulatory and sales-based milestones. We will also receive mid-single digit royalties on sales of commercialized products.

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation
The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on February 20, 2018. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Certain reclassifications have been made to the prior period condensed consolidated statement of cash flows within operating activities to conform to the current period presentation. There was no change to net cash used in operating activities. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.
The accompanying condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.

Cash Equivalents
Cash Equivalents and Marketable Securities
Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of September 30, 2018, our cash equivalents consisted of money market funds and commercial paper.

Marketable Securities
Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive gain (loss) and included as a separate component of stockholders’ equity (deficit). The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the condensed consolidated statements of operations. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses and declines in value judged to be other-than-temporary on marketable securities, if any, are included in investment and other income, net in the consolidated statements of operations.

Restricted Cash
Restricted Cash
Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases.

Fair Value of Financial Instruments
Fair Value of Financial Instruments
The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, we believe the fair value of long-term debt approximates its carrying value.
Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.

Inventories
Inventories
Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
We capitalize inventory costs associated with our drug candidates prior to receipt of regulatory approval, based on management’s judgment of probable future commercialization. We would be required to expense these capitalized costs upon a change in such judgment, due to, among other factors, a decision denying approval of the drug candidate by regulatory agencies.
Bulk rHuPH20 formulations manufactured for partner use prior to our partner receiving marketing approval from the U.S. Food and Drug Administration (“FDA”) or comparable regulatory agencies in foreign countries and with no alternative future use are recorded as research and development expense. All direct manufacturing costs incurred after the partner receives marketing approval are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in any stage of development or in commercial product, and ENHANZE drug product used by our partners in clinical trials, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.

Revenue Recognition
Revenue Recognition
We generate revenues from payments received under collaborative agreements and product sales. As of January 1, 2018, we adopted ASC 606, Revenue from Contracts with Customers (ASC 606) which affects how we recognize revenues in these arrangements. We applied the provisions of ASC 606 using the modified retrospective approach, with the cumulative effect of the adoption recognized as of January 1, 2018, to all contracts that had not been completed as of that date. Under ASC 606, we recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. Amounts reported in prior periods have not been adjusted. Accordingly, the reported revenue amounts for the three and nine months ended September 30, 2018 and 2017 are based on different accounting policies.
Prior to the ASC 606 adoption, revenue was recognized when all of the following criteria were met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the seller’s price to the buyer is fixed or determinable; and (4) collectibility is reasonably assured. Differences between the revenue recognition policies applicable prior to the adoption and ASC 606 are described in the following sections and in Note 4.
Revenues under Collaborative Agreements - as reported under ASC 606 beginning January 1, 2018
Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately engaged to perform research and development services.
We collect an upfront license payment from the collaboration partner, and are also entitled to receive event-based payments subject to the collaboration partner’s achievement of specified development, regulatory and sales-based milestones. In several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. In addition, the collaboration partner will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, the collaboration continues in effect until the later of: (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration, which is determined separately for each country. In the event such valid claims expire prior to the last to expire royalty term, the royalty rate is reduced for the remaining royalty term following such expiration. The collaboration partner may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon any such termination, the license granted to the collaboration partner (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement, the licenses granted will become perpetual, non-exclusive and fully paid.
Although these agreements are in form structured as collaborative agreements, we concluded for accounting purposes they represent contracts with customers, and are not subject to accounting literature on collaborative arrangements. This is because we grant to collaboration partners licenses to our intellectual property, and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. We do not develop assets jointly with collaboration partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements must be accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers.
Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE^® technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. The license grants the collaboration partners right to use our intellectual property as it exists on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the collaboration partner has received access to our intellectual property, usually at the inception of the agreement.
When collaboration partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new collaboration partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).
We provide standard indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements representations and are not obligations to provide goods or services.
We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our collaboration partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or SSP. Therefore, our collaboration partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.
Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals and successful completion of clinical trials. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.
When target exchange rights are held by collaboration partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target if the exchange right is exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.
Because our agreements only have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. We perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.
We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our collaboration partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our collaboration partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our collaborative partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our collaboration partners.
Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the collaboration partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the collaboration partner.
Sales-based milestones and royalties cannot be recognized until the underlying sales occur. We do not receive final royalty reports from our collaboration partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on preliminary reports provided by our collaboration partners. We will record a true-up in the following quarter if necessary, when final royalty reports are received. To date, we have not recorded any material true-ups.
In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the collaboration partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer.
Refer to Note 4 Revenue, for further discussion on our collaborative arrangements.
Prior to the adoption of ASC 606 on January 1, 2018, we recognized upfront amounts received under two of our collaborative agreements straight-line over the contract term in accordance with the accounting standards that were in effect in 2006-2007, when these collaborative agreements were entered into. In addition, we recognized royalty revenue in the period when we received final royalty reports from the collaboration partners, in the quarter following the quarter in which the corresponding sales occurred. There were no other differences in revenue to be recognized under the previously existing authoritative accounting literature and ASC 606 applied to our collaborative agreements.
Product Sales, Net - as reported under ASC 606 beginning January 1, 2018
Hylenex Recombinant
We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders. We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.
Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product.
We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.
Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.
We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.
Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustments.
In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of a practical expedient allowed in ASC 606.
Bulk rHuPH20
We sell bulk rHuPH20 to collaboration partners for use in research and development; subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce bulk rHuPH20 and have concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
We recognize revenue from bulk rHuPH20 formulations as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.
ENHANZE Drug Product
We sell ENHANZE drug product to collaboration partners for use in research and development in early phase clinical studies. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement, and delivery of units of ENHANZE drug product represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use a contract manufacturer to produce ENHANZE drug product and we concluded we are the principal in the sales to collaboration partners. The transaction price for each purchase order of ENHANZE drug product is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.
We recognize revenue from ENHANZE drug product as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us.
There were no differences in how the previously existing authoritative accounting literature applied to our product sales transactions.
Revenue Presentation
In our statements of operations, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms and sales of bulk rHuPH20 that has no alternative future use. We report royalties received from collaboration partners as a separate line in our statements of operations.
Revenues from sales of Hylenex recombinant, bulk rHuPH20 that has alternative future use and ENHANZE drug product are included in product sales, net.
In footnotes to our financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and development services), and additionally, by type of payment stream received under collaborative agreements (upfront amounts, event-based development and regulatory milestones and other fees, sales milestones and royalties).

Cost of Product Sales
Cost of Product Sales
Cost of product sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of Hylenex recombinant and bulk rHuPH20 and ENHANZE drug product that has alternative future use. Cost of product sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.

Research and Development Expenses
Research and Development Expenses
Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. When bulk rHuPH20 is manufactured for use in research and development by us or our partners and the product cannot be redirected for alternative use due to formulation and manufacturing specifications, the manufacturing costs are recorded as research and development expense. Bulk rHuPH20 that is manufactured for partner use prior to our partner receiving marketing approval from the FDA or comparable regulatory agencies in foreign countries and meet these specifications is recorded as research and development expenses. The manufacturing costs of bulk rHuPH20 for the approved collaboration products, Herceptin SC, MabThera SC (RITUXAN HYCELA™ in the U.S.) and HYQVIA, incurred after the receipt of marketing approvals are capitalized as inventory. Bulk rHuPH20 formulations manufactured for general partner and internal use, which can potentially be used by any collaboration partner or by us in any stage of development or in commercial products, is considered to have alternative future use and all manufacturing costs are capitalized as inventory. Inventories used in our clinical trials are expensed at the time the inventories are packaged for the clinical trials.
We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.
Milestone payments that we make in connection with in-licensed technology for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic value are expensed as research and development costs at the time the costs are incurred.

Clinical Trial Expenses
Clinical Trial Expenses
We make payments in connection with our clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of our obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones.
Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.

Share-Based Compensation
Share-Based Compensation
We record compensation expense associated with stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and RSUs with performance conditions (“PRSUs”) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.

Income Taxes
Income Taxes
We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities at each year end and their respective tax bases and are measured using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and the valuation allowance to record against our net deferred tax assets, which are based on complex and evolving tax regulations throughout the world. Deferred tax assets and other tax benefits are recorded when it is more likely than not that the position will be sustained upon audit. While we have begun to utilize certain of our net operating losses, we have not yet established a track record of profitability. Accordingly, valuation allowances have been recorded to reduce our net deferred tax assets to zero, with the exception of the alternative minimum tax ("AMT") credit carryover of $5.5 million. Under the Tax Cuts and Jobs Act (the “Act”) enacted in December 2017, the AMT credit carryover will either be utilized, or if unutilized fully refunded in 2022. For all other deferred tax assets the valuation allowance will reduce the net value to zero until such time as we can demonstrate an ability to realize them.

Net Loss Per Share
Net (Loss) Income Per Share
Basic net (loss) income per common share is computed by dividing net (loss) income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs and unvested PRSUs are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive.

Segment Information
Segment Information
We operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes. This segment also includes revenues and expenses related to (i) research and development and bulk rHuPH20 manufacturing activities conducted under our collaborative agreements with third parties and (ii) product sales of Hylenex recombinant. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.

Adoption and Pending Adoption of Recent Accounting Pronouncements
Adoption and Pending Adoption of Recent Accounting Pronouncements
The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters

In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall; Recognition and Measurement of Financial Assets and Financial Liabilities.

The new guidance supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities to be measured at fair value with changes in the fair value recognized through net income. The new guidance requires public business entities that are required to disclose fair value of financial instruments measured at amortized cost on the balance sheet to measure that fair value using the exit price notion consistent with Topic 820, Fair Value Measurement.

January 1, 2018

We currently do not hold equity securities. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.

In October 2016, the FASB issued ASU 2016-16, Income Taxes; Intra-Entity Transfers of Assets Other Than Inventory.

The new guidance removes the current requirement to defer the income tax effects of intercompany transfers of assets other than inventory (e.g., intangible assets) until the asset has been sold to an outside party. As a result, the income tax consequences of an intercompany transfer of assets other than inventory will be recognized in the current period income statement rather than being deferred until the assets leave the consolidated entity.

January 1, 2018

We adopted the new guidance on January 1, 2018. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.

Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In March, April, May and December 2016, the FASB issued additional guidance related to Topic 606.

The new standard superseded nearly all existing revenue recognition guidance. Under Topic 606, an entity is required to recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. Topic 606 defines a five-step process in order to achieve this core principle, which may require the use of judgment and estimates, and also requires expanded qualitative and quantitative disclosures relating to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including significant judgments and estimates used. The new standard also defines accounting for certain costs related to origination and fulfillment of contracts with customers, including whether such costs should be capitalized.

January 1, 2018

We adopted the new guidance on January 1, 2018 using the modified retrospective approach. Refer to Notes 2 “Revenue Recognition” and 4 for additional detail regarding the impact of this adoption.

Standard

Description

Effective Date

Effect on the Financial
Statements or Other Significant Matters
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In July 2018, the FASB issued additional guidance related to Topic 842.

The new guidance requires lessees to recognize assets and liabilities for most leases and provides enhanced disclosures.

January 1, 2019. Early adoption is permitted.

We plan to implement the guidance on January 1, 2019 using a modified retrospective transition basis for leases existing as of the period of adoption. In order to adopt the new standard, we will be using available practical expedients and newly implemented processes and internal controls for lease accounting. The practical expedients allow us to carry forward our historical assessment of whether existing agreements are or contain a lease and the classification of our existing lease arrangements. We expect all of our real-estate and automobile operating lease commitments will be recognized as lease liabilities with corresponding right-of-use assets upon adoption, resulting in an increase in the assets and liabilities of the consolidated balance sheet. We anticipate that the adoption will have a material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820).

The new guidance removes, modifies and adds to certain disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement.

January 1, 2020

We plan to adopt the new guidance on January 1, 2020. We do not anticipate the adoption will have a material impact on our condensed consolidated financial position or results of operations.

X

- Definition
Disclosure of accounting policy for clinical trial expenses.
+ References
No definition available.
+ Details

Name: halo_DisclosureOfAccountingPolicyForClinicalTrialExpensesPolicyTextBlock

Namespace Prefix: halo_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586
+ Details

Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 50
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68069731&loc=d3e63676-111659

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CostOfSalesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.M)
-URI http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.B.Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
A reconciliation of the numerators and the denominators of the basic and diluted net (loss) income per common share computations is as follows (in thousands, except per share amounts):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Numerator:

Net (loss) income

$
(27,850
)

$
2,749

$
(78,204
)

$
(60,911
)
Denominator:

Weighted average common shares outstanding for basic
net (loss) income per share

143,949

141,190

143,396

134,633

Net effect of dilutive common stock equivalents

—

2,046

—

—

Weighted average common shares outstanding for diluted
net (loss) income per share

143,949

143,236

143,396

134,633

Net (loss) income per share:

Basic

$
(0.19
)

$
0.02

$
(0.55
)

$
(0.45
)
Diluted

$
(0.19
)

$
0.02

$
(0.55
)

$
(0.45
)

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurement (Tables)
9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Available-for-sale marketable securities
Available-for-sale marketable securities consisted of the following (in thousands):

September 30, 2018

Amortized Cost

Gross Unrealized Gains

Gross Unrealized Losses

Estimated Fair Value

Asset-backed securities

$
39,721

$
—

$
(24
)

$
39,697

Corporate debt securities

74,699

—

(181
)

74,518

U.S. Treasury securities

99,716

—

(248
)

99,468

Commercial paper

95,664

—

—

95,664

$
309,800

$
—

$
(453
)

$
309,347

December 31, 2017

Amortized Cost

Gross Unrealized Gains

Gross Unrealized Losses

Estimated Fair Value

Corporate debt securities

$
117,427

$
—

$
(235
)

$
117,192

U.S. Treasury securities

66,601

—

(201
)

66,400

Commercial paper

116,882

—

—

116,882

$
300,910

$
—

$
(436
)

$
300,474

Fair Value, Assets Measured on Recurring Basis [Table Text Block]
The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):

September 30, 2018

December 31, 2017

Level 1

Level 2

Total estimated fair value

Level 1

Level 2

Total estimated fair value
Cash equivalents:

Money market funds

$
55,271

$
—

$
55,271

$
142,091

$
—

$
142,091

Commercial paper

—

—

—

—

15,700

15,700

Available-for-sale marketable
   securities:

Asset-backed securities

—

39,697

39,697

—

—

—

Corporate debt securities

—

74,518

74,518

—

117,192

117,192

U.S. Treasury securities

99,468

—

99,468

66,400

—

66,400

Commercial paper

—

95,664

95,664

—

116,882

116,882

$
154,739

$
209,879

$
364,618

$
208,491

$
249,774

$
458,265

X

- Definition
Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Collaborative Agreements (Tables)
9 Months Ended

Sep. 30, 2018

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Disaggregation of Revenue [Table Text Block]
Our disaggregated revenues were as follows (in thousands):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Royalties

$
18,710

$
17,119

$
59,643

$
45,839

Product sales, net

  Sales of bulk rHuPH20

$
2,402

$
9,748

$
6,350

$
26,825

  Sales of ENHANZE drug product

186

—

322

—

  Sales of Hylenex

3,681

3,841

10,881

10,978

Total product sales, net

6,269

13,589

17,553

37,803

Revenues under collaborative agreements:

  Upfront license fees

—

30,352

1,336

31,054

  Event-based development milestones and other fees

—

329

11,000

988

  Sales-based milestones

—

342

—

1,028

  Research and development services

577

2,000

2,098

10,337

Total revenues under collaborative agreements

577

33,023

14,434

43,407

Total revenue

$
25,556

$
63,731

$
91,630

$
127,049

Contract with Customer, Asset and Liability [Table Text Block]
Accounts receivable, net, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):

September 30, 2018

December 31, 2017
Accounts receivable, net

$
22,656

$
22,133

Other contract assets

5,000

—

Deferred revenues

9,754

60,865

Other collaborators [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]
contract assets of $5.0 million related to collaborative agreements as of September 30, 2018, for amounts considered probable to receive for development milestones that relate to intellectual property licenses granted to collaboration partners in prior periods. The following table presents amounts under our collaborative agreements included in the transaction price (i.e. cumulative amounts triggered or probable) as of September 30, 2018 (in thousands):

Upfront
(1)

Development
(2)

Sales
(3)

Royalty

Total
Collaboration partner and agreement date:

Roche (December 2006 and September 2017)

$
70,000

$
25,000

$
22,000

$
211,613

$
328,613

Baxalta (September 2007)

10,000

3,000

9,000

22,438

44,438

Pfizer (December 2012)

14,500

2,000

—

—

16,500

Janssen (December 2014)

15,250

15,000

—

—

30,250

AbbVie (June 2015)

23,000

6,000

—

—

29,000

Lilly (December 2015)

33,000

—

—

—

33,000

BMS (September 2017)

105,000

5,000

—

—

110,000

Alexion (December 2017)

40,000

5,000

—

—

45,000

X

- Definition
Tabular disclosure of contract balances and changes in contract balances.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68059916&loc=d3e50766-111635

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68059916&loc=SL6750900-111635
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Disaggregated Revenue (Tables)
9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]
Our disaggregated revenues were as follows (in thousands):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Royalties

$
18,710

$
17,119

$
59,643

$
45,839

Product sales, net

  Sales of bulk rHuPH20

$
2,402

$
9,748

$
6,350

$
26,825

  Sales of ENHANZE drug product

186

—

322

—

  Sales of Hylenex

3,681

3,841

10,881

10,978

Total product sales, net

6,269

13,589

17,553

37,803

Revenues under collaborative agreements:

  Upfront license fees

—

30,352

1,336

31,054

  Event-based development milestones and other fees

—

329

11,000

988

  Sales-based milestones

—

342

—

1,028

  Research and development services

577

2,000

2,098

10,337

Total revenues under collaborative agreements

577

33,023

14,434

43,407

Total revenue

$
25,556

$
63,731

$
91,630

$
127,049

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1

Certain Balance Sheet Items (Tables)
9 Months Ended

Sep. 30, 2018

Balance Sheet Related Disclosures [Abstract]

Summary of Accounts Receivable
Accounts receivable, net and other contract assets consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Accounts receivable from product sales to collaborators

$
1,980

$
18,475

Accounts receivable from revenues under collaborative agreements

451

2,142

Accounts receivable from royalty payments

18,777

—

Accounts receivable from other product sales

1,949

2,075

Other contract assets

5,000

—

     Subtotal

28,157

22,692

Allowance for distribution fees and discounts

(501
)

(559
)
     Total accounts receivable, net and other contract assets

$
27,656

$
22,133

Summary of Inventories
Inventories consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Raw materials

$
625

$
377

Work-in-process

15,401

2,131

Finished goods

2,259

2,638

     Total inventories

$
18,285

$
5,146

Summary of Prepaid Expenses and Other Assets
Prepaid expenses and other assets consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Prepaid manufacturing expenses

$
8,844

$
2,337

Prepaid research and development expenses

9,195

7,793

Other prepaid expenses

2,344

2,585

Other assets

6,527

6,717

     Total prepaid expenses and other assets

26,910

19,432

Less long-term portion

7,291

5,553

     Total prepaid expenses and other assets, current

$
19,619

$
13,879

Summary of Property and Equipment
Property and equipment, net consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Research equipment

$
9,528

$
9,268

Manufacturing equipment

3,979

1,702

Computer and office equipment

4,811

3,725

Leasehold improvements

4,160

2,715

     Subtotal

22,478

17,410

Accumulated depreciation and amortization

(15,688
)

(13,890
)
     Property and equipment, net

$
6,790

$
3,520

Summary of Accrued Expenses
Accrued expenses consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Accrued outsourced research and development expenses

$
19,786

$
18,757

Accrued compensation and payroll taxes

12,914

13,384

Accrued outsourced manufacturing expenses

4,743

2,504

Other accrued expenses

6,142

5,396

     Total accrued expenses

43,585

40,041

Less long-term portion

565

440

     Total accrued expenses, current

$
43,020

$
39,601

Summary of Deferred Revenue
Deferred revenue consisted of the following (in thousands):

September 30,
2018

December 31,
2017
Collaborative agreements

License fees and event-based payments:

Roche

$
—

$
39,379

Other

2,265

15,999

Total license fees and event-based payments

2,265

55,378

Product sales

7,489

5,487

Total deferred revenue

9,754

60,865

Less current portion

4,247

6,568

Deferred revenue, net of current portion

$
5,507

$
54,297

X

- References
No definition available.
+ Details

Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765
+ Details

Name: us-gaap_DeferredRevenueByArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfOtherAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1

Share-based Compensation (Tables)
9 Months Ended

Sep. 30, 2018

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Total share-based compensation expense related to share-based awards was comprised of the following (in thousands):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Research and development

$
4,407

$
3,060

$
13,107

$
9,891

Selling, general and administrative

4,460

4,702

13,577

13,377

Share-based compensation expense

$
8,867

$
7,762

$
26,684

$
23,268

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]
Share-based compensation expense by type of share-based award (in thousands):

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Stock options

$
4,645

$
4,973

$
14,026

$
14,971

RSAs, RSUs and PRSUs

4,222

2,789

12,658

8,297

$
8,867

$
7,762

$
26,684

$
23,268

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
The assumptions used in the Black-Scholes model were as follows:

Three Months Ended
September 30,

Nine Months Ended
September 30,

2018

2017

2018

2017
Expected volatility

58.6-60.6%

70.5-70.8%

58.7-70.1%

70.5-71.7%
Average expected term (in years)

5.4

5.6

5.5

5.6
Risk-free interest rate

2.75-2.87%

1.73-1.93%

2.25-2.87%

1.73-1.94%
Expected dividend yield

—

—

—

—

Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]
Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):

September 30, 2018

Unrecognized
Expense

Remaining
Weighted-Average
Recognition Period
(years)
Stock options

$
38,966

2.45
RSAs

$
2,743

1.09
RSUs

$
26,434

2.24

X

- Definition
Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which it is expected to be recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies Restricted Cash (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Restricted Cash and Investments, Current [Abstract]

Restricted cash $ 500 $ 500

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_RestrictedCashAndInvestmentsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies Inventories (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2018

Dec. 31, 2017

Inventory [Line Items]

Product sales expensed as R&D $ 1,700 $ 2,300

Inventory, Net 18,285 18,285 $ 5,146

Hylenex Recombinant [Member]

Inventory [Line Items]

Inventory, Net 2,400 2,400 2,900

bulk rHuPH20

Inventory [Line Items]

Inventory, Net 15,900 15,900 $ 2,200

Costs expensed to R&D [Domain]

Inventory [Line Items]

Inventory, Net $ 2,000 $ 2,000

X

- Definition
Product sales expensed as R&D
+ References
No definition available.
+ Details

Name: halo_ProductsalesexpensedasRD

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=halo_HylenexRecombinantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=halo_BulkrHuPH20Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=halo_CostsexpensedtoRDDomain

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies Research and development (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and Development Expense $ 35,540,000 $ 33,993,000 $ 113,602,000 $ 109,267,000

In-license technologies [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and Development Expense $ 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=halo_InlicensetechnologiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies Income tax (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Income Tax Disclosure [Abstract]

Deferred Tax Assets, Net $ 0 $ 0

Deferred Tax Assets, Tax Credit Carryforwards 5,500,000 5,500,000

Income tax expense $ 0 $ 580,000 $ 220,000 $ 970,000

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 43 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies Net Loss Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Loss Per Share Disclosure [Line Items]

Net income (loss) $ (27,850) $ 2,749 $ (78,204) $ (60,911)

Weighted Average Number of Shares Outstanding, Basic 143,949 141,190 143,396 134,633

Shares excluded from calculation of diluted net loss, amount 0 2,046 0 0

Weighted Average Number of Shares Outstanding, Diluted 143,949 143,236 143,396 134,633

Earnings Per Share, Basic $ (0.19) $ 0.02 $ (0.55) $ (0.45)

Earnings Per Share, Diluted $ (0.19) $ 0.02 $ (0.55) $ (0.45)

Net loss per share (Textuals) [Abstract]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 13,800 7,800 13,800 14,300

X

- Definition
Net income (loss) per share (Textuals) [Abstract]
+ References
No definition available.
+ Details

Name: halo_NetincomelosspershareTextualsAbstract

Namespace Prefix: halo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=96948231&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareDilutedLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=96947427&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 44 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies Segment information (Details)
9 Months Ended

Sep. 30, 2018

Segment

Segment Reporting [Abstract]

Number of Operating Segments 1

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1

Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) - USD ($)
$ in Millions
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Reclassification of restricted cash $ 0.5 $ 0.5

X

- Definition
Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurement (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Schedule of Available-for-sale Securities

Amortized cost $ 309,800 $ 300,910

Gross Unrealized Gains 0 0

Gross Unrealized Losses (453) (436)

Estimated fair value 309,347 300,474

Asset-backed Securities [Member]

Schedule of Available-for-sale Securities

Amortized cost 39,721

Gross Unrealized Gains 0

Gross Unrealized Losses (24)

Estimated fair value 39,697

Corporate Debt Securities [Member]

Schedule of Available-for-sale Securities

Amortized cost 74,699 117,427

Gross Unrealized Gains 0 0

Gross Unrealized Losses (181) (235)

Estimated fair value 74,518 117,192

US Treasury Securities [Member]

Schedule of Available-for-sale Securities

Amortized cost 99,716 66,601

Gross Unrealized Gains 0 0

Gross Unrealized Losses (248) (201)

Estimated fair value 99,468 66,400

Commercial Paper [Member]

Schedule of Available-for-sale Securities

Amortized cost 95,664 116,882

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 0

Estimated fair value $ 95,664 $ 116,882

X

- Definition
Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=75030427&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82896770&loc=d3e26610-111562
+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AssetBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurement Textuals (Details)
$ in Millions
9 Months Ended

Sep. 30, 2018

USD ($)

Fair Value Disclosures [Abstract]

Number of available-for-sale securities in unrealized loss position, less than one year 27

Other than Temporary Impairment Losses, Marketable Securities $ 0.0

X

- Definition
Number of investment positions in available-for-sale investments in a continuous unrealized loss position for less than one year or normal operating cycle, if longer, for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.
+ References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 8A
-URI http://asc.fasb.org/extlink&oid=82896770&loc=SL6284422-111562
+ Details

Name: us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 48 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurement Fair Value Measures (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets, Fair Value Disclosure $ 364,618 $ 458,265

Available-for-sale Securities 309,347 300,474

Fair Value, Assets, Level 1 to Level 2 Transfers, Amount 0 0

Money Market Funds [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure 55,271 142,091

US Treasury Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities 99,468 66,400

Commercial Paper [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure 0 15,700

Available-for-sale Securities 95,664 116,882

Corporate Debt Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities 74,518 117,192

Fair Value, Inputs, Level 1 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets, Fair Value Disclosure 154,739 208,491

Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure 55,271 142,091

Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities 99,468 66,400

Fair Value, Inputs, Level 2 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets, Fair Value Disclosure 209,879 249,774

Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure 0 15,700

Available-for-sale Securities 95,664 116,882

Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities 74,518 117,192

Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities 39,697

Fair Value, Inputs, Level 3 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure 0 $ 0

Asset-backed Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities $ 39,697

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=75030427&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82896770&loc=d3e26610-111562
+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 35
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82895926&loc=d3e24584-111560

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=75030427&loc=d3e22054-111558

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_InvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_AssetBackedSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1

Fair Value Measurement Maturities (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Available-for-sale Securities $ 309,347 $ 300,474

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=75030427&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82896770&loc=d3e26610-111562
+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Collaborative Agreements Textuals (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2018

Dec. 31, 2017

Deferred Revenue (Textual) [Abstract]

Deferred Revenue $ 9,754 $ 9,754 $ 60,865

Collaborative Agreements (Textual)

Deferred Revenue, Revenue Recognized 500 2,300

Additional Maximum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones 165,000 165,000

Roche [Member]

Deferred Revenue (Textual) [Abstract]

Deferred Revenue $ 0 0 $ 39,379

2017 Roche [Member]

Deferred Revenue (Textual) [Abstract]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement 1,000

Alexion [Member]

Deferred Revenue (Textual) [Abstract]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement 5,000

Development Fees [Member] | Alexion [Member]

Deferred Revenue (Textual) [Abstract]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement $ 5,000

X

- Definition
Additional maximum proceeds receivable from collaborator of license and collaborative agreement upon achievement of clinical development milestones for elected targets.
+ References
No definition available.
+ Details

Name: halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Collaborative agreements.
+ References
No definition available.
+ Details

Name: halo_CollaborativeAgreementsTextualAbstract

Namespace Prefix: halo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Deferred revenue.
+ References
No definition available.
+ Details

Name: halo_DeferredRevenueTextualAbstract

Namespace Prefix: halo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Nonrefundable upfront license fee payment received under collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously reported as deferred or unearned revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_A2017RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_AlexionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_DevelopmentFeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Collaborative Agreements tables (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Deferred Revenue $ 9,754 $ 9,754 $ 60,865

Document Fiscal Year Focus 2018

Proceeds from Partner of License and Collaborative Agreement 18,700 $ 70,600

Deferred Revenue, Revenue Recognized 500 2,300

Accounts Receivable, Net, Current 22,656 22,656 22,133

Contract with Customer, Asset, Net 5,000 5,000 $ 0

Royalty Revenue 18,710 $ 17,119 59,643 $ 45,839

Sales Revenue, Goods, Net 6,269 13,589 17,553 37,803

License and Services Revenue 577 33,023 14,434 43,407

Revenues 25,556 63,731 91,630 127,049

2017 Roche [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement $ 1,000

Roche [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 328613

Baxalta [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 44438

Lilly [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 33000

BMS [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 110000

Alexion [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement $ 5,000

Revenue, Information Used to Allocate Transaction Price 45000

AbbVie [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 29000

Janssen [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 30250

Pfizer [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 16500

Other collaborators [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Deferred Revenue 9,800 $ 9,800

bulk rHuPH20 [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Sales Revenue, Goods, Net 2,402 9,748 6,350 26,825

Hylenex Recombinant [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Sales Revenue, Goods, Net 3,681 3,841 10,881 10,978

Upfront fees [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

License and Services Revenue 0 30,352 1,336 31,054

Upfront fees [Member] | Roche [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement $ 25,000

Revenue, Information Used to Allocate Transaction Price 70000

Upfront fees [Member] | Baxalta [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 10000

Upfront fees [Member] | Lilly [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 33000

Upfront fees [Member] | BMS [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 105000

Upfront fees [Member] | Alexion [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 40000

Upfront fees [Member] | AbbVie [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 23000

Upfront fees [Member] | Janssen [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 15250

Upfront fees [Member] | Pfizer [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 14500

Development Fees [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

License and Services Revenue 0 329 $ 11,000 988

Development Fees [Member] | Roche [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 25000

Development Fees [Member] | Baxalta [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 3000

Development Fees [Member] | BMS [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 5000

Development Fees [Member] | Alexion [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement $ 5,000

Revenue, Information Used to Allocate Transaction Price 5000

Development Fees [Member] | AbbVie [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 6000

Development Fees [Member] | Janssen [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 15000

Development Fees [Member] | Pfizer [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 2000

Sales-based milestone [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

License and Services Revenue 0 342 $ 0 1,028

Sales-based milestone [Member] | Roche [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 22000

Sales-based milestone [Member] | Baxalta [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 9000

Royalty [Member] | Roche [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 211613

Royalty [Member] | Baxalta [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Revenue, Information Used to Allocate Transaction Price 22438

Research and Development Services [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

License and Services Revenue 577 $ 2,000 $ 2,098 $ 10,337

Difference between Revenue Guidance in Effect before and after Topic 606 [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets 71,200 71,200

Contract with Customer, Asset, Net 19,400 19,400

Accounting Standards Update 2014-09 [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Deferred Revenue (48,700) (48,700)

Accounts Receivable, Net, Current 18,700 18,700

Revenues $ 6,400 $ 2,600

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Nonrefundable upfront license fee payment received under collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from partner of license and collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84173487&loc=SL51747714-108306

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously reported as deferred or unearned revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cumulative effect of the change in accounting principle or new accounting pronouncement on retained earnings or other components of equity or net assets in the statement of financial position as of the beginning of the earliest period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794
+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of methods, inputs, and assumptions used to allocate transaction price. Includes, but not is limited to, estimating standalone selling price of promised good or service and allocating discount and variable consideration to specific part of contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130566-203045
+ Details

Name: us-gaap_RevenueInformationUsedToAllocateTransactionPrice

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_A2017RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_BaxaltaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_LillyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_BMSMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_AlexionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_AbbVieMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_JanssenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_PfizerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_BulkrHuPH20Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_HylenexRecombinantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_UpfrontfeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_DevelopmentFeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_SalesbasedmilestoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_RoyaltyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_ResearchandDevelopmentServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Revenue Adjustments - 606 Implementation (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Contract with Customer, Asset, Net $ 5,000 $ 5,000 $ 0

Revenues 25,556 $ 63,731 91,630 $ 127,049

Deferred revenue (9,754) (9,754) (60,865)

Accounts receivable, net 22,656 22,656 $ 22,133

Difference between Revenue Guidance in Effect before and after Topic 606 [Member]

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Contract with Customer, Asset, Net 19,400 19,400

Contract with Customer, Liability 51,800 51,800

New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets 71,200 71,200

Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Revenues 6,400 2,600

Deferred revenue 48,700 48,700

Accounts receivable, net $ 18,700 $ 18,700

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84173487&loc=SL51747714-108306

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cumulative effect of the change in accounting principle or new accounting pronouncement on retained earnings or other components of equity or net assets in the statement of financial position as of the beginning of the earliest period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794
+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Deferred Revenue Timing (Details) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue $ 9,754 $ 60,865

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue 4,500

bulk rHuPH20 [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue 3,000

Alexion [Member]

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement $ 5,000

X

- Definition
Nonrefundable upfront license fee payment received under collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-12-31

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_BulkrHuPH20Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_AlexionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Disaggregated Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Disaggregation of Revenue [Line Items]

Contract with Customer, Asset, Net $ 5,000 $ 5,000 $ 0

Revenues 25,556 $ 63,731 91,630 $ 127,049

License and Services Revenue 577 33,023 14,434 43,407

Royalty Revenue 18,710 17,119 59,643 45,839

Sales Revenue, Goods, Net 6,269 13,589 17,553 37,803

bulk rHuPH20 [Member]

Disaggregation of Revenue [Line Items]

Sales Revenue, Goods, Net 2,402 9,748 6,350 26,825

ENHANZE drug product [Member] [Domain]

Disaggregation of Revenue [Line Items]

Sales Revenue, Goods, Net 186 0 322 0

Hylenex Recombinant [Member]

Disaggregation of Revenue [Line Items]

Sales Revenue, Goods, Net 3,681 3,841 10,881 10,978

Upfront fees [Member]

Disaggregation of Revenue [Line Items]

License and Services Revenue 0 30,352 1,336 31,054

Development Fees [Member]

Disaggregation of Revenue [Line Items]

License and Services Revenue 0 329 11,000 988

Sales-based milestone [Member]

Disaggregation of Revenue [Line Items]

License and Services Revenue 0 342 0 1,028

Research and Development Services [Member]

Disaggregation of Revenue [Line Items]

License and Services Revenue $ 577 $ 2,000 2,098 $ 10,337

Alexion [Member]

Disaggregation of Revenue [Line Items]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement 5,000

Alexion [Member] | Development Fees [Member]

Disaggregation of Revenue [Line Items]

Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement $ 5,000

X

- Definition
Nonrefundable upfront license fee payment received under collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_NonrefundableUpfrontLicenseFeePaymentReceivedUnderCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84173487&loc=SL51747714-108306

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DisaggregationOfRevenueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_BulkrHuPH20Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_ENHANZEdrugproductMemberDomain

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_HylenexRecombinantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_UpfrontfeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_DevelopmentFeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_SalesbasedmilestoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_ResearchandDevelopmentServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=halo_AlexionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1

Revenue Performance Obligation (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred Revenue $ 9,754 $ 60,865

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred Revenue 4,500

bulk rHuPH20 [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred Revenue $ 3,000

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-12-31

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=halo_BulkrHuPH20Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1

Certain Balance Sheet Items - Accounts receivable (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Accounts Receivable, Net, Current [Abstract]

Accounts receivable from product sales to collaborators $ 1,980 $ 18,475

Accounts receivable from revenues under collaborative agreements 451 2,142

Accounts receivable from other product sales 1,949 2,075

Other contract assets 5,000 0

Accounts receivable from royalties 18,777 0

Accounts receivable, gross 28,157 22,692

Allowance for distribution fees and discounts (501) (559)

Total accounts receivable, net $ 27,656 $ 22,133

X

- Definition
Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.
+ References
No definition available.
+ Details

Name: halo_Accountsreceivablefromcollaborators

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accounts receivable from product sales
+ References
No definition available.
+ Details

Name: halo_Accountsreceivablefromproductsales

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accounts receivable from product sales to collaborators
+ References
No definition available.
+ Details

Name: halo_Accountsreceivablefromproductsalestocollaborators

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.
+ References
No definition available.
+ Details

Name: halo_Accountsreceivablefromroyalties

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Allowance for Discount and Distribution Fees
+ References
No definition available.
+ Details

Name: halo_AllowanceforDistributionFeesandDiscounts

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Other contract assets
+ References
No definition available.
+ Details

Name: halo_Othercontractassets

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_AccountsReceivableGrossCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsReceivableNetCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1

Certain Balance Sheet Items - Inventories (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Inventory Disclosure [Abstract]

Inventory, Raw Materials $ 625 $ 377

Inventory, Work in Process 15,401 2,131

Inventory, Finished Goods 2,259 2,638

Summary of Inventories

Total inventories $ 18,285 $ 5,146

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 58 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1

Certain Balance Sheet Items - Prepaid expenses and other assets (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Prepaid Expense and Other Assets, Current [Abstract]

Prepaid manufacturing expenses $ 8,844 $ 2,337

Prepaid research and development expenses 9,195 7,793

Other prepaid expenses 2,344 2,585

Other assets 6,527 6,717

Total prepaid expense and other assets 26,910 19,432

Less long-term portion 7,291 5,553

Total prepaid expense and other assets, current $ 19,619 $ 13,879

X

- Definition
Prepaid research and development
+ References
No definition available.
+ Details

Name: halo_Prepaidresearchanddevelopment

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765
+ Details

Name: us-gaap_OtherPrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.
+ References
No definition available.
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 59 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1

Certain Balance Sheet Items - Property and Equipment (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Property and equipment, gross $ 22,478 $ 17,410

Accumulated depreciation and amortization (15,688) (13,890)

Property and equipment, net 6,790 3,520

Research equipment

Property and equipment, gross 9,528 9,268

Manufacturing Equipment [Member] [Domain]

Property and equipment, gross 3,979 1,702

Computer and office equipment

Property and equipment, gross 4,811 3,725

Leasehold improvements

Property and equipment, gross $ 4,160 $ 2,715

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMemberDomain

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1

Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Depreciation and amortization

Depreciation and amortization $ 600 $ 500 $ 1,798 $ 1,668

X

- References
No definition available.
+ Details

Name: us-gaap_DepreciationAndAmortizationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 61 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1

Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Summary of Accrued Expenses

Accrued outsourced research and development $ 19,786 $ 18,757

Accrued compensation and payroll taxes 12,914 13,384

Accrued outsourced manufacturing expenses 4,743 2,504

Other accrued expenses 6,142 5,396

Total accrued expenses 43,585 40,041

Less long-term portion 565 440

Total accrued expenses, current $ 43,020 $ 39,601

X

- Definition
Accrued outsourced research and development expenses current.
+ References
No definition available.
+ Details

Name: halo_AccruedOutsourcedResearchAndDevelopmentExpensesCurrent

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Outsourced Research and Development Expenses Long-Term
+ References
No definition available.
+ Details

Name: halo_AccruedOutsourcedResearchandDevelopmentExpensesLongTerm

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued manufacturing expenses
+ References
No definition available.
+ Details

Name: halo_Accruedmanufacturingexpenses

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 62 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1

Certain Balance Sheet Items - Deferred Revenue (Details) - USD ($)
$ in Thousands

Sep. 30, 2018

Dec. 31, 2017

Deferred revenue

Total deferred revenue $ 9,754 $ 60,865

Less current portion 4,247 6,568

Deferred revenue, net of current portion 5,507 54,297

Roche [Member]

Deferred revenue

Total deferred revenue 0 39,379

Other collaborative agreements

Deferred revenue

Total deferred revenue 2,265 15,999

License fees and event-based payments

Deferred revenue

Total deferred revenue 2,265 55,378

Product [Member]

Deferred revenue

Total deferred revenue $ 7,489 $ 5,487

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueArrangementLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=halo_RocheMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=halo_InlicensetechnologiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1

Long-Term Debt, Net Long-Term Debt Textuals (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Mar. 31, 2017

Royalty-backed Loan

Debt Instrument [Line Items]

Issuance date Jan. 26, 2016

Total loan balance $ 150,000 $ 150,000

Debt Instrument, Description of Variable Rate Basis 8.75% plus the three-month LIBOR rate

Debt, Interest Rate 10.25% 10.25%

Debt Instrument, Maturity Date, Description final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050

Prepayment fee, percent 105.00% 105.00%

Debt instrument, covenant in compliance in compliance

Interest Costs Capitalized $ 0

Accrued Interest $ 500 $ 700

Lender Fee $ 1,500 1,500

Debt Issuance Cost 400 400

Interest Expense, debt 3,100 $ 4,200 10,500 12,400

Outstanding loan balance 101,000 101,000

Debt Instrument, Unamortized Discount 400 $ 400

Maturity date Dec. 31, 2050

Royalty-backed Loan | 2016 [Member]

Debt Instrument [Line Items]

Royalty payments to be applied to debt instrument 0.00%

Royalty-backed Loan | 2017 [Member]

Debt Instrument [Line Items]

Royalty payments to be applied to debt instrument 50.00%

Royalty-backed Loan | 2018 and thereafter [Member]

Debt Instrument [Line Items]

Royalty payments to be applied to debt instrument 100.00%

Royalty-backed Loan | 2017 Quarterly Maximum Payment [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment $ 13,750

Royalty-backed Loan | 2018 Quarterly Maximum Payment [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment 18,750

Royalty-backed Loan | 2019 Quarterly Maximum Payment [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment 21,250

Royalty-backed Loan | 2020 Quarterly Maximum Payment [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment $ 22,500

Royalty-backed Loan | Minimum [Member]

Debt Instrument [Line Items]

Debt Instrument, Basis Spread on Variable Rate 0.70%

Royalty-backed Loan | Maximum [Member]

Debt Instrument [Line Items]

Debt Instrument, Basis Spread on Variable Rate 1.50%

Secured Debt

Debt Instrument [Line Items]

Final payment $ 4,250

Senior Loans [Member]

Debt Instrument [Line Items]

Issuance date Jun. 07, 2016

Total loan balance 70,000 $ 70,000

Secured debt original draw $ 55,000 $ 55,000

Interest rate, stated percentage 8.25% 8.25%

Debt instrument, covenant in compliance in compliance

Interest Expense, debt $ 1,200 $ 1,400 $ 3,800 $ 4,100

Outstanding loan balance 45,500 45,500

Debt Instrument, Unamortized Discount 200 $ 200

Maturity date Jan. 01, 2021

Final payment as percent of original principal 5.50%

Debt Instrument, Unused Borrowing Capacity, Amount 15,000 $ 15,000

Debt Instrument, interest only period interest only payments for the first 18 months

Accrued interest, noncurrent 300 $ 300 $ 400

Accretion of debt balloon payment $ 2,000 $ 2,000

Senior Loans [Member] | Minimum [Member]

Debt Instrument [Line Items]

Prepayment fee, percent 1.00% 1.00%

Senior Loans [Member] | Maximum [Member]

Debt Instrument [Line Items]

Prepayment fee, percent 2.00% 2.00%

X

- Definition
Accretion of debt balloon payment
+ References
No definition available.
+ Details

Name: halo_Accretionofdebtballoonpayment

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Debt Instrument, Prepayment Fee,Percent
+ References
No definition available.
+ Details

Name: halo_DebtInstrumentPrepaymentFeePercent

Namespace Prefix: halo_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Final payment as percent of original principal
+ References
No definition available.
+ Details

Name: halo_Finalpaymentaspercentoforiginalprincipal

Namespace Prefix: halo_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Royalty payments to be applied to debt instrument
+ References
No definition available.
+ Details

Name: halo_Royaltypaymentstobeappliedtodebtinstrument

Namespace Prefix: halo_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Secured debt original draw
+ References
No definition available.
+ Details

Name: halo_Secureddebtoriginaldraw

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentCovenantCompliance

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentDescriptionOfVariableRateBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the fee that accompanies borrowing money under the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Increase for accrued, but unpaid interest on the debt instrument for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_DebtInstrumentIncreaseAccruedInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Date the debt instrument was issued, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentMaturityDateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the required periodic payments including both interest and principal payments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after accumulated amortization, of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Weighted average interest rate of debt outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_DebtWeightedAverageInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399
+ Details

Name: us-gaap_DeferredFinanceCostsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of interest capitalized during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391
+ Details

Name: us-gaap_InterestCostsCapitalized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_SecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=halo_RoyaltybackedLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2017Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2018andthereafterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2017QuarterlyMaximumPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2018QuarterlyMaximumPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2019QuarterlyMaximumPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=halo_A2020QuarterlyMaximumPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1

Share-based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense $ 8,867 $ 7,762 $ 26,684 $ 23,268

Stock options

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense 4,645 4,973 14,026 14,971

RSU, RSA, and PRSU awards [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense 4,222 2,789 12,658 8,297

Research and Development Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense 4,407 3,060 13,107 9,891

Selling, General and Administrative Expenses [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Allocated Share-based Compensation Expense $ 4,460 $ 4,702 $ 13,577 $ 13,377

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1

Share-based Compensation Share-based compensation textuals (Details) - shares
shares in Millions
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Share-based Compensation [Abstract]

Options, Grants in Period 0.4 0.1 2.3 2.5

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 66 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1

Share-based Compensation Share-based compensation, valuation (Details)
3 Months Ended 9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]

Fair Value Assumptions, Weighted Average Expected Term 5 years 5 months 5 years 7 months 5 years 6 months 5 years 7 months

Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00% 0.00% 0.00%

Fair Value Assumptions, Risk Free Interest Rate, Minimum 2.75% 1.73% 2.25% 1.73%

Fair Value Assumptions, Risk Free Interest Rate, Maximum 2.87% 1.93% 2.87% 1.94%

Minimum [Member]

Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]

Fair Value Assumptions, Weighted Average Volatility Rate 58.60% 70.50% 58.70% 70.50%

Maximum [Member]

Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]

Fair Value Assumptions, Weighted Average Volatility Rate 60.60% 70.80% 70.10% 71.70%

X

- Definition
[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]
+ References
No definition available.
+ Details

Name: halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems

Namespace Prefix: halo_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average expected volatility rate of share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 67 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1

Share-based Compensation Share-based compensation, unrecognized (Details)
$ in Thousands
9 Months Ended

Sep. 30, 2018

USD ($)

Stock options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation Cost Not yet Recognized $ 38,966

Compensation Cost Not yet Recognized, Period for Recognition 2 years 5 months 12 days

RSAs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation Cost Not yet Recognized $ 2,743

Compensation Cost Not yet Recognized, Period for Recognition 1 year 1 month 2 days

RSUs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation Cost Not yet Recognized $ 26,434

Compensation Cost Not yet Recognized, Period for Recognition 2 years 2 months 27 days

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stockholders' Equity (Deficit) Public Offering (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 9 Months Ended

May 31, 2017

Sep. 30, 2018

Sep. 30, 2017

Equity [Abstract]

Stock Issued During Period, Shares, New Issues 11.5

Stock Issued During Period Shares New Issues To Underwriter 1.5

Sale of Stock, Price Per Share $ 12.50

Proceeds from issuance of common stock, net $ 134,875 $ 0 $ 134,875

X

- Definition
Stock Issued During Period Shares New Issues To Underwriter
+ References
No definition available.
+ Details

Name: halo_StockIssuedDuringPeriodSharesNewIssuesToUnderwriter

Namespace Prefix: halo_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 69 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1

Stockholders' Equity (Deficit) (Details) - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Stockholders' equity (deficit) (textual)

Outstanding stock options and restricted stock units 13,400,000 14,700,000

Stock options

Stockholders' equity (deficit) (textual)

Number of shares of common stock issued as a result of stock option exercises 1,280,996 1,020,028

Stock options weighted average exercise price $ 11.13 $ 8.71

Net proceeds from stock options exercised $ 14.3 $ 8.9

Restricted stock units

Stockholders' equity (deficit) (textual)

Stock issued during period, shares, restricted stock award, net of forfeitures 438,536 375,906

Number of RSUs surrendered to pay for minimum withholding taxes 138,986 96,069

Payments for tax withholding for restricted stock units vested, net $ 4.2 $ 1.9

Restricted stock awards

Stockholders' equity (deficit) (textual)

Stock issued during period, shares, restricted stock award, net of forfeitures 67,959 98,945

X

- Definition
Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 25
-Paragraph 19A
-URI http://asc.fasb.org/extlink&oid=96949009&loc=SL79513924-113897

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=SL79508275-113901
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.
+ References
No definition available.
+ Details

Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 70 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1

Subsequent Event (Details)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2018

USD ($)

Sep. 30, 2018

USD ($)

Subsequent Event [Line Items]

Additional Minimum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones $ 160,000 $ 160,000

Recognized revenue in the fourth quarter 18,700 70,600

Additional Maximum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones $ 165,000 $ 165,000

X

- Definition
Additional maximum proceeds receivable from collaborator of license and collaborative agreement upon achievement of clinical development milestones for elected targets.
+ References
No definition available.
+ Details

Name: halo_AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Additional Minimum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones
+ References
No definition available.
+ Details

Name: halo_AdditionalMinimumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Proceeds from partner of license and collaborative agreement.
+ References
No definition available.
+ Details

Name: halo_ProceedsFromPartnerOfLicenseAndCollaborativeAgreement

Namespace Prefix: halo_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ""9DT?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ ()F32?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " @F9-75R<:NX K @ $0 &1O8U!R;W!S+V-O M&ULS9+!3L,P#(9?!>7>NMF@0E&7"X@32$A, G&+'&^+:-HH,6KW]J1E MZX3@ 3C&_O/YL^0&@\(^TG/L T5VE*Y&WW9)8=B( W-0 D/Y$TJ'\C'L(!C_,GF!5535X8F,-&YB 15B(0C<6%48RW,<3WN*"#Y^QG6$6@5KR MU'$"64H0>IH8CF/;P 4PP9BB3]\%L@MQKOZ)G3L@3LDQN24U#$,YK.=?)K^N[^^V#T*M*WA92%E6]E;62-ZJZ?I]< M?_A=A'UOW<[]8^.SH&[@UUWH+U!+ P04 " @F9-F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( ""9DTB5>B[9 ( !8( 8 >&PO=V]R:W-H965T&UL?5;;CML@$/T5RQ^P&'Q+(L=2DJIJI5:*MNKVF20DMA8;%TB\ M_?L"]KI>P'T)%Y\S9P9FF!0]XZ^B(D0&;PUMQ3:LI.PV (AS11HLGEA'6O7E MRGB#I5KR&Q =)_AB2 T%*(HRT."Z#4-9O M0QB^;SS7MTKJ#5 6';Z1'T3^[(YS>:!#.3'VJA=?+]LPTAX12LY2F\!J>) #H51;4G[\'HV&DZ8FSN?OUC^; MX%4P)RS(@=%?]456VW 5!A=RQ7&9"_80E M+@O.^H /M]5AG11P$ZO#/.M-CRC)WYZXJ4GAI[,Z*EU "XB\PND7H'4H>>6 M@(M8^04RKT#FT->6P(!(#:(=KA"FZRA>B"/WRN2.#+13Q0-9R)655V+E\JUD MV7L@"]FR]DJL77YB27@@J5\"1OZ:BEP+F5U5D7,G*((+]PX7:A>Z.G9NC9AL MCEE2\1;P#B)7Q4XP#P9%"RK^*H:Q:P':*AX,6E#Q%SMT:QG%UG,T8CY42Y*D M:9XF=J:!V2O;$'XS#4D$9W9O33><[4Y-;X?,*_T//G3,[YC?ZE8$)R;56V]> MY"MCDBB/HB?E2Z6:]+2@Y"KU-%=S/G2J82%9-W9A,/T5*/\"4$L#!!0 ( M ""9DTT*#='ZP, #T2 8 >&PO=V]R:W-H965T&UL MA9C=;N,V$(5?Q=#]KCA#4A0#VT#CQ:(%6B#8HNVU$M.QL9+E2DJ\??M2LF(X M,\/LC2729\@S_/DH:7ENN^_]/H1A\:.IC_TJVP_#Z2[/^Z=]:*K^H5)$WU>&8K9=3W4.W7K8O0WTXAH=NT;\T3=7] M=Q_J]KS*('NK^'9XW@]C1;Y>GJKG\&<8_CH]=+&47UO9'IIP[ _M<=&%W2K[ M!>XV6HT!D^+O0SCW-_>+,97'MOT^%G[;KC(U.@IU>!K&)JIX>0V;4-=C2]'' MOW.CV;7/,?#V_JWUKU/R,9G'J@^;MO[GL!WVJZS,%MNPJU[JX5M[_C7,"=EL M,6?_>W@-=92/3F(?3VW=3[^+IY=^:)NYE6BEJ7Y9K5,U+@JXTW$PG\;*:>RF_V*V?:Q] M7:-9YJ]C.[/D_B+!6\E[Q490V*LDC_U?3:!H J=X?1M?R/%:C-=3O+F-=R2) MB\1-DN,DL5:!)XEP%12E,THV8T0SAILIB9F+Q-YTHY77AGC>2#)EG)'=6-&- MY6Y(TO>6=8.NL 4Q(Z@0M):]%**7@GG1BG@I6"]08FF)%ZZR8!(KQHE6'+<" MQ(KC5GS!5HR@TJ7SLI=2]%)R+V2#W9>L%X/>(YTC+K.@M$/9C1?=>.Y&$S>> M=5,X3V9RPT7:8F(C@9+9I'X^2[/FMA^''BB@N,I:FUB\D" E<#<,E<#[471D M?B)Z[T4&)B#W8JD7Y(O&&*LH902=!>]-@N @(Q@T8[A.[$B0N0D5,FW,C(RYQ!2HR,C%#A##2,%IR-H#XSHH@XTID9( MQBAPCAI*=>",M,+^%%21_DZV@S)*D:/44*RC ,FX;^AR%F2 \?Q-$ QEFB*G MJ:$T10Y*1*6I'ZXJ(?&,A(GG3XY30W$J:>CY^['FO1,9H\@Q:E(S+6,4.48- M!1=R0+)9_DCRWH<,4.0 -118R,D(=. WHBAQ=*,,3^3PM!17R+'H"J]+^JXC MZ30HDUIQ,D"1 ]128"$GXR?C2NI'4MG47,GX1(Y/2V&%'(N?+'H-%.BR$+5+ M(!UE@"('J&7$XFA$[1T]J#>23I6Z2+UDR@S5G*&6(FO6W+Y!B@]=@DY\Z,IO MWN/'#RM_5-WSX=@O'MMA:)OIQ7W7MD.(;:K/,;]]J+;70AUVPWCKXGUW^:!Q M*0SM:?Y8DU^_&*W_!U!+ P04 " @F9-T/93R#D" "@!P & 'AL M+W=OO;0@%8R5[@P_\_\PW',991]D;+S$6SGM-&IZ[I1#M M!@!^+'&-^(JVN)%WSI352,@ENP#>,HQ.VE03X$,8@QI5C5MD>F_/BHQ>!:D: MO&<.O]8U8G^WF- N=SWWOO%274JA-D"1M>B"?V+QJ]TSN0)CE%-5XX97M'$8 M/N?N)V^S\Z R:,5KA3L^F3NJE .E;VKQ[92[4!%A@H]"A4!RN.$=)D1%DAQ_ MAJ#NF%,9I_-[]"^Z>%G, 7&\H^1W=1)E[J:N<\)G="7BA79?\5!0Y#I#]=_Q M#1,I5R0RQY$2KJ_.\IG)%"1,=HYK'];+5(?A;<)Y,,\JDW][/0]62V7N[J&4MH90F7+*G!TDNB21;YVT%HL#Q3S5@B*TNT9%D;+-$BB\GQ2#%CB*T, M\8(A-C)LXZ<,CQ0SAL3*D"P9C#>_33[T?3Q3S5A2*TNZ9#%^IVUJ?_/F0WDJ MF]&LK33K)4U@T*P7:;PPC'RS!]AD?I*N[32R\UN[$5SRA&8[@A\#LNHL1 M*M79]0.Q2]5PYT"%[+JZ-YXI%5C&A"L9K93'Y;@@^"S4-)%SUI\9_4+0=C@/ MP7@H%_\ 4$L#!!0 ( ""9DW"GTW&;P0 +<4 8 >&PO=V]R:W-H M965T&ULC9C;;N-&#(9?Q=!]HCD? L= ++MH@198[*+MM6)/ M8F,ERY64>/OV'1WB54@JZ8TMC3]RYN<<2,_R4M7?FT,([>)'69R:^^30MN>[ M-&UVAU#FS6UU#J?XRU-5EWD;7^OGM#G7(=_W1F61"L9,6N;'4[):]FU?ZM6R M>FF+XRE\J1?-2UGF];_K4%27^X0G;PU?C\^'MFM(5\MS_AR^A?;/\Y0Q:*HO,4Q_'/Z#2Y]MD93I_?O/_2BX]B'O,F9%7Q]W'?'NX3ERSV MX2E_*=JOU>77, K2R6)4_WMX#47$NY'$/G95T?2?B]U+TU;EZ"4.IUL,Y[Y8=O]-QNG9=8S\[_6\QGDUL?5T9O4Q?.S\CLAX0,47,>V2# M$7XETMC_=1""&L1:('/QOH,,$\:",7SJ9/NADW?#E&2L9&\OI_:.ME>DO>KM MU=3>@U@/B.V1TX ("&48XE([0&T(RFHM04PP):UCDI:E25D:R;(,R!H0/1V+ MLQQ0&4%9SJ$N3&EO%-2%*:6=]+0N0^HR6!<'N@P>BP7K,L.,E$R \6XPQ962 M"JC"5&38S"*VI"J+58%]LK:H%Z&U!GL^PY215H((;3#EN9%@YK>8XL(R-3-= MCA3FT.ZT,\O8D_8>!P:$?^VQ9 '#@ADG)8CP!D-*HU@KN3@J3WL.%3&"<2\/@84QQS(NY$YG/I"^.]1FHCQ-[RQD%]1%8 MG#EX_!"8$M;"\X? I&=*SZ@C\^(#%UB=A>H$/H,X@SLLHS!MM(+J,,8-#>S C.,1BM#>7->*&1/H)3RHNYU4DG M?*[PF31SIG$ZMW*<7!U,KIS(FQXE5X*RGL'P$,E5&PZ#0W2HN9@11B=7CK.K M@]F5XW1WHX2#)RZ%Q4+'06T$QK&[+:6-IUF.C;!.HZG# M''4P$=ZL]0ZF%8K3WJN9BIW3V98[K$]"?0[UA*1A1,,%OB$@(6 )04!^4H>^ MUT17 !R7 #!ZZY&QG\X9YH15:,X(;]8)AN:,X SS?.Y?%ET,"%P,.%@,C(R? M]L1N81&>$1B[A3E^0SO3H,\MC);T*6 P*6 @Z6 MP$F95DARL7B&"DF.4$APE,)T*S:MBK["YVGJFI#''Y7J/U!+ P04 " @F9-:E!P59H" M 2"0 & 'AL+W=O'.$KI#_[ M+68S:_*RKUO8D1IU!H:'E?GL+(N$XP7@5PTO9#8VN)(=0F]\\FV_,FV>$&Q@ M2;D'P%YGF,&FX8Y8&G]&G^84DA/GXZOW+T([T[(#!&:H^5WO:;4R8]/8PP,X M-?0%7;["44]@&J/X[_ ,&P;GF; 8)6J(>!KEB5#4CEY8*BUX']YU)]Z7T?^5 MIB>X(\&=""SV(X(W$KP/@O^0X(\$_W\C!",AD")8@W91S!Q0L$XQNAAXV X] MX+O.609LN4IN%*LCOK%Z$F8]K^,DM<[:2 VD;9AJ,I#97(0M'VDF%!N/?6>A(*R=2Y7B2G$A-51*C(AQ) MBXI8.!*FT&!"O918*R56IS%380PE"]+X8L?/DW]*&A@[?D$L*;-F/_06XJ/HKL0HT:FC_.3-K%,# M?W9Y0Y#L&V>9.1I[SAK^T)\_W ^WA1\ '^N.&#M$61L2S>* $(4L>_N)+4?% M+BC3I($'RH<1&^.A30\3BOKQ!F)-UZ#U/U!+ P04 " @F9-'E@H+E4$ M !)% & 'AL+W=O!=V$T"2[W/[[.H'ELN/COD!BSHS/.,YG MX\6I[;[U.^^'V?>F/O0/\]TP'.^SK-_L?%/U7]JC/X1?7MJNJ89PV[UF_;'S MU78*:NJ,\[S(FFI_F"\74]M3MURT;T.]/_BG;M:_-4W5_;OR=7MZF-/\H^'K M_G4WC W9YH]TOU9F#)@4?^W] MJ;^YGHVE/+?MM_'FU^W#/!\=^=IOAC%%%;[>_=K7]9@I^/CGDG1^[7,,O+W^ MR/[S5'PHYKGJ_;JM_]YOA]W#O)S/MOZE>JN'K^WI%W\IR,QGE^I_\^^^#O+1 M2>ACT];]]#G;O/5#VURR!"M-]?W\O3],WZ=+_H\P',"7 +X&D/G? '4)4#\" M]%3\V=E4ZD_54"T777N:=>>G=:S&24'W*@SF9FRU"P!C7%J]L:$O$:QNLI7M_& MEV(,SA([20[G(I0VH@X@*@ILQ$ C)B[$X?@"QA=1(93GHI*SQMR8O+,EYUK4 M F1%[BCQY"VT8Z-R*$\D*&&"$M0C)L^JC(R&02]E.4"EN"BQ&0?-.&!&"3,N MZH:LG$MK("I25BC';VT.S&CYWN9QT;F<#VND4C9E)P$1 G:,M$/QE&(J"ND' MR)Q.V('$>20&=B*J<=2/ J,3JS1SP@VF$RG@QDHW"@R.4DK: 3)-+F4(XXYB MWE$N@7<1"4Y(.[&(V"3,8.21 6:<-&-B,Q0]JEBD4M,8XY.*&%@WW7Q.@9%' M-BJ'HVIL/&K*%7)5!#)7I@87\Y-B@"JY'E",QCM2P9"T$^L,)V<>1BC%#%4D M_<1XO+/:6FDGEI7.)9XW8XHRH"A)/QSS,;QR1J[]0*9RF]B&,,8H XR27.\8 M\-&X>/H@'3ERB0T)8Y0R@U=")5)@_C'@'\FUBA'_+!=:$A )R956IQX]9B # M!I)EUJE5BS$)&9"0Y*K%B(3&218BF78)E#&F(8/=I"Q] MQ6"?6"II>XUDI*U.C1"&*X,-):6>.R8B@RTE24!SC+IH@&,)*5W:!)\9\Y#! MGI(EH!D T=C<24 C75A*R\0 *-=(*>58[D&0F<+E;*4^ <, M&,N2L2I&)Q6.M9S;0%>,*$XXPH!5 + L :MBS\,>>3S $>TK MNE^?3[5^I#D?LOU>=:_[0S][;H>A;:9#G)>V'7QPF'\)#G>^VEYO:O\RC)+P=WV?7T&PO=V]R:W-H965T&UL?5/1;MLP#/P501]0)4JZ=H%M MH&DQ;, &!!VV/2LV;0N51$^2X^[O)\F.YW7&7BR2YAV/%)4-:%]<"^#)JU;& MY;3UOCLPYLH6M' WV($)?VJT6OC@VH:YSH*H$D@KQC>;=TP+:6B1I=C)%AGV M7DD#)TM>=032Y"BQ>MX2I/.8>*_PM8!? +P-P V%DK*GX07169Q(':< M?2?B%6\//,RFC,$TBO0OB'BFV_"YCET@TY1S''+[,F3-88)]+\+421_X/ MG*_#=ZL*=PF^^TOA_3K!?I5@GPCV_VUQ+>?]FR)L,5,-MDG;Y$B)O4F;O(C. M"_O TYW\21^W_8NPC32.G-&'FTWSKQ$]!"F;F[!";7A@LZ.@]M&\"[8=UVQT M/';3"V+S,RY^ U!+ P04 " @F9-X7UL^K(! #2 P & 'AL+W=O M0.)7T0)\=#Z+K77"PJAAX!U_!?1O.QEML96F$ FT%:F*@+>G=X7C*0WP, M^"Y@LILS"95<$!^#\:DI:1($@83:!0;NMRO<@Y2!R,OXN7#2-64 ;L_/[!]B M[;Z6"[=PC_*':%Q?TEM*&FCY*-T#3A]AJ><-)4OQG^$*TH<')3Y'C=+&E=2C M=:@6%B]%\:=Y%SKNTWR39PML'Y N@'0%W,8\;$X4E;_GCE>%P8F8N?<##T]\ M.*:^-W5PQE;$.R_>>N^U.F1)P:Z!:(DYS3'I-F:-8)Y]39'NI3BE_\'3?7BV MJS"+\.POA2_DSW<)\DB0OUKB7LR_*MFFIPI,%Z?)DAI''2=YXUT']BZ-;_(G M?)[V+]QT0EMR0>=?-O:_173@I20W?H1Z_\%60T+KPO&=/YMYS&;#X;#\(+9^ MX^HW4$L#!!0 ( ""9DT^E^-.M@$ -(# 8 >&PO=V]R:W-H965T M&UL;5-A;]P@#/TKB!]0[I+T5IV22+U.52=MTJG3ML][ %!>:EGGTG4V9X^"DT' VQ Y*\;Q">9Z;BF9B_\*5Y ^/"CQ.2J4-JZD&JQ#-;-X*8J_ M3KO0<1^GF_0PP[8!R0Q(%L!=S,.F1%'Y9^YXF1LRN[&CU#G/]AB2&A<.'[R9S.-V60X[.&PO=V]R:W-H965T-"VQO0%61Y 4A";)-9&,*USFT7BSP#K\Y M'GC;N> @9=ZS%GZ#^].?C+?(PE)S"E/@T,VP;0&4 7P#[F(5.BJ/PKGV_!T4V$:X>D'A?MM M@FR3((L$V0>"VT\E;L1DR:0^?IOT7 M,RU7%IVU\R\;^]]H[&UL=5/;;IPP$/T5RQ\0+RQ)HQ4@95-5B=1*JU1MG[TP@!5?B&V6 M].\[-H22E+[8GO&<,V?&XWPT]MEU )Z\*JE=03OO^P-CKNI <7=E>M!XTQBK MN$?3MLSU%G@=04JR=+>[88H+3 GP)&MSJ34,G9 MF.=@/-8%W05!(*'R@8'C=H%[D#(0H8R7F9,N*0-P?7YC_Q)KQUK.W,&]D;]$ M[;N"WE)20\,'Z9_,^ !S/=>4S,5_A0M(# ]*,$=EI(LKJ0;GC9I94(KBK],N M=-S'Z2:[GF';@'0&I O@-N9A4Z*H_#/WO,RM&8F=>M_S\,3)(<7>5,$96Q'O M4+Q#[Z5,LB1GET TQQRGF'0=LT0P9%]2I%LICND_\'0;OM]4N(_P_3N%_R'( M-@FR2)"](]A_*'$K)ON0A*UZJL"V<9H&PO=V]R:W-H965T<"CKM_ M7\"NZW;^ MQQ[]V[XT@'-,^V 7#D5:O69K1QKCLP9HL&M+!7V$'K;RHT6CAO MFIK9SH H(T@KQC>;&Z:%;&F>1M_)Y"GV3LD63H;87FMA_AU!X9#1+7UW/,JZ M<<'!\K03-3R!^]V=C+?8S%)*#:V5V!(#54;OMH=C$N)CP!\)@UV<2:CDC/@< MC!]E1C=!$"@H7& 0?KO /2@5B+R,EXF3SBD#<'E^9_\>:_>UG(6%>U1_9>F: MC.XI*:$2O7*/.#S 5,\U)5/Q/^$"RH<')3Y'@?4_"U%$?^'YROPW>K"G<1OOND\&:=(%DE M2")!\HG@]DN):S'[+TG8HJ<:3!VGR9("^S9.\L([#^P=CV_R$3Y.^R]A:ME: MI="V0)WSO5[0FS5@63V0O>@_$VCC63.FZ8E MMC? Z@B2@M DN2*2<87+//J.ILSUX 17<#3(#E(R\W$ H<<"I_C3\M? 3W*_^:+Q%%I::2U"6:X4,- 6^3?>'+,3'@!<.HUV=4:CDI/5K,+[7 M!4Z"(!!0N<# _':&.Q B$'D9;S,G7E(&X/K\R?X0:_>UG)B%.RU^\]IU!;[! MJ(:&#<(]Z_$1YGHN,9J+_P%G$#X\*/$Y*BUL7%$U6*?ES.*E2/8^[5S%?9QN MKJ]FV#: S@"Z &YB'C(EBLKOF6-E;O2(S-3[GH4G3O?4]Z8*SMB*>.?%6^\] MEVGV+2?G0#3''*88NHY9(HAG7U+0K10'^A^<;L-WFPIW$;Y;9[],M@FR38(L M$F3_$*1?2MR*^:J2K'HJP;1QFBRJ]*#B)*^\R\#>TO@F?\.G:7]BIN7*HI-V M_F5C_QNM'7@IR84?H&UL?5-MC]0@$/XKA!]P;%]6+YNVR>T9HXDFFS/J9[:=MN2 J4"WY[\7:*]6 M;?P"S##/,\\,0S&A>;8]@",O2FI;TMZYX<28K7M0W-[A -K?M&@4=]XT';.# M =Y$D)(L/1S>,,6%IE41?1=3%3@Z*31<#+&C4MS\/(/$J:0)?74\B:YWP<&J M8N =? 'W=;@8;[&5I1$*M!6HB8&VI _)Z9R'^!CP3-TL:5U*-UJ!86+T7QEWD7.N[3?),E M"VP?D"Z = 7_ %!+ P04 " M@F9-WE2EY[0! #2 P &0 'AL+W=OW<NC@Q59)QKX M OYK=['!8C-+)348)]$0"W5.'[>G\S[&IX!O$@:W.)-8R17Q)1H?JYQNHB!0 M4/K((,)V@R=0*A(%&3\F3CJGC,#E^8W]?:H]U'(5#IY0?9>5;W-ZI*2"6O3* M/^/P :9Z#I1,Q7^"&Z@0'I6$'"4JEU92]LZCGEB"%"U>QUV:M _CS8%/L'4 MGP!\!AQ3'C8F2LK?"2^*S.) [-C[3L0GWIYXZ$T9G:D5Z2Z(=\%[*[:'^XS= M(M$4&PO=V]R:W-H965TM.2:1>IVF35NG4:>MG+G$25, 9D$O[[P]#^ID&CN/.F:9GM#? Z@I1D69+< M,,6%IF4>?2=3YC@X*32<#+MR\'D'B6-"4OCD>1=NYX&!EWO,6?H+[U9^, MM]C"4@L%V@K4Q$!3T+OT<-R'^!CP6\!H5V<2*CDC/@?C>UW0) @""94+#-QO M%[@'*0.1E_%GYJ1+R@!Y9.H75?06TIJ:/@@W2..WV"N MYYJ2N?@?< 'IPX,2GZ-":>-*JL$Z5#.+EZ+XR[0+'?=QNMFE,VP;D,V ; '< MQCQL2A25?^&.E[G!D9BI]ST/3YP>,M^;*CAC*^*=%V^]]U*FUY]S=@E$<\QQ MBLG6,4L$\^Q+BFPKQ3'[#YYMPW>;"G<1OEMGOTFV"?:;!/M(L']'D'XH<2OF MHTJVZJD"T\9ILJ3"0<=)7GF7@;W+XIO\"Y^F_8&;5FA+SNC\R\;^-X@.O)3D MRH]0YS_88DAH7#A^\FFS=G(2NFS5)>B&HD9R=G5)4D M#(*85*RH_4WN]O9RDXN;+HN:[Z6G;E7%Y)\=+T6[]JG_L?%27*[:;I!-WK + M_\'USV8OS8H,+*>BXK4J1.U)?E[[6[K:T=0:.,1KP5OU,/=L* D_J!I#1_G'^R?7? FF -3_%F4OXJ3OJ[] MU/=._,QNI7X1[1?>![3TO3[Z;_S.2P.WGAB-HRB5>WK'F]*BZEF,*Q5[[\:B M=F/;O8GCW@P;A+U!.!BD3H=T0L[S3TRS32Y%Z\GNXS?,_F.Z"LVW.=I-]RG< M.^.\,KOW#8VCG-PM48_9=9CP$3,@B&$?)$(DL0LGYB$VCZ"'D3./'M6C&?T% M)%@X@L5_(2Y&(2+,$HLLH<@2$,0C$81)L$@,16) D(Y$$";#(@D42:8$23 2 M09B9?Y)"D100A",1A(FP2 9%L@E!- YD"J') FO0 !=0 "B6XPI"H'A&9Z90 M*:!(QCH(E,[HP&K=TA!09&,= $J#&1U3$PZ! MYO( 'P 45'^4=Q:UVK<;#[M!1;$-W9_Z#=^W(=R8O1:V\@]#F MYG7WXUD(S8TOP9/YAU?3 0V+DI^UG29F+KLVH%MHT?0M#AGZK,U?4$L#!!0 M ( ""9DUQ\YE!MP$ -(# 9 >&PO=V]R:W-H965TIVF3-NG4:=MG+G$25, 9D$OW[P0.!9T3U\A/QEML8:F% FT%:F*@*>C]_G#,0GP,^"E@M*LS"96<$9^"\:4N MZ"XD!!(J%QBXWR[P %(&(I_&[YF3+I(!N#Z_L'^*M?M:SMS" \I?HG9=06\I MJ:'A@W2/.'Z&N9YK2N;BO\(%I \/F7B-"J6-*ZD&ZU#-+#X5Q9^G7>BXC]/- MS=T,VP8D,R!9 +=1ATU",?./W/$R-S@2,_6^Y^&)]X?$]Z8*SMB*>.>3M]Y[ M*?=W:?9%(MB2.R1MXL@U/-S-,(SQ=JZ?OZ&>;!%DD MR/XK,7M5XE;,]2L1MNJI M/&:;*DPD''25YYEX&]3^*;_ N?IOT;-ZW0EIS1 M^9>-_6\0'?A4=E=^A#K_P19#0N/"\8,_FVG,)L-A/_\@MGSC\B]02P,$% M @ ()F37=F+R?' 0 -P0 !D !X;"]W;W)K&UL;51M;YLP$/XKEG] G9"7IA$@-9VF3=JDJ-.ZSPX<8-7&S#:A^_<[&\I8 MZB_8=W[N>>Y\/M)!FU?; #CRIF1K,]HXUQT9LT4#BML[W4&+)Y4VBCLT3
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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 182 229 1 false 63 0 false 5 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.halozyme.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.halozyme.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 1004000 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.halozyme.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.halozyme.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Organization and Business Sheet http://www.halozyme.com/role/OrganizationAndBusiness Organization and Business Notes 7 false false R8.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Fair Value Measurement (Notes) Notes http://www.halozyme.com/role/FairValueMeasurementNotes Fair Value Measurement (Notes) Notes 9 false false R10.htm 2104100 - Disclosure - Revenue (Notes) Notes http://www.halozyme.com/role/RevenueNotes Revenue (Notes) Notes 10 false false R11.htm 2107100 - Disclosure - Certain Balance Sheet Items (Notes) Notes http://www.halozyme.com/role/CertainBalanceSheetItemsNotes Certain Balance Sheet Items (Notes) Notes 11 false false R12.htm 2108100 - Disclosure - Long-Term Debt, Net (Notes) Notes http://www.halozyme.com/role/LongTermDebtNetNotes Long-Term Debt, Net (Notes) Notes 12 false false R13.htm 2109100 - Disclosure - Share-based Compensation (Notes) Notes http://www.halozyme.com/role/ShareBasedCompensationNotes Share-based Compensation (Notes) Notes 13 false false R14.htm 2110100 - Disclosure - Stockholders' Equity (Deficit) Sheet http://www.halozyme.com/role/StockholdersEquityDeficit Stockholders' Equity (Deficit) Notes 14 false false R15.htm 2111100 - Disclosure - Commitments and Contingencies Sheet http://www.halozyme.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 2112100 - Disclosure - Subsequent Event (Notes) Notes http://www.halozyme.com/role/SubsequentEventNotes Subsequent Event (Notes) Notes 16 false false R17.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.halozyme.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 2303301 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.halozyme.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.halozyme.com/role/FairValueMeasurementNotes 19 false false R20.htm 2304301 - Disclosure - Revenue Collaborative Agreements (Tables) Sheet http://www.halozyme.com/role/RevenueCollaborativeAgreementsTables Revenue Collaborative Agreements (Tables) Tables 20 false false R21.htm 2304302 - Disclosure - Revenue Disaggregated Revenue (Tables) Sheet http://www.halozyme.com/role/RevenueDisaggregatedRevenueTables Revenue Disaggregated Revenue (Tables) Tables 21 false false R22.htm 2307301 - Disclosure - Certain Balance Sheet Items (Tables) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsTables Certain Balance Sheet Items (Tables) Tables http://www.halozyme.com/role/CertainBalanceSheetItemsNotes 22 false false R23.htm 2309301 - Disclosure - Share-based Compensation (Tables) Sheet http://www.halozyme.com/role/ShareBasedCompensationTables Share-based Compensation (Tables) Tables http://www.halozyme.com/role/ShareBasedCompensationNotes 23 false false R24.htm 2402403 - Disclosure - Summary of Significant Accounting Policies Restricted Cash (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesRestrictedCashDetails Summary of Significant Accounting Policies Restricted Cash (Details) Details 24 false false R25.htm 2402404 - Disclosure - Summary of Significant Accounting Policies Inventories (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails Summary of Significant Accounting Policies Inventories (Details) Details 25 false false R26.htm 2402406 - Disclosure - Summary of Significant Accounting Policies Research and development (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails Summary of Significant Accounting Policies Research and development (Details) Details 26 false false R27.htm 2402407 - Disclosure - Summary of Significant Accounting Policies Income tax (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxDetails Summary of Significant Accounting Policies Income tax (Details) Details 27 false false R28.htm 2402408 - Disclosure - Summary of Significant Accounting Policies Net Loss Per Share (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerShareDetails Summary of Significant Accounting Policies Net Loss Per Share (Details) Details 28 false false R29.htm 2402409 - Disclosure - Summary of Significant Accounting Policies Segment information (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails Summary of Significant Accounting Policies Segment information (Details) Details 29 false false R30.htm 2402410 - Disclosure - Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) Sheet http://www.halozyme.com/role/SummaryOfSignificantAccountingPoliciesAdoptionOfRecentAccountingPronouncementsDetails Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) Details 30 false false R31.htm 2403402 - Disclosure - Fair Value Measurement (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementDetails Fair Value Measurement (Details) Details http://www.halozyme.com/role/FairValueMeasurementTables 31 false false R32.htm 2403403 - Disclosure - Fair Value Measurement Textuals (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementTextualsDetails Fair Value Measurement Textuals (Details) Details 32 false false R33.htm 2403404 - Disclosure - Fair Value Measurement Fair Value Measures (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementFairValueMeasuresDetails Fair Value Measurement Fair Value Measures (Details) Details 33 false false R34.htm 2403405 - Disclosure - Fair Value Measurement Maturities (Details) Sheet http://www.halozyme.com/role/FairValueMeasurementMaturitiesDetails Fair Value Measurement Maturities (Details) Details 34 false false R35.htm 2404403 - Disclosure - Revenue Collaborative Agreements Textuals (Details) Sheet http://www.halozyme.com/role/RevenueCollaborativeAgreementsTextualsDetails Revenue Collaborative Agreements Textuals (Details) Details 35 false false R36.htm 2404404 - Disclosure - Revenue Collaborative Agreements tables (Details) Sheet http://www.halozyme.com/role/RevenueCollaborativeAgreementsTablesDetails Revenue Collaborative Agreements tables (Details) Details http://www.halozyme.com/role/RevenueCollaborativeAgreementsTables 36 false false R37.htm 2404405 - Disclosure - Revenue Revenue Adjustments - 606 Implementation (Details) Sheet http://www.halozyme.com/role/RevenueRevenueAdjustments606ImplementationDetails Revenue Revenue Adjustments - 606 Implementation (Details) Details 37 false false R38.htm 2404406 - Disclosure - Revenue Deferred Revenue Timing (Details) Sheet http://www.halozyme.com/role/RevenueDeferredRevenueTimingDetails Revenue Deferred Revenue Timing (Details) Details 38 false false R39.htm 2404407 - Disclosure - Revenue Disaggregated Revenue (Details) Sheet http://www.halozyme.com/role/RevenueDisaggregatedRevenueDetails Revenue Disaggregated Revenue (Details) Details http://www.halozyme.com/role/RevenueDisaggregatedRevenueTables 39 false false R40.htm 2404408 - Disclosure - Revenue Performance Obligation (Details) Sheet http://www.halozyme.com/role/RevenuePerformanceObligationDetails Revenue Performance Obligation (Details) Details 40 false false R41.htm 2407402 - Disclosure - Certain Balance Sheet Items - Accounts receivable (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivableDetails Certain Balance Sheet Items - Accounts receivable (Details) Details 41 false false R42.htm 2407403 - Disclosure - Certain Balance Sheet Items - Inventories (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails Certain Balance Sheet Items - Inventories (Details) Details 42 false false R43.htm 2407404 - Disclosure - Certain Balance Sheet Items - Prepaid expenses and other assets (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesAndOtherAssetsDetails Certain Balance Sheet Items - Prepaid expenses and other assets (Details) Details 43 false false R44.htm 2407405 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetails Certain Balance Sheet Items - Property and Equipment (Details) Details 44 false false R45.htm 2407406 - Disclosure - Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyAndEquipmentNetTextualsDetails Certain Balance Sheet Items - Property and Equipment, Net (Textuals) (Details) Details 45 false false R46.htm 2407407 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails Certain Balance Sheet Items - Accrued Expenses (Details) Details 46 false false R47.htm 2407408 - Disclosure - Certain Balance Sheet Items - Deferred Revenue (Details) Sheet http://www.halozyme.com/role/CertainBalanceSheetItemsDeferredRevenueDetails Certain Balance Sheet Items - Deferred Revenue (Details) Details 47 false false R48.htm 2408401 - Disclosure - Long-Term Debt, Net Long-Term Debt Textuals (Details) Sheet http://www.halozyme.com/role/LongTermDebtNetLongTermDebtTextualsDetails Long-Term Debt, Net Long-Term Debt Textuals (Details) Details 48 false false R49.htm 2409402 - Disclosure - Share-based Compensation (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationDetails Share-based Compensation (Details) Details http://www.halozyme.com/role/ShareBasedCompensationTables 49 false false R50.htm 2409403 - Disclosure - Share-based Compensation Share-based compensation textuals (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationTextualsDetails Share-based Compensation Share-based compensation textuals (Details) Details 50 false false R51.htm 2409404 - Disclosure - Share-based Compensation Share-based compensation, valuation (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationValuationDetails Share-based Compensation Share-based compensation, valuation (Details) Details 51 false false R52.htm 2409405 - Disclosure - Share-based Compensation Share-based compensation, unrecognized (Details) Sheet http://www.halozyme.com/role/ShareBasedCompensationShareBasedCompensationUnrecognizedDetails Share-based Compensation Share-based compensation, unrecognized (Details) Details 52 false false R53.htm 2410401 - Disclosure - Stockholders' Equity (Deficit) Public Offering (Details) Sheet http://www.halozyme.com/role/StockholdersEquityDeficitPublicOfferingDetails Stockholders' Equity (Deficit) Public Offering (Details) Details http://www.halozyme.com/role/StockholdersEquityDeficit 53 false false R54.htm 2410402 - Disclosure - Stockholders' Equity (Deficit) (Details) Sheet http://www.halozyme.com/role/StockholdersEquityDeficitDetails Stockholders' Equity (Deficit) (Details) Details http://www.halozyme.com/role/StockholdersEquityDeficit 54 false false R55.htm 2412402 - Disclosure - Subsequent Event (Details) Sheet http://www.halozyme.com/role/SubsequentEventDetails Subsequent Event (Details) Details http://www.halozyme.com/role/SubsequentEventNotes 55 false false All Reports Book All Reports halo-20180930.xml halo-20180930.xsd halo-20180930_cal.xml halo-20180930_def.xml halo-20180930_lab.xml halo-20180930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 77 0001159036-18-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001159036-18-000043-xbrl.zip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end

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Oct. 30, 2018
Document Information [Line Items]
Entity Registrant Name	HALOZYME THERAPEUTICS INC.
Trading Symbol	HALO
Entity Central Index Key	0001159036
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		144,557,543

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 55,019	$ 168,740
Marketable securities, available-for-sale	309,347	300,474
Accounts receivable, net	27,656	22,133
Inventories	18,285	5,146
Prepaid expenses and other assets	19,619	13,879
Total current assets	429,926	510,372
Property and equipment, net	6,790	3,520
Prepaid expenses and other assets	7,291	5,553
Restricted cash	500	500
Total assets	444,507	519,945
Current liabilities:
Accounts payable	3,331	7,948
Accrued expenses	43,020	39,601
Deferred revenue, current portion	4,247	6,568
Current portion of long-term debt, net	88,521	77,211
Total current liabilities	139,119	131,328
Deferred revenue, net of current portion	5,507	54,297
Long-term debt, net	57,940	125,140
Other long-term liabilities	2,203	814
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock - $0.001 par value; 200,000 shares authorized; 142,301 and 129,502 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	145	143
Additional paid-in capital	769,382	731,044
Accumulated other comprehensive loss	(478)	(450)
Accumulated deficit	(529,311)	(522,371)
Total stockholders' equity (deficit)	239,738	208,366
Total liabilities and stockholders' equity (deficit)	$ 444,507	$ 519,945

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000	200,000
Common stock, shares issued	144,522	142,789
Common stock, shares outstanding	144,522	142,789

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Product sales, net	$ 6,269	$ 13,589	$ 17,553	$ 37,803
Royalty Revenue	18,710	17,119	59,643	45,839
License and Services Revenue	577	33,023	14,434	43,407
Total revenues	25,556	63,731	91,630	127,049
Operating expenses:
Cost of product sales	626	8,332	4,514	23,664
Research and development	35,540	33,993	113,602	109,267
Selling, general and administrative	14,864	13,329	42,773	39,045
Total operating expenses	51,030	55,654	160,889	171,976
Operating income (loss)	(25,474)	8,077	(69,259)	(44,927)
Other income (expense):
Investment and other income, net	1,910	790	5,561	1,512
Interest expense	(4,286)	(5,538)	(14,286)	(16,526)
Income (loss) before income taxes	(27,850)	3,329	(77,984)	(59,941)
Income tax expense	0	580	220	970
Net income (loss)	$ (27,850)	$ 2,749	$ (78,204)	$ (60,911)
Earnings Per Share, Basic	$ (0.19)	$ 0.02	$ (0.55)	$ (0.45)
Earnings Per Share, Diluted	$ (0.19)	$ 0.02	$ (0.55)	$ (0.45)
Shares used in computing basic net income (loss) per share	143,949	141,190	143,396	134,633
Shares used in computing diluted net income (loss) per share	143,949	143,236	143,396	134,633

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Statement of Cash Flows [Abstract]
Capital Expenditures Incurred but Not yet Paid	$ 2,345	$ 266
Operating activities:
Net loss	(78,204)	(60,911)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	26,684	23,268
Depreciation and amortization	1,798	1,668
Non-cash interest expense	2,000	2,378
(Accretion of discounts) amortization of premiums on marketable securities, net	(2,166)	(94)
Deferral of unearned revenue	3,000	422
Recognition of deferred revenue	(2,333)	(4,192)
Recognition of deferred rent	(78)	125
Other	(10)	38
Changes in operating assets and liabilities:
Accounts receivable, net	13,962	985
Inventories	(13,139)	5,292
Prepaid expenses and other assets	(7,477)	8,998
Accounts payable and accrued expenses	(4,155)	3,077
Net cash used in operating activities	(59,962)	(19,196)
Investing activities:
Purchases of marketable securities	(272,643)	(198,748)
Proceeds from maturities of marketable securities	265,917	184,494
Purchases of property and equipment	(1,590)	(490)
Net cash used in investing activities	(8,316)	(14,744)
Financing activities:
Proceeds from issuance of common stock, net	0	134,875
Repayment of long-term debt	(57,099)	(10,988)
Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement	11,656	7,686
Net cash provided by financing activities	(45,443)	131,573
Net increase in cash, cash equivalents and restricted cash	(113,721)	97,633
Cash, cash equivalents and restricted cash beginning of period	169,240	67,264
Cash, cash equivalents and restricted cash end of period	55,519	164,897
Payments for Tenant Improvements	$ 1,322	$ 0

Organization and Business	9 Months Ended
Organization and Business	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Organization and Business Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies. Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds. The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex^® recombinant, and it works by temporarily breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE^® Drug Delivery Technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”) and Alexion Pharma Holding (“Alexion”).We receive royalties from two of these collaborations, including royalties from sales of one product from the Baxalta collaboration and two products from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates. Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is Pegvorhyaluronidase alfa (PVHA), also referred to as PEGylated recombinant human hyaluronidase (“PEGPH20”), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause increased pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. Through our efforts and efforts of our partners and collaborators, we are currently in Phase 3 clinical testing for PEGPH20 with ABRAXANE^®(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (HALO 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA^® (pembrolizumab) in non-small cell lung cancer and gastric cancer (HALO 107-101), in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq® (atezolizumab) in patients with previously treated metastatic PDA, in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with gastric cancer and in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX). Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.

Long-Term Debt, Net (Notes)	9 Months Ended
Long-Term Debt, Net (Notes)	Sep. 30, 2018
Debt Disclosure [Abstract]
Long-term Debt	Long-Term Debt, Net Royalty-backed Loan In January 2016, through our wholly-owned subsidiary Halozyme Royalty LLC (“Halozyme Royalty”), we received a $150 million loan (the “Royalty-backed Loan”) pursuant to a credit agreement (the “Credit Agreement”) with BioPharma Credit Investments IV Sub, LP and Athyrium Opportunities II Acquisition LP (the “Royalty-backed Lenders”). Under the terms of the Credit Agreement, Halozyme Therapeutics, Inc. transferred to Halozyme Royalty the right to receive royalty payments from the commercial sales of ENHANZE products owed under the Roche Collaboration and Baxalta Collaboration (“Collaboration Agreements”). The royalty payments from the Collaboration Agreements will be used to repay the principal and interest on the loan (the “Royalty Payments”). The Royalty-backed Loan bears interest at a per annum rate of 8.75% plus the three-month LIBOR rate. The three-month LIBOR rate is subject to a floor of 0.7% and a cap of 1.5%. The interest rate as of September 30, 2018 was 10.25%. The Credit Agreement provides that none of the Royalty Payments were required to be applied to the Royalty-backed Loan prior to January 1, 2017, 50% of the Royalty Payments are required to be applied to the Royalty-backed Loan between January 1, 2017 and January 1, 2018 and thereafter all Royalty Payments must be applied to the Royalty-backed Loan. However, the amounts available to repay the Royalty-backed Loan are subject to caps of $13.75 million per quarter in 2017, $18.75 million per quarter in 2018, $21.25 million per quarter in 2019 and $22.5 million per quarter in 2020 and thereafter. Amounts available to repay the Royalty-backed Loan will be applied first to pay interest and second to repay principal on the Royalty-backed Loan. Any accrued interest that is not paid on any applicable quarterly payment date, as defined, will be capitalized and added to the principal balance of the Royalty-backed Loan on such date. Halozyme Royalty will be entitled to receive and distribute to Halozyme any Royalty Payments that are not required to be applied to the Royalty-backed Loan or which are in excess of the foregoing caps. Because the repayment of the term loan is contingent upon the level of Royalty Payments received, the repayment term may be shortened or extended depending on the actual level of Royalty Payments. The final maturity date of the Royalty-backed Loan will be the earlier of (i) the date when principal and interest is paid in full, (ii) the termination of Halozyme Royalty’s right to receive royalties under the Collaboration Agreements, and (iii) December 31, 2050. Currently, we estimate that the loan will be repaid in the first quarter of 2020. This estimate could be adversely affected and the repayment period could be extended if future royalty amounts are less than currently expected. Under the terms of the Credit Agreement, at any time after January 1, 2019, Halozyme Royalty may, subject to certain limitations, prepay the outstanding principal of the Royalty-backed Loan in whole or in part, at a price equal to 105% of the outstanding principal on the Royalty-backed Loan, plus accrued but unpaid interest. The Royalty-backed Loan constitutes an obligation of Halozyme Royalty, and is non-recourse to Halozyme. Halozyme Royalty retains its right to the Royalty Payments following repayment of the loan. As of September 30, 2018, we were in compliance with all covenants under the Royalty-backed Loan and there was no material adverse change in our business, operations or financial condition. We began making principal and interest payments against the Royalty-backed Loan in the first quarter of 2017 and therefore had no capitalized interest in the three and nine months ended September 30, 2018. In addition, we recorded accrued interest, which is included in accrued expenses, of $0.5 million and $0.7 million as of September 30, 2018 and December 31, 2017, respectively In connection with the Royalty-backed Loan, we paid the Royalty-backed Lenders a fee of $1.5 million and incurred additional debt issuance costs totaling $0.4 million, which includes expenses that we paid on behalf of the Royalty-backed Lenders and expenses incurred directly by us. Debt issuance costs and the lender fee have been netted against the debt as of September 30, 2018, and are being amortized over the estimated term of the debt using the effective interest method. For the three months ended September 30, 2018 and 2017, the Company recognized interest expense, including amortization of the debt discount, related to the Royalty-backed Loan of $3.1 million and $4.2 million, respectively, and $10.5 million and $12.4 million for the nine months ended September 30, 2018 and 2017, respectively. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. The outstanding balance of the Royalty-backed Loan as of September 30, 2018 was $101.0 million, net of unamortized debt discount of $0.4 million. Oxford and SVB Loan and Security Agreement In June 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (collectively, the “Lenders”), providing a senior secured loan facility of up to an aggregate principal amount of $70.0 million, comprising a $55.0 million draw in June 2016 and an additional $15.0 million tranche, which we had the option to draw during the second quarter of 2017 and did not exercise. The initial proceeds were partially used to pay the outstanding principal and final payment of $4.25 million owed on a previous loan agreement with the Lenders. The remaining proceeds are being used for working capital and general business requirements. The senior secured loan facility carries a fixed interest rate of 8.25%. The repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date of January 1, 2021. The Loan Agreement provides for a final payment equal to 5.50% of the initial $55.0 million principal amount. The final payment is due when the Loan Agreement becomes due or upon the prepayment of the facility. We have the option to prepay the outstanding balance of the Loan Agreement in full, subject to a prepayment fee of 2% in the first year and 1% in the second year of the Loan Agreement. In connection with the Loan Agreement, the debt offering costs have been recorded as a debt discount in our condensed consolidated balance sheets which, together with the final payment and fixed interest rate payments, are being amortized and recorded as interest expense throughout the life of the loan using the effective interest rate method. The Loan Agreement is secured by substantially all of the assets of the Company and our subsidiary, Halozyme, Inc., except that the collateral does not include any equity interests in Halozyme, Inc., any of our intellectual property (including all licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by us, which covenants limit our ability to convey, sell, lease, transfer, assign or otherwise dispose of certain of our assets; engage in any business other than the businesses currently engaged in by us or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; make payments on any subordinated debt; enter into transactions with any of our affiliates outside of the ordinary course of business or permit our subsidiaries to do the same; and make any voluntary prepayment of or modify certain terms of the Royalty-backed Loan. In addition, subject to certain exceptions, we are required to maintain with SVB our primary deposit accounts, securities accounts and commodities, and to do the same for our subsidiary, Halozyme, Inc. The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, a material impairment in the perfection or priority of the Lender’s lien in the collateral or in the value of such collateral or the occurrence of an event of default under the Royalty-backed Loan. In the event of default by us under the Loan Agreement, the Lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Loan Agreement, which could harm our financial condition. As of September 30, 2018, we were in compliance with all covenants under the Loan Agreement and there was no material adverse change in our business, operations or financial condition. Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.2 million and $1.4 million for the three months ended September 30, 2018 and 2017, respectively, and $3.8 million and $4.1 million for the nine months ended September 30, 2018 and 2017, respectively. Accrued interest, which is included in accrued expenses, was $0.3 million and $0.4 million as of September 30, 2018 and December 31, 2017, respectively. The outstanding term loan balance was $45.5 million as of September 30, 2018, inclusive of $2.0 million of accretion of the final payment and net of unamortized debt discount related to offering costs of $0.2 million.

Stockholders' Equity (Deficit)	9 Months Ended
Stockholders' Equity (Deficit)	Sep. 30, 2018
Equity [Abstract]
Stockholders' Equity (Deficit)	Stockholders’ Equity In May 2017, we completed an underwritten public offering pursuant to which we sold 11.5 million shares of common stock, including 1.5 million shares sold pursuant to the full exercise of an option to purchase additional shares granted to the underwriters. All of the shares were offered at a public offering price of $12.50 per share, generating $134.9 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. We intend to use the net proceeds from this offering to fund continued development of our PEGPH20 oncology program and for other general corporate purposes. During the nine months ended September 30, 2018 and 2017, we issued an aggregate of 1,280,996 and 1,020,028 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $11.13 and $8.71 per share, respectively, for net proceeds of approximately $14.3 million and $8.9 million, respectively. For the nine months ended September 30, 2018 and 2017, we issued 438,536 and 375,906 shares of common stock, respectively, upon vesting of certain RSUs for which the RSU holders surrendered 138,986 and 96,069 RSUs, respectively, to pay for minimum withholding taxes totaling approximately $4.2 million and $1.9 million, respectively. In addition, we issued 67,959 and 98,945 shares of common stock in connection with the grants of RSAs during the nine months ended September 30, 2018 and 2017, respectively. Stock options and unvested restricted units totaling approximately 13.4 million shares and 14.7 million shares of our common stock were outstanding as of September 30, 2018 and December 31, 2017, respectively.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.

Subsequent Event (Notes)	9 Months Ended
Subsequent Event (Notes)	Sep. 30, 2018
Subsequent Event [Line Items]
Subsequent Events [Text Block]	Subsequent Events In October 2018, we entered into an agreement with Roche for the right to develop and commercialize one additional exclusive target and an option to select two additional targets within four years using our ENHANZE technology for an upfront payment of $25.0 million. We will receive potential milestone payments of up to $160.0 million to $165.0 million per target, subject to the achievement of specific development, regulatory and sales-based milestones. We will also receive mid-single digit royalties on sales of commercialized products.

Summary of Significant Accounting Policies Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Restricted Cash and Investments, Current [Abstract]
Restricted cash	$ 500	$ 500

Summary of Significant Accounting Policies Segment information (Details)	9 Months Ended
	Sep. 30, 2018 Segment
Segment Reporting [Abstract]
Number of Operating Segments	1

Summary of Significant Accounting Policies Adoption of Recent Accounting Pronouncements (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Reclassification of restricted cash	$ 0.5	$ 0.5

Fair Value Measurement (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Schedule of Available-for-sale Securities
Amortized cost	$ 309,800	$ 300,910
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(453)	(436)
Estimated fair value	309,347	300,474
Asset-backed Securities [Member]
Schedule of Available-for-sale Securities
Amortized cost	39,721
Gross Unrealized Gains	0
Gross Unrealized Losses	(24)
Estimated fair value	39,697
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities
Amortized cost	74,699	117,427
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(181)	(235)
Estimated fair value	74,518	117,192
US Treasury Securities [Member]
Schedule of Available-for-sale Securities
Amortized cost	99,716	66,601
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(248)	(201)
Estimated fair value	99,468	66,400
Commercial Paper [Member]
Schedule of Available-for-sale Securities
Amortized cost	95,664	116,882
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated fair value	$ 95,664	$ 116,882

Fair Value Measurement Textuals (Details) $ in Millions	9 Months Ended
Fair Value Measurement Textuals (Details) $ in Millions	Sep. 30, 2018 USD ($)
Fair Value Disclosures [Abstract]
Number of available-for-sale securities in unrealized loss position, less than one year	27
Other than Temporary Impairment Losses, Marketable Securities	$ 0.0

Fair Value Measurement Fair Value Measures (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets, Fair Value Disclosure	$ 364,618	$ 458,265
Available-for-sale Securities	309,347	300,474
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	0	0
Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	55,271	142,091
US Treasury Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	99,468	66,400
Commercial Paper [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	15,700
Available-for-sale Securities	95,664	116,882
Corporate Debt Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	74,518	117,192
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets, Fair Value Disclosure	154,739	208,491
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	55,271	142,091
Fair Value, Inputs, Level 1 [Member] \| US Treasury Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	99,468	66,400
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets, Fair Value Disclosure	209,879	249,774
Fair Value, Inputs, Level 2 [Member] \| Commercial Paper [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	15,700
Available-for-sale Securities	95,664	116,882
Fair Value, Inputs, Level 2 [Member] \| Corporate Debt Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	74,518	117,192
Fair Value, Inputs, Level 2 [Member] \| Asset-backed Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	39,697
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure	0	$ 0
Asset-backed Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities	$ 39,697

Fair Value Measurement Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Available-for-sale Securities	$ 309,347	$ 300,474

Revenue Deferred Revenue Timing (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 9,754	$ 60,865
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	4,500
bulk rHuPH20 [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-12-31
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	3,000
Alexion [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Nonrefundable Upfront License Fee Payment Received Under Collaborative Agreement	$ 5,000

Certain Balance Sheet Items - Accounts receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accounts Receivable, Net, Current [Abstract]
Accounts receivable from product sales to collaborators	$ 1,980	$ 18,475
Accounts receivable from revenues under collaborative agreements	451	2,142
Accounts receivable from other product sales	1,949	2,075
Other contract assets	5,000	0
Accounts receivable from royalties	18,777	0
Accounts receivable, gross	28,157	22,692
Allowance for distribution fees and discounts	(501)	(559)
Total accounts receivable, net	$ 27,656	$ 22,133

Certain Balance Sheet Items - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory, Raw Materials	$ 625	$ 377
Inventory, Work in Process	15,401	2,131
Inventory, Finished Goods	2,259	2,638
Summary of Inventories
Total inventories	$ 18,285	$ 5,146

Certain Balance Sheet Items - Prepaid expenses and other assets (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid manufacturing expenses	$ 8,844	$ 2,337
Prepaid research and development expenses	9,195	7,793
Other prepaid expenses	2,344	2,585
Other assets	6,527	6,717
Total prepaid expense and other assets	26,910	19,432
Less long-term portion	7,291	5,553
Total prepaid expense and other assets, current	$ 19,619	$ 13,879

Certain Balance Sheet Items - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Property and equipment, gross	$ 22,478	$ 17,410
Accumulated depreciation and amortization	(15,688)	(13,890)
Property and equipment, net	6,790	3,520
Research equipment
Property and equipment, gross	9,528	9,268
Manufacturing Equipment [Member] [Domain]
Property and equipment, gross	3,979	1,702
Computer and office equipment
Property and equipment, gross	4,811	3,725
Leasehold improvements
Property and equipment, gross	$ 4,160	$ 2,715

Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Summary of Accrued Expenses
Accrued outsourced research and development	$ 19,786	$ 18,757
Accrued compensation and payroll taxes	12,914	13,384
Accrued outsourced manufacturing expenses	4,743	2,504
Other accrued expenses	6,142	5,396
Total accrued expenses	43,585	40,041
Less long-term portion	565	440
Total accrued expenses, current	$ 43,020	$ 39,601

Certain Balance Sheet Items - Deferred Revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Deferred revenue
Total deferred revenue	$ 9,754	$ 60,865
Less current portion	4,247	6,568
Deferred revenue, net of current portion	5,507	54,297
Roche [Member]
Deferred revenue
Total deferred revenue	0	39,379
Other collaborative agreements
Deferred revenue
Total deferred revenue	2,265	15,999
License fees and event-based payments
Deferred revenue
Total deferred revenue	2,265	55,378
Product [Member]
Deferred revenue
Total deferred revenue	$ 7,489	$ 5,487

Share-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Share-based Compensation (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 8,867	$ 7,762	$ 26,684	$ 23,268
Stock options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	4,645	4,973	14,026	14,971
RSU, RSA, and PRSU awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	4,222	2,789	12,658	8,297
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	4,407	3,060	13,107	9,891
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 4,460	$ 4,702	$ 13,577	$ 13,377

Stockholders' Equity (Deficit) Public Offering (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended	9 Months Ended
	May 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Equity [Abstract]
Stock Issued During Period, Shares, New Issues		11.5
Stock Issued During Period Shares New Issues To Underwriter		1.5
Sale of Stock, Price Per Share		$ 12.50
Proceeds from issuance of common stock, net	$ 134,875	$ 0	$ 134,875

Subsequent Event (Details) $ in Thousands	3 Months Ended	9 Months Ended
Subsequent Event (Details) $ in Thousands	Sep. 30, 2018 USD ($)	Sep. 30, 2018 USD ($)
Subsequent Event [Line Items]
Additional Minimum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones	$ 160,000	$ 160,000
Recognized revenue in the fourth quarter	18,700	70,600
Additional Maximum Proceeds Receivable from Collaborator of License and Collaborative Agreement Upon Achievement of Clinical Development Milestones	$ 165,000	$ 165,000